moxifloxacin profile

Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	152946
CHEBI ID	63611
SCHEMBL ID	24007
MeSH ID	M0273433

Synonym
moxifloxacin [inn:ban]
AB00171653-14
moxifloxacin
151096-09-2
mxfx
mxf ,
(1's,6's)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
actira (hydrochloride)
avelox (hydrochloride)
bay 12-8039 (hydrochloride)
7-[(4as,7as)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid
DB00218
1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6h-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-8-methoxy-7-[(4as,7as)-octahydro-6h-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
mfx ,
avelox iv
zimoxin
chebi:63611 ,
7-[(4as,7as)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
D08237
moxifloxacin (inn)
avelox iv (tn)
avolex
hsdb 8026
unii-u188xyd42p
moxifloxacine
ccris 8690
3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6h-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-
u188xyd42p ,
1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
BCP9000962
bdbm50366824
BCP0726000137
moxifloxacin [inn]
moxifloxacin [who-dd]
moxifloxacin [vandf]
moxifloxacin [mi]
AM84644
3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4as,7as)-octahydro-6h-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-
AKOS015895251
S5535
CCG-221192
HY-66011A
CS-1895
AB00171653-11
SCHEMBL24007
AB00171653-13
FABPRXSRWADJSP-MEDUHNTESA-N
DTXSID3048491 ,
moxyfloxacin
AC-25913
AB00171653_15
7-[(4as,7as)-octahydro-1h-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
mfcd04117996
EX-A016
SR-01000763482-3
sr-01000763482
SBI-0206792.P001
HMS3715P05
rkl10080
3-quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4as,7as)-octahydro-6h-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-
BCP22895
Q424940
AS-41986
naproxendiisopropylamide
1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4ar,7ar)-octahydro-6h-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-8-methoxy-7-octahydro-6h-pyrrolo[3,4-b]pyridin-6-yl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
AR-270/43507941
NCGC00271749-08
gtpl10915
nsc782304
nsc-782304
bay128039
1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylicacid
EN300-1726094
moxifloxacinum
j01ma14
moxifloxacino
dtxcid9028465
s01ae07

Excerpt	Reference	Relevance
"Moxifloxacin (MXF) is a fluoroquinolone antibiotic that is effective against respiratory infections. "	( P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Brillault, J; Couet, W; De Castro, WV; Harnois, T; Kitzis, A; Olivier, JC, 2009)	2.07
"Moxifloxacin is a fluoroquinolone with a broad spectrum of activity and good penetration into many tissues, including bone. "	( Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. Bulitta, JB; Drusano, GL; Gusinde, J; Hennig, FF; Holzgrabe, U; Kinzig, M; Landersdorfer, CB; Sörgel, F, 2009)	2.15
"Moxifloxacin is a fourth-generation fluoroquinolone used as a second-line treatment for multiple bacterial infections. "	( Severe sequelae in bilateral acute iris transillumination syndrome secondary to the use of oral moxifloxacin: a case report. Arteaga-Rivera, K; de-la-Torre, A; Neira-Segura, N; Reyes-Guanes, J; Rivera-Valdivia, N, 2021)	2.28
"Moxifloxacin is a fluoroquinolone that is commonly used in adults, but not children. "	( Population Pharmacokinetics of Moxifloxacin in Children. Conrad, T; Ghazaryhan, V; Greenberg, RG; Gu, K; Harward, M; Kirkpatrick, CM; Landersdorfer, CB; Nakamura, A; Osborn, B; Rivera-Chaparro, N; Walter, EB, 2022)	2.45
"Moxifloxacin (MOX) is a fourth-generation fluoroquinolone and a broad spectrum antibiotic used in the management of bacterial keratitis (BK). "	( Cationic Chitosan/Pectin Polyelectrolyte Nanocapsules of Moxifloxacin as Novel Topical Management System for Bacterial Keratitis. Kesavan, K; Mohan, P; Rangari, VD, 2022)	2.41
"Moxifloxacin is a wide range antibacterial drug that is available as an eye drops for topical use for different types of ocular infections including post-operative endophthalmitis."	( Efficacy Of Injecting Intra-Vitreal Moxifloxacin In Acute Post-Operative Endophthalmitis. Ahmad, A; Rehman, M, )	1.13
"Moxifloxacin (MOX) is a fourth-generation fluoroquinolone used in the form of tablets, infusion solutions and ophthalmic solutions. "	( Moxifloxacin: Physical-chemical and Microbiological Analytical Methods in the Context of Green Analytical Chemistry. da Silva, TAC; Kogawa, AC; Lustosa, IA, 2023)	3.8
"Moxifloxacin is an important drug in the regimen for treating Drug-resistant TB and the decision to exclude this drug from the regimen should not be taken merely on the basis of mutational patterns. "	( Correlating clinical breakpoint concentration of moxifloxacin with gyrA mutations using the GenoType MTBDRsl assay Version 2.0. Chopra, KK; Dwivedi, KK; Hanif, M; Khanna, A; Sidiq, Z; Vashishat, BK, 2023)	2.61
"Moxifloxacin is a fourth-generation fluoroquinolone (FQ) that is approved for use in people to treat a variety of infections. "	( A pilot study on the comparative minimum inhibitory and mutant prevention concentration values for moxifloxacin and pradofloxacin against canine and human isolates of Staphylococcus pseudintermedius and S. schleiferi. Blondeau, JM; Levinson, M; Plowgian, C; Rosenkrantz, W, 2019)	2.17
"Moxifloxacin is a fourth generation widely used fluoroquinolone antibiotic. "	( Moxifloxacin-induced neutropenia in 26-year-old man. Aytekin, A; Bedir, O; Ispir, E; Kula Atik, T; Tas, D; Turhan, U; Yeniiz, E, 2018)	3.37
"Moxifloxacin is an orally administrated fourth-generation quinolone with broad-spectrum coverage against tumor-associated bacteria."	( Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. Bi, X; Huang, J; Huang, Z; Li, J; Shi, W; Shi, Y; Su, Y; Wang, S; Wang, X; Xia, W; Yuan, Z, 2020)	1.66
"Moxifloxacin is a BCS class I drug with a wide therapeutic index."	( Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride. Abdallah, DB; Abrahamsson, B; Charoo, NA; Cristofoletti, R; Dressman, J; Groot, DW; Langguth, P; Mehta, M; Parr, A; Parveen, T; Polli, JE; Shah, VP; Tajiri, T, 2020)	1.52
"Moxifloxacin is a third-generation fluoroquinolone antibiotic with broad spectrum activity and also used as component of anti-tubercular therapy (ATT). "	( Moxifloxacin induced encephalopathy in disseminated tuberculosis: A case report. Akhtar, SM; Kaur, H; Mittal, GK; Reddy, VASK, 2020)	3.44
"Moxifloxacin is a fourth-generation fluoroquinolone that has shown good antibacterial activity against both gram-positive cocci and gram-negative bacteria. "	( Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials. Fan, J; Sun, M, 2021)	3.51
"Moxifloxacin is an antibiotic used in the clinic to both treat and prevent bacterial infections, and it has both good pharmacokinetic properties for tissue penetration and intrinsic fluorescence under ultraviolet (UV) excitation."	( Clinically Compatible Fluorescence Microscopy Based on Moxifloxacin Antibiotic. Kim, KH; Lee, S, 2021)	1.59
"Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. "	( Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; Thee, S; van der Laan, LE; Wiesner, L; Winckler, JL, 2022)	3.61
"Moxifloxacin is a fluoroquinolone with excellent activity in community-acquired respiratory tract infections. "	( Moxifloxacin-induced oral erythema multiforme: An unusual adverse effect hitherto unreported. Das, S; Mallick, S; Rudra, O; Sharma, S, )	3.02
"Moxifloxacin (MX) is an 8-methoxyquinolone antimicrobial drug, which is often used as a positive control in thorough QT (TQT) studies. "	( Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. He, YC; Huang, JH; Li, LJ; Liang, LY; Wang, K; Xu, FY; Xu, L; Yang, J; Yin, F; Zheng, QS, 2017)	2.18
"Moxifloxacin is a second-line anti-TB drug that is useful in the treatment of drug-resistant TB. "	( Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. Bablishvili, N; Bernheim, A; Blumberg, HM; Derendorf, H; Gogishvili, S; Guarner, J; Heinrichs, MT; Kempker, RR; Little, BP; Nikolaishvili, K; Peloquin, CA; Sabulua, I; Tukvadze, N; Vashakidze, S, 2018)	3.37
"Moxifloxacin is an antibiotic used in clinics and has recently been used as a clinically compatible cell-labeling agent for two-photon (2P) imaging. "	( Three-photon tissue imaging using moxifloxacin. Jang, WH; Jun, YW; Kim, B; Kim, KH; Kim, MJ; Lee, JH; Lee, S; Wang, T; Yoon, Y, 2018)	2.2
"Moxifloxacin (MXF) is a broad-spectrum antibiotic orally administrated."	( Novel polymeric dressing to the treatment of infected chronic wound. Borges, FA; de Barros, NR; de Souza Salvador, SL; Del Arco, MC; Frade, MAC; Garms, BC; Herculano, RD; Leite, MN; Marcelino, MY; Oliveira, KSM; Pegorin, GS, 2019)	1.24
"Moxifloxacin is a widely used fluoroquinolone for the treatment of complicated intra-abdominal infections. "	( Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin. Coboeken, K; Eissing, T; Frei, M; Lippert, J; Stass, H; Sutter, G; Wendl, T; Willmann, S, 2019)	2.16
"Moxifloxacin is a Food and Drug Administration (FDA) approved antibiotic and was used as a cell labeling agent through topical administration."	( Fast and sensitive delineation of brain tumor with clinically compatible moxifloxacin labeling and confocal microscopy. Chang, H; Chung, E; Jang, WH; Kim, B; Kim, EH; Kim, KH; Kim, MJ; Kim, S; Lee, KH; Lee, S; Park, WY; Shin, Y, 2020)	1.51
"Moxifloxacin (MXF), is a fluoroquinolone drug thought to have some antifungal activity against Candida albicans. "	( Vitreous and aqueous penetration of intravitreally and orally administered moxifloxacin in an experimental rabbit model of fungal endophthalmitis. Aktas, Z; Arikan, S; Dinçel, A; Hasanreisoglu, B; Ozdek, S, 2013)	2.06
"Moxifloxacin is an interesting adjuvant to consider as it is effectively prevents encystation of the amoeba which often complicates infection resolution."	( Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba. Arnalich-Montiel, F; López-Arencibia, A; Lorenzo-Morales, J; Martín-Navarro, CM; Piñero, JE; Valladares, B, 2013)	1.35
"Moxifloxacin is an 8-methoxy quinolone with a broad spectrum of activity against clinically important pathogens. "	( Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. Chen, Y; Li, L; Li, R; Liang, X; Liu, S; Shi, W; Wang, WJ; Wang, X; Ye, Z; Yu, C; Zhang, B; Zhang, L; Zhuo, L, 2013)	2.16
"moxifloxacin monotherapy is an effective and relatively safe option for the treatment of cSSSIs."	( Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials. Chen, F; Du, YQ; Lin, JM; Tu, WF; Wang, Y; Wen, JL; Zheng, N, 2013)	1.41
"Moxifloxacin (MFLX) is a respiratory quinolone, and is effective against not only Gram-positive and negative bacteria but also anaerobes. "	( [Efficacy and safety of moxifloxacin in patients with nursing and healthcare-associated pneumonia]. Akata, K; Awaya, Y; Choujin, Y; Inoue, N; Ishimoto, H; Kawajiri, T; Kawanami, Y; Kawanaml, T; Mukae, H; Nagata, S; Nishida, C; Noguchi, S; Obata, H; Ogoshi, T; Orihashi, T; Suzuki, Y; Taura, Y; Tokuyama, S; Yamasaki, K; Yatera, K; Yoshida, Y; Yoshii, C, 2013)	2.14
"Moxifloxacin 400 mg is a widely used positive control in thorough QT (TQT) studies, but its QT-prolonging effects in Korean subjects have not been studied. "	( The effects of moxifloxacin on QTc interval in healthy Korean male subjects. An, H; Cho, JY; Chung, JY; Lee, J; Lim, KS; Moon, SJ; Yim, DS; Yu, KS, 2014)	2.2
"Moxifloxacin 400 mg is an adequate positive control in Korean TQT studies. "	( The effects of moxifloxacin on QTc interval in healthy Korean male subjects. An, H; Cho, JY; Chung, JY; Lee, J; Lim, KS; Moon, SJ; Yim, DS; Yu, KS, 2014)	2.2
"Moxifloxacin is a synthetic antibacterial agent belonging to the fluoroquinolone family. "	( Moxifloxacin modulates inflammation during murine pneumonia. Bals, R; Beisswenger, C; Bischoff, M; Honecker, A; Kamyschnikow, A; Tschernig, T, 2014)	3.29
"Moxifloxacin is a leading fourth generation quinolone antibiotic that has been used worldwide perioperatively."	( Comparison of the Anti-angiogenic and Anti-inflammatory Effects of Two Antibiotics: Clarithromycin Versus Moxifloxacin. Ambati, BK; Archer, B; Cho, YK; Das, SK; Uehara, H, 2016)	1.37
"Moxifloxacin is an effective therapeutic option for patients with AV."	( Efficacy of oral moxifloxacin for aerobic vaginitis. Fan, A; Geng, N; Han, C; Wang, C; Wang, Y; Xue, F; Yue, Y; Zhang, H, 2016)	1.5
"Moxifloxacin (MOX) is a Mycobacterium tuberculosis DNA gyrase inhibitor. "	( Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles. Devi, VK; Mustafa, S; Pai, RS, 2017)	2.15
"Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae."	( Moxifloxacin: a respiratory fluoroquinolone. Anzueto, A; Miravitlles, M, 2008)	2.51
"Moxifloxacin is an advanced-generation fluoroquinolone with a broad spectrum of antimicrobial activity that is not metabolized by cytochrome P450 system. "	( A significant interaction between moxifloxacin and warfarin in a patient with a mitral bioprosthetic valve. Candevir, A; Cayli, M; Kurtaran, B; Sümbül, Z; Yildiz, F, 2008)	2.07
"Moxifloxacin (MXF) is an 8-methoxyquinolone with high activity against Gram-positive bacteria. "	( Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA). Donta, I; Galani, L; Giamarellou, H; Iliopoulos, D; Karayiannakos, P; Pefanis, A; Sakka, V; Skiadas, I; Triantafyllidi, H, 2009)	2.1
"Moxifloxacin is a new fourth-generation 8-methoxy fluoroquinolone developed primarily for the treatment of community-acquired pneumonia and upper respiratory tract infections. "	( Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. Goudah, A; Hasabelnaby, S, 2010)	2.07
"Moxifloxacin is confirmed to be an effective alternative to ofloxacin/metronidazole for the treatment of PID in a large urban genitourinary clinic setting."	( A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Boothby, M; Page, J; Pryor, R; Ross, JD, 2010)	1.35
"Moxifloxacin (MFX) is a useful agent in the treatment of multi-drug-resistant tuberculosis (MDR-TB). "	( Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography- tandem mass spectrometry method. Alffenaar, JW; Greijdanus, B; Pranger, AD; Uges, DR; Wessels, AM, 2010)	2.14
"Moxifloxacin therapy is an effective alternative to teicoplanin for chronic implant-related MSSA osteomyelitis."	( Efficacy of moxifloxacin compared to teicoplanin in the treatment of implant-related chronic osteomyelitis in rats. Cakici, H; Guven, M; Kocoglu, E; Ozturan, KE; Yucel, I, 2010)	1.46
"Moxifloxacin is a quinolone up to 10 times more active against staphylococci than ciprofloxacin and the risk of resistance development during monotherapy against staphylococci is theoretically lower for moxifloxacin, but information regarding its use in bone infections is lacking."	( Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections. Aguado, JM; Caba, P; Chaves, F; Garcia-Reyne, A; Lizasoain, M; Llanos, F; López-Medrano, F; Resines, C; San Juan, R, 2010)	1.39
"Moxifloxacin is a fluoroquinolone antibiotic that demonstrates potent activity against Y."	( Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Brown, DL; Drusano, GL; Eichas, A; Fikes, S; Files, K; Heine, HS; Kinzig-Schippers, M; Liu, W; Louie, A; Sörgel, F; VanScoy, B, 2011)	1.34
"Moxifloxacin (MFX) is a powerful second-line anti-tuberculosis (TB) agent, but the optimal dose has not yet been established and long-term safety data are scarce. "	( Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Aarnoutse, RE; Alffenaar, JW; Kosterink, JG; Pranger, AD; Uges, DR; van Altena, R; van der Werf, TS; van Soolingen, D, 2011)	2.17
"Moxifloxacin is a fluoroquinolone antibiotic which has been associated with QT prolongation and, as a result, is recommended by the regulatory authorities as a positive control in thorough QT studies performed to evaluate the potential of new chemical entities to induce QT prolongation in humans."	( Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. Chen, X; Fermini, B; Gorczyca, WP; Holbrook, M; Sun, SZ; Umland, J; Van Der Graaf, PH; Watson, KJ; Zhang, Y, )	1.1
"Moxifloxacin (MFX) is a potential oral agent use in the treatment of multidrug-resistance tuberculosis (MDR-TB). "	( Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. Alffenaar, JW; Brouwers, JR; Koster, RA; Uges, DR; Vu, DH, 2011)	2.15
"Moxifloxacin (MFX) is a potent drug for multidrug resistant tuberculosis(TB) treatment and is also useful if first-line agents are not tolerated. "	( Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Aarnoutse, RE; Alffenaar, JW; Kosterink, JG; Pranger, AD; Uges, DR; van Altena, R; van der Werf, TS, 2011)	2.05
"Moxifloxacin is a respiratory quinolone that is expected to be useful for treating community-acquired bacterial pneumonia, but few clinical studies and not a detailed evaluation of its pharmacokinetics have been conducted in Japan in patients with pneumonia. "	( Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. Fukano, H; Hara, H; Kawanishi, M; Kimura, M; Kishimoto, M; Matsushima, T; Moriya, O; Niki, Y; Okimoto, N; Yoneyama, H; Yoshida, K, 2011)	2.12
"Moxifloxacin is an effective and relatively safe option for the treatment of patients with intra-abdominal infections."	( Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials. Deng, X; Liu, RL; Mu, YP; Wang, LQ; Wang, Y; Wei, MD; Zhu, N, 2012)	2.54
"Moxifloxacin is a quinolone antibiotic and is one of the treatment options."	( The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. Macklin-Doherty, A; Wilson, R, 2012)	1.49
"Moxifloxacin is an antibiotic of the fluoroquinolone class, marketed in France since 2002. "	( [Severe pseudouveitis associated with moxifloxacin therapy]. Chapuzet, C; Duncombe, A; Gueit, I; Gueudry, J; Massy, N; Muraine, M, 2013)	2.1
"Moxifloxacin is an advanced-generation, 8-methoxy fluoroquinolone that is active against a broad spectrum of pathogens, including antibiotic resistant Streptococcus pneumoniae. "	( Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry. Bartlett, MG; Stewart, JT; Vishwanathan, K, 2002)	2.1
"Moxifloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial rhinosinusitis. "	( Sinus tissue concentration of moxifloxacin after a single oral dose. Dinis, PB; Martins, ML; Monteiro, MC; Morais, JG; Silva, N, 2004)	2.05
"Moxifloxacin is an advanced-generation fluoroquinolone used primarily for the treatment of respiratory tract infections."	( Clinical experience with moxifloxacin in patients with respiratory tract infections. Arcuri, P; Brar, JS; Celesk, RA; Church, DA; Faich, GA; Haverstock, DC; Kowalsky, SF; Morganroth, J; Whitehouse, AB, 2004)	2.07
"Moxifloxacin is a recently developed fourth-generation methoxyquinolone with a broad spectrum of activity against both Gram-positive and Gram-negative aerobic bacteria and anaerobes. "	( Moxifloxacin penetration into human gastrointestinal tissues. Büchler, MW; Friess, H; Geiss, HK; Halaceli, I; Hoppe-Tichy, T; Kleeff, J; Swoboda, S; Wirtz, M, 2004)	3.21
"Moxifloxacin is a recent fluoroquinolone with an antibacterial spectrum encompassing both aerobic Gram-negative and Gram-positive strains, as well as anaerobic bacteria. "	( Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone. De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L; Tocalli, L, 2004)	2.17
"Moxifloxacin is a broad-spectrum, advanced-generation fluoroquinolone that has potent activity against respiratory tract infections in adults in both oral and IV formulations."	( Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Ball, P; Choudhri, S; Kubin, R; Owens, R; Stahlmann, R, 2004)	1.31
"Moxifloxacin is an 8-methoxy quinolone with a broad range of activity against clinically important pathogens. "	( Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. Ahmed, S; Fuhrmann, V; Jaeger, W; Schenk, P; Thalhammer, F, 2004)	2.09
"Moxifloxacin (Avelox) is a fluoroquinolone antibacterial with a methoxy group in the C-8 position and a bulky C-7 side chain. "	( Moxifloxacin: a review of its use in the management of bacterial infections. Keating, GM; Scott, LJ, 2004)	3.21
"Moxifloxacin is a quinolone antimicrobial that has potent activity against Mycobacterium tuberculosis. "	( Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. Deziel, MR; Drusano, GL; Gumbo, T; Louie, A; Parsons, LM; Salfinger, M, 2004)	2.12
"Moxifloxacin (Avelox) is a recently-developed fluoroquinolone that has a broad spectrum of antimicrobial activity, including typical respiratory pathogens, atypical and intracellular respiratory pathogens, Gram-negative pathogens and many anaerobes. "	( Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity. Caeiro, JP; Iannini, PB, 2003)	3.2
"Moxifloxacin is a newly developed fluoroquinolone with a potent antimicrobial activity."	( Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model. Cetinkaya, Z; Ermis, SS; Kiyici, H; Ozturk, F, 2005)	1.28
"Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against respiratory pathogens, including Gram-positive (Streptococcus pneumoniae), Gram-negative (Haemophilus influenzae, Moraxella catarrhalis), and atypical strains (Chlamydia pneumoniae, Mycoplasma pneumoniae), as well as multi-drug resistant S. "	( Moxifloxacin in respiratory tract infections. Miravitlles, M, 2005)	3.21
"Moxifloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum activity."	( Tolerability of moxifloxacin in patients with antibiotic hypersensitivity. Bozkurt, B; Kalyoncu, AF; Karakaya, G, )	1.2
"Moxifloxacin is an quinolone chemically different from other fluoroquinolones."	( Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity. Blasco, A; del Pozo, MD; González, I; Lobera, T, 2005)	1.31
"Moxifloxacin is a new generation fluoroquinolone antimicrobial agent used worldwide. "	( Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Borner, K; Burkhardt, O; Stass, H; Thuss, U; Welte, T, 2005)	2.02
"Moxifloxacin is a fluoroquinolone antimicrobial agent with proven efficacy against community-acquired respiratory pathogens. "	( Acute interstitial nephritis associated with moxifloxacin use. Argirov, M; Fischereder, M; Ricken, G; Zecher, D, 2005)	2.03
"Moxifloxacin is a fourth-generation fluoroquinolone approved for ophthalmic use as moxifloxacin ophthalmic solution 0.5% (VIGAMOX, Alcon, Fort Worth, TX)."	( Safety of moxifloxacin as shown in animal and in vitro studies. Holt, WF; Kastner, PR; McGee, DH; Rice, RL, 2005)	1.45
"Moxifloxacin was shown to be an effective and well tolerated treatment for this group of patients with RTIs and was highly rated by both physicians and patients because of rapid symptom improvement and good tolerability."	( Efficacy and tolerability of moxifloxacin in patients with respiratory tract infections treated in general practice: Results of a post-marketing surveillance study. Bai, C; Chen, W; Li, Z; Wu, C, 2006)	2.07
"Moxifloxacin is a new fluorquinolone with broad-spectrum activity. "	( Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36% and Dianeal PD1 3.86%). Cárceles, C; Escudero, E; Espuny, A; Fernández-Varón, E; Marín, P; Villamayor, L, 2006)	2.15
"Moxifloxacin, which is an 8-MeO-substituted fluoroquinolone, is less phototoxic than the other compounds."	( Photophysical and phototoxic properties of the antibacterial fluoroquinolones levofloxacin and moxifloxacin. Aloisi, GG; Amelia, M; Barbafina, A; Canton, M; Dall'Acqua, F; Elisei, F; Facciolo, L; Latterini, L; Vedaldi, D; Viola, G, 2004)	1.26
"Moxifloxacin (MXF) is a fluoroquinolone that acts against both Gram positive and Gram negative bacteria."	( Anti-inflammatory effects of moxifloxacin and human beta-defensin 2 association in human lung epithelial cell line (A549) stimulated with lipopolysaccharide. Buommino, E; Cozza, V; Donnarumma, G; Iovene, MR; Paoletti, I; Tudisco, L; Tufano, MA, 2007)	1.35
"Moxifloxacin is a novel antibacterial agent that undergoes extensive metabolism in the liver to the glucuronide M1 and the sulfate M2, which are eliminated via the bile. "	( Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. Ahmed, S; Gattringer, KB; Jäger, W; Thalhammer, F; Thalhammer, T; Vo, NT, 2008)	2.04
"Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens."	( Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M, 2007)	1.06
"Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against respiratory pathogens, including atypicals and those resistant to most common antibiotics."	( Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Miravitlles, M, 2007)	2.5
"Moxifloxacin is a respiratory fluoroquinolone with a community acquired pneumonia indication. "	( Fluoroquinolone resistance during 2000-2005: an observational study. Lindsell, C; Ryan, RJ; Sheehan, P, 2008)	1.79
"Moxifloxacin is a new 8-methoxyquinolone with high activity against gram-positive bacteria, including penicillin-resistant pneumococci. "	( Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Frimodt-Møller, N; Knudsen, JD; Ostergaard, C; Sørensen, TK, 1998)	2.1
"Moxifloxacin (BAY12-8039) is a new 8-methoxyquinolone shown to be active against Mycobacterium tuberculosis in vitro. "	( Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Bishai, WR; Chaisson, RE; Chen, JM; Miyazaki, E; Miyazaki, M, 1999)	3.19
"Moxifloxacin (BAY 12-8039) is an investigational 8-methoxy-fluoroquinolone with broad-spectrum gram-positive and gram-negative activity. "	( Absolute bioavailability of moxifloxacin. Agarwal, V; Ballow, C; Lettieri, J; Liu, P; Stass, H; Sullivan, JT, 1999)	2.04
"Moxifloxacin is an 8-methoxyquinolone compound with activity against a wide range of bacteria. "	( Activity of moxifloxacin against mycobacteria. Billington, O; Gillespie, SH, 1999)	2.13
"Moxifloxacin is a new 8-methoxyquinolone with improved in vitro activity against gram-positive bacteria."	( In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria. Malathum, K; Murray, BE; Singh, KV, 1999)	1.34
"Moxifloxacin is an extended-spectrum fluoroquinolone which has improved coverage against gram-positive cocci and atypical pathogens compared with older fluoroquinolone agents, while retaining good activity against gram-negative bacteria. "	( Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Balfour, JA; Lamb, HM, 2000)	3.19
"Moxifloxacin (BAY 12-8039) is a new 8-methoxy-fluoroquinolone antibacterial agent. "	( Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Nightingale, CH, 2000)	3.19
"Moxifloxacin is a novel 8-methoxyquinolone with enhanced potency against important Gram-positive pathogens, notably Streptococcus pneumoniae. "	( Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency. Ball, P, 2000)	3.19
"Moxifloxacin appears to be a promising choice for the treatment of pneumococcal infections, including situations where therapeutic choices are limited due to penicillin and macrolide resistance."	( Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae. Esposito, S; Ianniello, F; Noviello, S, )	1.95
"Moxifloxacin is a new fluoroquinolone. "	( Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Démolis, JL; Funck-Brentano, C; Kubitza, D; Tennezé, L, 2000)	2.03
"Moxifloxacin is a new broad-spectrum antibacterial agent for treatment of respiratory tract infection of pathogens, including the major pathogens isolated in respiratory tract infections. "	( Evaluation of the clinical microbiology profile of moxifloxacin. Krasemann, C; Meyer, J; Tillotson, G, 2001)	2.01
"Moxifloxacin is an oral 8-methoxyquinolone antimicrobial approved in December 1999 for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia."	( Moxifloxacin: clinical efficacy and safety. Culley, CM; Edwards, B; Klutman, N; Lacy, MK, 2001)	2.47
"Moxifloxacin is a new 8-methoxyfluoroquinolone with a broad antibacterial spectrum. "	( The influence of age and gender on the pharmacokinetics of moxifloxacin. Heller, AH; Lettieri, JT; Liu, P; Sullivan, JT, 2001)	2
"Moxifloxacin is a new oral 8-methoxy-quinolone with a wide spectrum of activity against Gram-negative and anaerobic bacteria, atypical micro-organisms and multi-resistant Gram-positive bacteria. "	( Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates. Blandino, G; Caccamo, F; Milazzo, I; Musumeci, R; Nicoletti, G; Speciale, A, 2002)	2
"Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections."	( Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Bartolozzi, F; Cammarota, G; Candelli, M; Cremonini, F; Di Caro, S; Gasbarrini, A; Lupascu, A; Nista, EC; Ojetti, V; Zocco, MA, 2002)	2.07
"Moxifloxacin is a fluoroquinolone antibacterial agent which attains good penetration into peripheral tissues and inflammatory fluids. "	( Moxifloxacin in uncomplicated skin and skin structure infections. Jarvis, B; Muijsers, RB, 2002)	3.2
"Moxifloxacin (MXF) is a new 8-methoxyquinolone with potent activity against Mycobacterium tuberculosis and a half-life of 9 to 12 h in humans. "	( Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Bishai, W; Chaisson, R; Grosset, J; Nuermberger, E; Tyagi, S; Yoshimatsu, T, 2002)	2

Excerpt	Reference	Relevance
"Moxifloxacin has a rapid bactericidal effect against intracellular reservoirs of bacteria, whereas amoxicillin is only bacteriostatic and appears to prevent cellular lysis and the subsequent bacterial spreading to adjacent cells."	( Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Desroches, MC; Grayo, S; Join-Lambert, O; Le Monnier, A, 2008)	1.33
"Moxifloxacin has an important role in the treatment of tuberculosis (TB). "	( Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. Aarnoutse, RE; Boeree, MJ; Bolwerk, C; Burger, DM; Greupink, R; Hoefsloot, W; Koenderink, JB; Kuipers, S; Litjens, CHC; Magis-Escurra, C; Ruslami, R; Russel, FGM; Svensson, EM; Te Brake, LHM; van Crevel, R; van den Broek, PHH; van den Heuvel, JJMW; van Ingen, J; van Laarhoven, A; Verscheijden, LFM, 2022)	2.52
"Moxifloxacin has an impressive spectrum of coverage and this pharmacokinetic study reinforces its potential as a prophylactic drug against intraocular infections, given the high aqueous levels post topical administration."	( Aqueous penetration of orally and topically administered moxifloxacin. Bairy, KL; Kamath, MG; Kamath, MM; Musmade, PB; Nayak, RR; Sharma, T, 2015)	2.1
"Moxifloxacin has a broad antibacterial spectrum and rapid bactericidal activity, and is thus a good option for the treatment of bacterial infections in patients who have undergone organ or bone marrow transplantation. "	( Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study. Bauer, S; Delesen, H; Kubitza, D; Mai, I; Roots, I; Stass, H, 2010)	3.25
"Moxifloxacin has a low potential to cause endotoxin-mediated detrimental clinical effects. "	( Low endotoxin release from Escherichia coli and Bacteroides fragilis during exposure to moxifloxacin. Holst, O; Lepper, PM; Scheibe, C; Trautmann, M; Wellinghausen, N, 2010)	2.03
"Moxifloxacin has an activity similar to rifampin in human subjects with pulmonary tuberculosis, suggesting that it should undergo further assessment as part of a short course regimen for the treatment of drug-susceptible tuberculosis."	( The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Bongard, E; Gillespie, SH; Gosling, RD; Kanduma, EG; Morris, RW; Nyindo, M; Sam, NE; Uiso, LO, 2003)	1.33
"Moxifloxacin has a broad spectrum of antibacterial activity, including activity against penicillin-resistant Streptococcus pneumoniae."	( Moxifloxacin: a review of its use in the management of bacterial infections. Keating, GM; Scott, LJ, 2004)	2.49
"Moxifloxacin has a spectrum of coverage that appropriately encompasses the most common organisms in endophthalmitis."	( Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Apte, RS; Blinder, KJ; Chi, J; Hariprasad, SM; Holekamp, NM; Mieler, WF; Prince, RA; Rosenblatt, B; Shah, GK; Thomas, MA, 2005)	1.29
"Moxifloxacin has a spectrum of coverage that encompasses the most common organisms in endophthalmitis. "	( Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Blinder, KJ; Feiner, L; Gao, H; Hariprasad, SM; Holekamp, NM; Mieler, WF; Prince, RA; Shah, GK, 2006)	2.02
"Moxifloxacin has a low propensity for causing phototoxic reactions relative to other fluoroquinolones, and animal data suggest that it has a low potential for causing excitatory CNS and hepatotoxic effects."	( Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Balfour, JA; Lamb, HM, 2000)	2.47
"Moxifloxacin has a greater bactericidal rate as determined by regression of log CFU versus time data."	( Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M, 2001)	1.29
"Moxifloxacin thus has a unique drug interaction profile that is advantageous for its safe use."	( Profile of moxifloxacin drug interactions. Kubitza, D; Stass, H, 2001)	1.42
"Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours."	( Moxifloxacin: clinical efficacy and safety. Culley, CM; Edwards, B; Klutman, N; Lacy, MK, 2001)	2.47
"Moxifloxacin has a rapid bactericidal effect against intracellular reservoirs of bacteria, whereas amoxicillin is only bacteriostatic and appears to prevent cellular lysis and the subsequent bacterial spreading to adjacent cells."	( Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Desroches, MC; Grayo, S; Join-Lambert, O; Le Monnier, A, 2008)	1.33
"Moxifloxacin has an important role in the treatment of tuberculosis (TB). "	( Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. Aarnoutse, RE; Boeree, MJ; Bolwerk, C; Burger, DM; Greupink, R; Hoefsloot, W; Koenderink, JB; Kuipers, S; Litjens, CHC; Magis-Escurra, C; Ruslami, R; Russel, FGM; Svensson, EM; Te Brake, LHM; van Crevel, R; van den Broek, PHH; van den Heuvel, JJMW; van Ingen, J; van Laarhoven, A; Verscheijden, LFM, 2022)	2.52
"Moxifloxacin has rarely been reported to be a drug that is associated with DRESS syndrome."	( A typical presentation of moxifloxacin-induced DRESS syndrome with pulmonary involvement: a case report and review of the literature. Cheng, Y; Wang, X; Zhang, Y, 2022)	1.74
"Moxifloxacin doses may have been insufficient in eyes with larger ACV."	( Endophthalmitis Prophylaxis Failures in Patients Injected With Intracameral Antibiotic During Cataract Surgery. Carolan, JA; Herrinton, L; Liu, L; Shorstein, NH, 2021)	1.34
"Moxifloxacin (MXF) has antibacterial activity in Gram‑positive and Gram‑negative bacteria."	( Bidirectional effects of moxifloxacin on the pro‑inflammatory response in lipopolysaccharide‑stimulated mouse peritoneal macrophages. Chen, B; Hu, X; Li, N; Qiu, Z; Su, F; Yang, X; Yuan, H, 2018)	1.51
"Moxifloxacin (MXF) has in vitro and in vivo activity against Mycobacterium avium complex (MAC) in experimental models. "	( Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Hong, G; Jeon, K; Jeong, BH; Kim, CK; Kim, SY; Koh, WJ; Kwon, OJ; Lee, SH; Park, HY; Shin, SJ, 2013)	2.06
"Moxifloxacin has potent bactericidal activity against Streptococcus pneumoniae; a major causative organism of lower respiratory tract infections. "	( Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios. Noreddin, AM; Salem, AH, 2014)	3.29
"Moxifloxacin has good MICs for M."	( Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. Gumbo, T; Leff, R; Meek, C; Pasipanodya, J; Sherman, CM; Srivastava, S, 2015)	1.38
"Moxifloxacin has an impressive spectrum of coverage and this pharmacokinetic study reinforces its potential as a prophylactic drug against intraocular infections, given the high aqueous levels post topical administration."	( Aqueous penetration of orally and topically administered moxifloxacin. Bairy, KL; Kamath, MG; Kamath, MM; Musmade, PB; Nayak, RR; Sharma, T, 2015)	2.1
"Moxifloxacin has bright intrinsic multiphoton fluorescence, good tissue penetration and high intracellular concentration."	( Moxifloxacin: Clinically compatible contrast agent for multiphoton imaging. Ahn, GO; Bok, S; Chung, E; Gho, YS; Hong, CP; Hwang, S; Jang, MH; Jang, WH; Kim, B; Kim, KH; Kim, MJ; Kim, S; Le, VH; Lee, G; Lee, J; Lee, JH; Lee, S; Myung, SJ; So, PT; Wang, T; Yoon, CJ; Yoon, Y, 2016)	2.6
"Moxifloxacin has demonstrated a faster resolution of symptoms in community-acquired pneumonia and exacerbations of chronic bronchitis patients compared with first-line therapy together with excellent eradication rates."	( Moxifloxacin: a respiratory fluoroquinolone. Anzueto, A; Miravitlles, M, 2008)	2.51
"Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited."	( Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Bernardo, J; Bozeman, L; Chaisson, RE; Choudhri, S; Dorman, SE; Goldberg, S; Grosset, JH; Guy, E; Guyadeen, P; Heilig, CM; Johnson, JL; Leus, MC; Maltas, G; Menzies, D; Muzanye, G; Nuermberger, EL; Padayatchi, N; Vernon, A; Villarino, M, 2009)	2.14
"Moxifloxacin has been used in the first-line treatment of Helicobacter pylori infection. "	( Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Amitrano, M; Grossi, L; Manzoli, L; Marzio, L; Sacco, F; Spezzaferro, M, 2010)	2.1
"Moxifloxacin has unique side chains at positions 7 and 8 on its bicyclic ring structure."	( Immediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature. Chang, B; Knowles, SR; Weber, E, 2010)	1.37
"Moxifloxacin has been the most commonly used positive control in "thorough" QTc (TQT) studies. "	( Statistical characteristics of moxifloxacin-induced QTc effect. Dang, Q; Ng, MJ; Yan, LK; Zhang, J, 2010)	2.09
"Moxifloxacin has a broad antibacterial spectrum and rapid bactericidal activity, and is thus a good option for the treatment of bacterial infections in patients who have undergone organ or bone marrow transplantation. "	( Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study. Bauer, S; Delesen, H; Kubitza, D; Mai, I; Roots, I; Stass, H, 2010)	3.25
"Moxifloxacin has a low potential to cause endotoxin-mediated detrimental clinical effects. "	( Low endotoxin release from Escherichia coli and Bacteroides fragilis during exposure to moxifloxacin. Holst, O; Lepper, PM; Scheibe, C; Trautmann, M; Wellinghausen, N, 2010)	2.03
"Moxifloxacin has demonstrated a broad spectrum coverage of both aerobic and anaerobic pathogens, good tissue penetration into the gastrointestinal tract, and a good tolerability profile."	( Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan. Chen, CW; Chen, YH; Hsueh, PR; Huang, CT; Ko, WC; Lau, YJ; Lee, WS; Lee, YJ; Liu, CY; Liu, HD; Liu, JW, 2012)	1.53
"Moxifloxacin monotherapy has similar efficacy to combination therapy."	( Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials. Deng, X; Liu, RL; Mu, YP; Wang, LQ; Wang, Y; Wei, MD; Zhu, N, 2012)	2.54
"Moxifloxacin (MXF) has been shown to possess immunomodulatory properties in addition to its antimicrobial effects. "	( Anti-inflammatory effects of moxifloxacin on rat airway smooth muscle cells exposed to allergen: Inhibition of extracellular-signal-regulated kinase and nuclear factor-κB activation and of interleukin-8 and eotaxin synthesis. Hao, L; He, S; Li, H; Zhu, S, 2012)	2.11
"Moxifloxacin has shown favorable safety and efficacy profiles in DFI patients and could be an alternative antibiotic therapy in the management of DFI."	( Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC, 2013)	2.12
"Moxifloxacin has enhanced potency against Staphylococcus aureus, lower propensity to select for resistant mutants, and higher bactericidal activity against highly resistant strains than ciprofloxacin. "	( Activity of and resistance to moxifloxacin in Staphylococcus aureus. Hooper, DC; Ince, D; Zhang, X, 2003)	2.05
"Moxifloxacin has an activity similar to rifampin in human subjects with pulmonary tuberculosis, suggesting that it should undergo further assessment as part of a short course regimen for the treatment of drug-susceptible tuberculosis."	( The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Bongard, E; Gillespie, SH; Gosling, RD; Kanduma, EG; Morris, RW; Nyindo, M; Sam, NE; Uiso, LO, 2003)	1.33
"Moxifloxacin has a broad spectrum of antibacterial activity, including activity against penicillin-resistant Streptococcus pneumoniae."	( Moxifloxacin: a review of its use in the management of bacterial infections. Keating, GM; Scott, LJ, 2004)	2.49
"Moxifloxacin has pharmacologic characteristics that support once-daily dosing regimens and dual routes of excretion that require little or no adjustment for renal or hepatic insufficiency."	( Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity. Caeiro, JP; Iannini, PB, 2003)	2.48
"Moxifloxacin has a spectrum of coverage that appropriately encompasses the most common organisms in endophthalmitis."	( Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Apte, RS; Blinder, KJ; Chi, J; Hariprasad, SM; Holekamp, NM; Mieler, WF; Prince, RA; Rosenblatt, B; Shah, GK; Thomas, MA, 2005)	1.29
"Moxifloxacin has been suggested as an option for monotherapy of intra-abdominal infections. "	( Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Hermsen, ED; Hovde, LB; Rodvold, KA; Rotschafer, JC; Sprandel, KA, 2005)	2.01
"Moxifloxacin has demonstrated a faster resolution of symptoms in CAP and exacerbations of CB patients compared with first-line therapy."	( Moxifloxacin in respiratory tract infections. Miravitlles, M, 2005)	2.49
"Moxifloxacin has been shown to induce QT prolongation in both clinical and preclinical models. "	( Effects of moxifloxacin on QT interval in conscious dogs. Hart, SM; Mittelstadt, SW, 2005)	2.16
"Moxifloxacin also has better mutant prevention characteristics than other fluoroquinolones."	( Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Alfonso, E; Schlech, BA, 2005)	1.35
"Moxifloxacin has a spectrum of coverage that encompasses the most common organisms in endophthalmitis. "	( Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Blinder, KJ; Feiner, L; Gao, H; Hariprasad, SM; Holekamp, NM; Mieler, WF; Prince, RA; Shah, GK, 2006)	2.02
"Moxifloxacin has promising preclinical activity against Mycobacterium tuberculosis, but has not been evaluated in multidrug treatment of tuberculosis in humans."	( Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Burman, WJ; Chaisson, RE; Choudhri, S; Daley, CL; Engle, M; Goldberg, S; Johnson, JL; Mosher, AW; Munsiff, SS; Muzanye, G; Vernon, A; Zhao, Z, 2006)	3.22
"Moxifloxacin has been demonstrated to penetrate efficiently into human pancreatic tissue following iv or oral administration. "	( Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. Adam, U; Drewelow, B; Förster, S; Hopt, UT; Klar, E; Mundkowski, RG; Wacke, R, 2006)	2.13
"Moxifloxacin has demonstrated better eradication in exacerbations of CB and COPD compared with standard therapy, in particular, with macrolides."	( Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Miravitlles, M, 2007)	2.5
"Moxifloxacin has a low propensity for causing phototoxic reactions relative to other fluoroquinolones, and animal data suggest that it has a low potential for causing excitatory CNS and hepatotoxic effects."	( Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Balfour, JA; Lamb, HM, 2000)	2.47
"Moxifloxacin also has excellent penetration into upper and lower respiratory tissues."	( Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Nightingale, CH, 2000)	2.47
"Moxifloxacin has a greater bactericidal rate as determined by regression of log CFU versus time data."	( Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M, 2001)	1.29
"Moxifloxacin also has excellent in vitro activity against strains resistant to penicillin, erythromycin, and other fluoroquinolones, such as levofloxacin."	( Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Talan, DA, 2001)	1.03
"Moxifloxacin thus has a unique drug interaction profile that is advantageous for its safe use."	( Profile of moxifloxacin drug interactions. Kubitza, D; Stass, H, 2001)	1.42
"Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours."	( Moxifloxacin: clinical efficacy and safety. Culley, CM; Edwards, B; Klutman, N; Lacy, MK, 2001)	2.47
"Moxifloxacin has good in vitro activity against common organisms associated with community and nosocomial infections, with the exception of enterococci, methicillin-resistant Staphylococcus aureus and ciprofloxacin-resistant gram-negative bacteria. "	( In vitro activity of moxifloxacin against local bacterial isolates. Ling, ML; Tan, PL, 2001)	2.07
"Moxifloxacin has immunomodulatory activity through its capacity to alter the secretion of IL-1alpha and TNF-alpha by human monocytes."	( Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. Araujo, FG; Remington, JS; Slifer, TL, 2002)	2.16
"Moxifloxacin has been developed to address many of these problems."	( Improving care for patients with respiratory tract infections. Garau, J; Lode, H, 2002)	1.04

Excerpt	Reference	Relevance
"Moxifloxacin had a much lower CR than other drugs and is, therefore, not recommended for the management of scrub typhus."	( Evaluation of the Therapeutic Effect of Antibiotics on Scrub Typhus: A Systematic Review and Network Meta-Analysis. Lu, D; Luo, Z; Qian, J; Wang, C; Wang, T; Ye, F; Zhang, J, 2022)	1.44
"Moxifloxacin seems to inhibit the yeast to Hyphal morphogenesis by affecting signaling pathways."	( The antibacterial agent, moxifloxacin inhibits virulence factors of Candida albicans through multitargeting. Bansode, B; Gade, W; Jadhav, A; Karuppayil, SM; Kharat, K; Patil, R; Phule, D; Shelar, A, 2017)	1.48
"Moxifloxacin caused an increase in the QTcI, with a lower bound of the 2-sided 95% CI always higher than 5 milliseconds, around the tmax of peak concentration, demonstrating assay sensitivity."	( Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. Falcão, A; Homery, MC; l'Hostis, P; Nunes, T; Patat, A; Pinto, R; Rocha, JF; Soares-da-Silva, P, 2015)	1.14

Excerpt	Reference	Relevance
"With moxifloxacin treatment, the mean (SD) time to improvement of symptoms was 3.0 (1.5), 3.4 (1.6) and 3.2 (1.5) days, and the time to resolution of symptoms was 4.8 (2.6) days, 5.7 (2.4) days and 5.5 (2.5) days, in the Asia Pacific, Europe and Middle East regions, respectively."	( Characterisation of patients receiving moxifloxacin for acute bacterial rhinosinusitis in clinical practice: results from an international, observational cohort study. Arvis, P; Desrosiers, M; Heldner, S; Mösges, R, 2013)	1.11
"Moxifloxacin-treated mice developed less pulmonary vascular permeability during pneumonia, but neither combination therapy with moxifloxacin and ampicillin in vivo nor examination of endothelial monolayer integrity in vitro supported direct barrier-stabilizing effects of moxifloxacin."	( Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia. Berg, J; Gruber, AD; Gutbier, B; Hellwig, K; Hippenstiel, S; Hocke, AC; Kershaw, O; Mayer, K; Müller-Redetzky, HC; Neudecker, J; Opitz, B; Rückert, J; Suttorp, N; Wienhold, SM; Witzenrath, M, 2015)	2.58
"Moxifloxacin-treated subjects (n = 4) were PCR negative within 1 week."	( Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women. Enger, M; Falk, L; Jensen, JS, 2015)	1.14
"moxifloxacin treatment were estimated after adjusting for pre-treatment demographics, health care resource use and pneumonia-specific risk factors using propensity score and exact factor matching."	( Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. Fisher, AC; Grant, R; Gu, A; Mody, SH; Ng, D; Raut, M; Schein, J; Sengupta, A; Sheng Duh, M; Signorovitch, JE, 2010)	1.31
"Moxifloxacin treatment was not associated with consistent changes in moxifloxacin susceptibility."	( Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Jones, PW; Miravitlles, M; Rubinstein, E; Sethi, S; Theron, MS; Wedzicha, JA; Wilson, R, 2010)	1.54
"Moxifloxacin treatment, on the other hand, exhibited a superior anti-biofilm activity and resulted in a 2.5- and 3.7-log reduction in the MRSA and MRSE bacterial bioburdens, respectively, after 24 h of exposure."	( Pharmacodynamics of moxifloxacin versus vancomycin against biofilms of methicillin-resistant Staphylococcus aureus and epidermidis in an in vitro model. Ahmed, GF; Elkhatib, WF; Noreddin, AM; Salem, AH, 2010)	1.41
"In moxifloxacin-treated rats, an increase in the EDHF response was observed, which was largely attributed to SK(Ca)-activation."	( The effect of levofloxacin and moxifloxacin on cardiovascular functions of rats with streptozotocin-induced diabetes. Absi, M; Ghareeb, H; Khalil, A; Ruegg, UT, 2013)	1.19
"Moxifloxacin treatment was associated with an improvement in survival in the SB animals (13 of 13 [100%] vs. "	( The impact of mechanical ventilation on the moxifloxacin treatment of experimental pneumonia caused by Streptococcus pneumoniae. Charles, PE; Chavanet, P; Croisier, D; Etienne, M; Lequeu, C; Piroth, L; Portier, H; Pugin, J, 2005)	2.03
"All moxifloxacin treatment regimens were well tolerated. "	( Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Borner, K; Burkhardt, O; Stass, H; Thuss, U; Welte, T, 2005)	1.13
"In moxifloxacin-treated mice, 75% survived infection compared to 10% of controls."	( Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice. Gyssens, IC; Kullberg, BJ; Stearne, LE; Vonk, AG, 2005)	0.84
"One moxifloxacin-treated patient had sustained monomorphic VT (> 30 s), and one levofloxacin-treated patient had torsade de pointes."	( A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS, 2005)	1.05
"Moxifloxacin treatment protocols were significantly more effective on both ITT and PP analyses than the clarithromycin based protocols with only one exception (MAL vs."	( High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Bago, J; Bago, P; Marusić, M; Rozankovic, M; Tomic, M; Vcev, A, 2007)	1.33
"Moxifloxacin treatment resulted in culture-negative vegetations in a total of 20 of 21 (95%) rats infected with P8, 10 of 11 (91%) rats infected with COL, and 19 of 24 (79%) rats infected with P8-4 (P < 0.05 compared to the results for the controls)."	( Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Entenza, JM; Glauser, MP; Moreillon, P; Que, YA; Vouillamoz, J, 2001)	1.39
"Treatment with moxifloxacin was associated with rapid relief in symptoms, with 93.2% of patients experiencing either complete resolution of symptoms or improvement at follow-up."	( Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study. Arvis, P; Bogner, JR; Esguerra-Alcalen, M; Heldner, S; Kutaiman, A, 2013)	2.17
"Eyes treated with moxifloxacin or moxifloxacin alternative formulation contained significantly fewer CFUs than untreated controls or besifloxacin-treated eyes with either treatment (P≤.0020)."	( Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections. Balzli, CL; Caballero, AR; O'Callaghan, RJ; Tang, A; Weeks, AC, 2010)	0.68
"Eyes treated with moxifloxacin/cholesterol had a significantly lower mean slit lamp examination (SLE) score than eyes treated with phosphate-buffered saline (PBS), moxifloxacin alone, or cholesterol alone (P ≤ 0.02). "	( Moxifloxacin and cholesterol combined treatment of pneumococcal keratitis. King, LB; Marquart, ME; Norcross, EW; Sanders, ME; Taylor, SD; Tolo, I; Tullos, NA, 2010)	2.14
"Treatment with moxifloxacin resulted in savings of 266 euro and 381 euro for Germany and France respectively, primarily due to the shorter length of hospital stay."	( An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Becker, DL; Chancellor, JV; Drummond, MF; Duprat-Lomon, I; Hux, M; Kubin, R; Sagnier, PP, 2003)	0.92
"Eyes treated with moxifloxacin healed faster and had smaller defects compared with those treated with gatifloxacin. "	( The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. Bower, KS; Burka, JM; Howard, RS; Kuzmowych, CP; Stutzman, RD; Vanroekel, RC, 2005)	0.9
"Treatment with moxifloxacin resulted in significant and sustained improvement."	( Treatment of ankylosing spondylitis with moxifloxacin. Ogrendik, M, 2007)	0.95

Excerpt	Reference	Relevance
" Safety and tolerability were assessed by evaluation of vital signs, electrocardiograms, electroencephalograms, clinical chemistry parameters, results of urinalysis, and adverse events."	( Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Dalhoff, A; Kubitza, D; Schühly, U; Stass, H, 1998)	0.53
" adverse effects on the central nervous and cardiovascular systems, phototoxicity, arthrotoxicity and oculotoxicity."	( Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. Schlüter, G; von Keutz, E, 1999)	0.58
" There were slightly more adverse events in the moxifloxacin group than in the cefuroxime axetil group, but there were fewer serious adverse events following moxifloxacin treatment (three vs."	( A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Bagger-Sjöbäck, D; Gehanno, P; Hampel, B; Ibanez, JM; Nikolaidis, P; Siegert, R; Sommerauer, B, 2000)	0.83
" Reported adverse effects were primarily gastrointestinal (nausea, diarrhea) and were mild to moderate in severity."	( Moxifloxacin: clinical efficacy and safety. Culley, CM; Edwards, B; Klutman, N; Lacy, MK, 2001)	1.75
" The adverse event profile was comparable between the three treatment groups."	( The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Hoeffken, G; Meyer, HP; Verhoef, L; Winter, J, 2001)	0.59
" There was a low incidence of adverse events (10."	( Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). Casali, L; Curti, E; Grassi, C; Lazzaro, C; Schito, G; Tellarini, M, 2002)	0.58
" Trovafloxacin recipients were also more than twice as likely to discontinue treatment due to adverse events than moxifloxacin-treated patients."	( Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. Arvis, P; Klossek, JM; Leberre, MA; Nikolaidis, P; Siegert, R, 2003)	0.8
"The established safety profile of the fluoroquinolones has been disrupted in the past decade by the detection of low-frequency but potentially serious adverse events that have led to the license suspension, voluntary withdrawal, or restricted use of specific members of the class."	( Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Ball, P; Choudhri, S; Kubin, R; Owens, R; Stahlmann, R, 2004)	0.59
" Overall treatment-emergent adverse events for both drugs (mostly gastrointestinal) were mild to moderate in intensity."	( Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Ferguson, BJ; Guzzetta, RV; Hadley, JA; Spector, SL, 2004)	0.56
" Drug-related adverse events occurred in 18."	( Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. Choudhri, S; Fogarty, CM; Hamed, K; Katz, E; Larsen, LS; Song, J, 2004)	0.58
" The primary endpoints included rates of treatment-emergent adverse events (all adverse events regardless of causality), drug-related adverse events, drug-related serious adverse events, deaths and premature discontinuations because of a treatment-emergent adverse event."	( Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Andriole, VT; Choudhri, SH; Haverstock, DC, 2005)	0.58
"Drug-related adverse event rates associated with oral moxifloxacin or the comparator therapy used in these studies did not significantly increase with advancing age."	( Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Andriole, VT; Choudhri, SH; Haverstock, DC, 2005)	0.83
" Safety evaluations included 72 h of digital continuous 12-lead Holter monitoring, 12-lead ECGs at baseline and at maximum serum concentration on day 3, and adverse events."	( A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS, 2005)	0.57
" There were no statistically significant differences between the treatment groups with regard to drug-related adverse events."	( Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI, 2006)	0.56
"Intravenous/oral moxifloxacin therapy was efficacious and safe for hospitalized elderly patients with CAP, achieving > 90% cure in all severity and age subgroups, and was associated with faster clinical recovery than intravenous/oral levofloxacin therapy, with a comparable safety profile."	( Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI, 2006)	0.9
" These results indicate that moxifloxacin is a safe intravitreal antibiotic in mouse and rabbit animal models."	( Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Gao, H; Holz, ER; Iyer, MN; Mieler, WF; Pennesi, ME; Qiao, X; Wu, SM, 2006)	0.99
" In addition, both drugs were well-tolerated in this trial, with the number of drug-related adverse events being comparable."	( Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. Liu, H; Liu, J; Xiong, S; Xiong, W; Xu, S; Xu, Y; Zhao, J, 2006)	0.61
"Moxifloxacin (250 microg/mL) seems to be safe as an additive agent for cornea storage media."	( Efficacy and safety of moxifloxacin as an additive in Optisol-GS a preservation medium for corneal donor tissue. Dahl, P; Hu, DN; Koplin, RS; McCormick, S; Meskin, SW; Ritterband, DC; Seedor, JA; Shah, MK; Shao, S; Shapiro, DE, 2006)	2.09
" The incidence of at least one treatment-related adverse event (AE) in the azithromycin and moxifloxacin groups was 18."	( Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Amsden, GW; Martinez, FJ; Rothermel, CD; Treadway, G; Zervos, M, 2007)	0.81
"Review of data from fluoroquinolone studies, with an emphasis on the associated rare, but potentially clinically important, adverse events in specific patient populations."	( The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Iannini, PB, 2007)	0.65
"A literature search was conducted using terms including fluoroquinolones, moxifloxacin, ciprofloxacin, levofloxacin, gatifloxacin, gemifloxacin, safety, adverse events, drug interactions, and pharmacokinetic parameters to identify literature providing information regarding the safety profile of specified fluoroquinolones in special patient populations (i."	( The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Iannini, PB, 2007)	0.89
"Fluoroquinolones, are associated with rare, but clinically important, adverse events in special patient populations (including the elderly; those with hepatic, renal, or glycemic disorders; and those at risk for cardiovascular events)."	( The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Iannini, PB, 2007)	0.65
"In vitro cell cultures are useful for evaluating cell response to potentially toxic insults, although cell cultures may lack tissue components that may prevent or ameliorate damage in vivo."	( Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells. Bezwada, P; Clark, LA; Schneider, S, 2008)	0.35
" Possible toxic effects and median inhibitory concentration were evaluated after 24 hours as well as under conditions of oxidative stress."	( In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. Kampik, A; Kernt, M; Neubauer, AS; Ulbig, MW; Welge-Lüssen, U, 2008)	0.63
"At concentrations higher than 150 microg/mL, moxifloxacin had adverse effects on primary RPE, ARPE19, and ONHA cell proliferation and viability."	( In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. Kampik, A; Kernt, M; Neubauer, AS; Ulbig, MW; Welge-Lüssen, U, 2008)	0.89
" Intravitreal use of moxifloxacin up to this concentration may be safe and effective for the treatment of endophthalmitis."	( In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. Kampik, A; Kernt, M; Neubauer, AS; Ulbig, MW; Welge-Lüssen, U, 2008)	0.95
" There are also concerns that there is currently no safe alternative to ciprofloxacin for patients with a nonintact eardrum."	( Ototoxicity of topical moxifloxacin in a chinchilla animal model. Akache, F; Daniel, SJ; Duval, M; Sahmkow, S, 2007)	0.65
" No drug-related adverse effects were reported."	( Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. Arbisser, LB, 2008)	0.66
" No study-related adverse events occurred."	( Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. Belani, S; Lane, SS; Masket, S; Osher, RH, 2008)	0.59
"050 mL intracameral injection of moxifloxacin, which appears to be safe in the prophylaxis of endophthalmitis after cataract surgery."	( Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. Belani, S; Lane, SS; Masket, S; Osher, RH, 2008)	0.88
"Earlier this year, a 'Dear Doctor' letter was sent to Dutch health care professionals, describing the rare occurrence of fulminant hepatitis and the Stevens-Johnson syndrome or toxic epidermal necrolysis in patients using moxifloxacin."	( [Novel side effects of moxifloxacin: making a balanced decision again]. Koopmans, RP; Prins, JM, 2008)	0.84
" Computed tomography revealed interstitial lung fibrosis which was attributed to the toxic effects of nitrofurantoin (50 mg/d) that the patient used for approximately one year for recurrent urinary tract infection."	( [Unwanted side effects of antibacterials--a diagnostic challenge]. Fux, R; Gleiter, CH; Mörike, K, 2008)	0.35
" Global analysis did not reveal significantly higher incidences of drug-related adverse effects than for comparators."	( Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Tulkens, PM; Van Bambeke, F, 2009)	0.61
" It is safe and effective for systemic and topical use, but only limited data are available on prophylactic intracameral administration to prevent endophthalmitis."	( Intracameral moxifloxacin: in vitro safety on human ocular cells. A, AK; Alge, CS; Eibl, KH; Kernt, M; Lackerbauer, CA; Liegl, RG; Neubauer, AS; Ulbig, MW, 2009)	0.72
" Possible toxic effects of moxifloxacin (10-750 microg/mL) in corneal endothelial cells (CEC), primary human trabecular meshwork cells (TMC), and primary human retinal pigment epithelial (RPE) cells were evaluated after 24 hours and under conditions of oxidative and inflammatory stress by treatment with tumor necrosis factor alpha, lipopolysaccharides, or interleukin-6."	( Intracameral moxifloxacin: in vitro safety on human ocular cells. A, AK; Alge, CS; Eibl, KH; Kernt, M; Lackerbauer, CA; Liegl, RG; Neubauer, AS; Ulbig, MW, 2009)	1.02
" The cumulative frequency of ocular adverse events was similar between treatments (12% and 14% with besifloxacin and moxifloxacin, respectively)."	( Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Brunner, LS; Comstock, TL; Haas, W; McDonald, MB; Morris, TW; Paterno, MR; Protzko, EE; Usner, DW, 2009)	0.79
" It is safe and effective for systemic and topical use; however, only very limited data are available on prophylactic intracameral administration to prevent endophthalmitis."	( [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application]. de Kaspar, H; Eibl, KH; Hirneiss, C; Kampik, A; Kernt, M; Liegl, RG; Neubauer, AS; Ulbig, MW; Wolf, A, 2010)	0.72
" Toxic effects were evaluated after 24 h (MTT assay and live-dead assay)."	( [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application]. de Kaspar, H; Eibl, KH; Hirneiss, C; Kampik, A; Kernt, M; Liegl, RG; Neubauer, AS; Ulbig, MW; Wolf, A, 2010)	0.72
" Primary RPEs, TMCs, LECs, and CECs showed adverse effects on proliferation and viability only at concentrations higher than 150 microg/ml moxifloxacin."	( [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application]. de Kaspar, H; Eibl, KH; Hirneiss, C; Kampik, A; Kernt, M; Liegl, RG; Neubauer, AS; Ulbig, MW; Wolf, A, 2010)	0.92
" Therefore, intracameral use of Vigamox at concentrations up to 150 microg/ml may be safe and effective for preventing endophthalmitis after intraocular surgery."	( [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application]. de Kaspar, H; Eibl, KH; Hirneiss, C; Kampik, A; Kernt, M; Liegl, RG; Neubauer, AS; Ulbig, MW; Wolf, A, 2010)	0.72
" Adverse event rates were comparable between treatment groups."	( Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Amábile-Cuevas, CF; Arvis, P; Bogner, JR; Cruz-Alcázar, J; Hernández-Oliva, G; Reimnitz, P; Vick-Fragoso, R, 2009)	0.6
" Fampridine was well tolerated, with a higher frequency of adverse events at the supratherapeutic dose."	( Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals. Cardi, T; March, B, 2009)	0.35
" Besifloxacin was well tolerated, with similar incidences of adverse events in the besifloxacin, vehicle, and moxifloxacin groups."	( Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Comstock, TL; Paterno, MR; Pichichero, ME; Usner, DW, 2010)	0.57
"6% was shown to be safe and effective for the treatment of bacterial conjunctivitis in children and adolescents aged 1-17 years."	( Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Comstock, TL; Paterno, MR; Pichichero, ME; Usner, DW, 2010)	0.36
"4 mm at 6 weeks and 3 months and any adverse events were determined."	( Efficacy and safety of adjunctive local moxifloxacin delivery in the treatment of periodontitis. Beikler, T; Flemmig, TF; Gravemeier, M; Mross, D; Petersilka, G; Prior, K; Völp, A; Yamamoto, J; Zilly, M, 2011)	0.64
" No correlation or systematic relationship between adverse events, including bacterial resistance against moxifloxacin, and the investigational gels was found."	( Efficacy and safety of adjunctive local moxifloxacin delivery in the treatment of periodontitis. Beikler, T; Flemmig, TF; Gravemeier, M; Mross, D; Petersilka, G; Prior, K; Völp, A; Yamamoto, J; Zilly, M, 2011)	0.85
" Rates of adverse events were lower in moxifloxacin- than in clindamycin-treated patients."	( Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial. Böger, RH; Cachovan, G; Giersdorf, I; Haddad, M; Hallier, O; Platzer, U; Schön, G; Sobottka, I; Streichert, T; Wegscheider, K, 2011)	0.92
" Two patients (11%) experienced three adverse effects [one nausea, another increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], but the events were not serious."	( Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. Fukano, H; Hara, H; Kawanishi, M; Kimura, M; Kishimoto, M; Matsushima, T; Moriya, O; Niki, Y; Okimoto, N; Yoneyama, H; Yoshida, K, 2011)	0.68
" There was no difference in adverse events or toxicities between the groups."	( Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. Arenz, D; Böll, B; Bredenfeld, H; Chemnitz, J; Cornely, OA; Cremer, B; Hallek, M; Kaul, I; Klein, F; Mahne, M; Moritz, G; Scheid, C; Vehreschild, JJ; Vehreschild, MJ; Wassmer, G, 2012)	0.69
" No study-related adverse events were noted."	( Safety of prophylactic intracameral moxifloxacin use in cataract surgery. Aslan, BS; Ekinci Koktekir, B, 2012)	0.65
"050 mL intracameral injection of moxifloxacin, which appears to be safe in the prophylaxis of endophthalmitis after cataract surgery."	( Safety of prophylactic intracameral moxifloxacin use in cataract surgery. Aslan, BS; Ekinci Koktekir, B, 2012)	0.94
"Treatments that offer two medications in a fixed combination have the potential to offer efficacious and safe treatment with advantages such as a regimen that is simpler than administering two separate solutions."	( Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis. Bartell, J; Belfort, R; Bell, B; Clark, L; Gabriel, L; Höfling-Lima, AL; Martins Bispo, PJ; Muccioli, C; Stroman, DW; Zacharias Serapicos, PC, 2012)	0.69
" Both regimens were safe and well tolerated."	( Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis. Bartell, J; Belfort, R; Bell, B; Clark, L; Gabriel, L; Höfling-Lima, AL; Martins Bispo, PJ; Muccioli, C; Stroman, DW; Zacharias Serapicos, PC, 2012)	0.69
"Crude incidences and relative risk estimates (Mantel-Haenszel analysis) of patients with any adverse event (AE), adverse drug reaction (ADR), serious AE (SAE), serious ADR (SADR), treatment discontinuation due to an AE or ADR, and fatal outcomes related to an AE or ADR."	( Moxifloxacin safety: an analysis of 14 years of clinical data. Arvis, P; Kruesmann, F; Tulkens, PM, 2012)	1.82
" Vigamox(®) containing moxifloxacin and Tosuflo(®) containing tosufloxacin were more toxic when compared with the other antibiotics."	( In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines. Ayaki, M; Iwasawa, A; Niwano, Y, 2012)	0.69
" Treatment-emergent cardiac adverse event (AE) rates were similar for moxifloxacin and comparators in PO (6."	( Update on the cardiac safety of moxifloxacin. Arvis, P; Fritsch, A; Haverkamp, W; Kruesmann, F; van Veenhuyzen, D, 2012)	0.9
" A similar proportion of patients (ITT population) experienced any adverse events in both treatment groups (MXF: 30."	( Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC, 2013)	0.68
"3%) patients had treatment-emergent adverse events (TEAEs) and 4 (0."	( Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). Chuchalin, A; Dokic, D; Marschall, HP; Petri, T; Tokić, M; Zakharova, M, 2013)	0.7
"Peroperative intracameral moxifloxacin injection for endophthalmitis prophylaxis is a safe and effective method in uncomplicated phacoemulsification surgery."	( Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model. Akova, YA; Asena, L; Bozkurt, A; Demiralay, E; Goktaş, MT; Karabay, G; Yaşar, U, 2013)	0.93
" QTcI was not affected by plasma concentrations of cangrelor metabolites, and cangrelor had no other adverse effects on electrocardiographic parameters."	( Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. Bellibas, SE; Green, CL; Krucoff, MW; Lambe, L; Prats, J; Whellan, DJ; Wijngaard, P, 2013)	0.6
" MFLX is effective and safe in patients with NHCAP."	( [Efficacy and safety of moxifloxacin in patients with nursing and healthcare-associated pneumonia]. Akata, K; Awaya, Y; Choujin, Y; Inoue, N; Ishimoto, H; Kawajiri, T; Kawanami, Y; Kawanaml, T; Mukae, H; Nagata, S; Nishida, C; Noguchi, S; Obata, H; Ogoshi, T; Orihashi, T; Suzuki, Y; Taura, Y; Tokuyama, S; Yamasaki, K; Yatera, K; Yoshida, Y; Yoshii, C, 2013)	0.7
" The primary safety endpoint was the incidence of treatment-emergent adverse events (TEAEs)."	( Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients. Clinch, TE; Majmudar, PA, 2014)	0.4
" Our study aimed to assess whether moxifloxacin in comparison to levofloxacin plus metronidazole are effective and safe in the treatment of community-acquired pneumonia with aspiration factors."	( Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Li, F; Liu, Y; Pu, C; Ren, X; Ren, Y; Sui, DJ; Sun, L; Sun, T; Wang, R; Yang, Z, 2014)	0.96
" The overall adverse event rate was 10."	( Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Li, F; Liu, Y; Pu, C; Ren, X; Ren, Y; Sui, DJ; Sun, L; Sun, T; Wang, R; Yang, Z, 2014)	0.69
"Moxifloxacin is effective and safe for treatment of community-acquired pneumonia with aspiration factors."	( Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Li, F; Liu, Y; Pu, C; Ren, X; Ren, Y; Sui, DJ; Sun, L; Sun, T; Wang, R; Yang, Z, 2014)	2.13
" The proportion of patients experiencing any treatment-emergent adverse events was slightly higher with moxifloxacin (67."	( Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials. Alder, J; Arvis, P; De Waele, JJ; Hussain, T; Kruesmann, F; Solomkin, JS; Tellado, JM; Weiss, G, 2014)	0.93
"9%) patients had treatment-emergent adverse events (TEAEs) and 40 (1."	( Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). Bezlepko, A; Iudina, L; Kondova Topuzovska, I; Kuzman, I; Marschall, HP; Petri, T; Rókusz, L, 2014)	0.71
"In the present study, there was no adverse effect associated with intracameral injection of 150-500 μg/mL MFLX."	( Safety of intracameral injection of moxifloxacin using total replacement technique (bag and chamber flushing). Gotou, T; Inoue, Y; Matsuura, K; Odawara, S; Sasaki, S; Suto, C, 2014)	0.68
" Except in 1 child with hepatotoxicity, all adverse effects were mild and nonpersistent."	( Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Castel, S; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Schaaf, HS; Thee, S; Wiesner, L, 2015)	0.7
" It highlights available intracameral antibiotics with respect to pharmacology, spectrum of activity, dosage and preparation, safety, and efficacy profiles, as well as toxic anterior segment syndrome risks to better define the potential use of these medications in the prevention of endophthalmitis."	( Intracameral antibiotics: Safety, efficacy, and preparation. Braga-Mele, R; Chang, DF; Henderson, BA; Mamalis, N; Talley-Rostov, A; Vasavada, A, 2014)	0.4
" The results also inspired us to think about a "supplementary regimen" to increase safety and decrease the adverse effect in the treatment of corneal infections."	( The effect of resveratrol on protecting corneal epithelial cells from cytotoxicity caused by moxifloxacin and benzalkonium chloride. Chen, RH; Chen, TC; Hu, FR; Su, MJ; Tsai, TH; Tsai, TY; Wang, IJ; Yeh, CY, 2015)	0.64
" We also assessed safety and tolerability by monitoring adverse events."	( Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F, 2015)	0.68
" Frequencies of adverse events were similar to standard treatment in all groups."	( Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F, 2015)	0.68
" Safety was assessed by the incidence of ocular and nonocular treatment-emergent adverse events (AEs), changes in visual acuity, and biomicroscopy and ophthalmoscopy findings."	( Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution. Comstock, TL; Garg, P; Mathur, U; Morris, TW; Sony, P; Tandon, R, )	0.35
"5 % moxifloxacin can be safely injected intracamerally following cataract surgery without additional postoperative antibiotic prophylaxis to prevent endophthalmitis without adverse effects on patient outcomes."	( Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery. Ambati, BK; Messenger, WB; Sargent, S; Zhou, AX, 2016)	1.27
" 43 (10%) of 155 treatment-emergent adverse events in the solithromycin group and 54 (13%) of 154 such events in the moxifloxacin group were deemed to be related to study drug."	( Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Antonovsky, Y; Barrera, CM; Clark, K; Das, AF; Doreski, PA; Fernandes, P; Flores-Figueroa, J; Horwith, G; Jamieson, B; Karimjee, N; Keedy, K; Metev, H; Mitha, I; Molina, JM; Mykietiuk, A; Nitu, MF; Oldach, D; Rewerska, B; Rowe, BH; Scott, D; Sheets, A; Tanaseanu, CM; Van Rensburg, DJ, 2016)	0.89
" Mostly mild/moderate infusion events led to higher incidence of adverse events overall in the solithromycin group."	( SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. Das, AF; Fernandes, P; File, TM; Gonong, JRV; Jamieson, BD; Keedy, K; Oldach, D; Rewerska, B; Sheets, A; Taylor, D; Vucinic-Mihailovic, V, 2016)	0.63
" Efficacy (by intention to treat) was analyzed using the inverse variance method; safety data were recorded as the occurrence of any adverse event."	( Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Gisbert, JP; Marin, AC; McNicholl, AG; Nyssen, OP, 2017)	0.46
"989), demonstrating that adding moxifloxacin to the recommended regimen does not cause more adverse events during TB treatment."	( Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis. Chen, H; Chen, S; Wang, F; Wu, M; Xu, J; Xu, P; Zhu, X, 2017)	2.18
"Current practice methods are unclear as to the most safe and effective prophylactic pharmacotherapy and method of delivery to reduce postoperative endophthalmitis occurrence."	( Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis. Ambati, BK; Bardsley, T; Bondalapati, S; Bowen, RC; Evans, PR; Greene, T; Kliethermes, M; Lawyer, TW; Mamalis, CA; McFarland, M; Rudnisky, CJ; Shi, D; Snow, KB; Zhou, AX, 2018)	0.71
" Although rare, vancomycin was associated with toxic retinal events."	( Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis. Ambati, BK; Bardsley, T; Bondalapati, S; Bowen, RC; Evans, PR; Greene, T; Kliethermes, M; Lawyer, TW; Mamalis, CA; McFarland, M; Rudnisky, CJ; Shi, D; Snow, KB; Zhou, AX, 2018)	0.71
" Safety variables included adverse events (AEs), lisamine green, fluorescein ocular surface stains, and clinical signs of tolerability."	( Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. Baiza-Durán, L; Casillas-Magallanes, M; Gómez-Bastar, PA; González-Lomelí, M; Lizárraga-Corona, A; Mercado-Sesma, AR; Montoya-Sánchez, IM; Mora-González, A; Ochoa-Tabares, JC; Olvera-Montaño, O; Oregon-Miranda, AA; Orozco-Carroll, M; Páez-Garza, JH; Pérez-Balbuena, AL; Sandoval-Delgadillo, LI; Saucedo-Rodríguez, LR; Villanueva-Najera, MA, 2018)	0.72
" Patient demographics, clinical characteristics, indication for moxifloxacin use, and adverse events (AEs) were extracted via chart review."	( Safety and Tolerability of Moxifloxacin in Children. Dixit, A; Jones, S; Karandikar, MV; Nakamura, MM, 2018)	1.02
"All grade 3 & 4 adverse events (AEs) and their relationship to treatment for patients who had taken at least one dose of therapy in the REMoxTB clinical trial were recorded."	( Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. Amukoye, EI; Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; McHugh, TD; Mendel, CM; Meredith, SK; Murphy, ME; Murthy, SE; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD; Wills, GH, 2018)	0.48
" The most common adverse events on standard therapy related to hepatobiliary, musculoskeletal and metabolic disorders."	( Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. Amukoye, EI; Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; McHugh, TD; Mendel, CM; Meredith, SK; Murphy, ME; Murthy, SE; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD; Wills, GH, 2018)	0.48
" There were few differences in the frequency of adverse effects between the two groups."	( Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy. Asano, Y; Kashiwagi, S; Nagayama, K; Noda, S; Ogawa, K; Ohira, M; Onoda, N; Takahashi, K; Takahashi, M; Takashima, T, 2019)	0.74
" Adverse events related to moxifloxacin were mild or moderate in intensity and showed no correlation with increased weight-adjusted doses."	( Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study. Arrieta, AC; Bradley, JS; James, LP; Lettieri, J; Stass, H; Sullivan, JE; Vanevski, KM; Willmann, S, 2019)	1.04
" No ocular or systemic study-related adverse events were observed."	( Safety and efficacy of intracameral moxifloxacin for prevention of post-cataract endophthalmitis: Randomized controlled clinical trial. Alves, M; Assis Filho, HL; Cardoso da Silva, I; Cavalcanti Lira, RP; Dias Freire, LM; Ferreira, BG; Leite Arieta, CE; Martini, AAF; Melega, MV; Pedreira Chaves, FR; Reis, RD, 2019)	0.79
"Lefamulin was noninferior to moxifloxacin for the primary efficacy endpoints and was generally safe and well tolerated."	( Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Das, A; File, TM; Gasink, LB; Gelone, SP; Goldberg, L; Paukner, S; Saviski, J; Seltzer, E; Sweeney, C; Talbot, GH; Wicha, WW, 2019)	0.81
" We aimed to examine fluoroquinolone (ciprofloxacin, levofloxacin and moxifloxacin) associated aortic aneurysm or dissection through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS)."	( Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system. Huang, H; Huang, J; Jia, Y; Meng, L; Qiu, F; Sun, S, 2019)	0.75
" Pharmacovigilance tools were used for quantitative detection of signals that is, drug-associated adverse events, including reporting odds ratio, proportional reporting ratio, information component given by a Bayesian confidence propagation neural network and empirical Bayes geometric mean."	( Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system. Huang, H; Huang, J; Jia, Y; Meng, L; Qiu, F; Sun, S, 2019)	0.51
"Based on 3721 adverse event reports, all three fluoroquinolones are associated with aortic aneurysm, and levofloxacin is associated with aortic dissection."	( Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system. Huang, H; Huang, J; Jia, Y; Meng, L; Qiu, F; Sun, S, 2019)	0.51
" Patients were followed up for sputum smear and culture conversion and adverse events during the treatment."	( Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V, 2019)	0.51
" 29 adverse events (AE) were reported among 17 patients and there were 11 deaths."	( Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V, 2019)	0.51
"BDQ and DLM given together in a salvage regimen is efficacious with low rate of adverse events."	( Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V, 2019)	0.51
" Pooled safety data across both studies suggested that the safety profile of odanacatib at high exposures was similar to placebo, with a small clustering of oral cavity adverse events."	( Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects. Brandquist, C; Chakravarthy, M; Gutierrez, M; Liu, C; Liu, F; Mahon, C; McCrea, J; Mostoller, K; Panebianco, D; Stoch, SA; Zajic, S, 2019)	0.51
" The use of IC-Mox (250 μg) for endophthalmitis prophylaxis appears to be safe in the pediatric population."	( Safety of intracameral moxifloxacin in the pediatric population: an equivalence study. Ali, A; Imtirat, A; Khalili, S; Mireskandari, K; Tehrani, N; Williams, S, 2020)	0.87
"This meta-analysis revealed that the addition of moxifloxacin to the recommended regimen significantly improved the rate of treatment success in the treatment of MDR-TB, with no additional adverse moxifloxacin events."	( Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults. Guan, Y; Liu, Y, 2020)	1.07
" Safety evaluations included treatment-emergent adverse events and laboratory measures."	( Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial. Chitra, S; McGovern, P; Pai, MP; Wilcox, M, 2021)	0.62
" Common adverse effects are gastrointestinal symptoms, headache, dizziness, etc."	( Moxifloxacin-induced oral erythema multiforme: An unusual adverse effect hitherto unreported. Das, S; Mallick, S; Rudra, O; Sharma, S, )	1.57
"Quinolones comprise a class of antibiotics that are globally preferred for treating a wide range of bacterial infections due to their potency, broad coverage, favorable pharmacologic profile, and mostly mild to moderate adverse reactions."	( Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system. Alami, A; Bjerre, LM; Gravel, CA; Krewski, D; Mattison, D; Momoli, F; Taher, MK; Tsui, D, 2022)	0.72
" The outcomes of interest were culture conversion and incidence of adverse events."	( Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis. Beraldi-Magalhães, F; Fernandez-Llimos, F; Imazu, P; Pontarolo, R; Santos, JM; Tonin, FS, 2022)	0.72
" The use of rifapentine 450 mg instead of rifampicin in the standard regimen demonstrated to be statistically safer than all other options for serious adverse events (e."	( Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis. Beraldi-Magalhães, F; Fernandez-Llimos, F; Imazu, P; Pontarolo, R; Santos, JM; Tonin, FS, 2022)	0.72
"The WHO standard regimen remains an overall effective and safe alternative for DS-TB."	( Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis. Beraldi-Magalhães, F; Fernandez-Llimos, F; Imazu, P; Pontarolo, R; Santos, JM; Tonin, FS, 2022)	0.72
" All adverse events were mild to moderate in severity, and no deaths occurred."	( A Randomized, Double-Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers. Franklin, H; Israel, RJ; Lee, J; Lester, R; Lowe, ER; O'Reilly, T; Slatkin, NE, 2023)	0.91
"Dropless cataract regime was found to be an effective and safe alternative that was easy to administer."	( Efficacy and safety of intravitreal injection of triamcinolone-moxifloxacin after cataract surgery in a low to middle income country - a one-year audit. Jeeva, IK; Masud, S; Siddiqui, MAR, 2023)	1.15
" A multidisciplinary team reviewed all adverse events and determined their relationship with moxifloxacin."	( Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia. He, YS; Ji, J; Liu, G; Qian, SY; Yang, M, 2023)	1.48
" As for the adverse events, 11 patients in moxifloxacin group were deemed to be doubtfully related and one possibly related to moxifloxacin; in the azithromycin group, four patients were regarded to be doubtfully related to azithromycin and one not related."	( Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia. He, YS; Ji, J; Liu, G; Qian, SY; Yang, M, 2023)	1.52
"Moxifloxacin was well tolerated and safe for treating SRMPP in children."	( Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia. He, YS; Ji, J; Liu, G; Qian, SY; Yang, M, 2023)	2.7
"Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis."	( A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxaci Aarnoutse, R; Boeree, M; Cho, YL; Dierig, A; Geiter, L; Gong, X; Heinrich, N; Hoelscher, M; Hoffmann, L; Jarchow-MacDonald, A; Liyoyo, A; Mbeya, B; McHugh, TD; Mhimbira, FA; Minja, LT; Mpagama, S; Ntinginya, N; Phillips, P; Rassool, M; Schultz, S; Sebe, M; Svensson, EM; Te Brake, L; Wallis, RS; Wildner, LM, 2023)	0.91
"DECODE is an innovative dose-finding trial, designed to support exposure-response modelling for safe and effective dose selection."	( A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxaci Aarnoutse, R; Boeree, M; Cho, YL; Dierig, A; Geiter, L; Gong, X; Heinrich, N; Hoelscher, M; Hoffmann, L; Jarchow-MacDonald, A; Liyoyo, A; Mbeya, B; McHugh, TD; Mhimbira, FA; Minja, LT; Mpagama, S; Ntinginya, N; Phillips, P; Rassool, M; Schultz, S; Sebe, M; Svensson, EM; Te Brake, L; Wallis, RS; Wildner, LM, 2023)	0.91

Excerpt	Reference	Relevance
" The pharmacodynamic data demonstrated that BAY 12-8039 has marked activity against gram-positive and gram-negative organisms (under both anaerobic and aerobic conditions) and anaerobes."	( Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Andrews, JM; Boswell, FJ; Wise, R, 1997)	0.3
" Within 4 to 5 h they fell to about 30 to 55% of the Cmax, and thereafter a terminal half-life of 11 to 14 h accounted for the major part of the area under the concentration-time curve (AUC)."	( Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Dalhoff, A; Kubitza, D; Schühly, U; Stass, H, 1998)	0.53
" The plasma concentration vs time courses of the unchanged compound (determined by HPLC) and the derived pharmacokinetic parameters were used to evaluate the absorption process, to compare the pharmacokinetics in these species and to perform an interspecies scaling."	( Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. Domdey-Bette, A; Henninger, K; Hucke, F; Kohlsdorfer, C; Siefert, HM; Stass, HH, 1999)	0.56
" The AUC for both formulations was comparable with bioequivalence criteria fulfilled, with Cmax after oral treatment approximately 31% lower."	( Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. Kubitza, D; Stass, H, 1999)	0.58
" Standard pharmacokinetic parameters were estimated by noncompartmental methods."	( Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Agarwal, V; Heller, AH; Krol, GJ; Leese, PT; Lettieri, J; Sullivan, JT; Watson, S; Woodruff, M, 1999)	0.56
" The pharmacodynamic parameters AUC/MIC, T > MIC, (AUC > MIC)/MIC (AUC = area under the curve, T = time) and WAUC ((AUC/MIC) (T > MIC/100)) (WAUC = weighted area under the curve) were related to AUBKC(24) and AUBKC(48) using an inhibitory sigmoid E(max) model."	( Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G. Bowker, KE; Holt, HA; MacGowan, AP; Wootton, M, 1999)	0.55
"2 mg/L, area under the curve (AUC) 37 mg x hour/L, and terminal elimination half-life 12."	( Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Nightingale, CH, 2000)	1.75
" With each organism, a series of monoexponential pharmacokinetic profiles of single doses of moxifloxacin (T:1/2 = 12."	( Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. Firsov, AA; Kononenko, OV; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH, 2000)	0.81
"The aim of the present investigation was to study and compare the killing activity of two new fluoroquinolone compounds, moxifloxacin and grepafloxacin, and a new generation macrolide, clarithromycin, against three clinical isolates of Streptococcus pneumoniae (penicillin-susceptible, -intermediate and -resistant) and two Streptococcus pyogenes (erythromycin-susceptible and -resistant) strains by simulating their human pharmacokinetics in a pharmacodynamic model."	( Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model. Esposito, S; Ianniello, F; Noviello, S, 2000)	0.82
"An in vitro pharmacokinetic model was used to compare the pharmacodynamics of moxifloxacin and levofloxacin against 3 Staphylococcus aureus and 3 Staphylococcus epidermidis strains."	( Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Lister, PD, 2001)	0.86
" The terminal elimination half-life was 14 to 15 hours, supporting once daily administration of the drug."	( Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Kubitza, D; Schühly, U; Stass, H, 2001)	0.57
"These studies indicate that, based on the safety profile and the pharmacokinetic behaviour of moxifloxacin, a dosage regimen of 400mg given once daily should be effective and well tolerated for the treatment of various infections."	( Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Kubitza, D; Schühly, U; Stass, H, 2001)	0.79
"Maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) were higher in elderly females than in elderly males; however, when normalised for bodyweight, these pharmacokinetic parameters were not significantly different between the groups."	( The influence of age and gender on the pharmacokinetics of moxifloxacin. Heller, AH; Lettieri, JT; Liu, P; Sullivan, JT, 2001)	0.55
"18 young, healthy, male volunteers were enrolled in the study, of whom 16 were considered evaluable for the pharmacokinetic analysis."	( Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Agarwal, V; Lettieri, J; Liu, P; Vargas, R, 2001)	0.55
"Pharmacokinetic parameters such as maximum concentration (Cmax), time to reach Cmax (tmax), area under the concentration-time curve from zero to 48 hours (AUC48h), AUC from zero extrapolated to infinity (AUCinfinity) and elimination half-life (t1/2z) were estimated using noncompartmental methods."	( Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Agarwal, V; Lettieri, J; Liu, P; Vargas, R, 2001)	0.55
" The plasma pharmacokinetics of moxifloxacin for treatments A and C were equivalent with respect to Css(max) (estimated true ratio 109%, 90% CI 97 to 123%) and AUCss(tau) (ratio 104%, 90% CI 100 to 108%); the median tmax values were also similar (0."	( Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Kubitza, D; Stass, H, 2001)	0.86
"An in vitro pharmacokinetic model (IVPM) was used to simulate the human serum pharmacokinetics of moxifloxacin, levofloxacin and sparfloxacin, and to compare their pharmacodynamics against Streptococcus pneumoniae exhibiting a wide range of susceptibilities to fluoroquinolones."	( Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. Lister, PD; Sanders, CC, 2001)	0.85
" The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy."	( Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Ghaffar, F; Hardy, RD; Jafri, HS; McCoig, CC; McCracken, GH; Michelow, IC; Olsen, K; Patel, C; Rodriguez-Cerrato, V, 2001)	0.78
"0001) were reduced with decreasing CLCR, mean Cmax was slightly reduced (Cmax-ratio 85."	( Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Delesen, H; Halabi, A; Kubitza, D; Stass, H, 2002)	0.64
"A new pharmacodynamic parameter, the composite recovery time (CRT), is described and used to calculate species-specific MIC breakpoints."	( Calculation of composite recovery time: a new pharmacodynamic parameter. Gould, IM; MacKenzie, FM; Milne, KE, 2002)	0.31
"The pharmacodynamics of moxifloxacin against Streptococcus pneumoniae and Pseudomonas aeruginosa were investigated in a pharmacokinetic infection model."	( Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Bowker, KE; Holt, HA; MacGowan, AP; Rogers, CA, 2003)	0.99
"The differential effects of moxifloxacin and levofloxacin on the development of resistance in four Streptococcus pneumoniae isolates were examined by using an in vitro pharmacodynamic model."	( Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Allen, GP; Kaatz, GW; Rybak, MJ, 2003)	0.86
"Our objective was to construct a population pharmacokinetic model for moxifloxacin disposition in plasma and bronchial secretions in patients with severe bronchopneumonia who were mechanically ventilated."	( Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Albanese, J; Arvis, P; Bruguerolle, B; Lacarelle, B; Martin, C; Sampol, E; Simon, N; Urien, S, 2003)	0.84
" The population pharmacokinetic modeling was performed with NONMEM."	( Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Albanese, J; Arvis, P; Bruguerolle, B; Lacarelle, B; Martin, C; Sampol, E; Simon, N; Urien, S, 2003)	0.6
" The population pharmacokinetic parameters were as follows (given as estimate with percent interindividual variability in parentheses except where otherwise indicated): clearance, 14."	( Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Albanese, J; Arvis, P; Bruguerolle, B; Lacarelle, B; Martin, C; Sampol, E; Simon, N; Urien, S, 2003)	0.6
" The pharmacokinetic findings of this investigation show that relatively high aqueous levels can be achieved after topical administration."	( Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Apte, RS; Blinder, KJ; Chi, J; Hariprasad, SM; Holekamp, NM; Mieler, WF; Prince, RA; Rosenblatt, B; Shah, GK; Thomas, MA, 2005)	0.57
"A complete a literature search was undertaken to establish the MIC90 values of the five microorganisms most frequently isolated in odontogenic infections and the pharmacokinetic parameters of 13 antibiotics used in these infections."	( [Pharmacokinetic/pharmacodynamic analysis of antibiotic therapy in dentistry and stomatology]. Ardanza-Trevijano, B; Canut, A; Isla, A; Labora, A; Pedraz, JL; Rodríguez-Gascón, A; Solinís, MA, 2005)	0.33
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."	( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. Jolivette, LJ; Ward, KW, 2005)	0.33
"The objective of this study was to determine the pharmacodynamic (PD) activity of moxifloxacin against four selected Bacteroides fragilis strains (three strains with low MICs and one strain with a high MIC) and two Escherichia coli strains (one strain with a low MIC and one strain with a high MIC) in a pharmacokinetic (PK) in vitro model in pure cultures as well as in mixed cultures."	( Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. Forberg, J; Goldstein, EJ; Rodloff, AC; Schaumann, R, 2005)	0.93
"The antibacterial effects of moxifloxacin against Bacteroides fragilis, Clostridium perfringens, and gram-positive anaerobic cocci (GPAC) were studied in an in vitro pharmacokinetic model."	( Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. Bowker, KE; Macgowan, AP; Noel, AR, 2005)	0.94
" The pharmacokinetic data suggest that intravitreal moxifloxacin may have a role in the treatment of bacterial endophthalmitis."	( Clearance of intravitreal moxifloxacin. Benz, MS; He, F; Holz, ER; Iyer, MN; Mieler, WF; Wensel, TG, 2006)	0.88
"To assess the pharmacokinetic and pharmacodynamic behaviour of moxifloxacin in 15 consecutive elderly patients with acute exacerbation of chronic bronchitis (AECB) treated with the fixed oral moxifloxacin 400 mg/day regimen with the intent of verifying which degree of exposure may be ensured by this standard regimen against AECB pathogens."	( Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Dolcet, F; Furlanut, M; Lugatti, E; Pavan, F; Pea, F; Screm, MC; Talmassons, G, 2006)	0.82
" Standard pharmacokinetic parameters and pharmacodynamic determinants (peak concentration [C(max)]/minimum inhibitory concentration [MIC], area under the plasma concentration-time curve during the 24-hour observational period [AUC(24)]/MIC, pharmacodynamic breakpoints [PDBPs]) were assessed."	( Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Dolcet, F; Furlanut, M; Lugatti, E; Pavan, F; Pea, F; Screm, MC; Talmassons, G, 2006)	0.58
"In patients with AECB the pharmacokinetic behaviour of moxifloxacin is not significantly altered by aging processes."	( Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Dolcet, F; Furlanut, M; Lugatti, E; Pavan, F; Pea, F; Screm, MC; Talmassons, G, 2006)	0.83
" These data demonstrate that not all fluoroquinolones share the same pharmacodynamic targets needed to maximize their antibacterial effect."	( Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations. Dalhoff, A; Schubert, S; Stass, H; Ullmann, U, 2005)	0.65
" Therefore, the attempt was made to introduce immunocompetence into an in vitro pharmacodynamic model."	( Contribution of immunocompetence to the antibacterial activities of ciprofloxacin and moxifloxacin in an in vitro pharmacodynamic model. Dalhoff, A, 2005)	0.55
" The method was successfully applied to an in vitro pharmacokinetic study and patient samples as well."	( Validation of a levofloxacin HPLC assay in plasma and dialysate for pharmacokinetic studies. Siewert, S, 2006)	0.33
" A pharmacokinetic computerized device was used to simulate serum and epithelial lining fluid (ELF) concentrations."	( A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. Aguilar, L; Alou, L; Cafini, F; Echeverría, O; Giménez, MJ; Pérez-Trallero, E; Prieto, J; Sevillano, D, 2006)	0.33
"An in vitro pharmacodynamic model was used to simulate the epithelial lining fluid (ELF) concentrations following oral administration of levofloxacin 500 mg once daily and moxifloxacin 400 mg once daily in older adults."	( Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. Deryke, CA; Du, X; Nicolau, DP, 2006)	0.75
" This method was applied in pharmacokinetic studies moxifloxacin preparations in healthy volunteers."	( High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma. Tatar Ulu, S, 2007)	0.84
" The area under the concentration-time curve (AUC) tended to be greater in exudate; the time to peak concentrations (T(max)) was longer in exudate than in plasma, as were half-life and mean residence time (MRT)."	( Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. Delesen, H; Kubitza, D; Rink, AD; Stass, H; Vestweber, KH, 2006)	0.59
"A correlation was seen between both the area under the serum concentration curve and MIC (AUC/MIC) and the peak concentration/MIC (Cmax/MIC) versus area under the bactericidal killing curve (AUBKC) or Deltalog0-24 cfu/mL."	( Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. Cars, O; Odenholt, I, 2006)	0.66
" The aim of the present study was to develop a semimechanistic pharmacokinetic (PK)/pharmacodynamic (PD) model characterizing the events seen in a bacterial system when it is exposed to antibacterial agents with different mechanisms of action."	( Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Cars, O; Karlsson, MO; Löwdin, E; Nielsen, EI; Sandström, M; Viberg, A, 2007)	0.34
"Members of the fluoroquinolone class are being actively evaluated for inclusion in tuberculosis chemotherapy regimens, and we sought to determine the best in vitro and pharmacodynamic predictors of in vivo efficacy in mice."	( Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL, 2007)	1.78
"To compare pharmacodynamic indices and minimal inhibitory concentrations for vancomycin, gatifloxacin, moxifloxacin, linezolid, and combined quinupristin and dalfopristin for historic and current human coagulase-negative staphylococcus (CoNS) endophthalmitis isolates."	( In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. Flynn, HW; Harper, T; Miller, D, 2007)	0.55
" Peak concentration (C(max)) was defined as the maximum attainable aqueous concentration using topical or oral therapy, or both."	( In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. Flynn, HW; Harper, T; Miller, D, 2007)	0.34
" Pharmacokinetic indices (C(max)/MIC90) for topical dosing were all <1."	( In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. Flynn, HW; Harper, T; Miller, D, 2007)	0.34
"Plasma, dialysate and urine pharmacokinetic parameters for moxifloxacin and its main metabolites were calculated after single and multiple (7 days) dosing with 400 mg day(-1)."	( The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction. Bührmann, S; Kribben, A; Kubitza, D; Mitchell, A; Möller, JG; Schäfers, RF; Stass, H; Wenzel, RR, 2007)	0.8
"The objective of this study was to investigate the relationship between pharmacokinetic and pharmacodynamic parameters, on the basis of the mutant prevention concentration (MPC) concept, and the emergence of resistant mutants of Streptococcus pneumoniae to fluoroquinolone antibacterials."	( Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Homma, T; Hori, T; Sugimori, G; Yamano, Y, 2007)	0.34
" In addition to standard pharmacokinetic parameters, the total dialysate concentration of both drugs was measured using a technically simple single-pass batch dialysis system for EDD."	( Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S, 2006)	0.66
"The purpose of this study was to examine the allometric analyses of marbofloxacin, moxifloxacin, danofloxacin and difloxacin using pharmacokinetic data from the literature."	( Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis. Cox, SK, 2007)	0.84
"The objective of this study was to determine the population pharmacokinetic parameters of levofloxacin, gatifloxacin, and moxifloxacin following multiple oral doses."	( Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA, 2008)	0.79
"This study used Monte Carlo simulations to assess the potential for attainment of pharmacodynamic targets with the fluoroquinolones garenoxacin, gemifloxacin, and moxifloxacin against Streptococcus pneumoniae in serum and epithelial lining fluid (ELF) from hospitalized patients with community-acquired pneumonia (CAP)."	( Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Hoban, DJ; Noreddin, AM; Ostroski, M; Reese, AA; Zhanel, GG, 2007)	0.78
"Data on the free AUC over 24 hours (fAUC(0-24)), a measure of drug exposure, were derived from previously described population pharmacokinetic models for therapeutic doses of the 3 fluoroquinolones."	( Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Hoban, DJ; Noreddin, AM; Ostroski, M; Reese, AA; Zhanel, GG, 2007)	0.58
" Thus, in addition to adequate drainage, empirical coverage with broad-spectrum antimicrobials is central to the management of such abscesses and an understanding of pharmacokinetic properties can be valuable when selecting antimicrobial agents."	( Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Delesen, H; Kubitza, D; Rink, AD; Stass, H; Vestweber, KH, 2008)	0.61
" Eight patients with CT or ultrasound evidence of a localized intra-abdominal abscess requiring interventional drainage without signs of generalized peritonitis were considered suitable candidates for pharmacokinetic analysis."	( Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Delesen, H; Kubitza, D; Rink, AD; Stass, H; Vestweber, KH, 2008)	0.61
" Half-life and mean residence time were longer in abscess fluid than in plasma, suggesting that moxifloxacin accumulates in abscess fluid."	( Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Delesen, H; Kubitza, D; Rink, AD; Stass, H; Vestweber, KH, 2008)	0.83
" Based on the pharmacokinetic data, moxifloxacin is a good candidate therapy for use in patients with intra-abdominal abscesses undergoing CT-guided percutaneous drainage and may also prove valuable in the general systemic management of intra-abdominal abscesses in the future."	( Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Delesen, H; Kubitza, D; Rink, AD; Stass, H; Vestweber, KH, 2008)	0.88
" The concentration-time data were analysed by compartmental (after IV dose) and non-compartmental (after IV, IM and SC administration) pharmacokinetic methods."	( Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep. Cárceles, CM; Escudero, E; Fernández-Varón, E; Marín, P, 2009)	0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" The developed assay method was applied to a pharmacokinetic study in human volunteers following oral administration of 400 mg GFC tablet."	( Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study. Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N, 2008)	0.56
" Ciprofloxacin, a carboxyfluoroquinolone, was previously observed to demonstrate the pharmacodynamic interactions with antifungal agents by altering their growth inhibitory activity against Candida albicans and Aspergillus fumigatus."	( Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. Meletiadis, J; Papaioannidou, P; Roilides, E; Sein, T; Stergiopoulou, T; Tsiouris, I; Walsh, TJ, 2009)	0.59
"The knowledge of the pharmacodynamic interactions between fluoroquinolones and antifungal agents may guide selection and potentially improve the outcome of immunosuppressed patients with concurrent bacterial and fungal infections."	( Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. Meletiadis, J; Papaioannidou, P; Roilides, E; Sein, T; Stergiopoulou, T; Tsiouris, I; Walsh, TJ, 2009)	0.59
" This bio-analytical method was finally applied to the analysis of samples which have been obtained from patients, participating in a pharmacokinetic study on moxifloxacin."	( Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. Boussery, K; Colpaert, K; De Paepe, P; De Smet, J; De Sutter, P; Decruyenaere, J; Van Bocxlaer, J, 2009)	0.75
"African green monkeys (vervets) have been proposed as an alternate species that might allow improved access and provide high-quality pharmacokinetic results comparable with other primates."	( Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions. Bhadresa, S; Coon, DJ; Lawrence, MS; Magiera, D; Struharik, M; Ward, KW, 2009)	0.35
"This study used a whole-body physiologically based pharmacokinetic (WB-PBPK) model for moxifloxacin, plus in vitro and in vivo literature data on its interaction with macrophages, to interpret biopsy results generated from patients undergoing primarily colorectal surgery."	( Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. Ahr, G; Edginton, AN; Stass, H; Willmann, S, 2009)	0.84
" observed biopsy half-life = 21 hours) was similar to that of moxifloxacin in macrophages (20."	( Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling. Ahr, G; Edginton, AN; Stass, H; Willmann, S, 2009)	0.86
" Pharmacokinetic parameters were estimated using standard noncompartmental methods."	( Pharmacokinetics of moxifloxacin in patients undergoing continuous ambulatory peritoneal dialysis. Boletis, J; Giamarellos-Bourboulis, EJ; Kanellakopoulou, K; Skalioti, C; Stamatiadis, D; Tsaganos, T, )	0.45
"Antibiotic pharmacodynamic modeling allows variations in pathogen susceptibility and human pharmacokinetics to be accounted for when considering antibiotic doses, potential bacterial pathogen targets for therapy, and clinical susceptibility breakpoints."	( Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints. Bowker, KE; MacGowan, AP; Noel, AR; Reynolds, R, 2009)	0.35
" Population pharmacokinetic parameters and their variability encountered in tuberculosis patients were utilized in Monte Carlo simulations to determine the probability that particular daily doses of the drugs would achieve or exceed the EC(90) in the epithelial lining fluid of 10,000 tuberculosis patients."	( New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Gumbo, T, 2010)	0.36
"This study investigates the potential pharmacokinetic interactions between an antimicrobial agent, moxifloxacin, and 2 immunosuppressant drugs, cyclosporine and tacrolimus, in kidney transplant recipients."	( Absence of pharmacokinetic interference of moxifloxacin on cyclosporine and tacrolimus in kidney transplant recipients. Basile, V; Capone, D; Carrano, R; Federico, S; Kadilli, I; Nappi, R; Polichetti, G; Sabbatini, M; Tarantino, G, 2010)	0.84
" Changes in QTcF mirrored the pharmacokinetic changes, and there was a linear relationship between plasma concentration of moxifloxacin and change in QTcF."	( Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies. Florian, JA; Garnett, CE; Mason, JW; Moon, TE; Selness, DS; Spaulding, RR, 2010)	0.82
" Pharmacokinetic analysis of disposition data indicated that intravenous administration data were best described by a two compartment open model, whereas intramuscular administration data were best described by a one compartment open model."	( Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. Pathania, R; Sharma, SK, 2010)	0.63
" Moxifloxacin pharmacokinetic parameters in the presence of ciclosporin were compared with previously published pharmacokinetic data for moxifloxacin in healthy individuals."	( Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study. Bauer, S; Delesen, H; Kubitza, D; Mai, I; Roots, I; Stass, H, 2010)	2.71
" The pharmacokinetic parameters for moxifloxacin were unaffected by the presence of ciclosporin."	( Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study. Bauer, S; Delesen, H; Kubitza, D; Mai, I; Roots, I; Stass, H, 2010)	2.08
"Concomitant administration of moxifloxacin does not alter the pharmacokinetic parameters of ciclosporin or ciclosporin plus its metabolites in immunosuppressed patients."	( Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study. Bauer, S; Delesen, H; Kubitza, D; Mai, I; Roots, I; Stass, H, 2010)	2.09
" After validation studies, the method was applied in order to conclude the effects of pregnancy on postoperative pharmacokinetic profiles of moxifloxacin."	( Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. Beksaç, MS; Eroglu, H; Katlan, D; Kir, S; Nemutlu, E; Oyüncü, O; Ozek, A; Özyüncü, Ö, 2010)	0.83
" Azithromycin also showed an extended half-life (65."	( Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Brubaker, K; Crean, CS; Haque, RM; Hwang, DG; Stewart, WC; Zink, RC, 2010)	0.63
"To increase our understanding of important subject characteristics and design variables affecting the performance of oral moxifloxacin in thorough QT studies, population pharmacokinetic and concentration-QTc models were developed by pooling data from 20 studies."	( Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. Brundage, R; Florian, JA; Garnett, CE; Parekh, A; Tornøe, CW, 2011)	0.82
" The SLOPE model, relating the QT increase as a linear function of concentration, provided a better description of the pharmacodynamic effect than did the Emax model."	( Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval. Grosjean, P; Urien, S, 2012)	0.72
" Since moxifloxacin has a longer half-life than rifampin, rifampin concentrations are <1% of the maximum concentration in serum (C(max)) on day 6 and nondetectable on day 7, while concentrations of moxifloxacin remain and are able to induce error-prone replication."	( Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. Brown, D; Drusano, GL; Eichas, A; Kulawy, R; Louie, A; Sgambati, N, 2011)	1.12
" This is despite the availability of antibiotics that have good activity against Mycobacterium tuberculosis in vitro and favorable pharmacokinetic profiles in plasma."	( Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D, 2012)	0.38
" Further, the method was also successfully applied to a single-dose pharmacokinetic study in rats."	( Development and validation of liquid chromatography-mass spectrometric method for simultaneous determination of moxifloxacin and ketorolac in rat plasma: application to pharmacokinetic study. Banerjee, SK; Borkar, RM; Padiya, R; Raju, B; Ramesh, M; Srinivas, R, 2012)	0.59
"A baseline pharmacokinetic study of MFX (400 mg once daily) was conducted in 36 healthy adults and repeated after one week of daily MFX with either RMP (450/600 mg) (n = 18) or INH (300 mg) (n = 18)."	( Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. Geetharani, A; Hemanth Kumar, AK; Nandhakumar, B; Nandini, R; Ramachandran, G; Srinivasan, R; Sugirda, P; Tharani, CB, 2012)	0.61
"Plasma peak concentration and exposure of MFX was significantly lower and plasma clearance significantly higher when combined with RMP (P<0."	( Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. Geetharani, A; Hemanth Kumar, AK; Nandhakumar, B; Nandini, R; Ramachandran, G; Srinivasan, R; Sugirda, P; Tharani, CB, 2012)	0.61
"To describe the plasma concentration-time profile of moxifloxacin after intravenous and enteral administration in intensive care unit (ICU) patients and to provide a pharmacodynamic (PD) evaluation with regard to pneumonia."	( Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. Haeberle, HA; Heininger, A; Kees, F; Kees, MG; Kloft, C; Schaeftlein, A, 2013)	0.86
" A population pharmacokinetic (PK) model was developed using NONMEM VII."	( Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. Haeberle, HA; Heininger, A; Kees, F; Kees, MG; Kloft, C; Schaeftlein, A, 2013)	0.61
"This study evaluated the pharmacokinetics of intravenous moxifloxacin 400 mg once and levofloxacin 500 mg twice daily in patients with lower respiratory tract infections (LRTIs) and assessed their pharmacodynamic adequacy against common respiratory pathogens."	( Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Papaioannou, M; Pitsiou, G; Sionidou, M, 2013)	0.96
" The validated method was applied to assay real plasma samples used for pharmacokinetic studies and therapeutic drug monitoring of the selected drugs."	( Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers. Helmy, SA, 2013)	0.63
"This assay method was valid within a wide range of plasma concentrations and may be proposed as a suitable method for pharmacokinetic studies, therapeutic drug monitoring implementation, and routine clinical applications, especially for some populations of patients who receive a combination of these drugs."	( Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers. Helmy, SA, 2013)	0.63
" Further studies should determine the optimal pharmacodynamic target for moxifloxacin in a multidrug regimen and clarify safety issues when it is administered at higher doses."	( Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Charalambous, S; Chigutsa, E; Denti, P; Harrison, T; Hatherill, M; Jindani, A; McIlleron, HM; Mungofa, S; Simonsson, US; Sirgel, FA; Wiesner, L; Zvada, SP, 2014)	2.08
" Pharmacokinetic parameters of moxifloxacin were determined in rats following oral administration to rats in the presence and absence of diclofenac."	( Effect of diclofenac on the pharmacokinetics of moxifloxacin in rats. Chen, L; Guo, S; Wu, LX; Xu, M; Zhang, JH, 2014)	0.94
" A single-dose pharmacokinetic study was performed after intravenous administration of 400 mg MXF."	( Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Papakosta, D; Pitsiou, G; Zarogoulidis, K, 2014)	1.85
" The method had been successfully applied to a pharmacokinetic study of fixed dose administration of PA-824, moxifloxacin, pyrazinamide and their combination in SD rat."	( LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study. Diao, C; Liang, L; Liu, X; Wang, L; Xu, Y; Zhang, J; Zhang, S, 2014)	0.86
" AUC₀₋₂₄ and other pharmacokinetic (PK) parameters were determined following intensive PK sampling in two Dutch TB referral centres."	( Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Aarnoutse, RE; Alffenaar, JW; Boeree, MJ; Broeders, J; Burger, DM; Donders, AR; Later-Nijland, HM; Magis-Escurra, C; van Altena, R; van Crevel, R; van der Werf, TS, 2014)	0.62
"The purpose of this study was to explore the population pharmacokinetic features of moxifloxacin in infected patients."	( Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients. Ji, S; Wang, N; Yang, W; Zhang, Y; Zhao, X; Zhu, L, 2014)	0.89
" A nonlinear mixed effect model was used to model the population pharmacokinetic (PK) behavior of moxifloxacin."	( Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients. Ji, S; Wang, N; Yang, W; Zhang, Y; Zhao, X; Zhu, L, 2014)	0.88
" The typical population values of moxifloxacin for the pharmacokinetic parameters of apparent clearance (CL) and apparent distribution volume (V) were 12."	( Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients. Ji, S; Wang, N; Yang, W; Zhang, Y; Zhao, X; Zhu, L, 2014)	0.94
"The present study developed population pharmacokinetic models for moxifloxacin in infected Chinese patients."	( Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients. Ji, S; Wang, N; Yang, W; Zhang, Y; Zhao, X; Zhu, L, 2014)	0.9
"5-10 mg/kg for children with multidrug-resistant (MDR) tuberculosis, but pharmacokinetic and long-term safety data of moxifloxacin in children with tuberculosis are lacking."	( Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Castel, S; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Schaaf, HS; Thee, S; Wiesner, L, 2015)	0.91
"In a prospective pharmacokinetic and safety study, children 7-15 years of age routinely receiving moxifloxacin 10 mg/kg daily as part of multidrug treatment for MDR tuberculosis in Cape Town, South Africa, for at least 2 weeks, underwent intensive pharmacokinetic sampling (predose and 1, 2, 4, 8, and either 6 or 11 hours) and were followed for safety."	( Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Castel, S; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Schaaf, HS; Thee, S; Wiesner, L, 2015)	0.92
"The purpose of this report was to assess the impact of poor compliance on the efficacy of levofloxacin (LFX) and moxifloxacin (MOX), two fluoroquinolones with different pharmacokinetic (PK) and pharmacodynamic (PD) properties, in respiratory infections."	( Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study. Carral, N; Lukas, JC; Oteo, I; Suarez, E, 2015)	0.88
" A two-compartment population pharmacokinetic model was developed, identifying as covariates total body weight on central and peripheral volume of distribution (V1, V2) and ideal body weight on clearance (CL), respectively."	( Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections. Haak, T; Kees, F; Kees, MG; Kloft, C; Wicha, SG; Zink, K, 2015)	0.66
" Accordingly, we determined the pharmacokinetic (PK) profile of moxifloxacin at 400 mg/day in 18 patients treated empirically for community-acquired pneumonia."	( Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. Brock, B; Hardlei, TF; Jensen-Fangel, S; Kragh Thomsen, M; Kreilgaard, M; Öbrink-Hansen, K; Petersen, E, 2015)	2.1
" Pharmacokinetic sampling was performed once in every patient during the first three critical days."	( Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Aarnoutse, R; Burger, D; Dian, S; Donders, R; Ganiem, AR; Ruesen, C; Ruslami, R; Te Brake, L; van Crevel, R, 2015)	0.64
" Thus, we aimed to develop a pharmacokinetic (PK)-pharmacodynamic (PD) model for moxifloxacin, to evaluate the time course of its effect on QT intervals in Koreans."	( Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects. Chung, JY; Han, S; Hong, T; Jeon, S; Lee, J; Lim, KS; Park, GJ; Park, WS; Yim, DS; Yu, KS, 2015)	0.88
" Moreover, both Cmax and AUC of moxifloxacin decreased and AUC of moxifloxacin sulfate conjugate metabolite increased significantly when moxifloxacin was administered to rats with DA pretreatment."	( Exogenous dopamine induces dehydroepiandrosterone sulfotransferase (rSULT2A1) in rat liver and changes the pharmacokinetic profile of moxifloxacin in rats. Chen, G; Ji, X; Li, J; Li, L; Lu, W; Shao, X; Wang, S; Xu, J; Zhou, T, 2015)	0.9
" To evaluate the pharmacokinetic (PK) characteristics of clinically relevant, multidrug treatment regimens and to improve the feasibility of TDM, we conducted an open-label, multiple-dosing study with 16 healthy subjects who were divided into two groups."	( Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS, 2015)	0.42
" Based on the MICs and the population pharmacokinetic parameters of the investigated antimicrobials, a Monte Carlo simulation was performed to simulate the pharmacokinetic/pharmacodynamic (PK/PD) indices of different regimens."	( A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia. Cai, X; Cui, J; Ni, W; Wei, C, 2015)	0.63
" A pharmacokinetic study of moxifloxacin N-sulfate after a single oral dose of moxifloxacin in rats was carried out using this new method."	( A Simple LC/MS/MS Method for the Determination of Moxifloxacin N-Sulfate in Rat Plasma and Its Application in a Pharmacokinetic Study. Fan, R; Li, J; Lu, W; Su, Q; Wang, S; Yuan, Y; Zhou, T, )	0.68
"A population pharmacokinetic analysis was performed to investigate the pharmacokinetics of moxifloxacin (400 mg) following a once-daily oral administration in 28 patients with respiratory tract infection disease."	( Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection. Endo, J; Funaguchi, N; Ito, F; Kaito, D; Kamamiya, F; Koumei, Y; Minatoguchi, S; Mori, H; Mori, M; Morishita, M; Ohno, Y; Toyoshi, S, 2016)	0.93
"To examine whether strict control of clinical trial conditions could reduce apparent differences of pharmacokinetic (PK) parameters among ethnic groups."	( Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. Hasunuma, T; Jang, IJ; Kaneko, M; Kaniwa, N; Kawai, S; Saito, Y; Takeuchi, M; Tohkin, M; Uyama, Y; Watanabe, H; Yamazoe, Y; Yimin, C, 2016)	0.68
" Cmax values of moxifloxacin and simvastatin, but not meloxicam, showed significant differences."	( Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. Hasunuma, T; Jang, IJ; Kaneko, M; Kaniwa, N; Kawai, S; Saito, Y; Takeuchi, M; Tohkin, M; Uyama, Y; Watanabe, H; Yamazoe, Y; Yimin, C, 2016)	1.03
" Plasma concentrations of moxifloxacin and rifampicin were determined using LC-MS at the designated time points after drug administration, and the main pharmacokinetic parameters were calculated."	( Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. Huang, L; Huang, Y; Liu, J; Shi, L; Xiao, H; Yu, X, 2016)	1.02
" Serial blood sampling was conducted for pharmacokinetic analysis of moxifloxacin."	( Population Pharmacokinetic-Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects. Amano, H; Choi, HK; Fujita, T; Ghim, JL; Jung, JA; Kumagai, Y; Lee, DH; Maeda, M; Mendzelevski, B; Shin, JG; Song, ID; Tabata, K, 2016)	0.9
" The concentration-effect analysis revealed that there was no change in slope (and confirmed that the difference was caused by a change in the pharmacokinetic model of moxifloxacin)."	( Population Pharmacokinetic-Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects. Amano, H; Choi, HK; Fujita, T; Ghim, JL; Jung, JA; Kumagai, Y; Lee, DH; Maeda, M; Mendzelevski, B; Shin, JG; Song, ID; Tabata, K, 2016)	0.86
" There are no studies describing the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials."	( Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis. Werth, BJ, 2017)	0.46
" The estimated pharmacokinetic parameters and the estimated slope of the MX concentration-QT/ΔQTc/ΔΔQTc relationship were described using models and were compared to results for other ethnicities from the literature."	( Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers. He, YC; Huang, JH; Li, LJ; Liang, LY; Wang, K; Xu, FY; Xu, L; Yang, J; Yin, F; Zheng, QS, 2017)	0.74
" Most patients (71%) had suboptimal steady-state serum Cmax (total drug) concentrations."	( Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. Bablishvili, N; Bernheim, A; Blumberg, HM; Derendorf, H; Gogishvili, S; Guarner, J; Heinrichs, MT; Kempker, RR; Little, BP; Nikolaishvili, K; Peloquin, CA; Sabulua, I; Tukvadze, N; Vashakidze, S, 2018)	1.92
"6% increased clearance, respectively) and ABCB1 SNP rs2032582 (40% reduced bioavailability in one individual) were significantly associated with changes in moxifloxacin pharmacokinetic parameters."	( Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Chaudhry, M; Chirehwa, M; Denti, P; McIlleron, H; Naidoo, A; Naidoo, K; Ngcapu, S; Padayatchi, N; Pepper, MS; Ramsuran, V; Singh, R; Yende-Zuma, N, 2018)	0.93
" Clinical relevance of the effects of genetic variation on moxifloxacin pharmacokinetic requires further investigation."	( Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Chaudhry, M; Chirehwa, M; Denti, P; McIlleron, H; Naidoo, A; Naidoo, K; Ngcapu, S; Padayatchi, N; Pepper, MS; Ramsuran, V; Singh, R; Yende-Zuma, N, 2018)	0.98
" The validated analytical method was successfully applied in a pharmacokinetic study of a single-dose oral administration of a moxifloxacin 400 mg tablet in Thai healthy volunteers."	( A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study. Jithavech, P; Kiatkumjorn, T; Na Bhuket, PR; Rojsitthisak, P; Thanawattanawanich, P; Wichitnithad, W, 2018)	0.92
" However, moxifloxacin blood levels demonstrated that the nanoparticle formulation and intramuscular route provided the longest half-life and longest time above the minimal inhibitory concentration."	( Nanoparticle Formulation of Moxifloxacin and Intramuscular Route of Delivery Improve Antibiotic Pharmacokinetics and Treatment of Pneumonic Tularemia in a Mouse Model. Clemens, DL; Dillon, BJ; Horwitz, MA; Lee, BY; Li, Z; Plamthottam, S; Tullius, MV; Wang, R; Yu, CJ; Zink, JI, 2019)	1.21
"This study aimed to evaluate the pharmacokinetic profile of moxifloxacin (MXF) in serum and sputum/bronchial secretions of 22 patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) hospitalized in the ward and intensive care unit (ICU)."	( Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients. Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Pitsiou, G; Sionidou, M; Zarogoulidis, P, 2019)	2.2
" A dosing strategy for each age cohort (Cohort 1: ≥6 years to ≤14 years; Cohort 2: ≥2 years to <6 years; Cohort 3: >3 month to <2 years) was developed using physiology-based pharmacokinetic modeling combined with a stepwise dosing scheme to obtain a similar exposure to adults receiving 400 mg of moxifloxacin."	( Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study. Arrieta, AC; Bradley, JS; James, LP; Lettieri, J; Stass, H; Sullivan, JE; Vanevski, KM; Willmann, S, 2019)	0.92
" We aim to compare the culture conversion between new-generation (levofloxacin and moxifloxacin) and old-generation (ciprofloxacin and ofloxacin) fluoroquinolones, develop pharmacokinetic models, and calculate target attainment for levofloxacin and moxifloxacin."	( Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA, 2019)	0.74
" We applied physiologically-based pharmacokinetic (PBPK) and population pharmacokinetic (popPK) modeling to support dose selection in pediatric patients."	( Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin. Coboeken, K; Eissing, T; Frei, M; Lippert, J; Stass, H; Sutter, G; Wendl, T; Willmann, S, 2019)	0.71
" Here, we used high-content imaging screening and pharmacodynamic intracellular (PDi) modeling to identify and prioritize fluoroquinolones for TB treatment."	( Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis. Aljayyoussi, G; Ardrey, A; Biagini, GA; Donnellan, S; Martinez-Rodriguez, C; Moyo, E; Ward, SA, 2019)	0.51
" Moxifloxacin CSF levels were obtained for pharmacokinetic analysis."	( The Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid Following Intravenous Administration: A Report of Successfully Treated Infant with Mycoplasma hominis Meningitis. Berman, DM; Messina, A; Namtu, K; Nohren, J; Peloquin, C; Tuite, G, 2020)	1.78
" The pharmacokinetic parameters of MOX were calculated based on the plasma drug concentration-time profile."	( Pharmacokinetics and Bioequivalence Study of a New Branded Generic Moxifloxacin Tablet Among Healthy Volunteers. Amran, A; Anand, AK; Ho, RM; Leong, CW; Tan, CY; Tan, KL, 2021)	0.86
" The pharmacodynamic study was conducted on rabbit eye model of induced keratitis and it is compared with marketed formulation (MF)."	( Cationic Polyelectrolyte Nanocapsules of Moxifloxacin for Microbial Keratitis Therapy: Development, Characterization, and Pharmacodynamic Study. Kesavan, K; Mohan, P, 2021)	0.89
"Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children."	( Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; Thee, S; van der Laan, LE; Wiesner, L; Winckler, JL, 2022)	3.61
" Pharmacokinetic simulations were performed to predict expected exposure and optimal weight-banded dosing."	( Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; Thee, S; van der Laan, LE; Wiesner, L; Winckler, JL, 2022)	2.16
" We developed a physiologically based pharmacokinetic model in Simcyp version 19, with available and newly generated in vitro and in vivo data, to estimate pharmacokinetic parameters of moxifloxacin alone and when administered with rifampicin."	( Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. Aarnoutse, RE; Boeree, MJ; Bolwerk, C; Burger, DM; Greupink, R; Hoefsloot, W; Koenderink, JB; Kuipers, S; Litjens, CHC; Magis-Escurra, C; Ruslami, R; Russel, FGM; Svensson, EM; Te Brake, LHM; van Crevel, R; van den Broek, PHH; van den Heuvel, JJMW; van Ingen, J; van Laarhoven, A; Verscheijden, LFM, 2022)	1.27
" Some pharmacokinetic parameters, calculated by the concentration of moxifloxacin in saliva and plasma, are statistically different."	( A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods. Kondratenko, SN; Shikh, EV; Zolkina, IV, 2020)	1.07
"The developed method of concentration extrapolation allows the use of saliva for pharmacokinetic studies of the tablet preparations of moxifloxacin."	( A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods. Kondratenko, SN; Shikh, EV; Zolkina, IV, 2020)	1.04
" Thus, we used this method to assess the pharmacokinetic (PK) characteristics of MFH and DSP in rabbit ocular tissues and plasma after single doses."	( Simultaneous Determination of Moxifloxacin Hydrochloride and Dexamethasone Sodium Phosphate in Rabbit Ocular Tissues and Plasma by LC-MS/MS: Application for Pharmacokinetics Studies. Qiao, H; Shao, Q; Yuan, Y; Zhao, X, 2022)	1.01

Excerpt	Reference	Relevance
"Killing kinetic experiments were performed with moxifloxacin, a novel fluoroquinolone, vancomycin, clarithromycin, cotrimoxazole, gentamicin, rifampicin and with moxifloxacin in combination with each of the above drugs against six methicillin-resistant Staphylococcus aureus clinical isolates."	( In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus. Bottura, P; Capra, R; Maggiolo, F; Migliorino, M; Pravettoni, G; Suter, F, 2000)	0.88
" Moxifloxacin at both concentrations in combination with ethambutol was significantly more active than each drug alone."	( Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Aralar, P; Bermudez, LE; Inderlied, CB; Kolonoski, P; Petrofsky, M; Wu, M; Young, LS, 2001)	1.6
"The bactericidal activity of moxifloxacin alone and in combination with cefepime or piperacillin-tazobactam against clinical isolates of Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii was evaluated by using time-kill methods and antimicrobial concentrations of one-half and one times the MIC."	( Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates. Choi, MK; Fish, DN; Husain, M; Jung, R, 2004)	0.91
"In previous studies, the diarylquinoline R207910 (also known as TMC207) was demonstrated to have high bactericidal activity when combined with first- or second-line antituberculous drugs."	( Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Andries, K; Chauffour, A; Ibrahim, M; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N, 2007)	0.34
" When the three FQs were individually combined with CLR in vitro, mild antagonism was observed for 53 to 57% of the tested isolates."	( In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Fukushima, K; Higashiyama, Y; Hirakata, Y; Kohno, S; Kohno, Y; Miyazaki, Y; Ohno, H; Yanagihara, K, 2007)	0.34
"Our objective is to determine in vitro efficiency of moxifloxacin (MXF) alone or in combination with cefotaxime (CTX) on Group B streptococcus (GBS)."	( [In vitro activity of moxifloxacin (8-methoxyquinolone) alone or in combination with cefotaxime against group B streptococci]. Collignon, A; Cruaud, P; Gaudelus, J; Jacquier, H; Lachassinne, E; Poilane, I, 2007)	0.9
" This study describes the synergistic activity of oritavancin in combination with gentamicin, linezolid, moxifloxacin, or rifampin in time-kill studies against methicillin-susceptible, vancomycin-intermediate, and vancomycin-resistant Staphylococcus aureus."	( Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Arhin, FF; Belley, A; McKay, GA; Moeck, G; Neesham-Grenon, E; Parr, TR, 2008)	0.56
"To evaluate the effectiveness of pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration."	( Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration. Bennett, MD; Bryan, JS; Yee, W, )	0.61
"This retrospective review included patients who received pegaptanib combined with 165 microg of moxifloxacin every 6 weeks."	( Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration. Bennett, MD; Bryan, JS; Yee, W, )	0.6
"Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration."	( Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration. Bennett, MD; Bryan, JS; Yee, W, )	0.64
" To assess drug-drug interactions, co-administration experiments were conducted with ketoconazole and either propranolol or erythromycin."	( Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions. Bhadresa, S; Coon, DJ; Lawrence, MS; Magiera, D; Struharik, M; Ward, KW, 2009)	0.35
"This thorough corrected QT (QTc) study evaluated the effect of sugammadex alone and in combination with rocuronium or vecuronium on the individually corrected QTc interval (QTcI)."	( Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. de Kam, PJ; Peeters, P; Prohn, M; Thomsen, T; van Kuijk, J, 2010)	0.36
"Based on the results of this study of healthy subjects, it can be concluded that sugammadex alone or in combination with rocuronium or vecuronium is not associated with QTc prolongation."	( Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. de Kam, PJ; Peeters, P; Prohn, M; Thomsen, T; van Kuijk, J, 2010)	0.36
" Simulated regimens included vancomycin (VAN) plus rifampin (RIF), moxifloxacin (MOX), and high doses (10 mg/kg of body weight/day) of daptomycin (DAP) alone or combined with RIF or clarithromycin (CLA)."	( Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Parra-Ruiz, J; Rose, WE; Rybak, MJ; Vidaillac, C, 2010)	0.85
"In vivo metabolites of moxifloxacin have been identified and characterized by using LC/ESI-MS/MS in combination with an online hydrogen/deuterium (H/D) exchange technique."	( In vivo metabolic investigation of moxifloxacin using liquid chromatography/electrospray ionization tandem mass spectrometry in combination with online hydrogen/deuterium exchange experiments. Banerjee, SK; Borkar, RM; Padiya, R; Raju, B; Ramesh, M; Srinivas, R, 2012)	0.97
"A total of 19 in vivo metabolites of moxifloxacin have been characterized using LC/ESI-MS/MS in combination with accurate mass measurements and online H/D exchange experiments."	( In vivo metabolic investigation of moxifloxacin using liquid chromatography/electrospray ionization tandem mass spectrometry in combination with online hydrogen/deuterium exchange experiments. Banerjee, SK; Borkar, RM; Padiya, R; Raju, B; Ramesh, M; Srinivas, R, 2012)	0.93
" Therefore, this fluoroquinolone seems to be the most appropriate in combination with this tyrosine kinase inhibitor."	( Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model. Grabowski, T; Grześkowiak, E; Karbownik, A; Sobańska, K; Szałek, E; Wolc, A, 2013)	0.39
"5 months) with PBCO underwent autogenously fecal peritonitis, and were treated with moxifloxacin combined with dexamethasone, and followed-up for 45 days."	( Severe autogenously fecal peritonitis in Wistar rats with permanent bilateral carotid occlusion. Response to intra peritoneal moxifloxacin combined with dexamethasone. Brandt, CT; Gadelha, DN; Melo, MC; Oliveira, TK, 2014)	0.83
"The treatment of severe autogenously fecal peritonitis with intraperitoneal moxifloxacin combined with dexamethasone was very effective in young rats without permanent bilateral carotid occlusion."	( Severe autogenously fecal peritonitis in Wistar rats with permanent bilateral carotid occlusion. Response to intra peritoneal moxifloxacin combined with dexamethasone. Brandt, CT; Gadelha, DN; Melo, MC; Oliveira, TK, 2014)	0.84
"To evaluate and compare the antimicrobial properties of propolis and calcium hydroxide alone and in combination with ciprofloxacin and moxifloxacin against Enterococcus faecalis (E."	( An in vitro Comparison of Endodontic Medicaments Propolis and Calcium Hydroxide alone and in Combination with Ciprofloxacin and Moxifloxacin against Enterococcus Faecalis. Gupta, K; Kumar, A; Rai, VK; Sabharwal, S; Shrivastava, R; Sinha, S; Tripathi, P, 2015)	0.83
"The laboratory study was carried out to test the effectiveness of propolis and calcium hydroxidealone as well as in combination with the established endodontic medicaments (moxifloxacin and ciprofloxacin)."	( An in vitro Comparison of Endodontic Medicaments Propolis and Calcium Hydroxide alone and in Combination with Ciprofloxacin and Moxifloxacin against Enterococcus Faecalis. Gupta, K; Kumar, A; Rai, VK; Sabharwal, S; Shrivastava, R; Sinha, S; Tripathi, P, 2015)	0.82
" Propolis in combination with antibiotics and alone is more effective than calcium hydroxide."	( An in vitro Comparison of Endodontic Medicaments Propolis and Calcium Hydroxide alone and in Combination with Ciprofloxacin and Moxifloxacin against Enterococcus Faecalis. Gupta, K; Kumar, A; Rai, VK; Sabharwal, S; Shrivastava, R; Sinha, S; Tripathi, P, 2015)	0.62
"Since propolis alone and in combination with antibiotics was observed to be more effective than calcium hydroxide, propolis can be considered as an intracanal medicament when compared to traditional calcium hydroxide."	( An in vitro Comparison of Endodontic Medicaments Propolis and Calcium Hydroxide alone and in Combination with Ciprofloxacin and Moxifloxacin against Enterococcus Faecalis. Gupta, K; Kumar, A; Rai, VK; Sabharwal, S; Shrivastava, R; Sinha, S; Tripathi, P, 2015)	0.62
" However, the potential drug-drug interactions between moxifloxacin and rifampicin were unknown."	( Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. Huang, L; Huang, Y; Liu, J; Shi, L; Xiao, H; Yu, X, 2016)	0.97
" Ultimately, the good permeability, moderate rates of metabolism and low risk of drug-drug interactions displayed by some of the synthesized compounds indicate that 2-(quinolin-4-yloxy)acetamides may yield candidates to use in the development of novel alternative therapeutics for tuberculosis treatment."	( New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. Abbadi, BL; Back, DF; Basso, LA; Campos, MM; Giacobbo, BC; Grams, ES; Machado, P; Pissinate, K; Rodrigues-Junior, V; Santos, DS; Sperotto, N; Subtil, FT; Trindade, RV; Villela, AD, 2017)	0.46
" In addition, the activity of the moxifloxacin + linezolid backbone in combination with one of the potentiator drugs was assessed."	( Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109. Aarnoutse, RE; de Knegt, GJ; de Steenwinkel, JE; de Vogel, CP; van der Meijden, A, 2017)	1.11
" In this regard, the present study was conducted with the aim of studying the efficacy of using fixed drug combination (Difluprednate and Moxifloxacin) in reducing ocular inflammation and pain in post-operative patients undergoing cataract surgery."	( Safety of Fixed drug Combination in Post -Operative Cataract Patients, at Tertiary Care Centre - In South India. Anuradha, A; Nishath, S; Rashmi, G; Shilpa, R; Vidyadevi, M, 2017)	0.66
"Our study clearly shows that fixed drug combination of antibiotic and steroid does not cause raised IOP in about 97% of cases of SICS in the post-operative period and also improves the compliance of the patients."	( Safety of Fixed drug Combination in Post -Operative Cataract Patients, at Tertiary Care Centre - In South India. Anuradha, A; Nishath, S; Rashmi, G; Shilpa, R; Vidyadevi, M, 2017)	0.46
"3% solutions alone or when treatment was combined with steroids, and to correlate these concentrations with the minimum inhibitory concentrations (MIC) for the most common endophthalmitis-causing organisms."	( Aqueous humor concentrations of topical fluoroquinolones alone or in combination with a steroid. Campos, M; Cruz, AC; Gomes, RLR; Lima, AAS; Melo, LAS; Suenaga, EM; Viana, RG, )	0.13
" Pretomanid (PA-824), a nitroimidazooxazine compound, is a new drug for the treatment of pulmonary TB that was recently approved in the United States and Europe in the context of a regimen combined with bedaquiline and linezolid."	( Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers. El-Amin, W; Everitt, D; Li, M; Makhene, MK; Nedelman, J; Osborn, B; Saviolakis, GA; Yang, TJ, 2021)	0.84
" Given the prohibitive drug-drug interactions between bedaquiline and rifampin or rifapentine, the BZMRb regimen represents the best opportunity to combine, in one regimen, the treatment-shortening potential of the rifamycin class with that of BZM and deserves high priority for evaluation in clinical trials."	( Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD, 2022)	0.97
" Delpazolid is administered in combination with bedaquiline, delamanid and moxifloxacin."	( A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxaci Aarnoutse, R; Boeree, M; Cho, YL; Dierig, A; Geiter, L; Gong, X; Heinrich, N; Hoelscher, M; Hoffmann, L; Jarchow-MacDonald, A; Liyoyo, A; Mbeya, B; McHugh, TD; Mhimbira, FA; Minja, LT; Mpagama, S; Ntinginya, N; Phillips, P; Rassool, M; Schultz, S; Sebe, M; Svensson, EM; Te Brake, L; Wallis, RS; Wildner, LM, 2023)	1.14

Excerpt	Reference	Relevance
" In common with other fluoroquinolones, moxifloxacin attains good penetration into respiratory tissues and fluids and its bioavailability is substantially reduced by coadministration with an antacid or iron preparation."	( Moxifloxacin. Balfour, JA; Wiseman, LR, 1999)	2.01
" To determine the absolute bioavailability of moxifloxacin, this open-label, randomized, crossover study compared the pharmacokinetic characteristics of a single 100-mg dose administered either orally or intravenously as a 60-minute infusion in 10 healthy male volunteers (mean age [+/- SD], 29."	( Absolute bioavailability of moxifloxacin. Agarwal, V; Ballow, C; Lettieri, J; Liu, P; Stass, H; Sullivan, JT, 1999)	0.86
" Bioavailability was high to moderate (91-52%) in all species."	( Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. Domdey-Bette, A; Henninger, K; Hucke, F; Kohlsdorfer, C; Siefert, HM; Stass, HH, 1999)	0.56
" The absolute bioavailability was 86%."	( Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. Kubitza, D; Stass, H, 1999)	0.58
" Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours."	( Moxifloxacin: clinical efficacy and safety. Culley, CM; Edwards, B; Klutman, N; Lacy, MK, 2001)	2.66
"The extent of absorption of moxifloxacin is not affected by concomitant Ca2+ intake, whereas the rate of absorption is slightly reduced, an effect not considered to be of clinical relevance."	( Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Delesen, H; Möller, JG; Stass, H; Wandel, C, 2001)	0.85
"To determine the effect of concomitant administration of the antacid Maalox 70 or the histamine H2 receptor antagonist ranitidine on the bioavailability of moxifloxacin."	( Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Böttcher, MF; Ochmann, K; Stass, H, 2001)	0.74
"3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97."	( Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Böttcher, MF; Ochmann, K; Stass, H, 2001)	0.54
"The bioavailability of moxifloxacin is not affected by concurrent administration of ranitidine."	( Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Böttcher, MF; Ochmann, K; Stass, H, 2001)	0.85
" The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12."	( Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Delesen, H; Möller, JG; Schühly, U; Stass, H, 2001)	0.79
"Concomitant ingestion with sucralfate and/or oral Al3+-containing antacids significantly reduces the bioavailability of moxifloxacin."	( Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Delesen, H; Möller, JG; Schühly, U; Stass, H, 2001)	0.77
" The concomitant administration of Eryfer reduced the bioavailability of moxifloxacin [geometric mean area under the plasma concentration-time curve 20."	( Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Kubitza, D; Stass, H, 2001)	0.79
"Concomitant ingestion of iron supplements significantly reduces the bioavailability of moxifloxacin."	( Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Kubitza, D; Stass, H, 2001)	0.78
" The bioavailability of moxifloxacin is substantially reduced by coadministration with antacids or iron preparations."	( Moxifloxacin in uncomplicated skin and skin structure infections. Jarvis, B; Muijsers, RB, 2002)	2.06
" The bioavailability and half-life of moxifloxacin provides potent bactericidal effects at a dose of 400mg/day."	( Moxifloxacin in respiratory tract infections. Miravitlles, M, 2005)	2.04
"To evaluate the extent to which enterohepatic recycling circulation contributes to moxifloxacin bioavailability in healthy, males by administration of activated charcoal and to evaluate the efficacy of activated charcoal administration in decreasing systemic concentrations of moxifloxacin in the event of overdose."	( Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Delesen, H; Kubitza, D; Möller, JG; Stass, H, 2005)	0.8
" The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35."	( Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Delesen, H; Kubitza, D; Möller, JG; Stass, H, 2005)	0.88
" The absolute bioavailability was 96."	( Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. Cárceles, CM; Escudero, E; Espuny, A; Fernández-Varón, E; Villamayor, L, 2006)	0.6
" These agents are highly bioavailable and can facilitate the oral treatment of certain patients who otherwise might be admitted to the hospital, as outpatients."	( Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. Niederman, MS, 2005)	0.55
" Thus, the rate of absorption of moxifloxacin was not affected by administration through a nasogastric tube."	( Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Borner, K; Burkhardt, O; Stass, H; Thuss, U; Welte, T, 2005)	0.85
"5% exhibits enhanced bioavailability due to a unique molecular structure that combines high lipophilicity for enhanced corneal penetration with high aqueous solubility at physiological pH."	( Ophthalmic infections and their anti-infective challenges. Alfonso, E; Crider, J, 2005)	0.33
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" The IM bioavailability was 96."	( Disposition kinetics of moxifloxacin in lactating ewes. Goudah, A, 2008)	0.65
" The bioavailability and half-life ofmoxifloxacin provides potent bactericidal effects at a dose of 400 mg once daily."	( Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Miravitlles, M, 2007)	2.06
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" Meanwhile, plasma protein binding and bioavailability of moxifloxacin were also estimated."	( Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. Goudah, A; Hasabelnaby, S, 2010)	0.87
"A high peak plasma concentration, area under the curve, rapid absorption and bioavailability following intramuscular and subcutaneous administration characterize the pharmacokinetics of moxifloxacin in calves."	( Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations. Goudah, A; Hasabelnaby, S, 2010)	0.82
" The systemic bioavailability (F) of moxifloxacin in buffalo calves was 80."	( Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. Pathania, R; Sharma, SK, 2010)	0.9
"Conventional eye drops show relatively low bioavailability due to poor precorneal contact time."	( Design and Development of Thermoreversible Ophthalmic In Situ Hydrogel of Moxifloxacin HCl. Patel, LD; Prajapati, ST; Shastri, DH, 2010)	0.59
" Mean (95% confidence interval) values for oral clearance, apparent volume of distribution, the first-order absorption rate constant, and mean transit time were 11."	( Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. Brundage, R; Florian, JA; Garnett, CE; Parekh, A; Tornøe, CW, 2011)	0.61
" Oral bioavailability was 79."	( Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. Horbach, T; Kees, F; Kees, MG; Weber, S, 2011)	0.69
" This anatomical alteration may affect the absorption and consequently the bioavailability of oral drugs."	( Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. Batens, H; Blot, S; Boussery, K; Colin, P; De Paepe, P; De Smet, J; Ruige, J; Van Bocxlaer, J; Van Bortel, LM; Van Nieuwenhove, Y; Vogelaers, D, 2012)	0.69
"3 mg · h/L after intravenous dosing, resulting in a mean oral bioavailability of 88."	( Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. Batens, H; Blot, S; Boussery, K; Colin, P; De Paepe, P; De Smet, J; Ruige, J; Van Bocxlaer, J; Van Bortel, LM; Van Nieuwenhove, Y; Vogelaers, D, 2012)	0.69
" Novel approaches for ophthalmic drug delivery need to be established to increase the ocular bioavailability by overcoming the inherent drawbacks of conventional dosage forms."	( Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride. Deshmukh, RV; Gaikwad, KR; Manvi, FV; Nanjwade, BK; Parikh, KA, 2012)	0.63
" An early switch from intravenous to enteral moxifloxacin may be considered because of its good oral bioavailability in healthy volunteers."	( Switch from intravenous to enteral moxifloxacin in critically ill patients: a pilot study. Boussery, K; Colpaert, K; de Paepe, P; de Smet, J; Decruyenaere, J; van Bocxlaer, J, 2012)	0.92
"Thorough QT studies are typically conducted for drugs with systemic bioavailability and include a positive control, typically moxifloxacin, with a well-described QTc effect."	( Impact of electrocardiographic data quality on moxifloxacin response in thorough QT/QTc studies. Garnett, C; Johannesen, L; Malik, M, 2014)	0.87
" Lead optimization resulted in the identification of potent compounds with improved oral bioavailability and reduced cardiac ion channel liability."	( Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J, 2014)	0.4
"The aim of this investigation was to identify the impact of physicochemical properties of three fluoroquinolones (second, third, and fourth generation) on bioavailability in relation to the Biopharmaceutics Classification System (BCS) by in silico and in vitro methods."	( Physicochemical properties of lomefloxacin, levofloxacin, and moxifloxacin relevant to the biopharmaceutics classification system. Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, F, 2014)	0.64
"The developed MEs are a viable alternative to conventional eye drops, because of its ability to enhance bioavailability through its longer precorneal residence time and its ability to sustain the release of the drug."	( Phase-transition W/O Microemulsions for Ocular Delivery: Evaluation of Antibacterial Activity in the Treatment of Bacterial Keratitis. Bharti, SK; Kesavan, K, 2017)	0.46
" However, the Caco-2 cell transwell experiment showed that moxifloxacin could not affect the absorption rate of rifampicin."	( Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. Huang, L; Huang, Y; Liu, J; Shi, L; Xiao, H; Yu, X, 2016)	0.96
"Currently, infections following cataract surgery are not as effectively managed with antibiotic eye drops, which suffer from poor bioavailability of drug and low patient compliance."	( Sustained Antibiotic-Eluting Intra-Ocular Lenses: A New Approach. Lim, SG; Tan, DW; Venkatraman, SS; Wong, TT, 2016)	0.43
"Tedizolid is an orally bioavailable oxazolidinone with once-daily dosing and broad-spectrum Gram-positive activity."	( Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis. Werth, BJ, 2017)	0.46
" The addition of other orally bioavailable anti-staphylococcal agents to tedizolid may be unlikely to improve killing but further research is warranted to assess the impact of these combinations on resistance prevention, or against biofilm-embedded organisms."	( Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis. Werth, BJ, 2017)	0.46
"6% increased clearance, respectively) and ABCB1 SNP rs2032582 (40% reduced bioavailability in one individual) were significantly associated with changes in moxifloxacin pharmacokinetic parameters."	( Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Chaudhry, M; Chirehwa, M; Denti, P; McIlleron, H; Naidoo, A; Naidoo, K; Ngcapu, S; Padayatchi, N; Pepper, MS; Ramsuran, V; Singh, R; Yende-Zuma, N, 2018)	0.93
" These compounds were found to be orally bioavailable and highly effective."	( Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety. Eswaran, S; Narayanan, S; Shivarudraiah, P; Shruthi, TG; Subramanian, S, 2019)	0.51
" Two modified melittin peptides displayed rapid bactericidal properties against antibiotic-resistant strains, low innate resistance development by pathogenic bacteria, remained nonimmunogenic for T lymphocytes, and increased bioavailability in tear fluids."	( Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin. Agrawal, R; Barathi, VA; Beuerman, RW; Chan, LW; Jie, TY; Koh, SK; Lakshminarayanan, R; Leng, ET; Mayandi, V; Sebastian, TM; Somaraju Chalasani, ML; Ting, DSJ; Urf Turabe Fazil, MH; Varadarajan, J; Verma, NK; Xi, Q; Zhou, L, 2020)	0.56
"Considering the low ocular bioavailability of conventional formulations used for ocular bacterial infection treatment, there is a need to design efficient novel drug delivery systems that may enhance precorneal retention time and corneal permeability."	( Moxifloxacin Hydrochloride-Loaded Eudragit® RL 100 and Kollidon® SR Based Nanoparticles: Formulation, In vitro Characterization and Cytotoxicity. Büyükköroğlu, G; Kırımlıoğlu, GY; Özer, S; Yazan, Y, 2021)	2.06
"Maribavir is an orally bioavailable benzimidazole riboside in clinical development for treatment of cytomegalovirus infection in patients who undergo transplantation."	( Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study. Ilic, K; Martin, P; Song, I; Wu, J, 2020)	0.56
"In situ gels have been extensively explored as ocular drug delivery system to enhance bioavailability and efficacy."	( Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. Al-Dhubiab, BE; Attimarad, M; Gupta, S; Jacob, S; Morsy, MA; Nair, AB; Shah, J; Shinu, P; Sreeharsha, N; Venugopala, KN, 2021)	0.62
" The estimated extent of oral bioavailability was highly variable (range 20-91%)."	( Population Pharmacokinetics of Moxifloxacin in Children. Conrad, T; Ghazaryhan, V; Greenberg, RG; Gu, K; Harward, M; Kirkpatrick, CM; Landersdorfer, CB; Nakamura, A; Osborn, B; Rivera-Chaparro, N; Walter, EB, 2022)	1.01
" To address this issue, we utilized a murine model of antibiotic-induced dysbiosis to assay the bioavailability of rifampicin, moxifloxacin, pyrazinamide, and isoniazid in mouse plasma over a period of 12 h following individual oral administration."	( The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability. Dartois, V; Mittereder, LR; Namasivayam, S; Oland, S; Sher, A; Wang, H; Zimmerman, M, 2023)	1.12

Excerpt	Relevance	Reference
" The activity of moxifloxacin could be described by a sigmoid dose-response curve with a maximum effect of -0."	( Moxifloxacin in the therapy of experimental pneumococcal meningitis. Brück, W; Chen, V; Dalhoff, A; Kohlsdorfer, C; Nau, R; Schmidt, H; Schneider, O; Stuertz, K; Trostdorf, F, 1998)	2.08
" tuberculosis, whereas both SPFX and MXFX were effective; administration six times weekly of either of the latter two drugs demonstrated dosage-dependent bactericidal effects, as measured by enumeration of CFU in the spleens, and MXFX appeared more bactericidal than the same dosage of SPFX."	( In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Bonnafous, P; Grosset, J; Ji, B; Lounis, N; Maslo, C; Truffot-Pernot, C, 1998)	0.58
" Gram-positive and gram-negative organisms were also exposed to concentrations of moxifloxacin, sparfloxacin and amoxycillin that simulated the drug concentrations obtained in human serum after standard oral dosing schedules."	( Bactericidal properties of moxifloxacin and post-antibiotic effect. Andrews, JM; Boswell, FJ; Dalhoff, A; Wise, R, 1999)	0.83
" and oral dosing similar concentrations of the unchanged compound were determined in skin suction blister fluid and plasma."	( Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. Kohlsdorfer, C; Siefert, HM; Steinke, W; Witt, A, 1999)	0.56
" On the basis of preclinical studies a terminal half-life appropriate for once-daily dosing in humans was predicted and confirmed by Phase I data."	( Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. Domdey-Bette, A; Henninger, K; Hucke, F; Kohlsdorfer, C; Siefert, HM; Stass, HH, 1999)	0.56
" After an overnight fast the volunteers were given a single 400 mg dosage of moxifloxacin either as a tablet or a 1 h infusion with a washout phase of at least 1 week between the two treatments."	( Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. Kubitza, D; Stass, H, 1999)	0.81
" Plasma moxifloxacin concentrations exceeded the MIC for Streptococcus pneumoniae throughout the 24-h dosing period."	( Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Agarwal, V; Heller, AH; Krol, GJ; Leese, PT; Lettieri, J; Sullivan, JT; Watson, S; Woodruff, M, 1999)	1
" It shows a low potential for drug interactions and dosage adjustment is not required for patients of advanced age or those with renal or mild hepatic impairment."	( Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Balfour, JA; Lamb, HM, 2000)	1.75
" Because of a balanced system of excretion, no dosage adjustments are required in patients with renal or hepatic impairment."	( Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Nightingale, CH, 2000)	1.75
" The possibility of once-daily dosing of the drug is strengthened."	( Effects of subinhibitory concentrations of moxifloxacin in an in-vitro dynamic model. Bartoli, A; Bottura, P; Capra, R; Maggiolo, F; Migliorino, M; Suter, F, 2000)	0.57
"4 (100%), respectively, over the dosing period."	( Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M, 2001)	0.57
" Administered as single doses, MXFX in a dosage of 150 mg per kg was more active than OFLO in the same dosage, and displayed the same level of activity as RMP in a dosage of 10 mg per kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT in a dosage of 10 mg per kg was more bactericidal than RMP administered in the same dosage, and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99."	( Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Grosset, J; Ji, B, 2000)	0.6
"The activity, pharmacokinetics, pharmacodynamics, efficacy, safety, drug interactions, and dosage and administration of moxifloxacin are reviewed."	( Moxifloxacin: clinical efficacy and safety. Culley, CM; Edwards, B; Klutman, N; Lacy, MK, 2001)	1.96
" Accumulation ratios ranged between 87% for the lowest dosage and 111% after repeated doses of 600mg once daily, indicating the absence of clinically relevant accumulation due to non-linear pharmacokinetics."	( Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Kubitza, D; Schühly, U; Stass, H, 2001)	0.57
"These studies indicate that, based on the safety profile and the pharmacokinetic behaviour of moxifloxacin, a dosage regimen of 400mg given once daily should be effective and well tolerated for the treatment of various infections."	( Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Kubitza, D; Schühly, U; Stass, H, 2001)	0.79
" Hence, moxifloxacin may be administered together with Ca2+ without dosage adjustments or special recommendations."	( Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Delesen, H; Möller, JG; Stass, H; Wandel, C, 2001)	0.99
" Moxifloxacin, given once daily, is free of many drug-drug interactions and requires no dosage adjustments in most renal hepatic deficient patients."	( The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Hoeffken, G; Meyer, HP; Verhoef, L; Winter, J, 2001)	1.5
" All quinolones tested selected for resistance; judicious use and proper dosing will be necessary to avoid resistance selection of newer broad-spectrum fluoroquinolones."	( Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. Appelbaum, PC; Davies, TA; Dewasse, BE; Jacobs, MR; Nagai, K, 2001)	0.52
"The aim of this study was to compare the efficacy and safety of once daily dosing with moxifloxacin (BAY 12-8039) with that of coamoxiclav given three times daily for the treatment of acute exacerbation of chronic bronchitis (AECB)."	( A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. Ballin, I; Bassaris, H; Hampel, B; Huchon, G; Reimnitz, P; Schaberg, T, )	0.59
" Gatifloxacin should be avoided in the same patient population, and the recommended dosage of 400 mg/day should not be exceeded."	( Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Frothingham, R, 2001)	0.53
" Dosage adjustments are not required in patients with renal impairment or in patients with mild to moderate hepatic insufficiency."	( Moxifloxacin in uncomplicated skin and skin structure infections. Jarvis, B; Muijsers, RB, 2002)	1.76
" The concentration at which the CRT equals the dosing interval is the minimum effective concentration, and is effectively the breakpoint."	( Calculation of composite recovery time: a new pharmacodynamic parameter. Gould, IM; MacKenzie, FM; Milne, KE, 2002)	0.31
"Most integral endpoints of antimicrobial effect, including area between the control growth and time-kill curves (ABBC), area above the curve (AAC) and area under the time-kill curve (AUBC) are determined over a dosing interval (tau), regardless of the actual effect duration."	( AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH, 2002)	0.53
" Sixteen hours after inoculation, therapy was given by intravenous administration of BMS at 20 mg/kg of body weight, followed 5 h later by administration at a dosage of 10 mg/kg (n = 9 animals) or MOX as two doses of 20 mg/kg every 5 h (n = 8 animals)."	( Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Barton, T; Bowlware, K; Hardy, RD; Iglehart, J; Katz, K; McCoig, CC; McCracken, GH; Michelow, IC; Rodriguez-Cerrato, V; Saavedra, J, 2003)	0.61
" AUC0-t/MIC was strongly associated with bacterial kill throughout the dosing interval."	( AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. Ariano, RE; Harding, GK; Iacovides, H; Sun, S; Zelenitsky, SA, 2003)	0.32
" For example, the cost implications of using manufacturers' recommendations for dosing in patients with renal dysfunction may be important, depending on the distribution of various levels of renal function within a patient population."	( A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Bosso, JA; Enzweiler, KA; White, RL, 2003)	0.32
" Also, costs of failing to adjust dosing regimens for decreased renal function were determined."	( A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Bosso, JA; Enzweiler, KA; White, RL, 2003)	0.32
" Costs potentially incurred by failing to adjust dosing for renal function were substantial."	( A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Bosso, JA; Enzweiler, KA; White, RL, 2003)	0.32
"Formulary decisions can be facilitated by considering factors such as patient characteristics and related dosing in addition to simple acquisition costs."	( A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Bosso, JA; Enzweiler, KA; White, RL, 2003)	0.32
" Penetration of moxifloxacin into the interstitial space fluid of healthy and inflamed subcutaneous adipose tissues was measured by use of in vivo microdialysis following administration of a single intravenous dosage of 400 mg in six diabetic and six nondiabetic patients with STIs."	( Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Joukhadar, C; Kovar, F; Lackner, E; Minar, E; Müller, M; Müller-Zellenberg, U; Stass, H, 2003)	1.02
" For a dose-response study, moxifloxacin was given immediately after MCAO in different doses and at different time points."	( Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. Braun, J; Dirnagl, U; Halle, E; Megow, D; Meisel, A; Meisel, C; Prass, K; Victorov, I; Volk, HD; Wolf, T, 2004)	0.62
" The described methods were successfully employed with high precision and accuracy for estimation of the total drug content of human plasma and for pharmaceutical dosage forms of moxifloxacin."	( Voltammetric behaviour and determination of moxifloxacin in pharmaceutical products and human plasma. Erk, N, 2004)	0.78
"To determine the steady-state, extracellular, and intracellular pulmonary disposition of moxifloxacin (MXF), levofloxacin (LEVO), and azithromycin (AZI) relative to that of the plasma over a 24-h dosing interval."	( Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C, 2004)	0.8
"0 micro g/mL) throughout the dosing interval."	( Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C, 2004)	0.58
" Significant increases in MIC were observed with monotherapy where moxifloxacin or doxycycline concentrations fell into the mutant selection window (MSW) for more than 80% of the dosing interval (AUC(24)/MIC 60 h)."	( Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH, 2004)	0.8
" A placebo-controlled and positive-controlled, period-balanced, double-blinded, 6-way crossover study evaluated therapeutic and supratherapeutic oral doses of vardenafil (10 and 80 mg, respectively) and sildenafil (50 and 400 mg, respectively), therapeutic doses of moxifloxacin (400 mg), and a placebo in 58 healthy men (mean age 53 years), with dosing every 3 days."	( Evaluation of vardenafil and sildenafil on cardiac repolarization. Boyle, DA; Dabiri, GA; Ilson, BE; Montague, TH; Morganroth, J; Patel, BR; Sethuraman, VS; Shaddinger, BC, 2004)	0.5
" Eyes were dosed according to a keratitis protocol; ie, every 15 minutes for 4 hours."	( Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. Herrygers, L; Lane, LC; Levine, JM; Nix, D; Noecker, RJ; Snyder, RW, 2004)	0.62
"In the keratitis dosing protocol, the mean concentration of moxifloxacin in the aqueous (n=9) was 11."	( Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. Herrygers, L; Lane, LC; Levine, JM; Nix, D; Noecker, RJ; Snyder, RW, 2004)	0.86
" There was no statistically significant difference between the 2 drugs in the cataract prophylaxis dosing model."	( Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. Herrygers, L; Lane, LC; Levine, JM; Nix, D; Noecker, RJ; Snyder, RW, 2004)	0.62
" Moxifloxacin has pharmacologic characteristics that support once-daily dosing regimens and dual routes of excretion that require little or no adjustment for renal or hepatic insufficiency."	( Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity. Caeiro, JP; Iannini, PB, 2003)	2.67
"To compare the effects of the commercial formulations of moxifloxacin and gatifloxacin on rabbit corneal epithelium using two dosing protocols: high-frequency dosing for bacterial keratitis and cataract surgery prophylaxis."	( Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols. Herrygers, LA; Lane, LC; Levine, JM; Noecker, RJ, 2005)	0.82
"Despite differences in formulations, with short-term dosing neither gatifloxacin nor moxifloxacin appears to be toxic to the corneal epithelium in this rabbit model."	( Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols. Herrygers, LA; Lane, LC; Levine, JM; Noecker, RJ, 2005)	0.8
" A dose-response effect on QT and QTc prolongation was observed."	( Effects of moxifloxacin on QT interval in conscious dogs. Hart, SM; Mittelstadt, SW, 2005)	0.72
" We evaluated with the same model similar regimens in which we increased the dosing of rifapentine from 10 to 15 mg/kg of body weight and of moxifloxacin from 100 to 400 mg/kg."	( Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Chauffour, A; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N, 2005)	0.81
" By selecting optimal antibiotics and dosing regimens, clinicians can avoid treatment failures and adverse events and can help prevent the emergence of further antibiotic resistance."	( Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Alfonso, E; Schlech, BA, 2005)	0.63
"5% ophthalmic solutions are toxic to the corneal epithelium when used with 1 of 2 dosing regimens in healthy human eyes."	( Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. Maclellan, D; Price, FW; Price, MO, 2005)	0.61
"5% did not result in clinically significant epithelial toxicity in healthy human corneas after dosing regimens of 4 times a day for 7 days or hourly for 10 hours dosing regimens."	( Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. Maclellan, D; Price, FW; Price, MO, 2005)	0.61
" Of note, the unmodified pharmacokinetic behaviour with no need for age-related dosage adjustments combined with the once-daily administration favouring compliance and the low potential for drug-drug pharmacokinetic interactions in case of polytherapy, make moxifloxacin particularly attractive in the treatment of elderly subpopulations at a very high risk of AECB."	( Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Dolcet, F; Furlanut, M; Lugatti, E; Pavan, F; Pea, F; Screm, MC; Talmassons, G, 2006)	0.76
"3% solution in the aqueous humor (AH) in humans after topical application with published levels of other available fluoroquinolones under similar dosing conditions."	( Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Aronowicz, JD; Caudle, D; McCulley, JP; Shine, WE, 2006)	0.33
" This regimen simulated a realistic postoperative dosing schedule."	( Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Aronowicz, JD; Caudle, D; McCulley, JP; Shine, WE, 2006)	0.33
"Aqueous humor antibiotic concentrations achieved at the time of cataract surgery after topical application can serve as an effective surrogate for what can be achieved with typical postoperative topical dosing (e."	( Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Aronowicz, JD; Caudle, D; McCulley, JP; Shine, WE, 2006)	0.33
" Dosing frequency had little effect on 2-mo culture status or tolerability of therapy."	( Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Burman, WJ; Chaisson, RE; Choudhri, S; Daley, CL; Engle, M; Goldberg, S; Johnson, JL; Mosher, AW; Munsiff, SS; Muzanye, G; Vernon, A; Zhao, Z, 2006)	1.78
"Once daily IV/PO moxifloxacin monotherapy was as least as effective as standard IV piperacillin-tazobactam/PO amoxicillin-clavulanate dosed multiple times daily for the treatment of cIAIs."	( Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Choudhri, S; Herrington, J; Malangoni, MA; Pertel, P; Song, J, 2006)	0.96
" Moxifloxacin causes no significant epithelial or endothelial toxicity, and has no effect on visual acuity or ocular surface integrity in healthy subjects treated using a dosing regimen that simulated prophylactic use following cataract surgery."	( The effect of moxifloxacin on the normal human cornea. Alfonso, EC; Donaldson, KE; Marangon, FB; Schatz, L; Venkatraman, AS, 2006)	1.6
" The value of dosing of antimicrobial agents based on MPC thresholds results in a rapid reduction in viable cells--even at higher inocula which are more reflective of organism burden in pneumonia."	( Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones. Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, C, 2006)	0.33
" The semimechanistic model that was developed might, after further refinement, serve as a tool for the development of optimal dosing strategies for antibacterial agents."	( Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Cars, O; Karlsson, MO; Löwdin, E; Nielsen, EI; Sandström, M; Viberg, A, 2007)	0.34
"Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin."	( Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases. Tyler, ME; Walter, K, 2006)	0.54
" The proposed methods were also applied for the determination of the investigated drugs in their pharmaceutical dosage forms and their validity was assessed using the standard addition technique with mean percentage recovery ranging from 100."	( Stability indicating methods for the determination of some fluoroquinolones in the presence of their decarboxylated degrades. Abd-El-Fattah, Lel-S; El-Guindi, NM; Mikael, HK; Salem, MY, 2006)	0.33
" The results demonstrated that the procedure is accurate, precise and reproducible (relative standard deviation <2%), while being simple, cheap and less time consuming and hence can be suitably applied for the estimation of moxifloxacin in different dosage forms and dissolution studies."	( Validated spectrophotometric methods for the estimation of moxifloxacin in bulk and pharmaceutical formulations. Ahmad, FJ; Chopra, S; Khar, RK; Motwani, SK, 2007)	0.77
" Pharmacokinetic indices (C(max)/MIC90) for topical dosing were all <1."	( In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. Flynn, HW; Harper, T; Miller, D, 2007)	0.34
"Plasma, dialysate and urine pharmacokinetic parameters for moxifloxacin and its main metabolites were calculated after single and multiple (7 days) dosing with 400 mg day(-1)."	( The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction. Bührmann, S; Kribben, A; Kubitza, D; Mitchell, A; Möller, JG; Schäfers, RF; Stass, H; Wenzel, RR, 2007)	0.8
" According to these findings, anuric critically ill patients who are undergoing EDD should be treated with the standard dosage of moxifloxacin (400 mg/d intravenously)."	( Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S, 2006)	0.86
"The present study was planned to investigate the plasma disposition kinetics and the pattern of moxifloxacin elimination in the milk of lactating ewes (n=6) following a single intravenous (IV) bolus or intramuscular (IM) injections at a dosage of 5 mg/kg in all animals."	( Disposition kinetics of moxifloxacin in lactating ewes. Goudah, A, 2008)	0.87
" Rabbits were subsequently dosed with 1 drop, 3 times per day for 4 days with either moxifloxacin, gatifloxacin, or a commercially available irrigating solution."	( Corneal wound healing in New Zealand White Rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%. Hiddemen, JW; McCartney, MD; Rice, RL; Shepard, AR; Wax, MB; Williams, KK, 2007)	0.78
"To evaluate the ocular surface and aqueous antimicrobial effects of gatifloxacin and moxifloxacin administered in two dosing regimens to patients undergoing phacoemulsification."	( Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery. Amico, LM; Bucci, FA; Evans, RE, 2008)	0.81
"8 years) undergoing elective pars plana vitrectomy were assigned to a dosing group: control (n = 3), which received no medication; single-dose (n = 11), which received one 400 mg oral dose of moxifloxacin 3 hours before surgery; and five-dose (n = 10), which received one 400 mg dose on each of the 4 days preceding surgery and a fifth dose 3 hours before surgery."	( Vitreal penetration of oral moxifloxacin in humans. Fuller, JJ; Hancock, HA; Lott, MN; Marcus, DM; McGwin, G; Singh, H; Singh, J, 2008)	0.83
"To evaluate the effect of 2 etravirine dosing regimens on QT/corrected QT interval (QTc) in HIV-negative volunteers and assess pharmacokinetic and additional safety parameters."	( Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. De Smedt, G; Hoetelmans, RM; Janssen, K; Kakuda, TN; Lachaert, R; Peeters, M; Schöller-Gyüre, M; Woodfall, B, 2008)	0.35
" Short-term dosing of etravirine in HIV-negative volunteers was generally safe and well tolerated."	( Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. De Smedt, G; Hoetelmans, RM; Janssen, K; Kakuda, TN; Lachaert, R; Peeters, M; Schöller-Gyüre, M; Woodfall, B, 2008)	0.35
" Placebo-adjusted mean changes from baseline in QTcF (Fridericia corrected), QTcI (individualized correction), PR, and QRS intervals were compared at each time point (time-matched analysis) and for values averaged across the dosing period (baseline-averaged analysis)."	( Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects. Ayalasomayajula, S; Bedigian, MP; Dieterich, HA; Dole, WP; Flannery, B; Howard, D; Vaidyanathan, S; Yeh, CM, 2008)	0.35
" In dose-response studies (0."	( Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin. Courvalin, P; Lismond, A; Mingeot-Leclercq, MP; Tulkens, PM; Van Bambeke, F, 2008)	0.54
"Both dosing regimens produced substantially higher aqueous concentrations than the known minimum inhibitory concentration for Staphylococcus epidermidis."	( Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin. Gajjar, D; Raj, SM; Vasavada, AR; Vasavada, V, 2008)	0.69
"5% administered three times daily is safe and cures bacterial conjunctivitis more effectively and significantly faster than polymyxin/trimethoprim dosed four times daily."	( A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. Cockrum, P; Dorfman, M; Granet, DB; Stroman, D, )	0.36
" Drug concentration analysis at various time points following instillation allows interpretation of the residence time and a rationale for dosing frequency."	( Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. O'Brien, TP; Torkildsen, G, 2008)	0.57
" After oral dosing of moxifloxacin, a substantial, dose-dependent increase in the QT-interval duration could be shown, as anticipated for this agent."	( Validation of the normal, freely moving Göttingen minipig for pharmacological safety testing. Guth, B; Klumpp, A; Markert, M; Mayer, K; Schuler-Metz, A; Schumacher, K; Stubhan, M; Trautmann, T, )	0.45
" Concentrations of all agents are predicted to exceed the MPC for ATCC 49226 for the entire dosage interval, while concentrations of moxifloxacin alone will exceed the MPC for m-49226."	( Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae. Allen, GP; Hankins, CD, 2009)	0.56
" coli (ATCC 25922, MG1655 and EC28044) were studied by exposing approximately 2 x 10(8) cfu/mL (20 mL) to escalating dosing regimens of moxifloxacin (ranging from 30 to 400 mg, once daily)."	( Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. Chang, KT; Hou, JG; Ledesma, KR; Prince, RA; Singh, R; Tam, VH, 2009)	0.88
" Electrocardiograms were recorded periodically over 24 hours at the end of placebo and highest dosing periods."	( Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. Chatterjee, DJ; Khutoryansky, N; Litwin, JS; Sprenger, CR; Zdravkovic, M, 2009)	0.35
" Once-daily dosing and proven efficacy suggest that moxifloxacin may be of value in acute, uncomplicated PID."	( A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Heystek, M; Ross, JD, 2009)	0.87
" The optimal dosage and duration have not been assessed."	( Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Amitrano, M; Grossi, L; Manzoli, L; Marzio, L; Sacco, F; Spezzaferro, M, 2010)	0.66
"1%) rates on day 5 +/- 1 of treatment (coprimary endpoints) in a randomized, double-blind, multicentre trial; both drugs were administered at a dosage of one drop in the affected eye(s) three times daily for 5 days."	( Besifloxacin ophthalmic suspension 0.6%. Carter, NJ; Scott, LJ, 2010)	0.36
" The patients were given ciclosporin (Sandimmun Optoral) capsules twice daily (total daily dosage 150-380 mg/day) throughout the study period."	( Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study. Bauer, S; Delesen, H; Kubitza, D; Mai, I; Roots, I; Stass, H, 2010)	1.8
" The once-daily dosing of moxifloxacin monotherapy may be a useful alternative for beta-lactam-based standard therapy."	( Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. An, MM; Cao, YB; Gao, PH; Jiang, YY; Shen, H; Zou, Z, 2010)	2.1
"To determine the aqueous humor concentrations of moxifloxacin and besifloxacin after routine preoperative topical dosing in patients having cataract surgery."	( Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. Kim, A; Pratzer, KA; Stark, WJ; Yoshida, J, 2010)	0.93
" Likewise, no safety/tolerability concerns were observed after either supratherapeutic or 20-mg dosing to either population."	( Evaluation of the effects of AZD3480 on cardiac repolarization: a thorough QT/QTc study using moxifloxacin as a positive control. Alverlind, S; Dalén, P; Hårdemark, HG; Jostell, KG; Vik, T, 2010)	0.58
"5% throughout the 7-day dosing period and for at least 7 days thereafter."	( Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Brubaker, K; Crean, CS; Haque, RM; Hwang, DG; Stewart, WC; Zink, RC, 2010)	0.63
"Azithromycin 1% demonstrated high, therapeutic levels in the conjunctiva that were maintained up to 7 days after completion of a 1-week dosing regimen."	( Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Brubaker, K; Crean, CS; Haque, RM; Hwang, DG; Stewart, WC; Zink, RC, 2010)	0.63
"3% eye drops administered in two different dosing regimens during phacoemulsification surgery."	( Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery. Akova, YA; Babaoğlu, MÖ; Bozkurt, A; Çetinkaya, A; Çolak, M; Güngör, SG; Yasar, Ü, 2011)	0.37
" The penetration of both antibiotics increased significantly when the dosage of the agent was doubled."	( Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery. Akova, YA; Babaoğlu, MÖ; Bozkurt, A; Çetinkaya, A; Çolak, M; Güngör, SG; Yasar, Ü, 2011)	0.37
" We had previously developed a mathematical modelling framework to describe the dynamics of bacterial populations under the effect of antimicrobials, which could facilitate the design of optimal dosing regimens."	( Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH, 2011)	0.37
" Based on the best-fit model parameters, the likelihood of resistance development associated with various dosing regimens was predicted."	( Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH, 2011)	0.37
"Bacterial regrowth and resistance development were observed with suboptimal dosing regimens."	( Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH, 2011)	0.37
"Our model was found to be reasonable in characterizing biphasic killing of fluoroquinolones and predicting dosing regimens to suppress resistance development."	( Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH, 2011)	0.37
"An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit."	( Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer. Berube, C; Lee, R; Wen, A, 2011)	1.81
" Use of pharmacodynamic/pharmacokinetic models has resulted in design of new doses and dosing schedules for disseminated MAC, as well as new susceptibility breakpoints for ethambutol and moxifloxacin."	( Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium. Deshpande, D; Gumbo, T, 2011)	0.56
" MOXI-AF or its vehicle was dosed one drop twice-daily for 3 days."	( Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. Bartell, J; Cupp, G; Garber, R; Stroman, D; Tauber, S; Vohra, F, 2011)	0.61
"5% moxifloxacin ophthalmic formulation, MOXI-AF, provides effective eradication of the three principle causative pathogens of bacterial conjunctivitis across all age groups when dosed twice-daily for 3 days."	( Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. Bartell, J; Cupp, G; Garber, R; Stroman, D; Tauber, S; Vohra, F, 2011)	1.23
"5, 1 (end of infusion), 2, 4, 8, 12, and 24 h after intravenous dosing of linezolid 600 and 1,200 mg."	( Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation. Alvey, C; Choo, HW; Cuozzo, C; Damle, B; Kirby, D; Labadie, RR; Riley, S, 2011)	0.37
" The selection and magnitude of the PK/PD index were, however, shown to be sensitive to differences in PK in subpopulations, uncertainty in MICs, and investigated dosing intervals."	( Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Cars, O; Friberg, LE; Nielsen, EI, 2011)	0.37
" Serial venous blood samples were drawn up to 72 h after dosing and moxifloxacin plasma levels were measured by a validated HPLC method with fluorescence detection."	( Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. Batens, H; Blot, S; Boussery, K; Colin, P; De Paepe, P; De Smet, J; Ruige, J; Van Bocxlaer, J; Van Bortel, LM; Van Nieuwenhove, Y; Vogelaers, D, 2012)	0.92
"4 mg · h/L after oral dosing and 52."	( Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. Batens, H; Blot, S; Boussery, K; Colin, P; De Paepe, P; De Smet, J; Ruige, J; Van Bocxlaer, J; Van Bortel, LM; Van Nieuwenhove, Y; Vogelaers, D, 2012)	0.69
" The dose of moxifloxacin was 400 mg daily in all studies, but dosing frequency differed from 3 to 7 days per week."	( Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis. Fouad, M; Gallagher, JC, 2011)	2.18
" Novel approaches for ophthalmic drug delivery need to be established to increase the ocular bioavailability by overcoming the inherent drawbacks of conventional dosage forms."	( Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride. Deshmukh, RV; Gaikwad, KR; Manvi, FV; Nanjwade, BK; Parikh, KA, 2012)	0.63
" Regarding antibiotic susceptibilities: (i) amoxicillin is still useful for empirical therapy but with a high daily dose; (ii) cefuroxime axetil and macrolides (but not telithromycin) are inappropriate for empirical therapy; and (iii) moxifloxacin and levofloxacin are the next 'best empirical choice' (no resistant isolates) but levofloxacin will require 500 mg twice-daily dosing for effective coverage."	( Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. Carbonnelle, S; De Bel, A; Dediste, A; Glupczynski, Y; Huang, TD; Jacobs, F; Jordens, P; Lismond, A; Schatt, P; Tulkens, PM; Van Bambeke, F; Verhaegen, J; Verschuren, F, 2012)	0.56
" Its primary objective was to compare supratherapeutic repeated dosing of strontium ranelate (4 g day⁻¹ for 15 days) with placebo on the largest time-matched mean QT(c) variation, from baseline to under treatment values, in healthy subjects."	( Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers. Arezina, R; Camm, AJ; Lorch, U; Naseem, A; Taubel, J; Wang, D, 2012)	0.38
"5 years) were included to receive 1 day of placebo followed by 15 days of supratherapeutic repeated dosing of strontium ranelate (4 g day⁻¹), in a 4 month, randomized, placebo (16 days) and positive-controlled (single dose of moxifloxacin 400 mg preceded by 15 days of placebo), double-blind, double dummy, crossover design."	( Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers. Arezina, R; Camm, AJ; Lorch, U; Naseem, A; Taubel, J; Wang, D, 2012)	0.56
"The safety of moxifloxacin is essentially comparable to that of standard therapies for patients receiving the currently registered dosage and for whom contraindications and precautions of use (as in the product label) are taken into account."	( Moxifloxacin safety: an analysis of 14 years of clinical data. Arvis, P; Kruesmann, F; Tulkens, PM, 2012)	2.18
" Ten second electrocardiograms were obtained for time-matched baseline on days -2 and -1, three time points after dosing on day 1 for moxifloxacin and five time points on day 7 for atomoxetine and placebo."	( Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. Allen, AJ; April, J; Beasley, CM; Haber, H; Jin, L; Kauffman, L; Kothare, PA; Loghin, C; Mitchell, MI, 2013)	0.59
" Triplicate ECGs were performed continuously at baseline (day 0), before dosing, and over 24 hours after dosing in each treatment period."	( Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers. Haugen, G; Kellerman, DJ; Kori, S; Voloshko, P, 2012)	0.38
"Multiple dosing with bitopertin 30 mg or 175 mg did not affect QTcF in these healthy male volunteers."	( Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. Banken, L; Hahn, M; Hofmann, C; Martin-Facklam, M; Nagel, S; Swearingen, D, 2012)	0.38
"There was no effect of vismodegib on the QTc interval when dosed daily at 150 mg to steady state."	( Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers. Ayache, JA; Chang, I; Dresser, MJ; Dufek, MB; Ezzet, F; Graham, RA; Jin, JY; Low, JA; Wang, B; Zerivitz, K, 2013)	0.39
" Physicians complied with the recommended 400 mg once-daily dose in a large proportion of patients, confirming the advantages of this simple dosing regimen."	( Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). Chuchalin, A; Dokic, D; Marschall, HP; Petri, T; Tokić, M; Zakharova, M, 2013)	0.7
"5 h after intravenous dosing with a supratherapeutic dose (1,500 mg) of ceftaroline fosamil, 400 mg moxifloxacin (positive control), and placebo."	( Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval. Llorens, L; Rank, D; Rekeda, L; Riccobene, TA, 2013)	0.61
"Levofloxacin dosing regimens with low AUC/MIC ratios select for efflux pump overexpression, leading to fluoroquinolone resistance."	( Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. Bowker, KE; Garvey, MI; Macgowan, AP; Noel, AR; Tomaselli, SG, 2013)	0.66
" The standard dosing provides sufficient drug exposure for treatment of CAP but for HAP it does so only when a highly susceptible pathogen is present."	( Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. Haeberle, HA; Heininger, A; Kees, F; Kees, MG; Kloft, C; Schaeftlein, A, 2013)	0.61
" The typical moxifloxacin PK profile is also altered by food prior to dosing reducing the Cmax and delays the peak effects on QTc up to several hours thereby reducing the overall magnitude of the effect and delaying the peak QTc prolongation."	( Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. Batchvarov, V; Camm, AJ; Ferber, G; Lorch, U; Savelieva, I; Taubel, J, 2014)	1.04
" The methods were validated in terms of accuracy and precision and were successfully applied to the determination of MOX in its pharmaceutical dosage form."	( New spectrophotometric methods for the determination of moxifloxacin in pharmaceutical formulations. Aboul-Enein, HY; Ebraheem, SA; Elbashir, AA; Elwagee, AH, 2013)	0.64
"The goal of this study was to assess the effect on cardiac repolarization (QTc interval) of repeated oral dosing of ipragliflozin at therapeutic (100 mg/d) and supratherapeutic (600 mg/d) levels in healthy subjects."	( Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study. Abeyratne, A; Dietz, A; Kadokura, T; Keirns, J; Krauwinkel, W; Smulders, R; Zhang, W, 2013)	0.39
" Study treatments were administered orally for 3 days in five separate periods in which subjects were dosed with (1) a single dose of 75 mg lomitapide on Day 1 followed by a single dose of 200 mg on Day 3; (2) ketoconazole 200 mg BID; (3) ketoconazole with a single dose of 75 mg lomitapide on Day 3; (4) a single dose of 400 mg moxifloxacin on Day 3 and (5) placebo."	( Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole. Darpo, B; Ferber, G; Sager, P; Sumeray, M; Zhou, M, 2013)	0.77
" Digital 12-lead ECGs were recorded at baseline and at 10 time points over 24 hours after dosing in each treatment period."	( Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. Carlson, G; Gottfridsson, C; Lappalainen, J; Sostek, M, 2013)	0.39
" Similar findings were observed using QTcB; the upper limits of the 2-sided 90% CI were <10 msec at all time points after dosing with naloxegol 25 or 150 mg."	( Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. Carlson, G; Gottfridsson, C; Lappalainen, J; Sostek, M, 2013)	0.39
" The primary end point was the comparison of evacetrapib effect on the population-corrected QT interval (QTcP) to that of placebo at 7 time points following dosing on day 10."	( Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants. Friedrich, S; Krueger, KA; Suico, JG; Zhang, W, 2014)	0.4
" A 1200-mg supratherapeutic dose of evacetrapib was considered to be well tolerated after 10 days of daily dosing in healthy participants."	( Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants. Friedrich, S; Krueger, KA; Suico, JG; Zhang, W, 2014)	0.4
"Given the ever increasing number of obese patients and obesity related bypass surgery, dosing recommendations in the post-bypass population are needed."	( Moxifloxacin dosing in post-bariatric surgery patients. Bortel, LM; Boussery, K; Colin, P; De Waele, J; Eleveld, DJ; Ruige, J; Struys, MM; T'Jollyn, H; Van Bocxlaer, J, 2014)	1.85
"25 mg l(-1) , standard moxifloxacin dosing does not attain adequate levels in this population."	( Moxifloxacin dosing in post-bariatric surgery patients. Bortel, LM; Boussery, K; Colin, P; De Waele, J; Eleveld, DJ; Ruige, J; Struys, MM; T'Jollyn, H; Van Bocxlaer, J, 2014)	2.16
"Throughout our PK-PD simulation study, it became apparent that, whenever optimal bacterial resistance suppression is deemed necessary, the standard moxifloxacin dosing will not be sufficient."	( Moxifloxacin dosing in post-bariatric surgery patients. Bortel, LM; Boussery, K; Colin, P; De Waele, J; Eleveld, DJ; Ruige, J; Struys, MM; T'Jollyn, H; Van Bocxlaer, J, 2014)	2.04
" The frequency of preoperative and/or postoperative dosing was generally lower for besifloxacin than that for moxifloxacin."	( Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients. Clinch, TE; Majmudar, PA, 2014)	0.61
" In non-adherent dosing scenarios, LFX 500 mg q24 h was not able to reach the PK/PD index guaranteeing clinical efficacy."	( Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study. Carral, N; Lukas, JC; Oteo, I; Suarez, E, 2015)	0.67
" It highlights available intracameral antibiotics with respect to pharmacology, spectrum of activity, dosage and preparation, safety, and efficacy profiles, as well as toxic anterior segment syndrome risks to better define the potential use of these medications in the prevention of endophthalmitis."	( Intracameral antibiotics: Safety, efficacy, and preparation. Braga-Mele, R; Chang, DF; Henderson, BA; Mamalis, N; Talley-Rostov, A; Vasavada, A, 2014)	0.4
" The two treatment groups consisted of SRP combined with systemically administered MOX at the dosage of 400 mg once daily for 7 days or SRP + placebo once daily for 7 days."	( Adjunctive moxifloxacin in the treatment of generalized aggressive periodontitis patients: clinical and microbiological results of a randomized, triple-blind and placebo-controlled clinical trial. Ardila, CM; Ariza-Garcés, AA; Boderth-Acosta, G; Guzmán, IC; Martelo-Cadavid, JF, 2015)	0.81
" The proposed method has been applied successfully for the estimation of moxifloxacin hydrochloride in tablet dosage form with no interference from the excipients."	( Development and validation of sensitive kinetic spectrophotometric method for the determination of moxifloxacin antibiotic in pure and commercial tablets. Ashour, S; Bayram, R, 2015)	0.87
" Modeling demonstrated that the discrepant results may have been due to a baseline shift after repeat dosing and baseline differences between the treatments."	( Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimod. Arya, N; Barbour, AM; Fossler, MJ; Glaser, R; Magee, M; Patel, BR; Shaddinger, B; Tao, W; Tombs, L, 2015)	0.42
" The effect of moxifloxacin on QT interval prolongation was well explained by the nonlinear dose-response (Emax) model, and the effect by 800 mg was only slightly greater than that of 400 mg."	( Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects. Chung, JY; Han, S; Hong, T; Jeon, S; Lee, J; Lim, KS; Park, GJ; Park, WS; Yim, DS; Yu, KS, 2015)	1.01
"5, 3, 4, 5, 6, 12, 18, and 24 h after dosing with delafloxacin at 300 mg intravenously (i."	( A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Benedict, MS; Cammarata, SK; Lawrence, LE; Litwin, JS; Sun, E; Thorn, MD, 2015)	0.42
" Each dose was administered on a separate dosing day."	( Effects of group housing on ECG assessment in conscious cynomolgus monkeys. Adkins, D; Hu, M; Lu, J; Oldman, K; Platz, S; Ren, J; Schofield, J; Skinner, M; Wang, S; Xing, G; Yu, H; Zhao, L; Zheng, W, )	0.13
"Therapeutic drug monitoring (TDM) of second-line antituberculosis drugs would allow for optimal individualized dosage adjustments and improve drug safety and therapeutic outcomes."	( Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS, 2015)	0.42
" The once-daily dosing of moxifloxacin monotherapy may be a useful alternative for other recommended antibiotic therapy."	( A Meta-analysis of Sequential Intravenous/Oral Moxifloxacin Monotherapy for Treatment of Skin and Skin Structure Infections. Chu, Y; Jiang, MY; Luo, YF; Qu, J; Qu, LY, 2015)	0.97
" The results of these studies suggest the continued effectiveness of the dosage of 400 mg a short course (7 days) over 15 years of practical use of the drug, which in its clinical efficacy is superior to amoxicillin/clavulanate, cefuroxime axetil and levofloxacin."	( [15-year experience of moxifloxacin in the treatment of patients with bacterial rhinosinusitis]. Edzhe, MA; Hon, EM; Korostelev, SA; Miroshnichenko, NA; Ovchinnikov, AY, 2015)	0.72
" ECG data were extracted from a continuous recording predose and serially after dosing on the treatment day."	( Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects. Bai, SA; Darpo, B; Ferber, G; Finn, A; Xiang, Q; Zhou, M, 2016)	0.43
" In ECG evaluations performed after dosing with pomalidomide 4 mg (therapeutic dose) or 20 mg (supratherapeutic dose), the upper limit of the two-sided 90 % CI for mean change from baseline and placebo-corrected QTcF was <10 ms at all postdose time points, which is below the defined threshold of regulatory concern."	( A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects. Assaf, M; Liu, L; Mondal, SA; O'Mara, E, 2016)	0.43
" These changes could enhance the drug efficacy, but they could also cause drug accumulation, which might induce adverse effect, so it was suggested that the drug dosage should be adjusted and the drug concentration in plasma should be monitored if moxifloxacin and rifampicin are co-administered."	( Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. Huang, L; Huang, Y; Liu, J; Shi, L; Xiao, H; Yu, X, 2016)	0.9
" Electrocardiograms (ECGs) and pharmacokinetic samples were obtained on each dosing day; baseline ECGs were taken pre-dose."	( Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study. Bowman, J; Chen, X; Punwani, N; Soloviev, M; Williams, W; Yeleswaram, S, 2014)	0.4
" Median rifapentine area under the concentration-time curve (AUC0-24) was 313 mcg*h/mL, similar to recent studies of rifapentine dosed at 450-600 mg daily."	( A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM, 2016)	0.69
"Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia."	( SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. Das, AF; Fernandes, P; File, TM; Gonong, JRV; Jamieson, BD; Keedy, K; Oldach, D; Rewerska, B; Sheets, A; Taylor, D; Vucinic-Mihailovic, V, 2016)	0.63
" All patients received 400 mg intravenously on day 1 and were permitted to switch to oral dosing when clinically indicated."	( SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. Das, AF; Fernandes, P; File, TM; Gonong, JRV; Jamieson, BD; Keedy, K; Oldach, D; Rewerska, B; Sheets, A; Taylor, D; Vucinic-Mihailovic, V, 2016)	0.63
" Surface modified NPs (MOX-PEG-WSC NPs) were prepared to provide controlled delivery and circulate in the bloodstream for an extended period of time, thus minimizing dosing frequency."	( Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles. Devi, VK; Mustafa, S; Pai, RS, 2017)	0.71
"To review current and past practices of intracameral antibiotic administration for infection prophylaxis in cataract surgery; to review the benefits and liabilities of available prophylactic drugs, dosage determination, and administration protocols; and to devise an optimum dose and administration protocol for intracameral moxifloxacin."	( Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis. Arshinoff, SA; Modabber, M, 2016)	0.87
" Animals received either vehicle or vehicle followed by ascending doses of moxifloxacin each on a different dosing day."	( Detecting drug-induced changes in ECG parameters using jacketed telemetry: Effect of different data reduction techniques. Lu, J; Oldman, K; Ren, J; Skinner, M; Xing, G, )	0.36
" There were fewer statistically significant differences between dosing days in animals given vehicle when the large duration averages and super-interval reduction techniques were used."	( Detecting drug-induced changes in ECG parameters using jacketed telemetry: Effect of different data reduction techniques. Lu, J; Oldman, K; Ren, J; Skinner, M; Xing, G, )	0.13
" Use of larger duration averages or super-intervals may facilitate data interpretation by reducing the incidence of spurious significant differences that occur by chance between dosing days."	( Detecting drug-induced changes in ECG parameters using jacketed telemetry: Effect of different data reduction techniques. Lu, J; Oldman, K; Ren, J; Skinner, M; Xing, G, )	0.13
" There were no serious side effects observed with the use of linezolid in reduced dosage of 600 mg×1/day for a duration of 9 months."	( Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy. Olesen, JS; Wang, M; Wejse, C, 2017)	0.46
"Tedizolid is an orally bioavailable oxazolidinone with once-daily dosing and broad-spectrum Gram-positive activity."	( Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis. Werth, BJ, 2017)	0.46
"We compared the pharmacokinetics of moxifloxacin during rifampicin co-treatment or when dosed alone in African patients with drug-susceptible recurrent TB."	( Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. Adamson, J; Chirehwa, M; Denti, P; Essack, S; Govender, K; Kimba-Phongi, E; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N; Yende-Zuma, N, 2017)	1
" Other options such as ertapenem and moxifloxacin may be reasonable where multiple daily dosing or intravenous administration is inappropriate."	( Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections. Hayashi, Y; Katayama, M; Suzuki, D; Takimoto, K; Wang, Q, 2017)	0.73
" There was no significant difference in SLE history, Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2000), Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SLICC/ACR), hematologic examination results, and corticosteroid dosage between 2 groups."	( Successful treatment using corticosteroid combined antibiotic for acute acalculous cholecystitis patients with systemic lupus erythematosus. Chen, W; He, X; Hong, T; Li, B; Liu, W; Qu, Q, 2017)	0.46
" Fixed drug combinations not only cut the cost but also the dosage and improve the compliance of patients in the immediate post operative period."	( Safety of Fixed drug Combination in Post -Operative Cataract Patients, at Tertiary Care Centre - In South India. Anuradha, A; Nishath, S; Rashmi, G; Shilpa, R; Vidyadevi, M, 2017)	0.46
" Dosing errors led to the majority of toxicities with cefuroxime."	( Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis. Ambati, BK; Bardsley, T; Bondalapati, S; Bowen, RC; Evans, PR; Greene, T; Kliethermes, M; Lawyer, TW; Mamalis, CA; McFarland, M; Rudnisky, CJ; Shi, D; Snow, KB; Zhou, AX, 2018)	0.71
" The developed sustained release in situ gel formulations could enhance patient's compliance by reducing the dosing frequency and also act as an alternative treatment to curb periodontitis."	( Investigation on solution-to-gel characteristic of thermosensitive and mucoadhesive biopolymers for the development of moxifloxacin-loaded sustained release periodontal in situ gels. Jnanendrappa, N; Meka, VS; Quah, SY; Sahu, PS; Sheshala, R; Tan, GC, 2019)	0.72
" After oral dosing of moxifloxacin to the dogs, a substantial, dose-dependent increase in the QT-interval duration could be shown, as anticipated for this agent."	( A new telemetry-based system for assessing cardiovascular function in group-housed large animals. Taking the 3Rs to a new level with the evaluation of remote measurement via cloud data transmission. Cioaga, M; Guth, BD; Krause, F; Markert, M; Mouriot, S; Trautmann, T; Wetzel, M, )	0.45
"A simplified dosing regimen was selected to follow the development of ophthalmic pazufloxacin based on its efficacy and safety profile."	( Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. Baiza-Durán, L; Casillas-Magallanes, M; Gómez-Bastar, PA; González-Lomelí, M; Lizárraga-Corona, A; Mercado-Sesma, AR; Montoya-Sánchez, IM; Mora-González, A; Ochoa-Tabares, JC; Olvera-Montaño, O; Oregon-Miranda, AA; Orozco-Carroll, M; Páez-Garza, JH; Pérez-Balbuena, AL; Sandoval-Delgadillo, LI; Saucedo-Rodríguez, LR; Villanueva-Najera, MA, 2018)	0.72
"There was a good correlation between QTcF and J-Tpeak_c prolongation after oral dosing of 400 mg moxifloxacin with placebo-adjusted, change-from-baseline (ΔΔ) J-Tpeak_c of ~12 ms at concentrations that caused ΔΔQTcF of ~20 ms."	( Challenges in implementing and obtaining acceptance for J-Tpeak assessment as the clinical component of CiPA. Couderc, JP; Darpo, B, )	0.35
" Through Monte Carlo simulations the quantitative output of this in vitro study was bridged to the human patient population to inform optimal dosage regimens while accounting for clinical minimum inhibitory concentration (MIC) distributions."	( Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. Brown, DL; Derendorf, H; Drusano, GL; Heinrichs, MT; Louie, A; Maynard, MS; Peloquin, CA; Rand, KH; Sy, SKB, 2019)	0.83
" However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized."	( The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. Alffenaar, JWC; Kosterink, JGW; Pranger, AD; van der Werf, TS, 2019)	0.51
" A dosing strategy for each age cohort (Cohort 1: ≥6 years to ≤14 years; Cohort 2: ≥2 years to <6 years; Cohort 3: >3 month to <2 years) was developed using physiology-based pharmacokinetic modeling combined with a stepwise dosing scheme to obtain a similar exposure to adults receiving 400 mg of moxifloxacin."	( Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study. Arrieta, AC; Bradley, JS; James, LP; Lettieri, J; Stass, H; Sullivan, JE; Vanevski, KM; Willmann, S, 2019)	0.92
" In study 1 (N = 12), the supratherapeutic dosing regimen achieved exposure ∼3."	( Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects. Brandquist, C; Chakravarthy, M; Gutierrez, M; Liu, C; Liu, F; Mahon, C; McCrea, J; Mostoller, K; Panebianco, D; Stoch, SA; Zajic, S, 2019)	0.51
" The resulting model proposed an age-dependent dosing regimen that was tested in a phase I study."	( Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin. Coboeken, K; Eissing, T; Frei, M; Lippert, J; Stass, H; Sutter, G; Wendl, T; Willmann, S, 2019)	0.71
" We previously reported this variability in a study of four human ether-a-go-go-related gene (hERG) potassium channel-blocking drugs in which each subject underwent intensive pharmacokinetic and pharmacodynamic sampling such that subjects had 15 time-matched plasma drug concentration and electrocardiogram measurements throughout 24 hours after dosing in a phase I clinical research unit."	( Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs. Blinova, K; Daluwatte, C; Patel, D; Schocken, D; Strauss, DG; Vicente, J; Wu, JC, 2019)	0.51
"To test the effect of injection volume and concentration on dosing and residence time of moxifloxacin in the anterior chamber (AC)."	( Injection volume and intracameral moxifloxacin dose. Gardner, S; Shorstein, NH, 2019)	1.01
" The AC concentrations and elimination rates of the drug for two AC volumes were modeled for each dosing method."	( Injection volume and intracameral moxifloxacin dose. Gardner, S; Shorstein, NH, 2019)	0.79
" The mathematical model predicted that variation in dosing in each group would result in differences of 12 minutes or less for the presence of the drug in the AC."	( Injection volume and intracameral moxifloxacin dose. Gardner, S; Shorstein, NH, 2019)	0.79
" A 12-lead electrocardiogram was recorded in triplicate before dosing and at selected time points up to 72 hours after dosing."	( A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects. Abbas, R; Bachinsky, M; Chappell, PB; Crownover, PH; Damle, B; LaBadie, RR; Riley, S, 2020)	0.56
"The present investigation explores the development and characterization of moxifloxacin hydrochloride and ketorolac tromethamine combination loaded Eudragit RL 100 nanosuspension for ocular drug delivery in order to overcome the problems associated with conventional dosage forms."	( Eudragit RL100 Based Moxifloxacin Hydrochloride and Ketorolac Tromethamine Combination Nanoparticulate System for Ocular Drug Delivery. Pawar, P; Salvi, V, 2020)	1.11
"In this monograph, literature data is reviewed to evaluate the feasibility of waiving in vivo bioequivalence testing and instead applying the Biopharmaceutics Classification System (BCS) based methods to the approval of immediate-release solid oral dosage forms containing moxifloxacin hydrochloride as the sole active pharmaceutical ingredient."	( Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride. Abdallah, DB; Abrahamsson, B; Charoo, NA; Cristofoletti, R; Dressman, J; Groot, DW; Langguth, P; Mehta, M; Parr, A; Parveen, T; Polli, JE; Shah, VP; Tajiri, T, 2020)	0.97
" 12-Lead Holter ECGs were recorded from 1 h before dosing until at least 24 h after each dose."	( Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus. Bolze, S; Dubourg, J; Felices, M; Fouqueray, P; Perrimond-Dauchy, S; Voiriot, P, 2020)	0.56
"The effect of AT on QT interval prolongation may not have been significant at the dosage of 400 mg."	( Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate. He, YC; Huang, JH; Li, LJ; Li, YF; Liang, LY; Wang, K; Xu, FY; Yang, J; Zheng, QS, 2020)	0.56
" Although supratherapeutic exposure of pretomanid relative to the now-recommended dosing with food was not achieved, these findings contribute to the favorable assessment of cardiac safety for pretomanid."	( Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers. El-Amin, W; Everitt, D; Li, M; Makhene, MK; Nedelman, J; Osborn, B; Saviolakis, GA; Yang, TJ, 2021)	0.84
"5% moxifloxacin eye drops alone, administered every 4 or 6 hours, achieve an AC concentration just above or at the mutant prevention concentration (MPC) for MSSA, respectively, whereas 8-hour dosing produces levels generally below the MPC."	( Incremental effect of topical and oral moxifloxacin administration with surgical intracameral prophylaxis. Arshinoff, SA; Hu, A; Lukewich, MK; Modabber, M, 2021)	1.51
" The results indicate that MOX-HME inserts could potentially provide a once-a-day application, consequently reducing the dosing frequency and acting as an alternative delivery system in the management of bacterial infections."	( Development and optimization of hot-melt extruded moxifloxacin hydrochloride inserts, for ocular applications, using the design of experiments. Dudhipala, N; Komanduri, N; Majumdar, S; Repka, MA; Thakkar, R; Tripathi, S, 2021)	0.87
"A reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the identification and quantification of moxifloxacin hydrochloride-related substances in finished dosage forms."	( A rapid RP-HPLC stability-indicating method development and validation of moxifloxacin hydrochloride-related substances in finished dosage forms. Algete, P; Boodida, S; Vankalapati, KR, 2021)	1.05
" The typical telemetry study involves a dose-response analysis of QTc intervals over time using a crossover (CO) design."	( Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis. Baublits, J; Chandra, FA; Chui, RW; Engwall, MJ; Jones, ZW; Vargas, HM, 2021)	0.98
" We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB."	( Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; Thee, S; van der Laan, LE; Wiesner, L; Winckler, JL, 2022)	2.5
" Model-based simulations of moxifloxacin pharmacokinetics predicted that current dosing recommendations are too low in children."	( Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; Thee, S; van der Laan, LE; Wiesner, L; Winckler, JL, 2022)	2.46
" Continuous electrocardiogram monitoring was performed from >60 min before dosing until 48 h after dosing."	( An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study. He, Y; Kallend, D; Koren, MJ; Mason, J; Smith, PF; Stoekenbroek, R; Wijngaard, P, 2022)	0.72
" Subsequently, the effects of pH value, photocatalyst dosage and MOX concentration on the photocatalytic behavior were also studied."	( Aminobenzaldehyde convelently modified graphitic carbon nitride photocatalyst through Schiff base reaction: Regulating electronic structure and improving visible-light-driven photocatalytic activity for moxifloxacin degradation. Bian, C; Dong, X; Li, Y; Liu, Y; Sun, P; Wang, W; Xiao, X; Xiao, Y, 2023)	1.1
" One oral dose of vehicle, LEVO (10 mg/kg/species) or moxifloxacin (MOXI; 30 mg/kg/dog; 80 mg/kg/NHP) was administered to instrumented animals (N = 8/species) using a cross-over dosing design; MOXI was the in-study positive control."	( Evaluation of levocetirizine in beagle dog and cynomolgus monkey telemetry assays: Defining the no QTc effect profile by timepoint and concentration-QTc analysis. Baublits, J; Chandra, FA; Chui, RW; Engwall, MJ; Jones, ZW; Vargas, HM; Wahlstrom, J, 2023)	1.16
" For designing an effective clinical cure, a combination of these three agents is required at a therapeutic dosage regimen."	( Simultaneous estimation of voriconazole, moxifloxacin, and pirfenidone in rabbit lacrimal matrix using LC-MS/MS: an application to preclinical ocular pharmacokinetics. Agrawal, S; Bhatta, RS; Bisen, AC; Biswas, A; Mishra, A; Sanap, SN; Verma, SK, 2023)	1.18
" The recommended volume to be injected is different for the 2 concentrations, and incorrect dosing can increase the risk of toxic anterior segment syndrome or endophthalmitis."	( ASCRS clinical advisory on intracameral moxifloxacin injection for infection prophylaxis. Chang, DF; Mah, FS; Mamalis, N; Miller, KM; Myers, WG; Shorstein, NH, 2023)	1.18
", minimizing total drug dosage and lowering time needed to sterilize granulomas."	( Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens. Borish, HJ; Budak, M; Chishti, HB; Cicchese, JM; Dartois, V; Fillmore, D; Flynn, JL; Frye, LJ; Kirschner, DE; Kracinovsky, K; Lin, PL; Linderman, JJ; Maiello, P; Sakal, J; Scanga, CA; Tomko, J; White, AG, 2023)	1.14

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
quinolinemonocarboxylic acid	Any aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent.
quinolone
cyclopropanes	Cyclopropane and its derivatives formed by substitution.
pyrrolidinopiperidine	Any organic heterobicyclic compound containing ortho-fused pyrrolidine and piperidine rings.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
quinolone antibiotic	An organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
fluoroquinolone antibiotic	An organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Voltage-dependent L-type calcium channel subunit alpha-1C	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	168.9000	0.0220	1.6422	8.9000	AID1207666
Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)	IC50 (µMol)	173.0000	0.0003	2.6311	9.0000	AID1207753
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	1,000.0000	0.1100	7.1903	10.0000	AID1449628
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	79.4328	0.0001	1.7536	10.0000	AID1207530
DNA gyrase subunit B	Staphylococcus aureus	IC50 (µMol)	14.8017	0.0040	1.5020	7.7000	AID1801385; AID1909942; AID275463; AID406832; AID595856; AID695234
DNA gyrase subunit A	Escherichia coli K-12	IC50 (µMol)	1.4000	0.0239	0.5629	5.2300	AID262137; AID530379
DNA gyrase subunit B	Escherichia coli K-12	IC50 (µMol)	1.4000	0.0050	0.4398	5.2300	AID262137; AID530379
DNA topoisomerase 4 subunit A	Staphylococcus aureus	IC50 (µMol)	0.8000	0.3000	3.5579	9.1600	AID261732; AID262138
DNA gyrase subunit B	Mycolicibacterium smegmatis	IC50 (µMol)	50.0000	0.0460	0.1610	0.2000	AID1188153; AID1194330; AID1252459
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	Ki	249.0000	0.0075	3.0083	9.1100	AID1805801
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	Ki	249.0000	0.0000	1.6307	9.0000	AID1805801
Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)	IC50 (µMol)	278.2980	0.1200	4.0480	10.0000	AID1207376; AID1207406
DNA gyrase subunit A	Staphylococcus aureus	IC50 (µMol)	73.5714	0.0040	1.9839	7.7000	AID1909942; AID275463; AID406832; AID406833; AID595856; AID595934; AID695234
Voltage-dependent L-type calcium channel subunit alpha-1C	Rattus norvegicus (Norway rat)	IC50 (µMol)	238.7699	0.0013	2.2495	6.9000	AID1207530; AID1207564
Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)	IC50 (µMol)	278.2980	0.1200	4.0480	10.0000	AID1207376; AID1207406
DNA gyrase subunit B	Mycobacterium tuberculosis H37Rv	IC50 (µMol)	10.3900	0.0150	2.4676	10.0000	AID1152759; AID1164298; AID1188154; AID1194333; AID1242343; AID1252462; AID1266236; AID1272956; AID1909946; AID530368
DNA gyrase subunit A	Mycobacterium tuberculosis H37Rv	IC50 (µMol)	15.6231	0.0150	3.4773	10.0000	AID1152759; AID1164298; AID1188154; AID1194333; AID1242343; AID1252462; AID1266236; AID1272956; AID1909946; AID530368; AID532977; AID532978; AID532979
Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)	IC50 (µMol)	173.0000	0.0003	2.5955	9.0000	AID1207753
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	137.0683	0.0009	1.9014	10.0000	AID1207470; AID1207530; AID161281; AID1750823; AID243151; AID243188; AID408340; AID420668; AID51930; AID576612; AID695451; AID755684
Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)	IC50 (µMol)	173.0000	0.0003	2.6311	9.0000	AID1207753
Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)	IC50 (µMol)	246.6690	0.0003	2.2545	9.6000	AID1207564; AID1207666; AID1207753
Sodium channel protein type 5 subunit alpha	Homo sapiens (human)	IC50 (µMol)	145.4998	0.0003	3.6484	9.2000	AID1207316; AID1207346
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
DNA gyrase subunit A	Escherichia coli K-12	CC25	0.5000	0.2000	0.3500	0.5000	AID530391
DNA gyrase subunit B	Escherichia coli K-12	CC25	0.5000	0.2000	0.3500	0.5000	AID530391
DNA gyrase subunit B	Mycobacterium tuberculosis H37Rv	CC25	2.0000	2.0000	4.5000	7.0000	AID530380
DNA gyrase subunit A	Mycobacterium tuberculosis H37Rv	CC25	2.0000	2.0000	4.5000	7.0000	AID530380
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	INH	129.0000	7.4000	7.4000	7.4000	AID1723736
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
detection of light stimulus involved in visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
DNA topological change	DNA gyrase subunit A	Escherichia coli K-12
DNA-templated transcription	DNA gyrase subunit A	Escherichia coli K-12
response to xenobiotic stimulus	DNA gyrase subunit A	Escherichia coli K-12
DNA-templated DNA replication	DNA gyrase subunit A	Escherichia coli K-12
DNA topological change	DNA gyrase subunit A	Escherichia coli K-12
response to antibiotic	DNA gyrase subunit A	Escherichia coli K-12
chromosome organization	DNA gyrase subunit A	Escherichia coli K-12
negative regulation of DNA-templated DNA replication	DNA gyrase subunit A	Escherichia coli K-12
DNA topological change	DNA gyrase subunit B	Escherichia coli K-12
DNA-templated transcription	DNA gyrase subunit B	Escherichia coli K-12
response to xenobiotic stimulus	DNA gyrase subunit B	Escherichia coli K-12
DNA-templated DNA replication	DNA gyrase subunit B	Escherichia coli K-12
DNA topological change	DNA gyrase subunit B	Escherichia coli K-12
response to antibiotic	DNA gyrase subunit B	Escherichia coli K-12
chromosome organization	DNA gyrase subunit B	Escherichia coli K-12
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
hematopoietic progenitor cell differentiation	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topological change	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA ligation	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA damage response	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromosome segregation	DNA topoisomerase 2-alpha	Homo sapiens (human)
female meiotic nuclear division	DNA topoisomerase 2-alpha	Homo sapiens (human)
apoptotic chromosome condensation	DNA topoisomerase 2-alpha	Homo sapiens (human)
embryonic cleavage	DNA topoisomerase 2-alpha	Homo sapiens (human)
regulation of circadian rhythm	DNA topoisomerase 2-alpha	Homo sapiens (human)
positive regulation of apoptotic process	DNA topoisomerase 2-alpha	Homo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediate	DNA topoisomerase 2-alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	DNA topoisomerase 2-alpha	Homo sapiens (human)
rhythmic process	DNA topoisomerase 2-alpha	Homo sapiens (human)
negative regulation of DNA duplex unwinding	DNA topoisomerase 2-alpha	Homo sapiens (human)
resolution of meiotic recombination intermediates	DNA topoisomerase 2-alpha	Homo sapiens (human)
sister chromatid segregation	DNA topoisomerase 2-alpha	Homo sapiens (human)
epithelial cell maturation	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
sensory perception of sound	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
male gonad development	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
vestibular nucleus development	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
secretory granule organization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cellular response to cAMP	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cellular response to acidic pH	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cellular response to light stimulus	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cardiac muscle cell contraction	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
negative regulation of protein targeting to membrane	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
regulation of delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
negative regulation of delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
gastrin-induced gastric acid secretion	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
glucose metabolic process	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
heart development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
sensory perception of sound	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
rhythmic behavior	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of heart contraction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of blood pressure	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
positive regulation of heart rate	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
iodide transport	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
erythrocyte differentiation	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
intracellular chloride ion homeostasis	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
response to insulin	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
social behavior	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
corticosterone secretion	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
inner ear morphogenesis	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
inner ear development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
intestinal absorption	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of sound	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
auditory receptor cell development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of gastric acid secretion	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
stomach development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
renal absorption	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
renal sodium ion absorption	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cellular response to cAMP	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cellular response to epinephrine stimulus	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
adrenergic receptor signaling pathway	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cardiac muscle cell contraction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
atrial cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cochlea development	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane repolarization during atrial cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
non-motile cilium assembly	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
action potential	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
sensory perception of sound	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
positive regulation of adenylate cyclase activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
positive regulation of calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarization	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion import	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
membrane depolarization during SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of potassium ion transmembrane transporter activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
skeletal system development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
extraocular skeletal muscle development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
striated muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
endoplasmic reticulum organization	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
myoblast fusion	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
neuromuscular junction development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
skeletal muscle adaptation	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
positive regulation of muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
skeletal muscle fiber development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
release of sequestered calcium ion into cytosol	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
cellular response to caffeine	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
immune system development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
heart development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
embryonic forelimb morphogenesis	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
camera-type eye development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of adenylate cyclase activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transport into cytosol	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channel	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of ventricular cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of heart rate	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac conduction system development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac ventricle development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
brainstem development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sodium ion transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
positive regulation of sodium ion transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
response to denervation involved in regulation of muscle adaptation	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
telencephalon development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cerebellum development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sodium ion transmembrane transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
positive regulation of action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac muscle contraction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cellular response to calcium ion	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of cardiac muscle cell contraction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
atrial cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
AV node cell to bundle of His cell communication	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of sodium ion transmembrane transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
DNA binding	DNA gyrase subunit A	Escherichia coli K-12
DNA topoisomerase activity	DNA gyrase subunit A	Escherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA gyrase subunit A	Escherichia coli K-12
protein binding	DNA gyrase subunit A	Escherichia coli K-12
ATP binding	DNA gyrase subunit A	Escherichia coli K-12
ATP-dependent activity, acting on DNA	DNA gyrase subunit A	Escherichia coli K-12
DNA negative supercoiling activity	DNA gyrase subunit A	Escherichia coli K-12
identical protein binding	DNA gyrase subunit A	Escherichia coli K-12
DNA binding	DNA gyrase subunit B	Escherichia coli K-12
DNA topoisomerase activity	DNA gyrase subunit B	Escherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA gyrase subunit B	Escherichia coli K-12
protein binding	DNA gyrase subunit B	Escherichia coli K-12
ATP binding	DNA gyrase subunit B	Escherichia coli K-12
ATP-dependent activity, acting on DNA	DNA gyrase subunit B	Escherichia coli K-12
DNA negative supercoiling activity	DNA gyrase subunit B	Escherichia coli K-12
metal ion binding	DNA gyrase subunit B	Escherichia coli K-12
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
magnesium ion binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromatin binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
RNA binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein kinase C binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
ATP binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
ATP-dependent activity, acting on DNA	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA binding, bending	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein homodimerization activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
ubiquitin binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein heterodimerization activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
potassium channel regulator activity	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
telethonin binding	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
protein-containing complex binding	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
transmembrane transporter binding	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
calmodulin binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
protein phosphatase 1 binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
outward rectifier potassium channel activity	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
protein kinase A catalytic subunit binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
protein kinase A regulatory subunit binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
transmembrane transporter binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
ankyrin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
small molecule binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
molecular function activator activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
calmodulin binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
fibroblast growth factor binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
enzyme binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein kinase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein domain specific binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ankyrin binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ubiquitin protein ligase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
transmembrane transporter binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nitric-oxide synthase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
scaffold protein binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
photoreceptor outer segment	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
chromosome	DNA gyrase subunit A	Escherichia coli K-12
cytoplasm	DNA gyrase subunit A	Escherichia coli K-12
cytosol	DNA gyrase subunit A	Escherichia coli K-12
membrane	DNA gyrase subunit A	Escherichia coli K-12
cytoplasm	DNA gyrase subunit A	Escherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex	DNA gyrase subunit A	Escherichia coli K-12
chromosome	DNA gyrase subunit B	Escherichia coli K-12
cytoplasm	DNA gyrase subunit B	Escherichia coli K-12
cytosol	DNA gyrase subunit B	Escherichia coli K-12
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex	DNA gyrase subunit B	Escherichia coli K-12
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
nucleolus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nuclear chromosome	DNA topoisomerase 2-alpha	Homo sapiens (human)
centriole	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromosome, centromeric region	DNA topoisomerase 2-alpha	Homo sapiens (human)
condensed chromosome	DNA topoisomerase 2-alpha	Homo sapiens (human)
male germ cell nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleoplasm	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-alpha	Homo sapiens (human)
cytoplasm	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein-containing complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
ribonucleoprotein complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
lysosome	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
apical plasma membrane	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
Z disc	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
membrane raft	Potassium voltage-gated channel subfamily E member 1	Homo sapiens (human)
early endosome	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
endoplasmic reticulum	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cytoplasm	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
lysosome	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
early endosome	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
late endosome	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
endoplasmic reticulum	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
basolateral plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
apical plasma membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
transport vesicle	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
cytoplasmic vesicle membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
neuron projection	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
neuronal cell body	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane raft	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
ciliary base	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
lumenal side of membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
basolateral part of cell	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
monoatomic ion channel complex	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
membrane	Potassium voltage-gated channel subfamily KQT member 1	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
sarcoplasmic reticulum	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
T-tubule	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
I band	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
dendrite	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
caveola	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nucleoplasm	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nucleolus	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
endoplasmic reticulum	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
caveola	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cell surface	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
intercalated disc	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
lateral plasma membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
Z disc	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
T-tubule	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sarcolemma	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3673)

Assay ID	Title	Year	Journal	Article
AID1318903	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID279207	Antibacterial activity against Streptococcus pneumoniae 3676 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1600103	Antibacterial activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID559069	Antibacterial activity against Acinetobacter baumannii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID571366	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID575079	Antimicrobial activity against Streptococcus pneumoniae serotype 7F assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID341089	Antimicrobial activity against Clostridium difficile clinical isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
AID570795	Half life in healthy human at 400 mg, po qd measured on day 4 by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID511393	Antibacterial activity against Levofloxacin resistant Streptococcus pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID518617	Antimicrobial activity against Mycobacterium avium by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID558629	Antimicrobial activity against Streptococcus pneumoniae isolate 3791 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID531526	Antibacterial activity against Bacteroides distasonis isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1740327	Antimicrobial activity against Listeria monocytogenes ATCC 19115 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID422657	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID279265	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3243 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1398607	Inhibition of human ERG expressed in CHOK1 cells at 30 uM	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID285973	Antimicrobial susceptibility against Haemophilus influenzae D4 isolate with GyrA Ser84Tyr, ParC Glu88Lys and AcrR Leu31His, Ile121Val and Gln134Lys mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID283400	Antimicrobial activity against Nocardia sp. after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID553806	Antimicrobial activity against Clostridium difficile PCR ribotype 001 expressing gyrB Glu466Lys mutant grown on fluoroquinolone-containing medium after 48 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID530596	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr8 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID530347	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID695234	Inhibition of Staphylococcus aureus DNA gyrase by supercoiling assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID508372	Antibacterial activity against Streptococcus pneumoniae harboring erm(B) and mef(A) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID530372	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID341068	Half life in human at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID574488	Antimicrobial activity against Bacteroides distasonis after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID563216	Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID574778	Antimicrobial activity against Clostridium difficile assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1877413	Antibacterial activity against Neisseria gonorrhoeae Barla194	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID522951	Antibacterial activity against methicillin-, ciprofloxacin-resistant Staphylococcus aureus by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1126755	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 741 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID580758	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID559078	Antibacterial activity against Klebsiella oxytoca by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1243290	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis clinical isolates by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID428781	Cmax in human at 400 mg, po administered once a day	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID456046	Antibacterial activity against vancomycin-resistant Enterococcus faecium after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID425813	Antimicrobial activity against avirulent Mycobacterium tuberculosis H37Ra	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID531517	Antibacterial activity against Bacteroides vulgatus assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID559172	Antimicrobial activity against Clostridium difficile BI2f harboring GyrB Arg447Lys and Asp426Asn mutant gene selected after 32 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID522967	Antibacterial activity against Serratia marcescens by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID249970	Ratio of MPC to MIC against methicillin resistant Staphylococcus aureus-5023	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1318901	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86052	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1152777	Antimycobacterial activity against 5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA D89N mutant	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID558700	Antimicrobial activity against Clostridium difficile 630 expressing tcdA and tcdB gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID562439	Antibacterial activity against Staphylococcus aureus SMH36633 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID573594	Antibacterial activity against Fusobacterium varium assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID580900	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID559533	Antibacterial activity against Klebsiella oxytoca assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID532675	Antimicrobial activity against ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID593809	Antimicrobial activity against Escherichia coli ATCC 8739 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID574760	Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID570689	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID425544	Antibacterial activity against Streptococcus pneumoniae HMC 1541 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1877420	Antibacterial activity against Neisseria gonorrhoeae WHO A	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID1067082	Antimicrobial activity against Staphylococcus aureus 209 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID559176	Antimicrobial activity against Clostridium difficile C253A selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1514449	Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis after 7 days by resazurin dye based colorimetric assay	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID574518	Antimicrobial activity against Prevotella intermedia after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1551299	Antibacterial activity against Quinolone-resistant Staphylococcus aureus CCARM 3505 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID1909954	Stabilization of mycobacterium tuberculosis DNA gyrase/Doubly-cleaved DNA complex at 100 uM incubated for 30 mins by gel electrophoresis method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID1164015	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID559488	Antibacterial activity against Peptostreptococcus sp. by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1348987	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1557288	Antibacterial activity against Clostridium perfringens by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID520108	Antimicrobial activity against Mycobacterium tuberculosis H37Rv at assessed as growth inhibition at 10 mg/kg following 24 days oxygen depletion by Wayne method relative to control	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
AID562457	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH36742	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID574734	Antimicrobial activity against Fusobacterium necrogenes after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID562646	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH36633	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID425548	Antibacterial activity against Streptococcus pneumoniae HMC 1062 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID520375	Ratio of AUC (0 to 24 hrs) in plasma to CSF in patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QID	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID576139	Antibacterial activity against 10'4 to 10'5 CFU Streptococcus pneumoniae after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID574482	Antimicrobial activity against Bacteroides fragilis after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID283159	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2526 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID571145	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID523161	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC4222 harboring gyrA S84L and parC S80F mutant gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID593900	Antimicrobial activity against Aspergillus niger ATCC 6275 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID425543	Antibacterial activity against Streptococcus pneumoniae HMC 1156 harboring S81F and S79F mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively showing efflux to ciprofloxacin, gemifloxacin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1381460	Toxicity in C57BL/6 mouse infected with Mycobacterium tuberculosis H37Rv at 30 mg/kg, po for 8 consecutive days starting from day 1 post infection	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
AID422650	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 38 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1297347	Antibacterial activity against Streptococcus pneumoniae ATCC 19615 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID571926	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-N623S-Q624S mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID562945	Upregulation of cwp84 gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1877410	Antibacterial activity against methicillin-resistant Staphylococcus aureus 196	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID1391313	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate CCARM 3167 after 24 hrs by two-fold serial dilution method	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives.
AID388870	Antibacterial activity against Staphylococcus aureus ATCC 13709 after 24 hrs by microdilution method	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
AID1398636	In vivo antibacterial activity against quinolone-sensitive and penicillin-resistant Streptococcus pneumoniae 033806 infected in CBA/JNCrj mouse assessed as reduction in bacterial count at 40 to 80 mg/kg, sc administered twice per day starting from 1 day a	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID436985	Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID562926	Antimicrobial activity against Clostridium difficile CD196 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID563057	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID559486	Antibacterial activity against Clostridium perfringens by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID571374	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID575005	Antimicrobial activity against Eubacterium sp. after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID586640	Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID422666	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 35 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID573581	Antibacterial activity against beta-lactamase producing Bacteroides caccae by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID581483	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID518802	Antimycobacterial activity against Mycobacterium intracellular serovar 16 after 21 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
AID571576	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID285284	Susceptibility of penicillin-resistant Streptococcus pneumoniae 334 by by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID528975	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID563050	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1053480	Antitubercular activity against Mycobacterium tuberculosis H37Rv expressing inhA M103L mutant assessed as parasite growth inhibition after 7 days by Alamar Blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
AID522964	Antibacterial activity against Enterobacter cloacae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID498187	Antibacterial activity against Stenotrophomonas maltophilia D457 containing chromosomally encoded Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID553685	Antimicrobial activity against Bacteroides sp. in three-stage chemostat gut model assessed as log reduction in bacterial count at 43 mg/liter administered daily for 7 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID570798	AUC (0 to 24 hrs ) in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID580761	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID530589	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr1 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID422658	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 49 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID540219	Volume of distribution at steady state in monkey after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID574746	Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID278600	Inhibitory activity against Klebsiella pneumoniae 07-006	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID433401	Inhibition of Mycobacterium leprae DNA gyrase subunit A G89C mutant assessed as DNA supercoiling inhibition	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1447483	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P264-104354 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID518629	Ratio of AUC (0 to 24 hrs) in Mycobacterium avium infected human THP1 cell-based pharmacokinetic-pharmacodynamic model to MIC for Mycobacterium avium at 90% maximal effective concentration	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID275450	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
AID563008	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID283396	Antimicrobial activity against Nocardia veterana after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID518803	Antimycobacterial activity against Mycobacterium chelonae after 3 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
AID573593	Antibacterial activity against Fusobacterium necrophorum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID559047	Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID580996	Ratio of Cmax in healthy human at 400 mg/kg, po administered as a single dose to MIC90 for Mycobacterium tuberculosis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID533425	Antimicrobial activity against Peptostreptococcus sp. by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1570244	Antimycobacterial activity against rifampicin-resistant Mycobacterium tuberculosis incubated for 7 days by rapid direct susceptibility test	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID342062	Antimicrobial activity against nonepidemic Clostridium difficile ATCC 9689 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID438557	Antimycobacterial activity against non replicating persistent form of Mycobacterium tuberculosis H37Rv after 10 days by low oxygen recovery assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.
AID323659	Antibacterial activity against Peptostreptococcus anaerobius	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.
AID534362	Ratio of MIC for Escherichia coli K-12 KD2934 harboring gyrB K447E mutant gene to MIC for Escherichia coli K-12 KD1397 harboring wild type gyrB gene	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.
AID559059	Antibacterial activity against non-levofloxacin susceptible Streptococcus pneumoniae by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID424334	Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CLSI-M11-A7 method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID571111	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571846	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1164298	Inhibition of Mycobacterium tuberculosis DNA gyrase-mediated relaxed pBR322 DNA supercoiling by gel electrophoresis	2014	ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9	2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
AID531521	Antibacterial activity against Bacteroides stercoris isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1903315	Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth measured after 8 days by Alamar blue assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Discovery of 3H-pyrrolo[2,3-c]quinolines with activity against Mycobacterium tuberculosis by allosteric inhibition of the glutamate-5-kinase enzyme.
AID1476364	Antitubercular activity against streptomycin resistant Mycobacterium tuberculosis H37Rv ATCC 35820 after 24 hrs by MABA method	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID425069	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae M7943 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID533135	Antimicrobial activity against Bacteroides ovatus by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574953	Antimicrobial activity against Streptococcus pneumoniae serotype 6C by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID520617	Antimicrobial activity against Nocardia brasiliensis HUJEG-1 by broth macrodilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.
AID522955	Antibacterial activity against Streptococcus pyogenes by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1399856	Antitubercular activity against fluoroquinolone-resistant Mycobacterium tuberculosis H37Rv harboring gyrA D94N mutant	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID406834	Inhibition of Staphylococcus aureus wild-type topoisomerase 4 decatenation activity assessed as unlinking of DNA microcircles from kinetoplast DNA	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID433404	Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as formation of DNA cleavable complex	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1318902	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1237403	Antibacterial activity against Staphylococcus aureus KCTC 209 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID1164003	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 12-2 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID1254068	Antibacterial activity against Staphylococcus aureus 209 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID323887	Antimicrobial activity against qnrA1 expressing Escherichia coli J53/pMG252 GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID1297325	Antibacterial activity against Klebsiella pneumoniae 14-1 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1318912	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID561324	Antimicrobial activity against Klebsiella pneumoniae isolate 132 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1890604	Antibacterial activity against methicillin resistant Staphylococcus aureus 5076 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method	2022	Bioorganic & medicinal chemistry letters, 05-01, Volume: 63	WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID323886	Antimicrobial activity against qnrA1 expressing Escherichia coli J53/pMG252 expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID1254074	Antibacterial activity against Pseudomonas aeruginosa 2004 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID563340	Effect on Cwp84 protease expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID581101	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID601779	Antibacterial activity against 10'4 CFU methicillin-resistant Staphylococcus aureus 08-1 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID529896	Antimicrobial activity against Leptospira interrogans serovar Pomona isolate 4 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID1750819	Cytotoxicity against human K562 cells after 72 hrs by CellTiter Glo assay	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID531522	Antibacterial activity against Bacteroides merdae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID581298	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID558622	Antimicrobial activity against Streptococcus pneumoniae isolate 3374 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID428771	Bactericidal activity against Streptococcus pneumoniae isolate SR-26137 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1391316	Antibacterial activity against Escherichia coli 1924 after 24 hrs by two-fold serial dilution method	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives.
AID164231	Antibacterial activity was evaluated against Pseudomonas aeruginosa	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID424326	Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CLSI-M11-A7 method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID1877417	Antibacterial activity against Neisseria gonorrhoeae WHO E	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID425564	Antibacterial activity against quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 5048 expressing mefA after 50 passages by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID425555	Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 99 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID494416	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 72 hrs by serial double dilution method	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives.
AID521152	Antibacterial activity against intracellular Listeria monocytogenes EGDe infected in bone marrow-derived BALB/c mouse macrophage assessed as prevention of bacterial release and spread of infection by preventing macrophage lysis after 24 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID562464	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH38002	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID581287	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID522953	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID573823	Antibacterial activity against beta-lactamase producing Clostridium paraputrificum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID428847	Time above the mutant prevention concentration in Streptococcus pneumoniae isolate SR-26134 infected human at 80 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID574051	Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1564359	Antimycobacterial activity against Mycobacterium avium subsp. avium ATCC 25291 by resazurin dye based fluorimetric assay	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	The synthesis and in vitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis.
AID586638	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrB gene and pBK-QnrB1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1256562	Antibacterial activity against Streptococcus pneumoniae ATCC 19615 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID574985	Antimicrobial activity against Actinomyces naeslundii assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID511392	Antibacterial activity against Levofloxacin susceptible Streptococcus pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID576132	Antibacterial activity against 10'4 to 10'5 CFU Haemophilus influenzae after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID322791	Antimicrobial activity against Bacteroides merdae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID728907	Inhibition of human ERG expressed in CHOK1 cells at 30 uM	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID1398590	Antibacterial activity against Staphylococcus aureus SMITH after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID562623	Antimicrobial activity against Coagulase-negative Staphylococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1318931	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 92014	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID532969	Antimicrobial activity against Mycobacterium tuberculosis isolate 13 isolated from Beijing	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID580766	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID571355	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1185144	Antimicrobial activity against 2-oxo-1-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)piperidin-1-yl)ethyl)-1,2-dihydroquinoline-7-carbonitrile resistant Mycobacterium tuberculosis H37Rv ATCC 27294 containing DNA gyrase A74V mutant	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.
AID322781	Antimicrobial activity against Bacteroides stercoris isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID562454	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH38002	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID699004	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv	2012	European journal of medicinal chemistry, May, Volume: 51	Tuberculosis: the drug development pipeline at a glance.
AID1067071	Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolate 3506 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID1318909	Antibacterial activity against gentamicin-resistant Escherichia coli isolate CAN-ICU 61714 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID581654	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in absence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID559182	Antimicrobial activity against Clostridium difficile C253D selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1297351	Antibacterial activity against Enterococcus faecalis 14-2 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID523175	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC8525 harboring wild type quinolone resistance-determining region assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID372979	Antimycobacterial activity against Mycobacterium intracellular JATA52-01 after 14 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID559512	Antibacterial activity against Lancefield Streptococcus sp. 'group G' assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID530380	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID425774	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB after 36 passages by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID562651	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH38002	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID508380	Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID544820	Antimicrobial activity against Staphylococcus epidermidis Xen 43 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID563013	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID430964	Antibacterial activity against Escherichia coli 1596 containing gyrA L83 and parC I80, G84 mutants assessed as increase in MIC by Etest relative to MIC for Escherichia coli 1608 containing gyrA mutant	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
AID521329	AUC (0 to 24 hrs) in CSF of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1067078	Antimicrobial activity against Escherichia coli CCARM 1356 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID570693	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID573796	Antibacterial activity against Prevotella bivia assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1164000	Antibacterial activity against Pseudomonas aeruginosa 12-14 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID518311	Cardiotoxicity in healthy human assessed as change in corrected QT interval at 400 mg/kg, po within 3 hrs by ECG	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
AID562633	Antimicrobial activity against Streptococcus pneumoniae assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID531629	Antimicrobial activity against Ureaplasma parvum by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
AID405456	Antibacterial activity against Escherichia coli C600Rif in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID341074	AUC (0 to 24 hrs) in human with MDR1 3435 CC or CT genotype at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg/kg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID518623	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 20% FBS	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID571841	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID669186	Antitubercular activity against Mycobacterium tuberculosis H37Rv in aerobic conditions after 7 days by microplate-based alamar blue assay	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases.
AID522959	Antibacterial activity against Enterococcus faecium by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1237405	Antibacterial activity against Streptococcus mutans 3065 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID425805	Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in CD-1 mouse lung after 1 day after 1st successive aerosol infection run	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID428814	Ratio of AUC (0 to 24 hrs) in human at 400 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae ATCC 49619	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID581667	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level after 24 hrs in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID570698	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID562624	Antimicrobial activity against Group A Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID511304	Antibacterial activity against ciprofloxacin and methicillin resistant Staphylococcus aureus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID559177	Antimicrobial activity against Clostridium difficile C253B selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID571144	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1256559	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-22 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID1551292	Antibacterial activity against Staphylococcus aureus KCTC503 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID511398	Antibacterial activity against Pseudomonas aeruginosa by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID571851	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID573591	Antibacterial activity against Fusobacterium nucleatum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID285971	Antimicrobial susceptibility against Haemophilus influenzae D2 isolate with GyrA Ser84Tyr, ParC Glu88Lys and AcrR Leu31His, Ile121Val and Gln134Lys mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID1256532	Antibacterial activity against Escherichia coli ATCC 25922 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID576612	Inhibition of human ERG	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID285291	Effect on 0.06 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID428859	Bactericidal activity against Streptococcus pneumoniae isolate SR-26134 assessed as prevention of bacterial regrowth under condition simulating oral administration of 400 mg once daily after 72 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID522960	Antibacterial activity against Haemophilus influenzae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID484799	Antibacterial activity against Staphylococcus aureus K1134 bearing wild-type GyrA and S80Y mutant GrlA by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID563058	Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID283149	Antimicrobial susceptibility of Staphylococcus lugdunensis isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID324749	Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing at 150 mg/kg/day after 9 months	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID1256541	Antibacterial activity against Klebsiella pneumoniae 14-2 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID511394	Antibacterial activity against Streptococcus pyogenes by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID1237415	Bactericidal activity against Streptococcus mutans 3065 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID531520	Antibacterial activity against Bacteroides fragilis assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1330187	Antibacterial activity against Staphylococcus aureus 209 measured after 24 hrs by two-fold serial dilution method	2016	Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24	Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
AID565328	Antibacterial activity against Mycoplasma genitalium M6282 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID544843	Antibacterial activity against Streptococcus pneumoniae U2A1693 harboring parC Asp83Asn mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID456027	Antibacterial activity against Staphylococcus epidermidis 56500 after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID563028	Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1403709	Antimycobacterial activity against Mycobacterium marinum ATCC BAA-535 infected in zebrafish at 5 mg/kg, po treated for 7 days by MPN assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.
AID1601848	Antibacterial activity against Escherichia coli CMCC 44568 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID534363	Ratio of MIC for Escherichia coli K-12 KD2932 harboring gyrB D426N mutant gene to MIC for Escherichia coli K-12 KD1397 harboring wild type gyrB gene	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.
AID558583	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID559153	Antimicrobial activity against Clostridium difficile 630e selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID580894	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID285300	Effect on 4 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID574526	Antimicrobial activity against Prevotella intermedia assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID484793	Antibacterial activity against Escherichia coli ATCC 25922 by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID1154327	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 5 days by standard microdilution method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
AID279817	Antimicrobial activity against Mycobacterium tuberculosis H37Rv in 7H9 broth	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID522970	Antibacterial activity against Citrobacter freundii by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID581480	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID571386	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571931	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-S623N mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID581074	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID584563	Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID543391	Antibacterial activity against Listeria monocytogenes EGD-e in BALB/c mouse central nervous system listeriosis model assessed as increase in mouse survival at 50 mg/kg, ip administered 36 hrs postinfection as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID558882	Antimicrobial activity against Clostridium difficile C253c selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID556021	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from basolateral to apical side	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID559081	Antibacterial activity against Moraxella catarrhalis by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID571876	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1179482	Antimycobacterial activity against Mycobacterium kansasii ATCC 12478 in 7H9 medium after 6 days and 18 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.
AID558613	Antimicrobial activity against Streptococcus pneumoniae isolate 2686 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID559075	Antibacterial activity against Enterobacter cloacae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID244998	Antibacterial activity against Enterococcus faecalis ATCC 19433 was determined	2004	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
AID323890	Antimicrobial activity against qnrA1 expressing Escherichia coli J53/p1960 expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID570808	Ratio of Apparent oral clearance in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose to Apparent oral clearance in healthy human at 400 mg, po qd m	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID570906	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559004	Antibacterial activity against Streptococcus pneumoniae W001 harboring wild-type parC and gyrA genes	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID1256546	Antibacterial activity against Pseudomonas aeruginosa 14-14 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID559048	Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1256549	Antibacterial activity against Pseudomonas aeruginosa 14-19 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID518626	Half life in Mycobacterium avium infected human THP1 cell-based pharmacokinetic-pharmacodynamic modell by LC analysis	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID341374	Antibacterial activity against Staphylococcus aureus at 0.5 mg/liter by time kill assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID425338	Antibacterial activity against azithromycin-susceptible Streptococcus pneumoniae ATCC 49619 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID562939	Effect on fbp69 gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID574776	Antimicrobial activity against Clostridium difficile after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID728918	Antibacterial activity against Klebsiella pneumoniae TYPE1 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID1760640	Antibacterial activity against Mycobacterium tuberculosis H37Ra ATCC2517 assessed as inhibition of bacterial growth measured after 17 hrs by resazurin based flourimetric assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synthesis and structure-activity studies of novel anhydrohexitol-based Leucyl-tRNA synthetase inhibitors.
AID565325	Antibacterial activity against Mycoplasma genitalium M6328 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID283392	Antimicrobial activity against Nocardia otitidiscaviarum after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID531530	Antibacterial activity against Bacteroides thetaiotaomicron isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1237427	Bactericidal activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID1909951	Antibacterial activity against Mycobacterium tuberculosis H37Rv gyrA -FDASTetON-1 hypomorph assessed as inhibition of bacterial growth incubated for 11 days	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID574782	Antimicrobial activity against Actinomyces odontolyticus after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID581487	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID574486	Antimicrobial activity against Bacteroides caccae after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1067073	Antimicrobial activity against Candida albicans 7535 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID1890603	Antibacterial activity against Staphylococcus aureus ATCC 25293 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method	2022	Bioorganic & medicinal chemistry letters, 05-01, Volume: 63	WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID1676599	Binding affinity to cupric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID562446	Antibacterial activity against Staphylococcus aureus SMH37276 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID573786	Antibacterial activity against Prevotella melaninogenica by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574995	Antimicrobial activity against Bifidobacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID580897	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID246829	Efficacy against mice infected with MRSA-33 upon s.c. administration	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID535772	Antimicrobial activity against Mycobacterium ulcerans 1059 agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID518618	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID556777	Volume of distribution in peripheral compartment in osteomyelitis patient at 400 mg, po administered for every 24 hrs by MAP-Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID586729	Antibacterial activity against qnrS gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrS1 assessed as mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID373002	Antimycobacterial activity against Mycobacterium avium complex N018 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID1877402	Antibacterial activity against Escherichia coli 202	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID1256539	Antibacterial activity against ESBL-positive Klebsiella pneumoniae 14-19 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID369227	Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae by microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
AID261737	Antibacterial activity against Streptococcus pneumoniae ATCC 49619	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID558910	Antimicrobial activity against Clostridium difficile CD5 1-g harboring GyrA Ala92Glu and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID521327	AUC (0 to 24 hrs) in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1600107	Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID523143	Antibacterial activity against Streptococcus pneumoniae isolate OC7348 assessed as log reduction in bacterial growth at 4 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID570889	Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1398596	Antibacterial activity against Escherichia coli NIHJ after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID728920	Antibacterial activity against Streptococcus pyogenes G-36 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID531524	Antibacterial activity against Bacteroides spp. isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1154349	Antimycobacterial activity against Mycobacterium tuberculosis over expressing TopA after 5 days by standard microdilution method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
AID521825	Antimicrobial activity against beta-lactam resistant Streptococcus pneumoniae clinical isolate by broth dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
AID559485	Antibacterial activity against Bacteroides fragilis by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID759325	Antibacterial activity against Escherichia coli CCARM 1356 after 24 hrs by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents.
AID565320	Antibacterial activity against Mycoplasma genitalium M2341 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1398595	Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID278601	Inhibitory activity against azide-resistant Escherichia coli J53 T07-006	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID285301	Effect on 8 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID580887	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID573834	Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID533421	Antimicrobial activity against Anaerococcus prevotii by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID586727	Antibacterial activity against qnrA gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrA1 assessed as mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1877415	Antibacterial activity against Neisseria gonorrhoeae WHO O	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID425547	Antibacterial activity against Streptococcus pneumoniae HMC 4026 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID565308	Antibacterial activity against Mycoplasma genitalium by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID245040	Minimum inhibitory concentration against Staphylococcus saprophyticus ATCC 15305	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID559073	Antibacterial activity against Citrobacter koseri by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559141	Antimicrobial activity against Clostridium difficile A422h harboring GyrA Asp81Asn mutant gene selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID244991	Minimum inhibitory concentration against vancomycin intermediate Staphylococcus aureus MU 50	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID562647	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH37099	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID672348	Antibacterial activity against Escherichia coli ATCC 25922	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives.
AID323874	Antimicrobial activity against qnrA1 expressing Klebsiella pneumoniae1960 GyrA Ser83Phe mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID422664	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID425572	Antibacterial activity against penicillin-, macrolide- and quinolone-susceptible Streptococcus pneumoniae HMC 63 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83Y mutation in QRDR of ParC gene and I460V mutation in QRDR	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID563011	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID518058	Toxicity in healthy human assessed as abdominal pain at 400 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
AID1601849	Antibacterial activity against Pseudomonas aeruginosa CMCC 27853 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID586633	Antibacterial activity against qnrA gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrA1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1330188	Antibacterial activity against Streptococcus mutans 3065 measured after 24 hrs by two-fold serial dilution method	2016	Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24	Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
AID406653	Antibacterial activity against Staphylococcus aureus ACH-0210 isolate with gyrA Ser84Leu and grlA Ser80Phe mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID518801	Antimycobacterial activity against Mycobacterium avium serovar 8 after 14 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
AID430965	Antibacterial activity against Escherichia coli 1596 containing parC K84 mutant assessed as decrease in MIC by Etest relative to MIC for Escherichia coli 1608 containing gyrA mutant	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
AID425549	Antibacterial activity against Streptococcus pneumoniae HMC 1068 harboring E85K mutation in quinolone-resistant determining regions of GyrA gene, S79Y, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene showing efflux to ciproflox	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID508378	Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring mef(A) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID581067	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID542718	Drug level in human plasma at 400 mg/day after 8 hrs	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.
AID1164006	Antibacterial activity against methicillin-resistant Staphylococcus aureus 12-2 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID1164013	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 12-1 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID484797	Antibacterial activity against Staphylococcus aureus SA-1199B norA++ and A116E GrlA mutation by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID586631	Antibacterial activity against qnrS gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrS1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID581314	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID283239	Reduction of bacterial counts in Mycobacterium tuberculosis H37Rv infected Swiss mouse lung at 100 mg/kg, po for 5 days/week after 1 month	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
AID1319010	Selectivity ratio of MIC for Pseudomonas aeruginosa PAO1 to MIC for Pseudomonas aeruginosa PAO750	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1126762	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1256 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID496637	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 assessed as 90% mutant prevention concentration	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID533128	Antimicrobial activity against Bacteroides caccae by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID425975	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1685385	Potentiation of conjugate 10-induced antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as conjugate 10 MIC measured after 18 hrs by CLSI protocol based microbroth dilution method (Rvb = 64 to 128 ug/ml)	2019	MedChemComm, Apr-01, Volume: 10, Issue:4	Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria.
AID562630	Antimicrobial activity against Group G Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID533428	Antimicrobial activity against Peptostreptococcus sp. assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID395715	Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23::qnr-cat promoter mutant by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID562622	Antimicrobial activity against Coagulase-negative Staphylococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1272963	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by alamar blue assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
AID1551291	Antibacterial activity against Staphylococcus aureus KCTC209 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID425351	Antibacterial activity against Streptococcus pneumoniae HMC 1147 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene showing efflux to gemifloxacin by	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID428848	Time above the mutant prevention concentration in Streptococcus pneumoniae isolate SR-26137 infected human at 80 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID523148	Antibacterial activity against Streptococcus pneumoniae isolate OC6585 assessed as log reduction in bacterial growth at 4 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1152767	Inhibition of Mycobacterium tuberculosis H37Rv DNA gyrase holoenzyme using pBR322 DNA as substrate assessed as linear DNA level at 0.02 to 11 uM after 60 mins by cleavable complex assay relative to control	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID322778	Antimicrobial activity against Bacteroides vulgatus isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID425552	Antibacterial activity against penicillin-, macrolide-susceptible and quinolone-resistant Streptococcus pneumoniae HMC 1074 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutat	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID584562	Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID543398	AUC (24 hrs) in brain of Listeria monocytogenes EGD-e infected BALB/c mouse central nervous system listeriosis model at 50 mg/kg, ip administered 36 hrs postinfection as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID1266238	Cytotoxicity against mouse RAW264.7 cells at 50 uM after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, Jan-01, Volume: 24, Issue:1	Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
AID261738	Antibacterial activity against Haemophilus influenzae type b ACH-0056	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID406845	Antibacterial activity against Escherichia coli TOP10 containing pS1B plasmid expressing quinolone resistance determinant QnrS1 by E-test	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID530371	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A, I85V, F96W and P101M mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID428816	Ratio of AUC (0 to 24 hrs) in human at 400 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-26134	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1391315	Antifungal activity against Candida albicans 7535 after 24 hrs by two-fold serial dilution method	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives.
AID533369	Antimicrobial activity against Bacteroides vulgatus by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID533401	Antimicrobial activity against Clostridium subterminale by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID575944	Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
AID246828	Efficacy against mice infected with MRSA-32 upon s.c. administration	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID558582	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID428773	Bactericidal activity against Streptococcus pneumoniae isolate SR-23958 assessed as mutant prevention concentration after 72 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1743460	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Ala-90-Val/gyrB Glu-540-Val mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID428778	Ratio of mutant prevention concentration for Streptococcus pneumoniae isolate SR-26134 to MIC for Streptococcus pneumoniae isolate SR-26134	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID556026	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from apical to basolateral side at 50 uM in presence of in presence of 25 uM of p-glycoprotein and MRP transport inducer rifampin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID574975	Antimicrobial activity against Actinomyces meyeri after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1243283	Antimicrobial activity against Staphylococcus aureus ATCC 25923 by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID573825	Antibacterial activity against beta-lactamase producing Clostridium tertium by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID728911	Antibacterial activity against Chlamydophila pneumoniae AR39 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID574003	Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1601841	Antibacterial activity against Staphylococcus aureus CMCC(B) 26003 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID574042	Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID695443	Antibacterial activity against fluoroquinolone resistant Staphylococcus aureus 2-FQR2M NY2746 expressing GyrA Ser84Leu mutant and GrlA Ser80Phe mutant	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID1164010	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 12-3 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID428805	Ratio of Cmax in human at 400 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-23958	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID368421	Antimicrobial activity against Escherichia coli KAM32 pSTV28 containing chloramphenicol-resistant vector by agar dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID51930	K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1	2002	Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18	Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID522954	Antibacterial activity against methicillin-, ciprofloxacin-resistant Staphylococcus epidermidis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID571105	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID573824	Antibacterial activity against beta-lactamase producing Clostridium septicum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID635060	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 10-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID456026	Antibacterial activity against Staphylococcus aureus FDA 209-P after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID428818	Ratio of AUC (0 to 24 hrs) in human at 80 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-26134	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID422690	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 30 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID559385	Antimicrobial activity against Clostridium difficile A422G harboring GyrA Thr82Ile and GyrB Leu451Phe mutant genes selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID593806	Antimicrobial activity against quinilone-pencillin-resistant Staphylococcus epidermidis clinical isolate by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID425994	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID556770	fAUC/MIC in osteomyelitis patient serum at 400 mg, po administered for every 24 hrs at PKPD breakpoint at 0.19 mg/liter	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID528973	Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1380669	Fraction unbound in mouse plasma at 1 uM by equilibrium dialysis method	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
AID1398598	Antibacterial activity against Haemophilus influenzae ATCC 49247 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID425074	Antimicrobial activity against Escherichia coli DH10B in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID1187836	Cytotoxicity against mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID425359	Antibacterial activity against Streptococcus pneumoniae HMC 1074 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID425545	Antibacterial activity against Streptococcus pneumoniae HMC 2527 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1256544	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID533635	Antimicrobial activity against Propionibacterium sp. by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523152	Antibacterial activity against Streptococcus pneumoniae isolate OC6610 assessed as log reduction in bacterial growth at 2 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1494120	Antibacterial activity against Enterococcus faecalis NCTC 12697 after 16 hrs by microdilution method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID521341	Tmax in CSF of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID559541	Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559051	Antibacterial activity against Staphylococcus lugdunensis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID406835	Inhibition of Staphylococcus aureus wild-type topoisomerase 4 grlA S80F mutant decatenation activity assessed as unlinking of DNA microcircles from kinetoplast DNA	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID573592	Antibacterial activity against Fusobacterium mortiferum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID341391	Toxicity in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit assessed as tissue valve damage median score at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 days after last dose by histopathology	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID581076	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1179483	Antimycobacterial activity against Mycobacterium bovis BCG ATCC 35734 in 7H12 medium after 6 days and 18 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.
AID1294769	Antibacterial activity against quinolone-resistant Streptococcus pneumoniae TPS3 after 18 to 24 hrs by broth microdilution method	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.
AID1242345	Antimycobacterial activity against 1-(2-(4-((5-chloro-6-methylpyridin-3-yl)methylamino)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-one resistant Mycobacterium tuberculosis H37Rv harboring DNA gyraseA D89N mutant incubated for 7 days by microdilu	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.
AID523178	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC12501 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID574730	Antimicrobial activity against Porphyromonas asaccharolytica after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID522957	Antibacterial activity against Streptococcus sp. group C by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID574032	Antibacterial activity against beta-lactamase producing Micromonas micros by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID261742	Antibacterial activity against Klebsiella pneumoniae ATCC 13883	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID559159	Antimicrobial activity against Clostridium difficile 630h harboring GyrB Asp26Val mutant gene selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID535771	Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 harboring pTY60H carrying the luxAB gene under the hsp60 promoter agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID586744	Antibacterial activity against qnrB gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrB1 assessed as earliest time required to resistant colonies visible one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID558587	Antimicrobial activity against Streptococcus pneumoniae 19A by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID586728	Antibacterial activity against qnrB gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrB1 assessed as mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID562458	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH36945	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID1319016	Inhibition of Pseudomonas aeruginosa DNA gyrase A assessed as inhibition of DNA supercoiling using PBR322 DNA as substrate after 30 mins by SYBR Gold staining based agarose gel electrophoresis	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1372636	Antibiofilm activity against Mycobacterium tuberculosis H37Rv at 10 ug/ml after 1 week	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Lead identification and optimization of bacterial glutamate racemase inhibitors.
AID1404053	Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in C57BL/6 mouse assessed as change in bacterial burden in lungs at 30 mg/kg, po once daily for 8 days	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	In vivo potent BM635 analogue with improved drug-like properties.
AID285307	Effect on 16 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID574492	Antimicrobial activity against Bacteroides ovatus after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID586650	Antibacterial activity against Escherichia coli ATCC 25922 assessed as mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1188154	Inhibition of Mycobacterium tuberculosis DNA gyrase supercoiling activity using relaxed pBR322 substrate incubated for 30 mins by ethidium bromide staining method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID524824	Antibacterial activity against erythromycin resistant Campylobacter sp. by agar plate dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID695442	Antibacterial activity against fluoroquinolone resistant Staphylococcus aureus 1-FQR2M BK2384 expressing GyrA Ser84Leu mutant and GrlA Ser80Phe mutant	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID456030	Antibacterial activity against Streptococcus mitis IID685 after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID563337	Induction of Cwp84 protease expression in Clostridium difficile CD196 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID574005	Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425967	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID562618	Antimicrobial activity against Heterovancomycin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID574004	Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID278858	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID285295	Effect on 32 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID601786	Antibacterial activity against 10'4 CFU Enterococcus faecium 06-7 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID570929	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID279271	Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 2527 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID341397	Drug level in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit serum at 20 mg/kg, iv administered every 12 hrs measured 12 hrs after seventh dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID633629	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 10-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID571764	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID601787	Antibacterial activity against 10'4 CFU Escherichia coli ATCC 25922 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID522961	Antibacterial activity against Moraxella catarrhalis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID559518	Antibacterial activity against Streptococcus constellatus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1909948	Antibacterial activity against Staphylococcus aureus ATTC 25923 assessed as inhibition of bacterial growth measured after 8 days by Alamar blue reagent based broth microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID581858	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID559490	Antibacterial activity against Propionibacterium acnes by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573572	Antibacterial activity against beta-lactamase producing Bacteroides uniformis by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID508386	Antibacterial activity against macrolide-resistant Streptococcus pyogenes harboring erm(B) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID559065	Antibacterial activity against Streptococcus mitis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID425567	Antibacterial activity against Streptococcus pneumoniae HMC 3041 after 50 passages by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID573394	Antibacterial activity against Bacteroides fragilis by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID416841	Antimycobacterial activity against Mycobacterium ulcerans isolate CU001 infected in BALB/c mouse left hind foot-pad assessed as bacterial load per culture-positive foot-pad at 100 mg/kg, po administered for 5 days per week measured after 4 weeks	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
AID1196883	Inhibition of Mycobacterium tuberculosis AlaDH using L-alanine as substrate after 20 mins by spectrophotometry	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors.
AID531512	Antibacterial activity against Bacteroides eggerthii assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID559507	Antibacterial activity against Staphylococcus saprophyticus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1877408	Antibacterial activity against Streptococcus pneumoniae ATCC 49169	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID523142	Antibacterial activity against Streptococcus pneumoniae isolate OC7348 assessed as log reduction in bacterial growth at 2 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID562632	Antimicrobial activity against Streptococcus pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID275464	Inhibition of human topoisomerase 2 by DNA cleavage assay	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
AID531527	Antibacterial activity against Bacteroides vulgatus isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID425335	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID572517	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Braenderup isolate s2856 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID322782	Antimicrobial activity against Bacteroides merdae isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID1610996	Antibacterial activity against mid-exponential growth phase of methicillin-resistant Staphylococcus aureus ATCC 700699 assessed as increase in cell lysis at 25 uM	2019	Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23	The plant-derived chalcone Xanthoangelol targets the membrane of Gram-positive bacteria.
AID1264564	Half-life in mouse at 2 mg/kg, iv by LC-MS/MS analysis	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1163993	Antibacterial activity against Klebsiella pneumoniae 12-2 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID559140	Antimicrobial activity against Clostridium difficile A422g harboring GyrA Asp81Asn mutant gene selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID322786	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID428775	Bactericidal activity against Streptococcus pneumoniae isolate SR-26137 ParC Ser79Phe assessed as mutant prevention concentration after 72 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1877407	Antibacterial activity against Pseudomonas aeruginosa 143	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID553812	Induction of cytotoxin production in Clostridium difficile PCR ribotype 001 in three-stage chemostat gut model at 43 mg/liter administered daily for 7 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID1154352	Antimycobacterial activity against TMC207R-resistant Mycobacterium tuberculosis clone 8.1 over expressing DprE1 mutant after 5 days by standard microdilution method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
AID1381413	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in C57BL/6 mouse assessed as log reduction in bacterial load in lungs at 30 mg/kg, po for 8 consecutive days starting from day 1 post infection measured on day 9 post last dose	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
AID515920	Antibacterial activity against kanamycin-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay	2010	Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20	Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID1601851	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID1179479	Antimycobacterial activity against Mycobacterium chelonae ATCC 35752 in 7H9 medium after 3 days and 4 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.
AID279284	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79Y and gyrA E85K mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID323871	Antimicrobial activity against qnrA1 expressing Klebsiella pneumoniae UAB1 GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID1154350	Antimycobacterial activity against Mycobacterium tuberculosis over expressing PimA after 5 days by standard microdilution method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
AID563331	Upregulation of slpA gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID559509	Antibacterial activity against Streptococcus agalactiae assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573599	Antibacterial activity against Fusobacterium nucleatum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID522987	Antibacterial activity against Streptococcus pneumoniae isolate OC5462 assessed as log reduction in bacterial growth at 2 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID523172	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC11223 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID342253	Drug level in Clostridium difficile infected CF1 mouse stool at 0.2 mg/day for 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID553803	Antimicrobial activity against Clostridium difficile PCR ribotype 027 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID484795	Antibacterial activity against Staphylococcus aureus SA-K1904 bearing norA++ efficient mutation by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID559202	Antibacterial activity against Streptococcus pneumoniae S003 harboring wild-type parC and gyrA Ser81Phe mutant genes	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID570922	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID406813	Antibacterial activity against Staphylococcus aureus ACH-0231 isolate with gyrA Ser84Leu, Glu88Lys and grlA Ser80Tyr, Glu84Gly mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID544858	Antibacterial activity against Streptococcus pneumoniae H548 clinical isolate harboring gyrA Ser81Phe mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID574764	Antimicrobial activity against Finegoldia magna after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1154547	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 Rv1937/F426C mutant assessed as growth inhibition after 5 days by microdilution method	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID279293	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parE D435N and gyrA E85K mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID1264560	Antibacterial activity against Streptococcus pneumoniae 402 infected in sc dosed mouse assessed as reduction in 2 log CFU in lung compound administered as BID for 1 day measured 24 hrs after last dose	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID531528	Antibacterial activity against Bacteroides caccae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID562944	Upregulation of fbp68 gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID576326	Antibacterial activity against 10'4 to 10'5 CFU methicillin-susceptible Staphylococcus aureus after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID559071	Antibacterial activity against Acinetobacter lwoffii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID279837	Reduction of Mycobacterium tuberculosis H37Rv in orally dosed BALB/c mouse lung	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID559066	Antibacterial activity against Streptococcus oralis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID562636	Antimicrobial activity against Listeria monocytogenes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID520366	Ratio of AUC (0 to 24 hrs) in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg to MIC for Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID278857	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID518620	Antimicrobial activity against intracellular Mycobacterium avium subsp. hominissuis ATCC 700898 after 7 days by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID570673	Antibacterial activity against Enterobacteriaceae by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID540215	Volume of distribution at steady state in rat after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID573551	Antibacterial activity against Bacteroides fragilis assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1494124	Antibacterial activity against Norfloxacin-resistant Staphylococcus aureus 1199B over-expressing NorA after 16 hrs by microdilution method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID245237	Minimum inhibitory concentration against vancomycin-resistant Staphylococcus aureus (Hershey)	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID522993	Antibacterial activity against Streptococcus pneumoniae isolate OC7376 assessed as log reduction in bacterial growth at 4 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID765272	Cmax/MIC in Mycobacterium tuberculosis infected mouse	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID1514448	Antitubercular activity against rifampicin-resistant Mycobacterium tuberculosis after 7 days by resazurin dye based colorimetric assay	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID1652708	Induction of Escherichia coli K12 MG1655 recN promotor measured at 30 mins interval for 20 hrs by fluorescence assay relative to control
AID342256	Effect on growth of fluoroquinolone-resistant epidemic Clostridium difficile NAP1 in CF1 mouse assessed as increase in bacterial density in cecal content at 2.0 mg/day, sc for 5 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID283162	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2622 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID369965	AUC (0 to 24 hrs) in human serum at 400 mg, po administered as single dose	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID558607	Antimicrobial activity against Streptococcus pneumoniae isolate 1384 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID285296	Susceptibility of penicillin-resistant Streptococcus pneumoniae 217 by by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID531523	Antibacterial activity against Bacteroides eggerthii isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID559410	Antimicrobial activity against Clostridium difficile BI2E harboring GyrB Glu466Lys mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID571339	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559510	Antibacterial activity against Lancefield Streptococcus sp. 'group C' assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID558893	Antimicrobial activity against Clostridium difficile C253h harboring GyrA Ala118Ser mutant gene selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1207286	Inhibition of long-lasting type calcium current (ICaL) in HEK293 cells (alpha1C/beta2a/alpha2delta1) cells measured using IonWorks Barracuda automated patch clamp platform
AID532960	Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 4	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID572523	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Corvallis isolate s2052 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID581478	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID518799	Antimycobacterial activity against Mycobacterium fortuitum after 3 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
AID558630	Antimicrobial activity against Streptococcus pneumoniae isolate 4747 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1393792	Antibacterial activity against multidrug resistant Mycobacterium tuberculosis ATTC 27294 by Alamar Blue assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Fluoroquinolone derivatives and their anti-tubercular activities.
AID496649	Antibacterial activity against Streptococcus pneumoniae 1151 assessed as mutant prevention concentration by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID570802	Apparent oral clearance in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID533125	Antimicrobial activity against Bacteroides distasonis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID565312	Antibacterial activity against Mycoplasma genitalium R32 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID586632	Antibacterial activity against qnrB gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrB1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID243188	Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state	2005	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6	A two-state homology model of the hERG K+ channel: application to ligand binding.
AID428799	Ratio of AUC (0 to 24 hrs) in human at 80 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-26137	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID531511	Antibacterial activity against Bacteroides merdae assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID571127	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID562660	Ratio of AUC (0 to 24 hrs) to MIC required for 3-log drop in bacterial count in Staphylococcus aureus SMH37503	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID574589	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 obtained from pus of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID562635	Antimicrobial activity against Corynebacterium spp. assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID558592	Antimicrobial activity against Streptococcus pneumoniae 4 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID574766	Antimicrobial activity against Finegoldia magna assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID584555	Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID243151	Inhibitory concentration against potassium channel HERG	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID593804	Antimicrobial activity against quinilone-pencillin-resistant Staphylococcus aureus isolate SAR 4790 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID1237416	Bactericidal activity against Escherichia coli KCTC 1924 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID1348982	Elimination half life in ICR mouse at 50 mg/kg, po by HPLC analysis
AID1877418	Antibacterial activity against Neisseria gonorrhoeae WHO C	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID521343	Cmin in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID368424	Ratio of MIC for Escherichia coli KAM32 pSTVqepA mutant to MIC for Escherichia coli KAM32 pSTV28 mutant	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID559260	Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID586644	Antibacterial activity against qnrB gene expressing Escherichia coli ATCC 25922 harboring ParC S80R mutant, ParC S80R mutant and pBK-QnrB1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1743461	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Asp-94-Gly/gyrB Asp-500-Asn mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID533381	Antimicrobial activity against Bacteroides nordii by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID575099	Antimicrobial activity against Streptococcus pneumoniae serotype 15A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID1237424	Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID581481	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID563101	Upregulation of fbp68 gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID571368	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID562824	Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1740319	Antimicrobial activity against Escherichia coli NCTC 11954 producing penicillinase assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID1256552	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-2 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID1861192	Antimycobacterial activity against drug-sensitive Mycobacterium tuberculosis assessed as mycobacterial growth inhibition	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent.
AID595855	Inhibition of wild-type Staphylococcus aureus topoisomerase 4-mediated decatenation of kDNA after 30 mins by gel electrophoresis assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
AID1207346	Inhibition of fast sodium current (INa) in HEK293 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID341392	Toxicity in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit assessed as inflammatory cell infiltration median score at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 days after last dose by histopathology	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID405462	Antibacterial activity against Escherichia coli TOP10 in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID733007	Inhibition of Mycobacterium leprae DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 2 hrs at 30 degC by ethidium bromide based gel electrophoresis	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID286043	Susceptibility of Streptococcus pneumoniae ATCC 49619 by microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID571352	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID278432	Antibacterial activity against Streptococcus pyogenes M12 by time-kill curve assay	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
AID518797	Antimycobacterial activity against quinolone-resistant multidrug-resistant Mycobacterium tuberculosis after 21 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
AID601790	Antibacterial activity against 10'4 CFU Klebsiella pneumoniae 09-23 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID1163991	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli 12-15 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID558609	Antimicrobial activity against Streptococcus pneumoniae isolate 1397 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID511386	Antibacterial activity against ciprofloxacin resistant Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID570804	Ratio of AUC (0 to 24 hrs ) in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose to AUC (0 to 24 hrs ) in healthy human at 400 mg, po qd measured on	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID580907	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID559536	Antibacterial activity against Moraxella catarrhalis assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID586726	Antibacterial activity against Escherichia coli ATCC 25922 harboring GyrA S83L mutant assessed as mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID286082	fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 50 mg	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID581105	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1330192	Antibacterial activity against Pseudomonas aeruginosa 2742 measured after 24 hrs by two-fold serial dilution method	2016	Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24	Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
AID484794	Antibacterial activity against Staphylococcus aureus ATCC 25923 by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID425339	Antibacterial activity against azithromycin-resistant Streptococcus pneumoniae ATCC 49619 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID581108	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID556782	Ratio of drug level in cancellous bone to serum in osteomyelitis patient at 400 mg, po administered for every 24 hrs by MAP-Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID580883	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID559074	Antibacterial activity against Enterobacter aerogenes by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID590141	Antitubercular activity against Mycobacterium tuberculosis H37Rv by LORA assay	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
AID1465261	Antibacterial activity against multidrug resistant Staphylococcus aureus by broth microdilution assay
AID635058	Antibacterial activity against methicillin-resistant Staphylococcus aureus 10-3 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID1318917	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID428854	Bactericidal activity against Streptococcus pneumoniae isolate SR-23958 assessed as reduction in number of viable cells under condition simulating oral administration of 400 mg once daily	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID580905	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID511302	Antibacterial activity against methicillin susceptible Staphylococcus aureus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID595933	Inhibition of Staphylococcus aureus topoisomerase 4 Ser80Phe mutant-mediated decatenation of kDNA after 30 mins by gel electrophoresis assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
AID559052	Antibacterial activity against Staphylococcus saprophyticus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1163988	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli 12-2 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID574752	Antimicrobial activity against Anaerococcus prevotii after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID581072	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1185139	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.
AID1075024	Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in C57BL/6 mouse assessed as reduction of bacterial CFU in lung at 30 mg/kg, po administered for 8 days measured 24 hrs post last dose relative to control	2014	Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4	Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.
AID283390	Antimicrobial activity against Nocardia cyriacigeorgica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID425803	Cmax in human at 400 mg, po	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID1743452	Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in human macrophages assessed as intracellular bacterial load at 0.5 MIC measured after 6 days (Rvb = 5.57 to 6.43 logCFU/ml)	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID405466	Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID1437920	Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 by broth microdilution method	2017	Journal of natural products, 01-27, Volume: 80, Issue:1	Antibacterial and Cytotoxic Phenolic Metabolites from the Fruits of Amorpha fruticosa.
AID574948	Antimicrobial activity against Streptococcus pneumoniae serotype 19A by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID511390	Antibacterial activity against Proteus mirabilis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID544868	Antibacterial activity against Streptococcus pneumoniae U2A1414 harboring gyrA Glu85Lys parC Ser79Phe mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID570806	Ratio of Tmax in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose to Tmax in healthy human at 400 mg, po qd measured on day 6	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID593813	Antimicrobial activity against Saccharomyces cerevisiae ATCC 9763 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID584565	Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID575076	Antimicrobial activity against Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID406623	Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolates assessed as percent resistant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
AID518628	Ratio of AUC (0 to 24 hrs) in Mycobacterium avium infected human THP1 cell-based pharmacokinetic-pharmacodynamic model to MIC for Mycobacterium avium at 80% maximal effective concentration	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID521334	Cmax in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID595858	Antibacterial activity against Escherichia coli ATCC25922 after 24 hrs by microdilution method	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
AID559171	Antimicrobial activity against Clostridium difficile BI2e harboring GyrB Arg447Lys and Asp426Asn mutant gene selected after 32 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID422665	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID406646	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID508369	Antibacterial activity against Streptococcus pneumoniae harboring erm(B) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID508379	Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring erm(B) and mef(A) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID406806	Antibacterial activity against Staphylococcus aureus ACH-0201 isolate with gyrA Ser84Leu, Glu88Val and grlA Ser80Phe, Ala116Val mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID1297323	Antibacterial activity against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae 14-18 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID523293	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in B6 mouse assessed as 2 log reduction in bacterial burden in lungs orally treated in water-20% captisol upto 8 days	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
AID1430297	Antibacterial activity against Listeria monocytogenes ATCC 7644 incubated after 24 hrs by resazurin dye based broth microdilution assay	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID581104	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID523154	Antibacterial activity against Streptococcus pneumoniae isolate OC6610 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID544295	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID559484	Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID576136	Antibacterial activity against 10'4 to 10'5 CFU Enterococcus faecalis after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID562931	Antimicrobial activity against Clostridium difficile 6269 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID425978	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1256563	Antibacterial activity against Enterococcus faecalis 14-1 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID422683	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID559053	Antibacterial activity against Staphylococcus warneri by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1819732	Antimycobacterial activity against Mycobacterium abscessus K21 assessed as inhibition of mycobacterial growth incubated for 3 days by broth microdilution method	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Structure-Activity Relationship of Anti-
AID511385	Antibacterial activity against vancomycin resistant Enterococcus faecium by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID581297	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID544854	Antibacterial activity against Streptococcus pneumoniae U2A1686 harboring gyrA Glu85Lys mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID565291	Antimicrobial activity against Mycoplasma hominis by agar dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID369980	Antibacterial activity against ciprofloxacin and methicillin-resistant Staphylococcus aureus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID695450	Inhibition of human ERG expressed in mammalian cells at 10 uM by patch clamp method	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID322777	Antimicrobial activity against Bacteroides uniformis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID518622	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 10% FBS	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID323877	Antimicrobial activity against qnrA1 expressing Klebsiella pneumoniae 1132 GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID1868111	Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID422672	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 19 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID425580	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene and I460V, D435N mutation in QRDR of ParE g	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1256535	Antibacterial activity against Escherichia coli 14-1 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID581071	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID581277	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1750826	Plasma protein binding in CD1 mouse at 10 uM after 4 hrs by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID571763	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-F628F mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID633638	Antibacterial activity against Streptococcus pneumoniae 10-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID570988	Tmax in healthy human assessed as 25-desacetyl-rifapentine level at 900 mg, po thrice weekly measured on day 19 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID584556	Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID425969	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 20 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID556196	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from apical to basolateral side at 50 uM	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID563033	Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID341394	Toxicity in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit assessed as fibrous content median score at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 days after last dose by histopathology	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID542549	Antimicrobial activity against Nocardia brasiliensis HUJEG-1 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.
AID574500	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID573601	Antibacterial activity against Fusobacterium necrophorum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1600110	Bactericidal activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1164012	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 12-8 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID425808	Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in CD-1 mouse lung measured after 28 days of aerosol infection run	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID584111	Bacteriostatic activity against Escherichia coli K-12 DM4100	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.
AID563334	Upregulation of slpA gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID342257	Effect on growth of fluoroquinolone-susceptible epidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content dosed sc for 5 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID580890	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID601704	Antibacterial activity against 10'4 CFU methicillin-sensitive Staphylococcus aureus 08-1 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID1512393	Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in C57BL/6 mouse assessed as reduction in bacterial load in lungs at 30 mg/kg administered once daily starting from 5 days post infection for 4 consecutive days and measured on day	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Novel Pyrazole-Containing Compounds Active against
AID511389	Antibacterial activity against Enterobacter cloacae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID563227	Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID283171	Decrease in biofilm formation of Staphylococcus lugdunensis assessed as percent biofilm forming isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID728925	Antibacterial activity against levofloxacin-resistant and methicillin-resistant Staphylococcus aureus 870307 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID559152	Antimicrobial activity against Clostridium difficile 630d selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID533131	Antimicrobial activity against Bacteroides fragilis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1909949	Antibacterial activity against Escherichia coli ATTC 25922 assessed as inhibition of bacterial growth measured after 8 days by Alamar blue reagent based broth microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID571340	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1318913	Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa isolate CAN-ICU 62308 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1868118	Anti-tubercular activity against Mycobacterium tuberculosis CF152 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID1398597	Antibacterial activity against Klebsiella pneumoniae TYPE 1 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID518804	Antimycobacterial activity against Mycobacterium abscessus after 3 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
AID530390	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA M74I and A83S mutant/GyrB R447K mutant gene assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID249969	Ratio of MPC to MIC against methicillin resistant Staphylococcus aureus-33	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID286050	Peak free concentration at 50 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID285283	Effect on 16 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID523317	Antibacterial activity against Streptococcus pneumoniae OC7453 harboring gyrA S81F mutant gene by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID574987	Antimicrobial activity against Bifidobacterium adolescentis after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID635057	Antibacterial activity against methicillin-resistant Staphylococcus aureus 10-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID1194330	Inhibition of Mycobacterium smegmatis GyrB ATPase activity expressed in Escherichia coli BL21 (DE3) pLysS cells after 100 mins by inorganic phosphate release detection based malachite green reagent assay	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID565326	Antibacterial activity against Mycoplasma genitalium M6090 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID508376	Antibacterial activity against quinolone-resistant Streptococcus pneumoniae after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID544846	Antibacterial activity against Streptococcus pneumoniae R6 Tr10 harboring gyrA Ser81Tyr parC Ser79Tyr mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID559077	Antibacterial activity against non-ciprofloxacin-susceptible Haemophilus influenzae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1691029	Antibiofilm activity against Mycobacterium tuberculosis assessed as log reduction in bacterial growth at 10 uM measured after 1 week relative to control	2020	European journal of medicinal chemistry, May-01, Volume: 193	Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors.
AID562448	Antibacterial activity against Staphylococcus aureus SMH36945 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID574952	Antimicrobial activity against Streptococcus pneumoniae serotype 11A by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID559381	Antimicrobial activity against Clostridium difficile A422F harboring GyrB Leu451Phe mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID581663	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1154544	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 C387S mutant assessed as growth inhibition after 5 days by microdilution method	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID558930	Antimicrobial activity against Clostridium difficile A422f selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID322776	Antimicrobial activity against Bacteroides thetaiotaomicron isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID428783	Cmax in human at 80 mg, po administered once a day	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID533365	Antimicrobial activity against Bacteroides uniformis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID530599	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr11 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID522962	Antibacterial activity against ciprofloxacin-susceptible, -intermediate Escherichia coli by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID285972	Antimicrobial susceptibility against Haemophilus influenzae D3 isolate with GyrA Ser84Tyr, ParC Glu88Lys and AcrR Leu31His, Ile121Val and Gln134Lys mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID559060	Antibacterial activity against Streptococcus pyogenes by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID574484	Antimicrobial activity against Bacteroides thetaiotaomicron after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID341373	Antibacterial activity against Staphylococcus aureus by manual microdilution technique	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID69597	Antibacterial activity was evaluated against Escherichia coli	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID559497	Antibacterial activity against vancomycin- resistant Enterococcus faecalis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID531857	Tmax in tuberculosis patient at 400 mg/day, po administered for 7 days by HPLC	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
AID576135	Antibacterial activity against 10'4 to 10'5 CFU Enterococcus faecium after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID368420	Antimicrobial activity against Escherichia coli KAM32 pHPA containing mutated GyrA gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID522979	Antibacterial activity against Streptococcus pneumoniae isolate OC7189 assessed as log reduction in bacterial growth at 2 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID581288	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID563221	Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID286077	fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 100 mg	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID405117	Antimicrobial activity against Escherichia coli TOP10 harbouring pVS2 expressing quinolone resistant Vibrio splendidus LGP32 QnrVS2 gene	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID575084	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 6B assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID508375	Antibacterial activity against quinolone-susceptible Streptococcus pneumoniae after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID522997	Antibacterial activity against Streptococcus pneumoniae isolate OC6790 assessed as log reduction in bacterial growth at 2 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID533372	Antimicrobial activity against Bacteroides vulgatus assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID558589	Antimicrobial activity against Streptococcus pneumoniae 1 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID531525	Antibacterial activity against Bacteroides ovatus isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID522956	Antibacterial activity against Streptococcus agalactiae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID278861	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID559534	Antibacterial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID279264	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3676 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID565315	Antibacterial activity against Mycoplasma genitalium TW48-5G by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID581082	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1909950	Antibacterial activity against wild type Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth incubated for 11 days	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID544293	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID556780	Apparent intercompartmental clearance in osteomyelitis patient at 400 mg, po administered for every 24 hrs by three stage hierarchical Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID422684	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1243284	Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolates by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID565317	Antibacterial activity against Mycoplasma genitalium M2282 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1750815	Selectivity index, ratio of MIC for Fluoroquinolone-resistant Staphylococcus aureus ATCC 49951 to MIC for Fluoroquinolone-sensitive Staphylococcus aureus ATCC 49951	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID563032	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID522950	Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID372985	Antimycobacterial activity against Mycobacterium avium JATA51-01 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID286094	fAUC/MIC ratio of Staphylococcus aureus BSP-2443 at 50 mg	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID556768	fAUC/MIC in osteomyelitis patient cortical bone at 400 mg, po administered for every 24 hrs at PKPD breakpoint at 0.5 mg/liter	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID405460	Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID576138	Antibacterial activity against 10'4 to 10'5 CFU methicillin-resistant coagulase-negative Staphylococcus after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID574770	Antimicrobial activity against Clostridium perfringens after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID522985	Antibacterial activity against Streptococcus pneumoniae isolate OC6608 assessed as log reduction in bacterial growth at 4 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID559063	Antibacterial activity against Streptococcus constellatus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID533397	Antimicrobial activity against Clostridium paraputrificum by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID428291	Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeABC adeIJK double mutant isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID285533	Antibacterial activity against ethidium bromide-resistant Staphylococcus aureus BSA678 after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID1154353	Antimycobacterial activity against moxifloxacin-resistant Mycobacterium tuberculosis clone 4.1 over expressing DprE1 mutant after 5 days by standard microdilution method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
AID1297320	Antibacterial activity against Escherichia coli 14-1 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1557286	Antibacterial activity against Streptococcus pyogenes by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID556192	Apparent passive permeability across human Calu3 cells at 350 ug/ml	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID1297331	Antibacterial activity against Pseudomonas aeruginosa 14-14 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1380643	Antibacterial activity against wild type Escherichia coli ATCC 25922 by CLSI M100-S17 protocol based method	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
AID581490	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID573784	Antibacterial activity against Prevotella bivia by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1348986	Antimycobacterial activity against isoniazid/rifampicin/ethambutol-resistant Mycobacterium tuberculosis after 3 days by rapid direct susceptibility test
AID279828	AUC(0-infinity) in BALB/c mouse at 6 to 400 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID406832	Inhibition of Staphylococcus aureus wild-type DNA gyrase supercoiling activity assessed as effect on conversion of relaxed pBR322 DNA to supercoiled form	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID1600109	Antibacterial activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID574504	Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID559487	Antibacterial activity against Fusobacterium sp. by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559083	Antibacterial activity against Neisseria meningitidis by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1393811	Antitubercular activity against replicating Mycobacterium tuberculosis H37Rv by Alamar Blue assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Fluoroquinolone derivatives and their anti-tubercular activities.
AID456045	Antibacterial activity against vancomycin-resistant Enterococcus faecalis after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1403711	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv dormant stage assessed as log reduction in bacterial load at 10 ug/ml incubated for 7 days	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.
AID484791	Antibacterial activity against Staphylococcus aureus SA-K1902 bearing norA- deficient mutation by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID633744	Antibacterial activity against Pseudomonas aeruginosa 10-3 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID522946	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID428857	Bactericidal activity against Streptococcus pneumoniae ATCC 49619 assessed as prevention of bacterial regrowth under condition simulating oral administration of 400 mg once daily after 72 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID511397	Antibacterial activity against Acinetobacter baumannii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID544849	Antibacterial activity against Streptococcus pneumoniae U2A1414 harboring gyrA Glu85Lys parC Ser79Phe mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID522968	Antibacterial activity against Proteus mirabilis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID424333	Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CLSI-M11-A7 method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID558614	Antimicrobial activity against Streptococcus pneumoniae isolate 2688 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID533413	Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574954	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19A by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1243289	Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID425542	Antibacterial activity against Streptococcus pneumoniae HMC 1139 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1297340	Antibacterial activity against methicillin-resistant Staphylococcus aureus 14-5 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID759328	Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents.
AID342064	Antimicrobial activity against epidemic Clostridium difficile BI9 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID498191	Antibacterial activity against Stenotrophomonas maltophilia MBS101 containing plasmid encoded Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID574726	Antimicrobial activity against Prevotella oralis assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID563208	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID581491	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID508382	Antibacterial activity against Streptococcus pyogenes harboring erm(B) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID279244	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3676 with GyrA E85G, GyrB S478I and ParC S79Y mutation after 50 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID528848	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID728903	Plasma protein binding in human at 5 ug/mL by ultrafiltration method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID244977	Antibacterial activity against Klebsiella pneumoniae type II was determined	2004	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
AID1330190	Antibacterial activity against Escherichia coli 1356 measured after 24 hrs by two-fold serial dilution method	2016	Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24	Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
AID1126759	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 821 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1254076	Antifungal activity against Candida albicans 7535 by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID1551290	Antibacterial activity against Staphylococcus aureus RN4220 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID577487	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus SH1000 assessed as inhibition of bacterial biofilm formation by CLSI broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID406810	Antibacterial activity against Staphylococcus aureus ATCC 700699 isolate with gyrA Ser84Leu, Glu409Lys and grlA Ser80Phe mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID531719	Antibacterial activity against Bacteroides fragilis isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID573563	Antibacterial activity against beta-lactamase producing Bacteroides vulgatus by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID559245	Antibacterial activity against Streptococcus pneumoniae D002 harboring parC Ser79Phe and gyrA Ser81Phe mutant genes assessed as mutation prevention concentration after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID341077	Plasma concentration in human with MDR1 3435 CC genotype at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg/kg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID576137	Antibacterial activity against 10'4 to 10'5 CFU Streptococcus pyogenes after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID562661	Ratio of AUC (0 to 24 hrs) to MIC required for 3-log drop in bacterial count in Staphylococcus aureus SMH38002	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID580862	Cmax in patients with pulmonary tuberculosis at 400 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID1256567	Antibacterial activity against Enterococcus faecium 14-5 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID562614	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID563040	Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1297318	Antibacterial activity against extended-spectrum beta-lactamase-producing Escherichia coli 14-1 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID520381	Antimicrobial activity against Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID532975	Antimicrobial activity against multidrug-resistant Mycobacterium tuberculosis isolate 19	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID499771	Antimicrobial activity against quinolone and penicillin-resistant Pseudomonas aeruginosa after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID533412	Antimicrobial activity against Finegoldia magna assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID422667	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID428844	Time above the mutant prevention concentration in Streptococcus pneumoniae isolate SR-23958 infected human at 400 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID553689	Antimicrobial activity against Clostridium in three-stage chemostat gut model assessed as log reduction in bacterial count at 43 mg/liter administered daily for 7 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID576140	Antibacterial activity against 10'4 to 10'5 CFU methicillin-susceptible coagulase-negative Staphylococcus after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID245138	Minimum inhibitory concentration against methicillin-resistant Staphylococcus aureus-33	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID523180	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC8530 harboring gyrA S84L and parC I143V mutant gene assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID675093	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis clinical isolate after 18-24 hrs by two-fold serial dilution method	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety.
AID1494125	Antibacterial activity against erythromycin-resistant Staphylococcus aureus RN4220 after 16 hrs by microdilution method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID1600104	Bactericidal activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1890605	Antibacterial activity against methicillin resistant Staphylococcus aureus 5076 harbouring DNA gyrase and topoisomerase IV mutant and efflux pump assessed as inhibition of bacterial growth incubated for 18 hrs in presence of efflux inhibitor by CLSI based	2022	Bioorganic & medicinal chemistry letters, 05-01, Volume: 63	WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID522963	Antibacterial activity against ciprofloxacin-resistant Escherichia coli by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID428824	Ratio of Cmax in human at 400 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae ATCC 49619	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID571132	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID556761	fAUC/MIC in osteomyelitis patient cortical bone at 400 mg, po administered for every 24 hrs at PKPD breakpoint at 0.25 mg/liter	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID559068	Antibacterial activity against Streptococcus sanguinis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID522971	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1430294	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 incubated after 24 hrs by resazurin dye based broth microdilution assay	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID442254	Antimalarial activity against Plasmodium falciparum 3D7	2009	Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24	Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID341076	AUC (0 to 24 hrs) in human with MDR1 3435 CC or CT genotype at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID522999	Antibacterial activity against Streptococcus pneumoniae isolate OC6790 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID559045	Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1243287	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae clinical isolates by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID1557281	Antibacterial activity against Klebsiella by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID574811	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis H37Rv by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID633644	Antibacterial activity against Enterococcus faecalis 09-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID561327	Antimicrobial activity against Klebsiella pneumoniae isolate 202 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID563224	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID559072	Antibacterial activity against Citrobacter freundii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID728922	Antibacterial activity against quinolone, penicillin-resistant Streptococcus pneumoniae 104835 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID531630	Antimicrobial activity against Ureaplasma urealyticum by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
AID570691	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571126	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID425345	Antibacterial activity against Streptococcus pneumoniae HMC 1060 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID544857	Antibacterial activity against Streptococcus pneumoniae U2A1266 harboring gyrA Ser81Cys mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID494417	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives.
AID533417	Antimicrobial activity against Micromonas micros by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID518059	Toxicity in healthy human assessed as dizziness at 400 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
AID286065	Half life at 75 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID765269	fT>MIC in Mycobacterium tuberculosis infected mouse	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID562455	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH38004	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID633743	Antibacterial activity against Pseudomonas aeruginosa 10-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID428774	Bactericidal activity against Streptococcus pneumoniae isolate SR-26134 assessed as mutant prevention concentration after 72 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID532685	Antimicrobial activity against ciprofloxacin-nonsusceptible, BT PFGE pattern, emm28 type Streptococcus pyogenes with ST52 sequence type, ParC D83G mutant isolated from skin/soft tissue infection	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID456044	Antibacterial activity against penicillin-intermediate resistant Streptococcus pneumoniae after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1318918	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 100036	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID543394	Antibacterial activity against Listeria monocytogenes EGD-e in BALB/c mouse central nervous system listeriosis model assessed as log reduction in bacterial CFU in brain at 50 mg/kg, ip administered 36 hrs postinfection as single dose measured within 1 hr	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID392220	Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23 promoter by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID586743	Antibacterial activity against qnrA gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrA1 assessed as earliest time required to resistant colonies visible one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1297337	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-3 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID565329	Antibacterial activity against Mycoplasma genitalium M6283 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID572519	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Typhimurium isolate s2425 harboring wild type ParC gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID574768	Antimicrobial activity against Finegoldia magna assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID406833	Inhibition of Staphylococcus aureus DNA gyrase gyrA S84L mutant supercoiling activity assessed as effect on conversion of relaxed pBR322 DNA to supercoiled form	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID553809	Drug level in human feces	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID563024	Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID562444	Antibacterial activity against Staphylococcus aureus SMH38002 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID499681	Antimicrobial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID531633	Bactericidal activity against Mycoplasma pneumoniae at MIC after 48 hrs	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
AID559079	Antibacterial activity against Klebsiella pneumoniae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID586642	Antibacterial activity against Escherichia coli ATCC 25922 harboring GyrA S83L mutant and ParC S80R mutant by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID563213	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID521335	Cmax in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID571849	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID531726	Antibacterial activity against Bacteroides fragilis assessed as percent resistant isolates	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1600100	Bactericidal activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID530374	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA S69V, A71G, E72D, T73V, M74I, N76K, A83S, S84A, I85V, F96W and P101M mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID544304	Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS5 harboring GyrA S84L, E88K and GrlA S80F, E84G mutant after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID574050	Antibacterial activity against beta-lactamase producing Finegoldia magna by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID283163	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2639 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID544859	Antibacterial activity against Streptococcus pneumoniae R6 Tr1 harboring parC Ser79Tyr mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID574758	Antimicrobial activity against Peptoniphilus asaccharolyticus after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID781330	pKa (acid-base dissociation constant) as determined by potentiometric titration	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1163999	Antibacterial activity against Pseudomonas aeruginosa 12-12 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID581662	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU after 72 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1685386	Potentiation of conjugate 11-induced antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as conjugate 11 MIC measured after 18 hrs by CLSI protocol based microbroth dilution method (Rvb = 64 to 128 ug/ml)	2019	MedChemComm, Apr-01, Volume: 10, Issue:4	Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria.
AID208611	Antibacterial activity was determined against clinically isolated penicillin resistant Streptococcus pneumoniae (PRSP) strains (50 strains)	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID369969	AUC (0 to 24 hrs) in Staphylococcus aureus infected rabbit arthritis model at 45 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID511384	Antibacterial activity against Enterococcus faecium by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID559483	Antibacterial activity against Serratia marcescens by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1154543	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 OE mutant assessed as growth inhibition after 5 days by microdilution method	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID1364755	Antibacterial activity against Mycobacterium marinum ATCC BAA-535 infected in Zebra fish assessed as log reduction in bacterial counts at 10 mg/kg, po administered for 7 days by MPN assay	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors.
AID520365	Ratio of AUC (0 to 24 hrs) in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg to MIC for Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID562649	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH37390	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID573552	Antibacterial activity against Bacteroides fragilis assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID461171	Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate Alamar blue assay	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	Synthesis, antimalarial and antitubercular activity of acetylenic chalcones.
AID522949	Antibacterial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID565324	Antibacterial activity against Mycoplasma genitalium M6286 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID544303	Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS3 harboring GyrA S84L and GrlA S80F, E84K mutant after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID559056	Antibacterial activity against Lancefield Streptococcus sp. group F by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1181171	Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_16.5 assessed as fold shift in MIC relative to parent strain	2014	Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID1272956	Inhibition of Mycobacterium tuberculosis DNA gyrase assessed as inhibition of DNA supercoiling after 30 mins by electrophoresis	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
AID523316	Antibacterial activity against Streptococcus pneumoniae OC7452 harboring parC S79Y mutant gene by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID580760	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1164004	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 12-4 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID283172	Effect on biofilm formation of Staphylococcus lugdunensis assessed as percent non-biofilm forming isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID484801	Antibacterial activity against Staphylococcus aureus K1628 bearing S84L mutant GyrA and S80F mutant GrlA by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID1557280	Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID563055	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID373140	Antimycobacterial activity against Mycobacterium avium complex N084 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID511387	Antibacterial activity against ciprofloxacin susceptible Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID1237429	Bactericidal activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID570793	Cmax in healthy human at 400 mg, po qd measured on day 4 by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID530370	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A and I85V mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID286051	Peak free concentration at 75 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID528972	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID425560	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1318934	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 80621	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID341075	AUC (0 to 24 hrs) in human with MDR1 3435 CC genotype at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID341079	Plasma concentration in human with MDR1 3435 CC genotype at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID522948	Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID532681	Antimicrobial activity against ciprofloxacin-nonsusceptible, AD PFGE pattern, emm89 type Streptococcus pyogenes with ST382 sequence type, ParC S79A mutant isolated from oropharyngeal colonization	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID405121	Antimicrobial activity against Escherichia coli TOP10	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID433578	Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A G89A mutant assessed as formation of DNA cleavable complex	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1126742	Antibacterial activity against 1 ug/ml Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID586641	Antibacterial activity against Escherichia coli ATCC 25922 harboring GyrA S83L mutant by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID430963	Antibacterial activity against Escherichia coli 1608 containing gyrA L83, L87 mutants assessed as increase in MIC by Etest relative to MIC for wild type Escherichia coli 1609	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
AID571874	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID544827	Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 20 microamperes of electric current by bioelectric effect assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID286154	Bactericidal activity against Staphylococcus aureus BSP-2443 at fAUC/MIC of 16 after 24 to 48 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID586736	Ratio of mutant prevention concentration to MIC for qnrB gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrB1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID532023	Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 7 days determined according to CFU count by bioluminescence method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID581097	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID593805	Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1256534	Antibacterial activity against ESBL-positive Escherichia coli 14-2 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID1126761	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1237 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID244926	Minimum inhibitory concentration against Bacteroides vulgatus ATCC 29327	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1430298	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 incubated after 24 hrs by resazurin dye based broth microdilution assay	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID531513	Antibacterial activity against Bacteroides spp. assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID533392	Antimicrobial activity against Clostridium perfringens assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID425988	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 29 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID499670	Antimicrobial activity against quinolone and penicillin-resistant Staphylococcus aureus SAR72 after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID559042	Antibacterial activity against vancomycin- resistant Enterococcus faecalis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID425561	Antibacterial activity against penicillin-, quinolone-resistant Streptococcus pneumoniae HMC 1541 harboring mutation in L4 protein by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID559489	Antibacterial activity against Prevotella sp. by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID497758	Apparent permeability across basolateral to apical side in human Calu3 cells	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID1224810	CL/F in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID341390	Cardiovascular activity in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit assessed as increase in fractional shortening at 20 mg/kg, iv administered every 12 hrs for 5 days by ECG	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID559061	Antibacterial activity against Streptococcus anginosus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID562627	Antimicrobial activity against Group B Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1067070	Antimicrobial activity against quinolone-resistant Staphylococcus aureus clinical isolate 3505 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID406649	Antibacterial activity against Staphylococcus aureus ACH-0221 isolate with gyrA Ser84Leu mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID424324	Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID535775	Antimicrobial activity against Mycobacterium ulcerans 1059 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 14 days determined according to RLU count by real-time luminescence method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID562829	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID279268	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81F mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID428788	Antibacterial activity against 80 mg q.d. moxifloxacin-pretreated Streptococcus pneumoniae isolate SR-26134 after 48 hrs of incubation by population analysis	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID571356	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID574999	Antimicrobial activity against Eubacterium lentum after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID695446	Antibacterial activity against fluoroquinolone resistant Staphylococcus aureus 5-FQR4M BSA678 expressing GyrA Ser84Leu and Ser85Pro mutant and GrlA Ser80Phe and Glu84Lys mutant	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID574762	Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID563018	Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID283394	Antimicrobial activity against Nocardia beijingensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID529892	Antimicrobial activity against Leptospira interrogans isolate 7 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID286049	Peak free concentration at 400 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID559058	Antibacterial activity against levofloxacin-susceptible Streptococcus pneumoniae by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1740332	Antifungal activity against Penicillium chrysogenum ATCC 10106 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID698997	Antimycobacterial activity against Mycobacterium tuberculosis infected in human assessed as log reduction of bacterial count at 400 mg, qd measured up to 2 days	2012	European journal of medicinal chemistry, May, Volume: 51	Tuberculosis: the drug development pipeline at a glance.
AID570989	Toxicity in healthy human assessed as incidence of adverse events at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID1256547	Antibacterial activity against Pseudomonas aeruginosa 14-15 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID581090	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID574530	Antimicrobial activity against Prevotella bivia assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID496652	Antibacterial activity against Streptococcus pneumoniae 1065 assessed as mutant prevention concentration by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID528846	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID496642	Antibacterial activity against Streptococcus pneumoniae 1151 by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID586733	Ratio of mutant prevention concentration to MIC for Escherichia coli ATCC 25922 expressing qnrS gene and pBK-QnrS1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1297327	Antibacterial activity against Klebsiella pneumoniae 14-3 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID496644	Antibacterial activity against Streptococcus pneumoniae 1058 by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID520107	Oral bioavailability in mouse at 300 mg/kg, po measured after 2 hrs	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
AID530368	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID559057	Antibacterial activity against Lancefield Streptococcus sp. 'group G' by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID571835	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID532686	Antimicrobial activity against ciprofloxacin-nonsusceptible, CJ PFGE pattern, emm89 type Streptococcus pyogenes with ST101 sequence type isolated from tonsillitis/pharyngitis	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID342080	Effect on growth of nonepidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.4 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID279237	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81F and ParC D83N mutation after 19 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID323873	Antimicrobial activity against qnrA1 expressing Klebsiella pneumoniae N5 GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID508374	Antibacterial activity against Streptococcus pneumoniae harboring mutation in 23S rRNA after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID574041	Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID572518	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Typhimurium isolate s2705 harboring wild type ParC gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID1430286	Inhibition of Escherichia coli DNA gyrase assessed as inhibition of enzyme-mediated supercoiling of relaxed pHOT1 DNA substrate at 1.95 to 15.6 ug/ml after 30 mins by gel electrophoresis method	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID323895	Antimicrobial activity against Klebsiella pneumoniae C2 GyrA Ser83Phe/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID581295	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1126756	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 753 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID1743456	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Ala-90-Val mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID322784	Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID433402	Inhibition of Mycobacterium leprae DNA gyrase subunit A A91V mutant assessed as DNA supercoiling inhibition	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID573397	Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID571149	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID285294	Effect on 4 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID586635	Antibacterial activity against qnrB gene expressing Escherichia coli ATCC 25922 harboring ParC S80R mutant and pBK-QnrB1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID283166	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5204 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID560259	Antimicrobial activity against Salmonella enterica serovar Typhimurium STYM61/9 expressing qnrB19 gene variant carried by IncL/M-like plasmid by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium.
AID323660	Antibacterial activity against Peptostreptococcus stomatis	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.
AID574742	Antimicrobial activity against Peptostreptococcus micros after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID570899	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1398603	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 033806 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID544636	Antimicrobial activity against Staphylococcus aureus Xen 30 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID245331	Antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) 870307 was determined	2004	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
AID456033	Antibacterial activity against Klebsiella pneumoniae type 2 after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID531516	Antibacterial activity against Bacteroides caccae assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID521330	fAUC (0 to 24 hrs) in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID556779	Apparent intercompartmental clearance in osteomyelitis patient at 400 mg, po administered for every 24 hrs by MAP-Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID497761	Apparent permeability across basolateral to apical side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID571372	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1465260	Antibacterial activity against clinical isolates of Escherichia coli by broth microdilution assay
AID1254071	Antibacterial activity against Escherichia coli KCTC 1924 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID523312	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC17042 harboring gyrA S84L/G106D, parC S80F and parE D732N mutant gene assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID285280	Effect on 0.5 ug/ml sitofloxacin-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID368422	Antimicrobial activity against Escherichia coli KAM32 pSTVqepA containing qepA gene ligated to pSTV28 plasmid by agar dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID544867	Antibacterial activity against Streptococcus pneumoniae U2A1060 harboring gyrA Ser81Phe parC Asp83His mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID283158	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2492 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID563336	Induction of Cwp84 protease expression in Clostridium difficile 6425 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID574512	Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1750818	Cytotoxicity against human HepG2 cells after 72 hrs by CellTiter Glo assay	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID559183	Antimicrobial activity against Clostridium difficile C253E selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1297328	Antibacterial activity against Klebsiella pneumoniae 14-4 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID406812	Antibacterial activity against Staphylococcus aureus BSA678 isolate with gyrA Ser84Leu, Ser85Pro and grlA Ser80Phe, Glu84Gly mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID522966	Antibacterial activity against Klebsiella pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID341383	Concentration in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit serum at 20 mg/kg, iv administered every 12 hrs measured 30 mins after third dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID424327	Antimicrobial activity against Dialister propionicifaciens by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID540232	Dose normalised AUC in monkey after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID556769	fAUC/MIC in osteomyelitis patient cancellous bone at 400 mg, po administered for every 24 hrs at PKPD breakpoint at 0.375 mg/liter	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID1163997	Antibacterial activity against extended-spectrum beta-lactamase producin Klebsiella pneumoniae 12-7 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID562456	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH37276	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID574524	Antimicrobial activity against Prevotella oralis after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID66572	Antibacterial activity was determined against clinically isolated vancomycin-A resistant enterococci (VRE) strains (33 strains)	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID533377	Antimicrobial activity against Bacteroides merdae by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1398606	Antibacterial activity against methicillin-resistant Staphylococcus aureus after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID518796	Antimycobacterial activity against drug-susceptible Mycobacterium tuberculosis after 21 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
AID533389	Antimicrobial activity against Clostridium perfringens by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574965	Antimicrobial activity against Actinomyces odontolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1676602	Binding affinity to ferric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID559049	Antibacterial activity against Staphylococcus haemolyticus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1819733	Antimycobacterial activity against Mycobacterium avium 11 assessed as inhibition of mycobacterial growth incubated for 3 days by broth microdilution method	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Structure-Activity Relationship of Anti-
AID522947	Antibacterial activity against ciprofloxacin-resistant Streptococcus pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1194335	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth at 50 uM after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID518630	Ratio of AUC (0 to 24 hrs) in Mycobacterium avium infected human THP1 cell-based pharmacokinetic-pharmacodynamic model to MIC for Mycobacterium avium at 1 log10 CFU/ml bacterial concentration	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID511388	Antibacterial activity against Klebsiella pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID572270	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID428804	Ratio of Cmax in human at 400 mg, po administered once daily to MIC for Streptococcus pneumoniae ATCC 49619	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID531626	Antimicrobial activity against Mycoplasma genitalium by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
AID571384	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID586746	Antibacterial activity against Escherichia coli ATCC 25922 assessed as resistant colonies recovered one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1380685	Antibacterial activity against Escherichia coli infected in cyclophosphamide treated neutropenic CD1 mouse septicemia model assessed as mouse survival at 1.5 mg/kg, iv dosed at 1 hr post infection followed by redosing at 5 hrs post infection measured at 9	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
AID586734	Ratio of mutant prevention concentration to MIC for Escherichia coli ATCC 25922 harboring GyrA S83L mutant	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID433581	Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A G89C mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID497760	Apparent permeability across apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID1743458	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Gly-88-Cys mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID1272964	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth at 50 uM after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
AID425347	Antibacterial activity against Streptococcus pneumoniae HMC 1070 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID574520	Antimicrobial activity against Prevotella bivia after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1318914	Antibacterial activity against gentamicin/tobramycin-resistant Pseudomonas aeruginosa isolate CANWARD-2011 96846 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID570986	AUC (0 to 48 hrs) in healthy human assessed as 25-desacetyl-rifapentine level at 900 mg, po thrice weekly measured on day 19 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID424319	Antimicrobial activity against Dialister pneumosintes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID425554	Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID586645	Antibacterial activity against qnrS gene expressing Escherichia coli ATCC 25922 harboring ParC S80R mutant, ParC S80R mutant and pBK-QnrS1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1524623	Antibacterial activity against Streptococcus mutans 3289 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID574774	Antimicrobial activity against Clostridium perfringens assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID586637	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrA gene and pBK-QnrA1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID285535	Effect on cellular viability of methicillin-sensitive Staphylococcus aureus ATCC 29213 by measuring the time required for recovery at 10 times MIC after 1 hr	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID323879	Antimicrobial activity against Escherichia coli DH10B GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID530592	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr4 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID323870	Antimicrobial activity against qnrA1 expressing Klebsiella pneumoniae UAB1 expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID581098	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1676592	Binding affinity to Gallium ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID571343	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID262136	Cytotoxicity against human Hep2 laryngeal carcinoma cell line	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
AID249968	Ratio of MPC to MIC aganist methicillin resistant Staphylococcus aureus-32	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID523156	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC11223 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1372631	Antibacterial activity against non replicating Mycobacterium tuberculosis H37Rv assessed as log reduction in bacterial count at 10 ug/ml incubated for 7 days followed by compound dilution measured after 4 weeks	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Lead identification and optimization of bacterial glutamate racemase inhibitors.
AID496635	Antibacterial activity against Streptococcus pneumoniae ATCC 49619	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID1600105	Antibacterial activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID323882	Antimicrobial activity against qnrA1 expressing Escherichia coli DH10B expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID425986	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 41 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID369972	Ratio of Cmax in Staphylococcus aureus infected rabbit arthritis model at 45 mg/kg, po to MIC for methicillin-sensitive Staphylococcus aureus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID571367	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID279292	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parE D435N and gyrA S81Y mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID530385	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID574951	Antimicrobial activity against Streptococcus pneumoniae serotype 7F by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID322779	Antimicrobial activity against Bacteroides caccae isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID456051	Inhibition of Staphylococcus aureus DNA gyrase Ser84Leu mutant	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID573783	Antibacterial activity against Prevotella buccae by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID728914	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID1600116	Bactericidal activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID559146	Antimicrobial activity against Clostridium difficile 630a selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID484792	Antibacterial activity against methicillin and ciprofloxacin-resistant Staphylococcus aureus 25A by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID562620	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID372984	Antimycobacterial activity against Mycobacterium avium JATA51-01 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID508365	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID521103	Antimicrobial activity against Streptococcus sp. 'group B' isolate 1 harboring gyrA Glu85Lys mutant, parC Ser79Tyr mutant and parE Ileu495Leu mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
AID574993	Antimicrobial activity against Bifidobacterium sp. after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID570931	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID278859	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID581077	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID341396	Drug level in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit serum at 20 mg/kg, iv administered every 12 hrs measured 30 mins after seventh dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID1256564	Antibacterial activity against Enterococcus faecalis 14-2 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID323894	Antimicrobial activity against Klebsiella pneumoniae C2 GyrA Ser83Phe mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID372982	Antimycobacterial activity against Mycobacterium avium complex N084 after 14 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID285162	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID341375	Antibacterial activity against Staphylococcus aureus by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID424325	Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CLSI-M11-A7 method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID559043	Antibacterial activity against vancomycin- resistant Enterococcus faecium by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID373141	Antimycobacterial activity against Mycobacterium avium complex N084 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID528849	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID574490	Antimicrobial activity against Bacteroides vulgatus after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID571106	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID580763	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID425563	Antibacterial activity against penicillin-, macrolide- and quinolone-susceptible Streptococcus pneumoniae HMC 63 after 50 passages by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1564360	Antimycobacterial activity against Mycobacterium bovis BCG ATCC 35737 by resazurin dye based fluorimetric assay	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	The synthesis and in vitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis.
AID558627	Antimicrobial activity against Streptococcus pneumoniae isolate 3587 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID508366	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID283088	Antibacterial activity against Staphylococcus aureus SA1199B overexpressing NorA at 5 ug by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID584559	Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1297339	Antibacterial activity against methicillin-resistant Staphylococcus aureus 14-4 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID563339	Induction of Cwp84 protease expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID633630	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 10-3 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID1585702	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 3 to 7 days by rapid direct susceptibility test	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Fluoroquinolone-isatin hybrids and their biological activities.
AID556348	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained from bronchial aspirations expressing 23S rRNA A2063G mutant gene and P1 RFLP type I gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
AID1364752	Antibacterial activity against Mycobacterium tuberculosis H37Rv nutrient starvation model assessed as log reduction in bacterial colonies at 10 ug/ml measured after 7 days by MPN assay	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors.
AID428290	Antimicrobial activity against Acinetobacter baumannii BM4454 isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID523318	Antibacterial activity against Streptococcus pneumoniae OC6755 harboring gyrA S81F and parC S79Y mutant gene by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID210029	Antibacterial activity was determined against Streptococcus pneumoniae J-24 strain after incubation at 37 degrees C for 18 h	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID405468	Antibacterial activity against Escherichia coli TOP10 containing pAT851 in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID576133	Antibacterial activity against 10'4 to 10'5 CFU Moraxella catarrhalis after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID563333	Upregulation of cwp84 gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID518041	Cardiotoxicity in healthy human assessed as change in corrected QT interval at 400 mg/kg, po within 12 hrs by ECG	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
AID540218	Clearance in monkey after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID496647	Antibacterial activity against Streptococcus pneumoniae 1072 assessed as mutant prevention concentration by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID559055	Antibacterial activity against Lancefield Streptococcus sp. 'group C' by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID428835	TMSW in Streptococcus pneumoniae isolate SR-23958 infected human at 400 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID577500	Bactericidal activity against Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in biofilm bacterial count at 400 mg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID561313	Antimicrobial activity against Enterobacter cloacae isolate 37 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID520368	Ratio of AUC (0 to 24 hrs) in CSF of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg to MIC for Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID523314	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC11521 harboring gyrA S84L/S85P, parC E84G mutant gene assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1224808	CL/F in CSF of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID425577	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I460	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID559080	Antibacterial activity against Legionella pneumophila by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID563212	Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID581485	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1126743	Antibacterial activity against 0.5 ug/ml Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID456043	Antibacterial activity against ciprofloxacin, methicillin-resistant Staphylococcus aureus after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1504965	Antitubercular activity against Mycobacterium tuberculosis H37Rv measured after 7 days under aerobic condition by alamar blue assay	2017	ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12	Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.
AID535774	Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 harboring pTY60H containing pCK0601 carrying the luxAB gene under the hsp60 promoter after 14 days determined according to RLU count by real-time luminescence method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID733004	Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB G89C mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID559076	Antibacterial activity against ciprofloxacin-susceptible Haemophilus influenzae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID285279	Effect on 0.06 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID562663	Ratio of AUC (0 to 24 hrs) to MIC required for 3-log drop in bacterial count in Staphylococcus aureus SMH37276	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID405119	Antimicrobial activity against Escherichia coli TOP10 harbouring pS2 plasmid expressing quinolone resistant QnrS2 gene	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID581282	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID283157	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2414 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID581309	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1256550	Antibacterial activity against Staphylococcus aureus CMCC 26003 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID553687	Antimicrobial activity against Bifidobacterium in three-stage chemostat gut model assessed as log reduction in bacterial count at 43 mg/liter administered daily for 7 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID518800	Antimycobacterial activity against Mycobacterium avium serovar 4 after 14 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
AID543403	Cmax in brain of Listeria monocytogenes EGD-e infected BALB/c mouse central nervous system listeriosis model at 50 mg/kg, ip administered 36 hrs postinfection as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID559005	Antibacterial activity against Streptococcus pneumoniae W002 harboring wild-type parC and gyrA genes	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID562451	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH37312	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID559499	Antibacterial activity against Listeria monocytogenes assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID562462	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH37390	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID562659	Ratio of AUC (0 to 24 hrs) to MIC required for 3-log drop in bacterial count in Staphylococcus aureus SMH37390	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID556771	Drug level in osteomyelitis patient cortical bone at 400 mg, po administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID1600117	Antibacterial activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID558929	Antimicrobial activity against Clostridium difficile A422e selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID559064	Antibacterial activity against Streptococcus intermedius by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1252464	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 50 uM incubated for 48 hrs at 37 degC by MTT assay relative to control	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
AID556772	Drug level in osteomyelitis patient cancellous bone at 400 mg, po administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID581086	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID508368	Antibacterial activity against macrolide-susceptible Streptococcus pneumoniae after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID1154347	Antimycobacterial activity against Mycobacterium tuberculosis over expressing DprE1 after 5 days by standard microdilution method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
AID556030	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from basolateral to apical side at 50 uM in presence of in presence of 10 uM of p-glycoprotein and MRP transport inducer rifampin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID456052	Selectivity ratio of IC50 for Staphylococcus aureus DNA gyrase Ser84Leu mutant to IC50 for Staphylococcus aureus wild type DNA gyrase	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID286160	Bactericidal activity against Staphylococcus aureus BSP-2443 with parC S52G, N91D mutation and gyrA S114G mutation at fAUC/MIC of 24 after 96 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID699003	Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate	2012	European journal of medicinal chemistry, May, Volume: 51	Tuberculosis: the drug development pipeline at a glance.
AID285966	Antimicrobial susceptibility against Haemophilus influenzae C1 isolate with GyrA Asp88Asn, AcrR Leu31His and Arg34Glu mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID571148	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID496638	Ratio of 50% mutant prevention concentration to MIC50 in Streptococcus pneumoniae ATCC 49619	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID570898	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID728913	Antibacterial activity against Mycoplasma pneumoniae 18-1 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID559392	Antimicrobial activity against Clostridium difficile 630B selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID279279	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parE D435N mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID533368	Antimicrobial activity against Bacteroides uniformis assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1126764	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1288 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID581291	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1398033	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in C57BL/6J mouse assessed as log10 CFU reduction in bacterial lung count at 30 mg/kg, po administered once daily for 8 days measured post last dose relative to control	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	An efficient synthetic route for preparation of antimycobacterial wollamides and evaluation of their in vitro and in vivo efficacy.
AID286155	Bactericidal activity against Staphylococcus aureus BSP-2443 at fAUC/MIC of 24 after 24 to 48 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID1318924	Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 91433	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1399840	Antibacterial activity against Mycobacterium tuberculosis H37Rv	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID571856	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1242343	Inhibition of Mycobacterium tuberculosis H37Rv DNA gyrase assessed as supercoiling of pBR322 DNA after 90 mins by agarose gel electrophoresis method	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.
AID571845	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID428808	Ratio of Cmax in human at 80 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-26134	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID556198	P-glycoprotein-mediated transport in human Calu3 cells assessed as efflux ratio of permeability from apical to basolateral side over basolateral to apical side at 50 uM	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID1256545	Antibacterial activity against Pseudomonas aeruginosa 14-9 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID558880	Antimicrobial activity against Clostridium difficile C253a selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID571123	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID593814	Antimicrobial activity against Candida tropicalis ATCC 1369 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID574949	Antimicrobial activity against Streptococcus pneumoniae serotype 3 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID1207436	Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform
AID574989	Antimicrobial activity against Bifidobacterium adolescentis assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID581305	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID571385	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID580875	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID543393	Antibacterial activity against Listeria monocytogenes EGD-e in BALB/c mouse central nervous system listeriosis model assessed as log reduction in bacterial CFU per ml of blood at 50 mg/kg, ip administered 36 hrs postinfection as single dose measured withi	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID543401	Ratio of Cmax in plasma in Listeria monocytogenes EGD-e infected BALB/c mouse to MIC for Listeria monocytogenes EGD-e	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID558924	Antimicrobial activity against Clostridium difficile A422c selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID532977	Inhibition of DNA supercoiling activity of wild type Mycobacterium tuberculosis DNA gyrase A	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID571122	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID558605	Antimicrobial activity against Streptococcus pneumoniae isolate 1146 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1585699	Antimycobacterial activity against Mycobacterium smegmatis CMCC 93202 after 72 hrs by double dilution method	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Fluoroquinolone-isatin hybrids and their biological activities.
AID573557	Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID498781	Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID562616	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID581310	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID511401	Antibacterial activity against levofloxacin resistant Neisseria gonorrhoeae isolates by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID570686	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID523147	Antibacterial activity against Streptococcus pneumoniae isolate OC6585 assessed as log reduction in bacterial growth at 2 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID323880	Antimicrobial activity against Escherichia coli DH10B/pACYC184 expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID601781	Antibacterial activity against 10'4 CFU methicillin-resistant Staphylococcus epidermidis 09-2 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID563048	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID341072	Tmax in human at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID511396	Antibacterial activity against Streptococcus viridans by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID559054	Antibacterial activity against Streptococcus agalactiae by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID574006	Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID369967	Antibacterial activity against methicillin-sensitive Staphylococcus aureus by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID1237412	Bactericidal activity against Staphylococcus aureus RN4220 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID244988	Minimum inhibitory concentration against Streptococcus pneumoniae ATCC 6303	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID544837	Antibacterial activity against Streptococcus pneumoniae U2A1051 harboring gyrA Ser81Tyr mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID601780	Antibacterial activity against 10'4 CFU methicillin-sensitive Staphylococcus epidermidis 09-6 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID425810	Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in CD-1 mouse lung measured after 53 days after aerosol infection	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID1266237	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by alamar blue assay	2016	Bioorganic & medicinal chemistry, Jan-01, Volume: 24, Issue:1	Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
AID574981	Antimicrobial activity against Actinomyces naeslundii after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID573800	Antibacterial activity against Prevotella bivia assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1391311	Antibacterial activity against Staphylococcus aureus 4220 after 24 hrs by two-fold serial dilution method	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives.
AID544833	Antibacterial activity against Streptococcus pneumoniae CP1000 by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID323872	Antimicrobial activity against qnrA1 expressing Klebsiella pneumoniae N5 expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID1164007	Antibacterial activity against methicillin-resistant Staphylococcus aureus 12-4 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID1207470	Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform
AID576325	Antibacterial activity against 10'4 to 10'5 CFU methicillin-resistant Staphylococcus aureus after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID580768	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID574809	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 horboring rpoB H526Y, katG D329A/R463L, gyrA D94G/S95T, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID574802	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID1318911	Antibacterial activity against gentamicin/tobramycin/ciprofloxacin-resistant Escherichia coli isolate CANWARD-2011 97615 harboring AAC3-2A after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID559067	Antibacterial activity against Streptococcus salivarius by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID580764	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID533130	Antimicrobial activity against Bacteroides distasonis assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID520367	Ratio of AUC (0 to 24 hrs) in CSF of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg to MIC for Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID262134	Antimicrobial activity against Staphylococcus aureus ATCC 29213	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
AID1601852	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID571840	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID558597	Antimicrobial activity against Streptococcus pneumoniae 9 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID533393	Antimicrobial activity against Clostridium innocuum by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID544829	Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 2000 microamperes of electric current by bioelectric effect assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID562664	Ratio of AUC (0 to 24 hrs) to MIC required for 3-log drop in bacterial count in Staphylococcus aureus SMH36742	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID1207564	Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform
AID286153	Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 449 after 24 to 96 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID531856	Cmax in tuberculosis patient at 400 mg/day, po administered for 7 days by HPLC	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
AID1557313	Half life in human at 0.4 g, po by HPLC analysis	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID581109	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID575007	Antimicrobial activity against Eubacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID422675	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 25 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1264551	Antibacterial activity against Staphylococcus aureus 1118 infected in sc and iv dosed mouse assessed as septicemia compound administered 1 hr post-infection twice for 1 day measured for 7 days	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID530348	Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID586747	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrA gene and pBK-QnrA1 assessed as resistant colonies recovered one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1398613	Binding affinity to human serum albumin after 60 mins at 37 degC by ultrafiltration-based LC-MS analysis	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID759321	Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents.
AID322785	Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID532963	Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 7	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID420669	Lipophilicity, log D at pH 7.0	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1398592	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae J41 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID1256560	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-37 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID279833	Ratio of fraction AUC in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 38 to 19000 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID422680	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID275468	Cytotoxicity against rat hepatocytes after 48 hrs	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
AID66574	Antibacterial activity was determined against clinically isolated vancomycin-B resistant enterococci (VRE) strains (10 strains)	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1297335	Antibacterial activity against Staphylococcus aureus CMCC 26003 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1380667	Clearance in CD1 mouse plasma at 10 mg/kg, iv by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
AID511381	Antibacterial activity against methicillin resistant coagulase negative Staphylococcus epidermidis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID422653	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 38 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1391314	Antibacterial activity against Streptococcus mutans 3289 after 24 hrs by two-fold serial dilution method	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives.
AID1740320	Antimicrobial activity against Escherichia coli ATCC 8739 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID553805	Antimicrobial activity against Clostridium difficile PCR ribotype 027 expressing gyrB Glu466Lys mutant grown on fluoroquinolone-containing medium after 48 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID425072	Antimicrobial activity against Escherichia coli DH10B expressing pCRQB10 in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID1318906	Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID428785	Cmax in human at 200 mg, po administered twice a day	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1318915	Antibacterial activity against Stenotrophomonas maltophilia isolate CAN-ICU 62584 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID278595	Inhibitory activity against Escherichia coli 12-1502	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID559545	Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID581300	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID456042	Antibacterial activity against levofloxacin, methicillin-resistant Staphylococcus aureus after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID261739	Antibacterial activity against Moraxella catarrhalis ATCC 8176	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID511400	Antibacterial activity against ciprofloxacin resistant Neisseria gonorrhoeae isolates by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID278603	Inhibitory activity against azide-resistant Escherichia coli J53 T03-222	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID562650	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH37503	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID279261	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3665 with GyrA S81Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID580864	Half life in patients with pulmonary tuberculosis at 400 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID279280	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with gyrA S81Y mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574732	Antimicrobial activity against Fusobacterium varium after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID508367	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID425578	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID244995	Minimum inhibitory concentration against Streptococcus agalactiae ATCC 13813	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID369968	Cmax in Staphylococcus aureus infected rabbit arthritis model at 45 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID416848	Antimycobacterial activity against Mycobacterium ulcerans isolate CU001 infected in BALB/c mouse left hind foot-pad assessed as bacterial load at 100 mg/kg, po administered for 5 days per week measured after 8 weeks	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
AID1318922	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 262-101856	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID580750	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID523136	Antibacterial activity against Streptococcus pneumoniae isolate OC7368 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID562941	Effect on fbp69 gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID580868	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1600113	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID580876	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID572522	Antimicrobial activity against qnrA-positive Salmonella enterica serovar Mbandaka isolate s2093 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID1164011	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 12-6 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID558581	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1196885	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors.
AID323875	Antimicrobial activity against qnrA1 expressing Klebsiella pneumoniae 1960 GyrA Ser83Phe/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID558591	Antimicrobial activity against Streptococcus pneumoniae 3 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID580895	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID559526	Antibacterial activity against Acinetobacter lwoffii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID571373	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1242341	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days by microdilution method	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.
AID342066	Antimicrobial activity against fluoroquinolone-resistant epidemic Clostridium difficile NAP1 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID565314	Antibacterial activity against Mycoplasma genitalium TW10-6G by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID528966	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID581099	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID499677	Antimicrobial activity against quinolone and penicillin-resistant Acinetobacter baumannii after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID520371	Ratio of fAUC (0 to 24 hrs) in CSF of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg to MIC for Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID523179	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC12501 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID496646	Antibacterial activity against Streptococcus pneumoniae 1135 by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID511383	Antibacterial activity against vancomycin resistant Enterococcus faecalis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID581085	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID563035	Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1348983	Half life in mouse microsomes
AID1570247	Cmax in SPF ICR mouse at 100 mg/kg, sc	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID574956	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 6B by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID425344	Antibacterial activity against Streptococcus pneumoniae HMC 1058 harboring S79F, K137N mutation in quinolone-resistant determining regions of ParC gene and 460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID559204	Antibacterial activity against Streptococcus pneumoniae D001 harboring parC Ser79Phe and gyrA Gly85Lys mutant genes	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID532022	Antimicrobial activity against Mycobacterium ulcerans 1059 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 14 days determined according to CFU count by bioluminescence method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID586629	Antibacterial activity against qnrS gene expressing Escherichia coli ATCC 25922 harboring ParC S80R mutant and pBK-QnrS1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID341087	Half life in human with MDR1 3435 CC genotype at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID565290	Antimicrobial activity against Mycoplasma pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
AID580881	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID728921	Antibacterial activity against Enterococcus faecalis ATCC 19433 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID1601850	Antibacterial activity against Pseudomonas aeruginosa CMCC 10104 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID244996	Minimum inhibitory concentration against Streptococcus pneumoniae ATCC 49619	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1319017	Ratio of MIC for Pseudomonas aeruginosa PAO1 after 25 serial passages to MIC for Pseudomonas aeruginosa PAO1 prior to 25 serial passages	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1909942	Inhibition of Staphylococcus aureus ATTC 25923 DNA gyrase	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID1237411	Antifungal activity against Candida albicans 7535 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID1318925	Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 101243	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID584112	Bactericidal activity against Escherichia coli K-12 DM4100 after 2 hrs in presence of protein synthesis inhibitor chloramphenicol treated 10 mins before compound challenge	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.
AID283170	Increase in biofilm formation of Staphylococcus lugdunensis assessed as percent biofilm forming isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID530387	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB R447K mutant gene assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1256557	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 14-2 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID574728	Antimicrobial activity against Prevotella oralis assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID559539	Antibacterial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID522980	Antibacterial activity against Streptococcus pneumoniae isolate OC7189 assessed as log reduction in bacterial growth at 4 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID496651	Antibacterial activity against Streptococcus pneumoniae 1058 assessed as mutant prevention concentration by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID425340	Antibacterial activity against quinolone-susceptible Streptococcus pneumoniae ATCC 49619 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID425973	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID533360	Antimicrobial activity against Bacteroides ovatus assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574748	Antimicrobial activity against Peptostreptococcus micros assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574997	Antimicrobial activity against Bifidobacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID601783	Antibacterial activity against 10'4 CFU Enterococcus faecalis 08-10 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID1164005	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 12-5 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID425358	Antibacterial activity against Streptococcus pneumoniae HMC 1072 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID571133	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID574969	Antimicrobial activity against Actinomyces israelii after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID518798	Antimycobacterial activity against Mycobacterium kansasii after 7 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
AID559046	Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID581488	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID559084	Antibacterial activity against Proteus mirabilis by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID532957	Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 1	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID425355	Antibacterial activity against Streptococcus pneumoniae HMC 1055 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID573785	Antibacterial activity against Prevotella intermedia by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID559405	Antimicrobial activity against Clostridium difficile BI2C selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1557283	Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID558912	Antimicrobial activity against Clostridium difficile CD5i harboring GyrA Ala92Glu and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID544865	Antibacterial activity against Streptococcus pneumoniae R6 Tr10 harboring gyrA Ser81Tyr parC Ser79Tyr mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1243291	Antimicrobial activity against Escherichia coli ATCC 25922 by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID1254075	Antibacterial activity against Salmonella typhimurium 2421 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID1468619	Antibacterial activity against Staphylococcus aureus ATCC 29213 infected in C57BL6 mouse cornea assessed as mean corneal thickness at 0.3% administered tropically 2 times on day 1, 4 times on day 2 and 2 times on day 3 starting from 6 hrs post infection m	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo.
AID544294	Antibacterial activity against hospital acquired methicillin-resistant Staphylococcus aureus after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID563225	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID523164	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC11521 harboring gyrA S84L/S85P, parC E84G mutant gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID633637	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 10-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID574522	Antimicrobial activity against Prevotella buccae after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID391988	Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23::qnr-cat promoter mutant by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID581063	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID456048	Inhibition of Staphylococcus aureus DNA topoisomerase 4 Ser80Phe mutant	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID391989	Antibacterial activity against Lactococcus lactis IL-1419 by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1890607	Induction of drug resistance in methicillin resistant Staphylococcus aureus assessed as increase in MIC measured after 10 passages (Rvb = 0.4 ug/ml)	2022	Bioorganic & medicinal chemistry letters, 05-01, Volume: 63	WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID494414	Antimycobacterial activity against Mycobacterium smegmatis CMCC 93202 after 72 hrs by serial double dilution method	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives.
AID523311	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC17042 harboring gyrA S84L/G106D, parC S80F and parE D732N mutant gene assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID733008	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 1 hr at 37 degC by ethidium bromide based gel electrophoresis	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID574033	Antibacterial activity against beta-lactamase producing Micromonas micros assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1743457	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Asp-94-Gly mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID633631	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 10-4 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID1256566	Antibacterial activity against Enterococcus faecium 14-2 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID544297	Antibacterial activity against vancomycin-susceptible methicillin-resistant Staphylococcus aureus 32 harboring GyrA S84L and GrlA S80Y mutant after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID405454	Antibacterial activity against Escherichia coli C600Rif by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID556783	Ratio of drug level in cortical bone to serum in osteomyelitis patient at 400 mg, po administered for every 24 hrs by by three stage hierarchical Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID575001	Antimicrobial activity against Eubacterium lentum assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID559528	Antibacterial activity against Citrobacter koseri assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID759326	Antibacterial activity against Staphylococcus aureus KCTC 503 after 24 hrs by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents.
AID1256555	Antibacterial activity against methicillin-resistant Staphylococcus aureus 14-4 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID556190	Cmax in healthy human at 400 mg/kg	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID286157	Bactericidal activity against Staphylococcus aureus BSP-2443 with parC S52G, N91D mutation and gyrA S81Y mutation at fAUC/MIC of 16 after 72 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID571134	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID389912	Antibacterial activity against Staphylococcus aureus ATCC 13709 after 24 hrs by microdilution method	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.
AID428780	AUC (0 to 24 hrs) in human at 400 mg, po administered once a day	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1888648	Antibacterial activity against rifampicin resistant Staphylococcus aureus harboring RpoBH481Y mutant assessed as inhibition of bacterial growth	2022	Bioorganic & medicinal chemistry letters, 02-01, Volume: 57	Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
AID1163994	Antibacterial activity against Klebsiella pneumoniae 12-4 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID66578	Antibacterial activity was determined against clinically isolated vancomycin-B resistant enterococci (VRE) strains (10 strains)	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1890601	Antibacterial activity against methicillin resistant Staphylococcus aureus 032 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method	2022	Bioorganic & medicinal chemistry letters, 05-01, Volume: 63	WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID542717	Cmax in Nocardia brasiliensis HUJEG-1 infected BALB/c mouse at 25 mg/kg, sc every 8 hrs by HPLC	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.
AID406648	Antibacterial activity against Staphylococcus aureus ACH-0206 isolate with gyrA Ser84Leu mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID563036	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID586639	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrS gene and pBK-QnrS1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID559241	Antibacterial activity against Streptococcus pneumoniae S002 harboring parC Ser79Phe mutant and wild-type gyrA genes assessed as mutation prevention concentration after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID601784	Antibacterial activity against 10'4 CFU Enterococcus faecalis 08-12 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID565309	Antibacterial activity against Mycoplasma genitalium by quantitative TaqMan PCR method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID571353	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1254070	Antibacterial activity against Streptococcus mutans 3065 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID529903	Antimicrobial activity against Leptospira kirschneri serovar Grippotyphosa isolate 13 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID1256565	Antibacterial activity against Enterococcus faecium 14-1 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID1447480	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 101885 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1626632	Bactericidal activity against methicillin-sensitive Staphylococcus aureus 29213 infected in mouse macrophages assessed as induction of bacterial kill at 4 ug/ml in presence of 4 ug/ml rifampin after 24 hrs	2016	Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14	Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
AID1297341	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 14-2 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID559062	Antibacterial activity against Streptococcus bovis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID533373	Antimicrobial activity against Bacteroides eggerthii by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1318910	Antibacterial activity against amikacin-resistant Escherichia coli isolate CAN-ICU 63074 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID408340	Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique	2008	Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11	Support vector machines classification of hERG liabilities based on atom types.
AID562449	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH36633	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID532961	Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 5	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID556022	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from apical to basolateral side at 50 uM in presence of 100 uM of p-glycoprotein and MRP inhibitor verapamil	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID571844	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570665	Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID556034	P-glycoprotein-mediated transport in human Calu3 cells assessed as efflux ratio of permeability from apical to basolateral side over basolateral to apical side at 50 uM in presence of 100 uM of MRP inhibitor Probenecid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID573590	Antibacterial activity against Fusobacterium varium by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID406622	Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolates assessed as percent susceptible isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
AID484798	Antibacterial activity against Staphylococcus aureus K1035 bearing wild-type GyrA and S80F mutant GrlA by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID531627	Antimicrobial activity against Mycoplasma hominis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
AID1319007	Antimicrobial activity against Pseudomonas aeruginosa PAO200	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID571115	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1819734	Antibacterial activity against Staphylococcus aureus assessed as inhibition of bacterial growth incubated for 3 days by broth microdilution method	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Structure-Activity Relationship of Anti-
AID279291	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parE D435N and gyrA S81F mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID563016	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID574023	Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID523162	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC2838 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID581270	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1207753	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	2013	Scientific reports, , Volume: 3	MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID498782	Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID1437918	Antibacterial activity against methicilin-resistant Staphylococcus aureus ATCC 700699 by broth microdilution method	2017	Journal of natural products, 01-27, Volume: 80, Issue:1	Antibacterial and Cytotoxic Phenolic Metabolites from the Fruits of Amorpha fruticosa.
AID372997	Antimycobacterial activity against Mycobacterium avium complex N016 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID285308	Susceptibility of methicillin-sensitive/resistant Staphylococcus aureus single-step mutant by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID571765	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID580865	Plasma protein binding in healthy human at 400 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID245330	Antibacterial activity against Penicillin-resistant Streptococcus pneumoniae (PRSP) J-24 was determined	2004	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
AID461172	Antitubercular activity against Mycobacterium tuberculosis H37Rv by low-oxygen-recovery assay	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	Synthesis, antimalarial and antitubercular activity of acetylenic chalcones.
AID572512	Antimicrobial activity against Salmonella enterica serovar Montevideo isolate s2317 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID283398	Antimicrobial activity against Nocardia carnea after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID528977	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID67078	Antibacterial activity was determined against Enterococcus faecalis ATCC 19433 strain after incubation at 37 degrees C for 18 h	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID573822	Antibacterial activity against beta-lactamase producing Clostridium perfringens by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425995	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID520380	Renal toxicity in patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID323876	Antimicrobial activity against qnrA1 expressing Klebsiella pneumoniae 1132 expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID278856	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID728916	Antibacterial activity against Haemophilus influenzae ATCC 49247 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID425557	Antibacterial activity against quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 5048 expressing mefA by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1163996	Antibacterial activity against extended-spectrum beta-lactamase producin Klebsiella pneumoniae 12-4 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID571925	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-G616N mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID532965	Antimicrobial activity against multidrug-resistant Mycobacterium tuberculosis isolate 9	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID1187837	Selectivity index, ratio of CC50 for mouse RAW264.7 cells to MIC for Mycobacterium tuberculosis H37Rv	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID286149	Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 32 after 96 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID1447485	Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 101243 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID533361	Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574516	Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID278597	Inhibitory activity against azide-resistant Escherichia coli J53 T12-1183	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID279246	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3243 after 20 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID559178	Antimicrobial activity against Clostridium difficile C253C selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID695236	Cytotoxicity against human Hep2 cell line after 72 hrs	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID695232	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID1600099	Antibacterial activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID425361	Antibacterial activity against Streptococcus pneumoniae HMC 1078 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID573819	Antibacterial activity against Veillonella parvula by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID544291	Antibacterial activity against Staphylococcus aureus after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID405464	Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID558697	Antimicrobial activity against Clostridium difficile C253 expressing tcdA and tcdB gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID428845	Time above the mutant prevention concentration in Streptococcus pneumoniae isolate SR-26134 infected human at 400 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID428853	Bactericidal activity against Streptococcus pneumoniae ATCC 49619 assessed as reduction in number of viable cells under condition simulating oral administration of 400 mg once daily	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID531628	Antimicrobial activity against Mycoplasma fermentans by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
AID1877397	Antibacterial activity against methicillin-resistant Staphylococcus aureus 197	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID563029	Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID422674	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 21 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID556029	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from basolateral to apical side at 50 uM in presence of 100 uM of MRP inhibitor Probenecid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID1868123	Anti-tubercular activity against Mycobacterium tuberculosis infected in mouse J774.A1 cells assessed as inhibition of intracellular bacilli growth incubated for 72 hrs	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID422682	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID559508	Antibacterial activity against Staphylococcus warneri assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID581068	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID558618	Antimicrobial activity against Streptococcus pneumoniae isolate 3263 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID575077	Antimicrobial activity against Streptococcus pneumoniae serotype 3 assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID601793	Cytotoxicity against MDCK cells after 48 hrs by CPE assay	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID406647	Antibacterial activity against Staphylococcus aureus ACH-0204 isolate with gyrA Ser84Leu mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID574034	Antibacterial activity against beta-lactamase producing Micromonas micros assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1600095	Antibacterial activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID559050	Antibacterial activity against Staphylococcus hominis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1862200	Antimycobacterial activity against clinical isolate multidrug resistant Mycobacterium tuberculosis H37Rv assessed as bacterial growth inhibition	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
AID425341	Antibacterial activity against quinolone-resistant Streptococcus pneumoniae ATCC 49619 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1602937	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 5 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID562932	Antimicrobial activity against Clostridium difficile 6425 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID601791	Antibacterial activity against 10'4 CFU Pseudomonas aeruginosa ATCC 27853 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID322326	Antimicrobial activity against Streptococcus pneumoniae WB4 by broth macrodilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
AID522994	Antibacterial activity against Streptococcus pneumoniae isolate OC7376 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID558590	Antimicrobial activity against Streptococcus pneumoniae 2 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID563210	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID322773	Antimicrobial activity against Bacteroides fragilis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID1181169	Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_18 assessed as fold shift in MIC relative to parent strain	2014	Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID574955	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19F by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID581659	Fraction unbound in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID279256	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81F and ParC D83N mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID511305	Antibacterial activity against methicillin resistant coagulase negative Staphylococcus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID1877405	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID728923	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae J24 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID341069	Half life in human at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID425353	Antibacterial activity against Streptococcus pneumoniae HMC 2538 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene showing efflux to ciproflox	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1600102	Bactericidal activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1862201	Antimycobacterial activity against clinical isolate drug susceptible Mycobacterium tuberculosis H37Rv assessed as bacterial growth inhibition	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
AID279259	Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID520363	Half-life in CSF of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID571767	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-M626I mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID497762	Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID1256537	Antibacterial activity against ESBL-positive Klebsiella pneumoniae 14-17 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID422670	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID341377	Antibacterial activity against Staphylococcus aureus infection-induced aortic valve endocarditis in rabbit assessed as cured animals in blood culture at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 hrs after end of treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID593811	Antimicrobial activity against Haemophilus influenzae ATCC 19418 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID531625	Antimicrobial activity against Mycoplasma pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
AID581095	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1600111	Antibacterial activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID558887	Antimicrobial activity against Clostridium difficile C253e selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1819731	Antimycobacterial activity against Mycobacterium abscessus subsp. massiliense CCUG 48898T assessed as inhibition of mycobacterial growth incubated for 3 days by broth microdilution method	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Structure-Activity Relationship of Anti-
AID1316917	Inhibition of Mycobacterium tuberculosis ADH assessed as decrease in conversion of L-alanine to pyruvate by measuring NADH by spectrophotometry	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues endowed with high activity toward non-replicative Mycobacterium tuberculosis.
AID559514	Antibacterial activity against non-levofloxacin susceptible Streptococcus pneumoniae assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573837	Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID511391	Antibacterial activity against Citrobacter freundii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID562626	Antimicrobial activity against Group B Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID580997	Antimicrobial activity against Mycobacterium tuberculosis infected in patients with tuberculosis assessed as percentage of patients with negative culture after 4 weeks	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID1126757	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 758 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID570687	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559158	Antimicrobial activity against Clostridium difficile 630g harboring GyrB Asp26Val mutant gene selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID559387	Antimicrobial activity against Clostridium difficile A422I harboring GyrA Thr82Ile and GyrB Leu451Phe mutant genes selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID543396	Antibacterial activity against Listeria monocytogenes EGD-e in BALB/c mouse central nervous system listeriosis model assessed as reduction in bacterial count in liver at 50 mg/kg, ip administered 36 hrs postinfection as single dose measured within 1 hr	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID520379	Renal toxicity in patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1391312	Antibacterial activity against quinolone-resistant Staphylococcus aureus isolate CCARM 3505 after 24 hrs by two-fold serial dilution method	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives.
AID1819729	Antimycobacterial activity against Mycobacterium abscessus ATCC 19977 assessed as inhibition of mycobacterial growth incubated for 3 days by broth microdilution method	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Structure-Activity Relationship of Anti-
AID1318932	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 108590	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID279821	Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 1	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID422652	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID563015	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID561316	Antimicrobial activity against Enterobacter cloacae isolate 101 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID279249	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81F mutation after 32 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID433580	Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as formation of DNA cleavable complex	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID511303	Antibacterial activity against ciprofloxacin susceptible and methicillin resistant Staphylococcus aureus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID425964	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 48 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID581307	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID556781	Ratio of drug level in cortical bone to serum in osteomyelitis patient at 400 mg, po administered for every 24 hrs by MAP-Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID262135	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 700699	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
AID586731	Ratio of mutant prevention concentration to MIC for Escherichia coli ATCC 25922 expressing qnrA gene and pBK-QnrA1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1435844	Antimycobacterial activity against Mycobacterium tuberculosis CDCT-4 (1105/09) clinical isolate after 7 days by resazurin reduction microplate assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.
AID279818	Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774A.1 macrophages	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID1601854	Antibacterial activity against multidrug-resistant Pseudomonas aeruginosa ATCC BAA-2111 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID283155	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL856 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID558601	Antimicrobial activity against Streptococcus pneumoniae isolate 24 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1318908	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID285298	Effect on 0.5 ug/ml sitafloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID581312	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1465273	Antibacterial activity against wild-type Escherichia coli ATCC 25922 infected in iv dosed CD-1 mouse assessed as mouse survival treated for 1 hr followed by reinfection with bacteria measured at 96 hrs post infection
AID572515	Antimicrobial activity against Salmonella enterica serovar Stanley isolate s2043 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID105998	In vitro inhibitory activity on MRC5 fibroblast tissue cultures inoculated with virulent RH strain of Toxoplasma gondii	2004	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11	Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
AID496640	Antibacterial activity against Streptococcus pneumoniae 1072 by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID1264565	Clearance in mouse at 2 mg/kg, iv by LC-MS/MS analysis	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1676589	Binding affinity to Nickel cation assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID574532	Antimicrobial activity against Prevotella bivia assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1514453	Antitubercular activity against moxifloxacin-resistant Mycobacterium tuberculosis after 7 days by resazurin dye based colorimetric assay	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID533380	Antimicrobial activity against Bacteroides merdae assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID595854	Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
AID1237407	Antibacterial activity against Escherichia coli CCARM 1356 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID558698	Antimicrobial activity against Clostridium difficile CD25 expressing tcdA, tcdB gene and GyrB Ser416Ala mutant by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID322790	Antimicrobial activity against Bacteroides eggerthii assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID562653	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH37276	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID571379	Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID580904	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID518619	Antimicrobial activity against extracellular Mycobacterium avium subsp. hominissuis ATCC 700898 after 7 days by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID279286	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79F and gyrA S81Y mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID577495	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 by CLSI broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID283399	Antimicrobial activity against Nocardia brasiliensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID530594	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr6 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID581075	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID498190	Antibacterial activity against Stenotrophomonas maltophilia MBS82 deficient in Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID528838	Antimicrobial activity against vancomycin-resistant Enterococcus sp. assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID369973	Cmin in synovial fluid of Staphylococcus aureus infected rabbit arthritis model at 45 mg/kg, po after 7 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID581664	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID442255	Antimalarial activity against Plasmodium falciparum NF54	2009	Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24	Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID406652	Antibacterial activity against Staphylococcus aureus ACH-0126 isolate with gyrA Ser84Leu and grlA Ser80Phe mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID246862	Efficacy against mice infected with Staphylococcus aureus ATCC 25923 upon s.c. administration	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID484796	Antibacterial activity against wild-type norA expressing Staphylococcus aureus SA-1199 by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID581083	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID508373	Antibacterial activity against Streptococcus pneumoniae harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID570799	Cmax in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID559403	Antimicrobial activity against Clostridium difficile BI2A selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID425558	Antibacterial activity against penicillin-, quinolone-resistant and macrolide-susceptible Streptococcus pneumoniae HMC 1058 harboring S79F, K137N mutation in quinolone-resistant determining regions of ParC gene and 460V mutation in QRDR of ParE gene by br	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID562928	Antimicrobial activity against Clostridium difficile ATCC 43603 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID279834	Ratio of fraction Cmax in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 38 to 19000 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID530383	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A, I85V, F96W and P101M mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1254079	Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID497756	Distribution coefficient, log D of the compound	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID532956	Antimicrobial activity against Mycobacterium tuberculosis ATCC 35802	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID520362	Half-life in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1570241	Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID574502	Antimicrobial activity against Bacteroides caccae assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID576134	Antibacterial activity against 10'4 to 10'5 CFU vancomycin-resistant Enterococcus after 18 hrs by CLSI 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
AID574977	Antimicrobial activity against Actinomyces meyeri assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1868112	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID574514	Antimicrobial activity against Bacteroides ovatus assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID559397	Antimicrobial activity against Clostridium difficile 630D harboring GyrA Ala118Val mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1187835	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID209273	Antibacterial activity was determined against Streptococcus pyogenes G-36 strain after incubation at 37 degrees C for 18 h	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID574750	Antimicrobial activity against Peptostreptococcus micros assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID556033	P-glycoprotein-mediated transport in human Calu3 cells assessed as efflux ratio of permeability from apical to basolateral side over basolateral to apical side at 50 uM in presence of 3 uM of p-glycoprotein transport inhibitor PSC-833	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID695449	Cytotoxicity against human HepG2 cell line after 72 hrs	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID556773	Apparent total clearance in osteomyelitis patient at 400 mg, po administered for every 24 hrs by MAP-Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID1152773	Bactericidal activity against Mycobacterium tuberculosis infected in human THP1 cells at 1 ug/ml for 7 days	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID428846	Time above the mutant prevention concentration in Streptococcus pneumoniae isolate SR-26137 infected human at 400 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1297330	Antibacterial activity against Pseudomonas aeruginosa 14-9 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1067076	Antimicrobial activity against Pseudomonas aeruginosa 2004 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID245696	Mutant prevention concentration aganist methicillin resistant Staphylococcus aureus-33 done for 48 hr at 37 degree C with compound	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID285968	Antimicrobial susceptibility against Haemophilus influenzae C3 isolate with GyrA Asp88Asn, ParC Ser84Ile, AcrR Leu31His and Arg34Glu mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID570907	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID522995	Antibacterial activity against Streptococcus pneumoniae isolate OC7376 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1551297	Antibacterial activity against Methicillin-resistant Staphylococcus aureus CCARM 3167 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID1524626	Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID1318964	Antibacterial activity against extremely drug-resistant Pseudomonas aeruginosa isolate 104354 infected in Galleria mellonella assessed as larvae survival at 75 mg/kg administered as single dose measured after 96 hrs	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID530591	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr3 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID533409	Antimicrobial activity against Finegoldia magna by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID425337	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1551300	Antibacterial activity against Quinolone-resistant Staphylococcus aureus CCARM 3519 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID1154348	Antimycobacterial activity against Mycobacterium tuberculosis over expressing InhA after 5 days by standard microdilution method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
AID324746	Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID279254	Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81Y and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID559500	Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID561326	Antimicrobial activity against Klebsiella pneumoniae isolate 135 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1601847	Antibacterial activity against Escherichia coli CMCC 25922 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID581268	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID563020	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID425553	Antibacterial activity against penicillin- and quinolone-susceptible Streptococcus pneumoniae HMC 5055 expressing mefA by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID522952	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1348984	Cmax in ICR mouse at 50 mg/kg, po by HPLC analysis
AID544860	Antibacterial activity against Streptococcus pneumoniae U2A1053 harboring parC Ser79Phe mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID406807	Antibacterial activity against Staphylococcus aureus ACH-0141 isolate with gyrA Ser84Leu, Glu88Val and grlA Ser80Phe, Ala116Val mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID1476363	Antitubercular activity against capreomycin resistant Mycobacterium tuberculosis H37Rv after 24 hrs by MABA method	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.
AID584554	Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID341081	Tmax in human with MDR1 3435 CC genotype at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg/kg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID1381459	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in C57BL/6 mouse assessed as bacterial load in lungs at 30 mg/kg, po for 8 consecutive days starting from day 1 post infection measured on day 9 post last dose (Rvb = 6.8 +/- 0.2	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID528974	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID695447	Cytotoxicity against human CHO cell line after 72 hrs	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID1570245	Antimycobacterial activity against multidrug (isoniazid and rifampicin) resistant Mycobacterium tuberculosis 1 incubated for 7 days by rapid direct susceptibility test	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID279242	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3665 with GyrA S81Y mutation after 38 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1164001	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID565318	Antibacterial activity against Mycoplasma genitalium M2300 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID275466	Antibacterial activity against fluoroquinolone-resistant Staphylococcus aureus 273/T/T/T	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
AID733009	Antimicrobial activity against Mycobacterium tuberculosis H37Rv assessed as drug concentration causing =<1% reduction in bacterial growth incubated for 21 to 30 days by proportion method	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID563223	Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID574026	Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID406846	Antibacterial activity against Escherichia coli TOP10 containing pS1A plasmid expressing quinolone resistance determinant QnrB4 by E-test	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID580896	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID581296	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1278845	Antimycobacterial activity against nutrient starved Mycobacterium tuberculosis H37Rv assessed as reduction in bacterial load for 7 days measured after 28 days by microplate reader analysis	2016	Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6	Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
AID341085	Half life in human with MDR1 3435 CC genotype at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg/kg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID580754	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID395718	Antibacterial activity against Escherichia coli DH10B containing ORI23::qnr-cat promoter mutant by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID322780	Antimicrobial activity against Bacteroides eggerthii isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID728909	Antibacterial activity against levofloxacin-intermediate and levofloxacin-resistant Streptococcus pneumoniae after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID1861191	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis assessed as mycobacterial growth inhibition	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent.
AID1152781	Ratio of MIC for 5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA D89N mutant to MIC for wild-type Mycobacterium tuber	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID405116	Antimicrobial activity against Escherichia coli TOP10 harbouring pVS1 expressing quinolone resistant Vibrio splendidus 12B01 QnrVS1 gene	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID580882	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1750817	Dissociation constant, pKa of the compound by UV metric method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID559085	Antibacterial activity against Proteus vulgaris by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID572525	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Corvallis isolate s2017 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID522936	Antibacterial activity against Streptococcus pneumoniae isolate OC6608 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID562662	Ratio of AUC (0 to 24 hrs) to MIC required for 3-log drop in bacterial count in Staphylococcus aureus SMH38004	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID544844	Antibacterial activity against Streptococcus pneumoniae U2A1411 harboring parC Asp83Gly mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID499679	Antimicrobial activity against quinolone and penicillin-resistant Escherichia coli after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1600106	Bactericidal activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID580857	Antimicrobial activity against rifampicin-sensitive Mycobacterium tuberculosis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID580902	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID586643	Antibacterial activity against qnrA gene expressing Escherichia coli ATCC 25922 harboring ParC S80R mutant, ParC S80R mutant and pBK-QnrA1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID428834	TMSW in Streptococcus pneumoniae ATCC 49619 infected human at 400 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID323884	Antimicrobial activity against Escherichia coli J53 expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID1053481	Antitubercular activity against Mycobacterium tuberculosis H37Rv expressing inhA M103I mutant assessed as parasite growth inhibition after 7 days by Alamar Blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
AID323897	Antimicrobial activity against Klebsiella pneumoniae C2/pMG252 GyrA Ser83Phe/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID1723736	Inhibition of human ERG by whole-cell patch clamp method	2020	Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20	Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
AID573801	Antibacterial activity against Prevotella intermedia assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425767	Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 99 after 41 passages by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID518057	Toxicity in healthy human assessed as diarrhea at 400 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
AID508388	Antibacterial activity against macrolide-resistant Streptococcus pyogenes harboring erm(A) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID574950	Antimicrobial activity against Streptococcus pneumoniae serotype 35B by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID544848	Antibacterial activity against Streptococcus pneumoniae U2A1060 harboring gyrA Ser81Phe parC Asp83His mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID558899	Antimicrobial activity against Clostridium difficile CD5b harboring GyrB Ser416Ala mutant gene selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1380670	AUC (0 to 24 hrs) in CD1 mouse plasma at 3 mg/kg, iv by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
AID571358	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID425350	Antibacterial activity against Streptococcus pneumoniae HMC 1146 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, and D435N mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1179481	Antimycobacterial activity against Mycobacterium avium ATCC 15769 in 7H9 medium after 6 days and 18 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.
AID372990	Antimycobacterial activity against Mycobacterium intracellular JATA52-01 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID484802	Antibacterial activity against Staphylococcus aureus K1640 bearing S84L mutant GyrA and S80Y mutant GrlA by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID533863	Antibacterial activity against toxin-positive Clostridium difficile clinical isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
AID1185145	Antimicrobial activity against 5-(((3S,4R)-3-fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile resistant Mycobacterium tuberculosis H37Rv ATCC 27294 containing DNA gyrase D89N mutant	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.
AID575080	Antimicrobial activity against Streptococcus pneumoniae serotype 11A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID283165	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2664 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID285289	Effect on 32 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID759322	Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents.
AID601782	Antibacterial activity against 10'4 CFU Streptococcus pneumoniae 08-4 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID1312205	Antibacterial activity against actively replicative Mycobacterium tuberculosis H37Rv measured after 7 days by MABA assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Design and development of new class of Mycobacterium tuberculosisl-alanine dehydrogenase inhibitors.
AID1743462	Antitubercular activity against Mycobacterium tuberculosis XDR measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID522983	Antibacterial activity against Streptococcus pneumoniae isolate OC6608 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID369974	Ratio of Cmin in synovial fluid of Staphylococcus aureus infected rabbit arthritis model at 45 mg/kg, po to MIC for methicillin-sensitive Staphylococcus aureus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID544853	Antibacterial activity against Streptococcus pneumoniae R6 Tr6 harboring gyrA Ser81Phe mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID559492	Antibacterial activity against Clostridium perfringens assessed as percent susceptible isolates by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID522965	Antibacterial activity against Enterobacter aerogenes by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1416246	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 measured after 7 days by microplate alamar blue assay	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant
AID586742	Antibacterial activity against Escherichia coli ATCC 25922 harboring GyrA S83L mutant assessed as earliest time required to resistant colonies visible one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID523153	Antibacterial activity against Streptococcus pneumoniae isolate OC6610 assessed as log reduction in bacterial growth at 4 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID508384	Antibacterial activity against Streptococcus pyogenes harboring erm(A) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID523151	Antibacterial activity against Streptococcus pneumoniae isolate OC6610 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID573802	Antibacterial activity against Prevotella melaninogenica assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID341385	AUC (0 to 12 hrs) in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit at 20 mg/kg, iv administered every 12 hrs measured after third dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID728906	Inhibition of human ERG expressed in CHOK1 cells at 100 uM	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID1256533	Antibacterial activity against ESBL-positive Escherichia coli 14-1 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID1601844	Antibacterial activity against Streptococcus pneumoniae CMCC 31968 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID424323	Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID544847	Antibacterial activity against Streptococcus pneumoniae U2A1056 harboring gyrA Ser81Tyr parC Asp83His mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID498188	Antibacterial activity against Stenotrophomonas maltophilia MBS108 containing both chromosomally and plasmid encoded Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID562443	Antibacterial activity against Staphylococcus aureus SMH37503 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID520113	Antimicrobial activity against Mycobacterium tuberculosis H37Rv by alamar blue assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
AID581272	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1303042	Antibacterial activity against methicillin-susceptible Staphylococcus aureus 42 incubated for 18 to 24 hrs by broth microdilution assay	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design.
AID559523	Antibacterial activity against Streptococcus sanguinis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559086	Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID323878	Antimicrobial activity against Escherichia coli DH10B expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID559082	Antibacterial activity against Morganella morganii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1318916	Antibacterial activity against Acinetobacter baumannii isolate CAN-ICU 63169 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID574740	Antimicrobial activity against Peptostreptococcus anaerobius after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID559165	Antimicrobial activity against Clostridium difficile BI2b harboring GyrB Arg447Lys mutant gene selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID285528	Antibacterial activity against ethidium bromide-resistant Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID1546639	Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as log reduction in bacterial population at 10 ug/ml under starvation condition after 7 days by MPN assay	2020	Journal of natural products, 01-24, Volume: 83, Issue:1	Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents.
AID571766	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-N616 mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID581477	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID405461	Antibacterial activity against Escherichia coli TOP10 by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID571104	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID563217	Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID571870	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID543397	AUC (24 hrs) in plasma in Listeria monocytogenes EGD-e infected BALB/c mouse central nervous system listeriosis model at 50 mg/kg, ip administered 36 hrs postinfection as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID1557287	Antibacterial activity against Enterococcus by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID1819098	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv clinical isolates 3 assessed as reduction in bacterial growth incubated for 7 days by resazurin dye based assay	2022	ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1	Structural Rigidification of
AID559044	Antibacterial activity against Listeria monocytogenes by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID558611	Antimicrobial activity against Streptococcus pneumoniae isolate 1564 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID563220	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1297352	Antibacterial activity against Enterococcus faecalis 14-3 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID283156	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2394 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID563045	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID571120	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1297319	Antibacterial activity against extended-spectrum beta-lactamase-producing Escherichia coli 14-2 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID559411	Antimicrobial activity against Clostridium difficile BI2F harboring GyrB Glu466Lys mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID544292	Antibacterial activity against methicillin-susceptible Staphylococcus aureus after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID285304	Effect on 0.5 ug/ml sitafloxacin-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID559537	Antibacterial activity against Morganella morganii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID574510	Antimicrobial activity against Bacteroides vulgatus assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID562940	Effect on fbp69 gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID580756	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID563341	Induction of Cwp84 protease expression in Clostridium difficile 6269 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID586740	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrB gene and pBK-QnrB1 assessed as earliest time required to resistant colonies visible one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID571350	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID572271	Antimicrobial activity against methicillin-resistant Staphylococcus aureus NB01021 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID571371	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1264557	Antibacterial activity against Streptococcus pneumoniae for 18 to 24 hrs by broth microdilution method	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1243292	Antimicrobial activity against ciprofloxacin-resistant Escherichia coli clinical isolates by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID511382	Antibacterial activity against Enterococcus faecalis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID1743453	Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in human macrophages assessed as intracellular bacterial load at MIC measured after 6 days (Rvb = 5.57 to 6.43 logCFU/ml)	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID581660	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU after 5 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1524627	Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID574991	Antimicrobial activity against Bifidobacterium adolescentis assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID559164	Antimicrobial activity against Clostridium difficile BI2a harboring GyrB Arg447Lys mutant gene selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID279263	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3676 with GyrA E85G, GyrB S478I and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID428827	Ratio of Cmax in human at 400 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-26137	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1403707	Antibiofilm activity against Mycobacterium tuberculosis H37Rv assessed as log reduction in bacterial load at 10 ug/ml incubated for 1 week by MPN assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.
AID581285	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1447484	Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 91433 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID559194	Antimicrobial activity against Clostridium difficile CD5D harboring GyrB Ser416Ala mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1237409	Antibacterial activity against Pseudomonas aeruginosa 2004 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID497757	Apparent permeability across apical to basolateral side in human Calu3 cells	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID405459	Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID518625	Volume of distribution in Mycobacterium avium infected human THP1 cell-based pharmacokinetic-pharmacodynamic modell by LC analysis	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID556189	Apparent passive permeability across human Calu3 cells at < 10 ug/ml	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID570902	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID523173	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC11223 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID563047	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID245697	Mutant prevention concentration aganist methicillin resistant Staphylococcus aureus-5023 done for 48 hr at 37 degree C with compound	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID559200	Antibacterial activity against Streptococcus pneumoniae S001 harboring parC Asp83Asn mutant and wild-type gyrA genes	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID556027	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from basolateral to apical side at 50 uM in presence of 100 uM of p-glycoprotein and MRP inhibitor verapamil	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID533631	Antimicrobial activity against Propionibacterium acnes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID558621	Antimicrobial activity against Streptococcus pneumoniae isolate 3346 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID559166	Antimicrobial activity against Clostridium difficile BI2c harboring GyrB Arg447Lys mutant gene selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID406654	Antibacterial activity against Staphylococcus aureus ACH-0186 isolate with gyrA Ser84Leu and grlA Ser80Phe, Ala116Val mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID279822	Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 7	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID581102	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID563041	Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1297345	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-37 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID456029	Antibacterial activity against Streptococcus pyogenes G-36 after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1318923	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 264-104354	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1252459	Inhibition of Mycobacterium smegmatis DNA gyrase B expressed in Escherichia coli BL21 (DE3) pLysS cells assessed as reduction in ATPase activity incubated for 100 mins by inorganic phosphate detection assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
AID559238	Antibacterial activity against Streptococcus pneumoniae W001 harboring wild-type parC and gyrA genes assessed as mutation prevention concentration after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID530389	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA A83S mutant/GyrB R447K mutant gene assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID562927	Antimicrobial activity against Clostridium difficile ATCC 43603-M1 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID580906	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID341379	Antibacterial activity against Staphylococcus aureus infection-induced aortic valve endocarditis in rabbit assessed as cured animals in blood culture at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 days after last dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID540230	Dose normalised AUC in rat after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID580753	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID544866	Antibacterial activity against Streptococcus pneumoniae U2A1056 harboring gyrA Ser81Tyr parC Asp83His mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID532964	Antimicrobial activity against streptomycin-resistant Mycobacterium tuberculosis isolate 8	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID580874	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID559505	Antibacterial activity against Staphylococcus hominis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID562628	Antimicrobial activity against Group C Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID581093	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID558922	Antimicrobial activity against Clostridium difficile A422a selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID341376	Antibacterial activity against Staphylococcus aureus infection-induced aortic valve endocarditis in rabbit assessed as number of survival days at 20 mg/kg, iv administered every 12 hrs for 5 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID562450	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH37099	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID1740333	Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID416842	Antimycobacterial activity against Mycobacterium ulcerans isolate CU001 infected in BALB/c mouse left hind foot-pad assessed as bacterial load per culture-positive foot-pad at 10 mg/kg, po administered for 5 days per week measured after 8 weeks	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
AID425348	Antibacterial activity against Streptococcus pneumoniae HMC 1073 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID571351	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID520374	Cardiotoxicity in patient with intracerebral and leptomeningeal tuberculosis assessed as QT prolongation at 800 mg/kg, po QID	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID635055	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID261730	Antibacterial activity against Staphylococcus aureus ATCC 29213	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID323892	Antimicrobial activity against Escherichia coli J53/p1132 negative expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID571865	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID590140	Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
AID528839	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1655164	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774.1 cells assessed as reduction in bacterial colony at 1 to 10 times MIC incubated for 72 hrs by colony counting method	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Improving the Potency of
AID395716	Antibacterial activity against Escherichia coli DH10B by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1600101	Antibacterial activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID498189	Antibacterial activity against Stenotrophomonas maltophilia MBS109 containing chromosomally encoded Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID523174	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC8525 harboring wild type quinolone resistance-determining region assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID581303	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1152775	Antimycobacterial activity against spontaneously resistant mutant of Mycobacterium tuberculosis H37Rv at 10 to 20 times MIC up to 6 to 8 weeks	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID581283	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID341082	Tmax in human with MDR1 3435 CC or CT genotype at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg/kg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID369977	Antibacterial activity against methicillin-sensitive Staphylococcus aureus infected rabbit arthritis model assessed as change in bacterial load per gram of synovial fluid at 45 mg/kg, po after 7 days by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID562929	Antimicrobial activity against Clostridium difficile CD196 M1 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1254080	Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID1664938	Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity.
AID535776	Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 harboring pTY60K containing pMH94 carrying the luxAB gene under the hsp60 promoter after 7 days determined according to RLU count by real-time luminescence method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID245137	Minimum inhibitory concentration against methicillin-resistant Staphylococcus aureus-32	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID522958	Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID532976	Antimicrobial activity against multidrug drug-resistant Mycobacterium tuberculosis isolate 20	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID1676600	Binding affinity to zinc ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID581269	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID558606	Antimicrobial activity against Streptococcus pneumoniae isolate 1147 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID577501	Bactericidal activity against Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in planktonic cell count at 400 mg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID1252462	Inhibition of DNA gyrase GyrA/GyrB in Mycobacterium tuberculosis incubated for 30 mins assessed as reduction in supercoiling of relaxed relaxed pBR322 DNA by ethidium bromide staining based agarose gel electrophoresis method	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
AID559154	Antimicrobial activity against Clostridium difficile 630f selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID544863	Antibacterial activity against Streptococcus pneumoniae U2A1411 harboring parC Asp83Gly mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID728919	Antibacterial activity against Bacillus subtilis IID 685 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID559195	Antimicrobial activity against Clostridium difficile CD5E harboring GyrB Ser416Ala mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID581281	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID528976	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID286059	Peak free concentration at 800 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID1514452	Antitubercular activity against kanamycin-resistant Mycobacterium tuberculosis after 7 days by resazurin dye based colorimetric assay	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID433579	Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A A91V mutant assessed as formation of DNA cleavable complex	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID559205	Antibacterial activity against Streptococcus pneumoniae D002 harboring parC Ser79Phe and gyrA Ser81Phe mutant genes	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID559501	Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID563044	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID285160	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID573583	Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID522978	Antibacterial activity against Streptococcus pneumoniae isolate OC7189 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID558596	Antimicrobial activity against Streptococcus pneumoniae 8 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID558918	Antimicrobial activity against Clostridium difficile CD5i harboring GyrA Ala118Ser, Thr82Ala and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID456028	Antibacterial activity against Streptococcus pneumoniae J-24 after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID521342	Cmin in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1312204	Antibacterial activity against nutrient-starved dormant Mycobacterium tuberculosis H37Rv assessed in log reduction in bacterial count at 10 ug/ml measured after 7 days by MPN assay relative to control	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Design and development of new class of Mycobacterium tuberculosisl-alanine dehydrogenase inhibitors.
AID1264555	Antibacterial activity against methicillin-resistant Staphylococcus aureus 1118 for 18 to 20 hrs by broth microdilution method	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1750827	Plasma protein binding in Sprague-Dawley rat at 10 uM after 4 hrs by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID581079	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID285290	Susceptibility of penicillin-resistant Streptococcus pneumoniae 216 by by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID341387	Concentration in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit serum at 20 mg/kg, iv administered every 12 hrs measured 30 mins after seventh dose in presence of Dexamethasone	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID1676595	Binding affinity to Ferric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1626633	Bactericidal activity against methicillin-resistant Staphylococcus aureus 29213 infected in mouse macrophages assessed as induction of bacterial kill at 4 ug/ml in presence of 4 ug/ml rifampin after 24 hrs	2016	Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14	Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
AID1053479	Antitubercular activity against Mycobacterium tuberculosis H37Rv expressing inhA G96V mutant assessed as parasite growth inhibition after 7 days by Alamar Blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
AID422686	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID544296	Antibacterial activity against quinolone-resistant Staphylococcus aureus after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID206214	Antibacterial activity was determined against Staphylococcus epidermis 56500 strain after incubation at 37 degrees C for 18 h	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID341084	Tmax in human with MDR1 3435 CC or CT genotype at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID520100	Antimicrobial activity against Mycobacterium tuberculosis Erdman injected into gamma interferon gene knockout C57BL/6 mouse assessed as bacterial load in lung of mouse at 300 mg/kg measured 9 days post drug treatment	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
AID1601845	Antibacterial activity against Enterococcus faecalis CMCC 29212 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID562938	Upregulation of cwp84 gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID342078	Effect on growth of epidemic Clostridium difficile BI9 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID633739	Antibacterial activity against Klebsiella pneumoniae 10-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID484800	Antibacterial activity against Staphylococcus aureus K1305 bearing wild-type GyrA and E84K mutant GrlA by microdilution technique	2010	Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11	From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID1316915	Antimycobacterial activity against dormant stage of Mycobacterium tuberculosis H37Rv assessed as reduction in bacterial growth under nutrient starved conditions at 10 ug/ml for 7 days measured after 28 days	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues endowed with high activity toward non-replicative Mycobacterium tuberculosis.
AID286162	fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 800 mg	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID285306	Effect on 16 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID574810	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 horboring rpoB D516V, katG S315T/R463L, gyrA D94G/S95T/R128S/Y129C, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID342254	Effect on growth of fluoroquinolone-resistant epidemic Clostridium difficile NAP1 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 5 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID528847	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1468618	Antibacterial activity against Staphylococcus aureus ATCC 29213 infected in C57BL6 mouse cornea assessed as decrease in corneal infiltrates at 0.3% administered tropically 2 times on day 1, 4 times on day 2 and 2 times on day 3 starting from 6 hrs post in	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo.
AID574736	Antimicrobial activity against Fusobacterium nucleatum after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID428837	TMSW in Streptococcus pneumoniae isolate SR-26137 infected human at 400 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID342255	Effect on growth of fluoroquinolone-resistant epidemic Clostridium difficile NAP1 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 5 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID416839	Antimycobacterial activity against Mycobacterium ulcerans isolate CU001	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
AID755684	Inhibition of human ERG current by patch clamp assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID428819	Ratio of AUC (0 to 24 hrs) in human at 80 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-26137	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1398600	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID428806	Ratio of Cmax in human at 400 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-26134	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID323888	Antimicrobial activity against qnrA1 expressing Escherichia coli J53/pN5 expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID425571	Antibacterial activity against penicillin-, macrolide-susceptible and quinolone-resistant Streptococcus pneumoniae HMC 1074 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutat	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1551294	Antibacterial activity against Escherichia coli 1924 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID532684	Antimicrobial activity against ciprofloxacin-nonsusceptible, AM PFGE pattern, emm6 type Streptococcus pyogenes with ST382 sequence type, ParC S79A mutant isolated from oropharyngeal colonization	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID586630	Antibacterial activity against Escherichia coli ATCC 25922 harboring ParC S80R mutant by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID593808	Antimicrobial activity against quinilone-pencillin-resistant Acinetobacter baumannii clinical isolate by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID544861	Antibacterial activity against Streptococcus pneumoniae U2A1413 harboring parC Ser79Tyr mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID571370	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID577494	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus SH1000 by CLSI broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID1163989	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli 12-3 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID534364	Antibacterial activity against wild type Escherichia coli K-12 KD1397 harboring gyr gene	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.
AID532687	Antimicrobial activity against ciprofloxacin-nonsusceptible, K PFGE pattern, emm5 type Streptococcus pyogenes with ST99 sequence type, ParC D83G isolated from oropharyngeal colonization	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID425360	Antibacterial activity against Streptococcus pneumoniae HMC 1077 harboring S81Y and S79F mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1750823	Inhibition of human ERG expressed in CHO cells by whole cell patch-clamp method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID581308	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID584557	Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1740328	Antifungal activity against Candida albicans ATCC 10231 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID521150	Antibacterial activity against intracellular Listeria monocytogenes EGDe infected in bone marrow-derived BALB/c mouse macrophage assessed as changes in morphology of intracellular bacteria observed to be ghostly, chained, and elongated at >= MIC after 48	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID562937	Upregulation of cwp84 gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID553686	Antimicrobial activity against Enterococcus in three-stage chemostat gut model assessed as log reduction in bacterial count at 43 mg/liter administered daily for 7 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID285281	Effect on 1 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID572524	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Stanley isolate s2018 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID556766	Antimicrobial activity against Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID586652	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrB gene and pBK-QnrB1 assessed as mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1254073	Antibacterial activity against Pseudomonas aeruginosa 2742 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID531529	Antibacterial activity against Bacteroides uniformis isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1600108	Bactericidal activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID496653	Antibacterial activity against Streptococcus pneumoniae 1135 assessed as mutant prevention concentration by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID368418	Antimicrobial activity against multidrug-resistant Escherichia coli C316 pHPA containing mutated GyrA gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID285959	Antimicrobial susceptibility against Haemophilus influenzae A2 with GyrA Glu83Cys, ParC Ser84Arg and AcrR 97stop codon mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID164393	Antibacterial activity was determined against Pseudomonas aeruginosa PAO1 strain after incubation at 37 degrees C for 18 h	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID586752	Antibacterial activity against qnrA gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrA1 assessed as resistant colonies recovered one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID341071	Tmax in human at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID425972	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID540221	Volume of distribution at steady state in human after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID571388	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID508370	Antibacterial activity against Streptococcus pneumoniae harboring mef(A) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID575082	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID561322	Antimicrobial activity against Escherichia coli isolate 48 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID633742	Antibacterial activity against Pseudomonas aeruginosa 10-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID524825	Antibacterial activity against erythromycin susceptible Campylobacter sp. by agar plate dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID558904	Antimicrobial activity against Clostridium difficile CD5d harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID369966	Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID570692	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1557284	Antibacterial activity against Staphylococcus aureus by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID286048	Peak free concentration at 200 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID496645	Antibacterial activity against Streptococcus pneumoniae 1065 by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID424320	Antimicrobial activity against Dialister micraerophilus by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID285286	Effect on 0.5 ug/ml sitafloxacin-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID522969	Antibacterial activity against Providencia stuartii by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID561315	Antimicrobial activity against Enterobacter cloacae isolate 101 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1399858	Antitubercular activity against rifampicin-resistant Mycobacterium tuberculosis H37Rv harboring RpoB S522L mutant	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID563226	Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID562648	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH37312	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID556762	fAUC/MIC in osteomyelitis patient cancellous bone at 400 mg, po administered for every 24 hrs at PKPD breakpoint at 0.25 mg/liter	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID285302	Susceptibility of penicillin-resistant Streptococcus pneumoniae 218 by by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID559070	Antibacterial activity against Acinetobacter calcoaceticus by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1570248	Half life in SPF ICR mouse at 100 mg/kg, sc	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID556197	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from basolateral to apical side at 50 uM	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID562452	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH37390	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID728905	Aqueous solubility of the compound	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID570794	Tmax in healthy human at 400 mg, po qd measured on day 4 by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID559375	Antimicrobial activity against Clostridium difficile A422C selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID593812	Antimicrobial activity against Pseudomonas aeruginosa ATCC 9027 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID285530	Antibacterial activity against ethidium bromide-resistant Staphylococcus aureus Mu50 after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID565331	Antibacterial activity against Mycoplasma genitalium M6287 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID1237413	Bactericidal activity against Staphylococcus aureus KCTC 209 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID1877421	Antibacterial activity against Neisseria gonorrhoeae WHO Z	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID322787	Antimicrobial activity against Bacteroides uniformis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID1740329	Antifungal activity against Aspergillus flavus ATCC 9643 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID515921	Antibacterial activity against clofazimine-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay	2010	Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20	Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID556191	Activity at P-glycoprotein in human Calu3 cells	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID1430303	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID533405	Antimicrobial activity against Clostridium tertium by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID496636	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 assessed as 50% mutant prevention concentration	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID388878	Protective effect against Staphylococcus aureus ATCC 13709-induced bone infection in CD rat at 10 mg/kg, iv administered as single dose 1 hr before bacterial challenge	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
AID533385	Antimicrobial activity against Clostridium difficile by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID520359	Cmin in CSF of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID406844	Antibacterial activity against Escherichia coli TOP10 by E-test	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID511399	Antibacterial activity against Haemophilus influenzae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID520105	Oral bioavailability in mouse at 300 mg/kg, po measured after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
AID1868113	Selectivity index, ratio of IC50 for cytotoxicity against mouse J774.A1 cells to MIC90 for anti-tubercular activity against Mycobacterium tuberculosis H37Rv	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID279269	Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81Y and ParC D83Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID369964	Cmax in human serum at 400 mg, po administered as single dose after 1 hr	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID562634	Antimicrobial activity against Corynebacterium spp. by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID406658	Antibacterial activity against Staphylococcus aureus ACH-0129 isolate with gyrA Ser84Leu, Glu88Val and grlA Ser80Phe, Ala116Val mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID530590	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr2 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID581489	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID499678	Antimicrobial activity against Escherichia coli ATCC 8739 after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID574052	Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID245695	Mutant prevention concentration against methicillin resistant Staphylococcus aureus-32 done for 48 h at 37 degree C with compound	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1318927	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86053	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID562619	Antimicrobial activity against Heterovancomycin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID279273	Antibacterial activity against Streptococcus pneumoniae assessed as period of suppression of bacterial growth	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID530593	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr5 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID535769	Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID279272	Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 37 with GyrA S81Y, GyrB E474K and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1868110	Anti-tubercular activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID556195	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as minimum apparent permeability from basolateral to apical side	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID1611014	Induction of membrane integrity impairment in methicillin-resistant Staphylococcus aureus ATCC 700699 at 20 uM measured for 30 mins by DiOC2(3) probe based fluorescence assay	2019	Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23	The plant-derived chalcone Xanthoangelol targets the membrane of Gram-positive bacteria.
AID278853	Cytotoxicity against primary human osteoblasts at 400 ug/ml assessed as LDH release after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID559391	Antimicrobial activity against Clostridium difficile 630A selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1602928	Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID497759	Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID728926	Antibacterial activity against Staphylococcus aureus FDA 209-P after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID559520	Antibacterial activity against Streptococcus mitis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID535773	Antimicrobial activity against Mycobacterium ulcerans 1059 harboring pTY60K carrying the luxAB gene under the hsp60 promoter agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID425336	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID406657	Antibacterial activity against Staphylococcus aureus ACH-0129 isolate with gyrA Ser84Leu, Glu88Val and grlA Ser80Phe, Ala116Val mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID575102	Antimicrobial activity against Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID491950	Antibacterial activity against Staphylococcus aureus ATCC 12600 after 48 hrs by microtiter plate assay	2010	Journal of natural products, Jul-23, Volume: 73, Issue:7	Mayamycin, a cytotoxic polyketide from a Streptomyces strain isolated from the marine sponge Halichondria panicea.
AID581289	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID425573	Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 99 harboring S81Y and S79Y mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively after 41 passages	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID580909	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1585700	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by rapid direct susceptibility test	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Fluoroquinolone-isatin hybrids and their biological activities.
AID283391	Antimicrobial activity against Nocardia farcinica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID158681	In vitro inhibitory activity against chloroquine-resistant Plasmodium falciparum NF54-R in blood	2004	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11	Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
AID581267	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID425977	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID558894	Antimicrobial activity against Clostridium difficile C253i harboring GyrA Ala118Ser mutant gene selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID544824	Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID511395	Antibacterial activity against Streptococcus agalactiae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID626867	Antimicrobial activity against replicating Mycobacterium tuberculosis after 8 days by micro plate alamar blue assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin.
AID1297348	Antibacterial activity against Enterococcus faecium 14-1 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID543402	Antibacterial activity against Listeria monocytogenes EGD-e in BALB/c mouse central nervous system listeriosis model assessed as mouse survival at 50 mg/kg, ip administered 36 hrs postinfection every 12 hrs for 5 days measured after 2 months	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID570792	AUC (0 to 24 hrs ) in healthy human at 400 mg, po qd measured on day 4 by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID581673	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1476361	Antitubercular activity against moxifloxacin resistant Mycobacterium tuberculosis H37Rv after 24 hrs by MABA method	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.
AID279206	Antibacterial activity against Streptococcus pneumoniae 3243 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID533866	Antibacterial activity against toxin-positive Clostridium difficile clinical isolate assessed as percent of susceptible isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
AID425562	Antibacterial activity against penicillin- and quinolone-susceptible Streptococcus pneumoniae HMC 5055 expressing mefA after 50 passages by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID161281	Inhibition of human Potassium channel HERG expressed in mammalian cells	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID425352	Antibacterial activity against Streptococcus pneumoniae HMC 1150 harboring S81C mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1207376	Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform
AID562656	Ratio of AUC (0 to 24 hrs) to MIC required for 3-log drop in bacterial count in Staphylococcus aureus SMH36633	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID279836	Toxicity in Mycobacterium tuberculosis infected BALB/c mouse model at 38 to 19000 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID559532	Antibacterial activity against non-ciprofloxacin-susceptible Haemophilus influenzae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID583102	Apparent permeability from apical to basolateral side of human Calu3 cells after 6 hrs	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats.
AID562617	Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID422676	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 19 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID581084	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID574724	Antimicrobial activity against Prevotella buccae assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID562946	Upregulation of slpA gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID406621	Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
AID531635	Antimicrobial activity against fluoroquinolone-resistant Ureaplasma parvum by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
AID244957	Minimum inhibitory concentration against Streptococcus sanguis ATCC 10556	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID586739	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrA gene and pBK-QnrA1 assessed as earliest time required to resistant colonies visible one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID562440	Antibacterial activity against Staphylococcus aureus SMH37099 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID1398610	Inhibition of human ERG expressed in CHOK1 cells at 100 uM	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID633642	Antibacterial activity against Enterococcus faecium 09-5 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID342077	Effect on growth of nonepidemic Clostridium difficile J29 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID1393810	Antitubercular activity against non-replicating Mycobacterium tuberculosis H37Rv after 10 days by low oxygen recovery assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Fluoroquinolone derivatives and their anti-tubercular activities.
AID580759	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1256543	Antibacterial activity against Klebsiella pneumoniae 14-4 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID406651	Antibacterial activity against Staphylococcus aureus ACH-0218 isolate with grlA Glu84Lys mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID574534	Antimicrobial activity against Prevotella buccae assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID562637	Antimicrobial activity against Listeria monocytogenes assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID425984	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID286148	Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 32 after 72 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID1254078	Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID1318930	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86141	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID428839	TMSW in Streptococcus pneumoniae isolate SR-26137 infected human at 80 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID558881	Antimicrobial activity against Clostridium difficile C253b selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID518060	Toxicity in healthy human assessed as headache at 400 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
AID1237414	Bactericidal activity against Staphylococcus aureus KCTC 503 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID424329	Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID593902	Inhibition of Escherichia coli topoisomerase 4 assessed as decatenation of kDNA after 30 mins by electrophoresis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID425575	Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene after 22 passages with moxifloxacin measured afte	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1187838	Inhibition of Mycobacterium tuberculosis GyrA/GyrB using relaxed pBR322 as substrate at 0.97 uM after 30 mins by DNA supercoiling assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID285285	Effect on 0.06 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID558898	Antimicrobial activity against Clostridium difficile CD5a harboring GyrB Ser416Ala mutant gene selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID533388	Antimicrobial activity against Clostridium difficile assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1319008	Antimicrobial activity against Pseudomonas aeruginosa PAO750	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1256536	Antibacterial activity against Escherichia coli 14-2 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID520360	Cmin in CSF of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID279831	Half life in BALB/c mouse at 6 to 400 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID586735	Ratio of mutant prevention concentration to MIC for qnrA gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrA1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1600094	Lipophilicity, log k of the compound at 100 ug/ml by micellar electrokinetic chromatography	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID1447482	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P262-101856 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID562934	Upregulation of slpA gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID428826	Ratio of Cmax in human at 400 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-26134	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1909953	Selectivity ratio of MIC99 for wild type Mycobacterium tuberculosis H37Rv to MIC99 for Mycobacterium tuberculosis H37Rv gyrA -FDASTetON-1 hypomorph	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID422128	Antimicrobial activity against Mycobacterium smegmatis by broth microdilution assay	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Antimicrobial ambiguine isonitriles from the cyanobacterium Fischerella ambigua.
AID584561	Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID561323	Antimicrobial activity against Klebsiella pneumoniae isolate 132 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID521145	Antibacterial activity against extracellular Listeria monocytogenes EGDe assessed as reduction in bacterial count at four times of MIC after 6 hrs by time-kill study	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID275463	Inhibition of Staphylococcus aureus DNA gyrase by supercoiling assay	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
AID626868	Antimicrobial activity against non-replicating Mycobacterium tuberculosis after 11 days by luminescence based low oxygen recovery assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin.
AID556776	Volume of distribution in central compartment in osteomyelitis patient at 400 mg, po administered for every 24 hrs by three stage hierarchical Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID433403	Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as DNA supercoiling inhibition	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID570690	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID530595	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr7 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID279202	Antibacterial activity against Streptococcus pneumoniae 3009 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID425354	Antibacterial activity against Streptococcus pneumoniae HMC 5041 harboring S81F and S79F mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID586754	Antibacterial activity against qnrS gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrS1 assessed as resistant colonies recovered one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID428776	Ratio of mutant prevention concentration for Streptococcus pneumoniae ATCC 49619 to MIC for Streptococcus pneumoniae ATCC 49619	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID573798	Antibacterial activity against Prevotella melaninogenica assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID341083	Tmax in human with MDR1 3435 CC genotype at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID531519	Antibacterial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1600097	Antibacterial activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID561318	Antimicrobial activity against Enterobacter cloacae isolate 153 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID584113	Ratio of LD99 for Escherichia coli K-12 DM4100 to MIC for Escherichia coli K-12 DM4100	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.
AID586741	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrS gene and pBK-QnrS1 assessed as earliest time required to resistant colonies visible one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1570246	Antimycobacterial activity against multidrug (isoniazid and rifampicin) resistant Mycobacterium tuberculosis 2 incubated for 7 days by rapid direct susceptibility test	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID563038	Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID581652	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1398605	Antibacterial activity against Escherichia coli 5-037042'98 harboring gyrase A Asp87Gly mutation after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID456049	Selectivity ratio of IC50 for Staphylococcus aureus DNA topoisomerase 4 Ser80Phe mutant to IC50 for Staphylococcus aureus wild type DNA topoisomerase 4	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID1430292	Antibacterial activity against Escherichia coli ATCC 35218 incubated after 24 hrs by resazurin dye based broth microdilution assay	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID285965	Antimicrobial susceptibility against Haemophilus influenzae C isolate with AcrR Leu31His and Arg34Glu mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID1237422	Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID1819097	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv clinical isolates 4 assessed as reduction in bacterial growth incubated for 7 days by resazurin dye based assay	2022	ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1	Structural Rigidification of
AID581103	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID558617	Antimicrobial activity against Streptococcus pneumoniae isolate 3260 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID580767	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID635059	Antibacterial activity against methicillin-resistant Staphylococcus aureus 10-4 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID699002	Cmax in human at 400 mg, po	2012	European journal of medicinal chemistry, May, Volume: 51	Tuberculosis: the drug development pipeline at a glance.
AID1868119	Anti-tubercular activity against Mycobacterium tuberculosis CF161 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID1600118	Bactericidal activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID341088	Half life in human with MDR1 3435 CC or CT genotype at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID559524	Antibacterial activity against Acinetobacter baumannii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1316914	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by MABA	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues endowed with high activity toward non-replicative Mycobacterium tuberculosis.
AID581656	Antibacterial activity against revertant Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1237404	Antibacterial activity against Staphylococcus aureus KCTC 503 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID556023	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from apical to basolateral side at 50 uM in presence of 3 uM P-gp inhibitor PSC-833	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID428836	TMSW in Streptococcus pneumoniae isolate SR-26134 infected human at 400 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID96072	Antibacterial activity was determined against Klebsiella pneumoniae type II strain after incubation at 37 degrees C for 18 h	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID286152	Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 236 after 24 to 96 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID1750814	Antibacterial activity against Fluoroquinolone-resistant Staphylococcus aureus ATCC 49951 assessed as reduction in bacterial growth by CLSI based broth microdilution method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID540233	Dose normalised AUC in human after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID759323	Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents.
AID581657	Antibacterial activity against normal phenotype Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID286147	Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 32 after 24 to 48 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID341381	Antibacterial activity against Staphylococcus aureus infection-induced aortic valve endocarditis in rabbit assessed as reduction in bacterial burdens in heart valve tissue culture at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 hrs afte	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID573582	Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID633632	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 10-5 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID438556	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv replicating form by alamar blue assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.
AID580870	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1372638	Antibacterial activity against Mycobacterium marinum ATCC BAA-535 infected in zebra fish assessed as log reduction in bacterial load at 10 mg/kg, po for 7 days	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Lead identification and optimization of bacterial glutamate racemase inhibitors.
AID559399	Antimicrobial activity against Clostridium difficile 630F harboring GyrA Ala118Val mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1890606	Antibacterial activity against beta-lactams, macrolide and fluoroquinolone resistant Streptococcus pneumoniae 718 infected in po dosed Swiss mouse septicemia model assessed as protective dose administered on 1 and 5 hrs post infection and measured on day	2022	Bioorganic & medicinal chemistry letters, 05-01, Volume: 63	WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID1154351	Antimycobacterial activity against BTZ043-resistant Mycobacterium tuberculosis over expressing DprE1 C387S mutant after 5 days by standard microdilution method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
AID580995	Drug excretion in feces of healthy human at 800 mg/kg	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID559147	Antimicrobial activity against Clostridium difficile 630b selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID562643	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH37276	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID581070	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID563021	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID286159	Bactericidal activity against Staphylococcus aureus BSP-2443 with parC S52G, N91D mutation and gyrA S114G mutation at fAUC/MIC of 24 after 72 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID341393	Toxicity in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit assessed as collagenization median score at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 days after last dose by histopathology	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID563026	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID603876	Antitubercular activity against non-replicating Mycobacterium tuberculosis H37Rv ATCC 27294 incubated 10 days under anaerobic condition measured after 28 hrs of recovery in air by luciferase based low oxygen recovery assay	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.
AID695448	Cytotoxicity against human HeLa cell line after 72 hrs	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID1600115	Antibacterial activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID574784	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2403 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID1888649	Antibacterial activity against wild type Staphylococcus aureus assessed as inhibition of bacterial growth	2022	Bioorganic & medicinal chemistry letters, 02-01, Volume: 57	Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
AID553804	Antimicrobial activity against Clostridium difficile PCR ribotype 001 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID570706	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID341066	Plasma concentration in human at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID529893	Antimicrobial activity against Leptospira interrogans serovar Bataviae isolate 1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID1601853	Antibacterial activity against multidrug-resistant Escherichia coli ATCC BAA-196 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID523146	Antibacterial activity against Streptococcus pneumoniae isolate OC6585 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID244990	Antibacterial activity against Staphylococcus aureus FDA 209P was determined	2004	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
AID433400	Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as DNA supercoiling inhibition	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID369963	Half life in human serum at 400 mg, po administered as single dose	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID1877414	Antibacterial activity against Neisseria gonorrhoeae WHO Q	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID558615	Antimicrobial activity against Streptococcus pneumoniae isolate 2874 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1494123	Antibacterial activity against methicillin-resistant Staphylococcus aureus NCTC 13373 after 16 hrs by microdilution method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID279239	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 35 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID285293	Effect on 2 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID586753	Antibacterial activity against qnrB gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrB1 assessed as resistant colonies recovered one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID279277	Antimicrobial activity agaisnt Streptococcus pneumoniae R6 transformants with parC S79Y mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID405115	Antimicrobial activity against Vibrio splendidus LGP32 expressing plasmid-mediated QnrS-like quinolone resistance determinants	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID571378	Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID422668	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 35 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID633847	Antibacterial activity against Enterococcus faecium 09-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID581665	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID428789	Antibacterial activity against 200 mg b.i.d. levofloxacin-pretreated Streptococcus pneumoniae isolate SR-26134 after 48 hrs of incubation by population analysis	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID558594	Antimicrobial activity against Streptococcus pneumoniae 6 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID560261	Antimicrobial activity against Escherichia coli CSH26RifR receiving qnrB19 gene variant carried by IncL/M-like plasmid from Salmonella enterica serovar Typhimurium STYM61/9 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium.
AID1330186	Antibacterial activity against Staphylococcus aureus 4220 measured after 24 hrs by two-fold serial dilution method	2016	Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24	Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
AID1237408	Antibacterial activity against Pseudomonas aeruginosa 2742 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID562645	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH36945	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID556031	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from basolateral to apical side at 50 uM in presence of in presence of 25 uM of p-glycoprotein and MRP transport inducer rifampin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID521830	Antimicrobial activity against Streptococcus pneumoniae isolated from meningitis patient assessed as percent susceptible isolates by CLSI method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
AID584560	Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID523160	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC8530 harboring gyrA S84L and parC I143V mutant gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID286081	fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 400 mg	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID373004	Antimycobacterial activity against Mycobacterium avium complex N018 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID530376	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB N464S mutant gene	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID580911	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID581088	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID593798	Antimicrobial activity against Bacillus cereus ATCC 11778 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID342083	Effect on growth of epidemic Clostridium difficile BI6-8-17 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.4 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID1740323	Antimicrobial activity against Salmonella enterica ATCC 13312 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID422649	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1699553	Induction of cell membrane permeabilization in methicillin resistant Staphylococcus aureus ATCC 700699 measured at 5 mins interval for 2 hrs by propidium iodide staining based fluorescence assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Nature-Inspired (di)Azine-Bridged Bisindole Alkaloids with Potent Antibacterial
AID581106	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1699554	Induction of cell membrane permeabilization in GFP-expressing Staphylococcus aureus ATCC 700699 assessed as increase in cellular ATP leakage at 5 fold MIC measured after 0.5 hrs by Bactiter-glo assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Nature-Inspired (di)Azine-Bridged Bisindole Alkaloids with Potent Antibacterial
AID574494	Antimicrobial activity against Bacteroides fragilis assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID570803	Volume of distribution in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID428772	Bactericidal activity against Streptococcus pneumoniae ATCC 49619 assessed as mutant prevention concentration after 72 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID279276	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79F mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID559530	Antibacterial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1164009	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 12-1 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID283240	Reduction of bacterial counts in Mycobacterium tuberculosis H37Rv infected Swiss mouse lung at 100 mg/kg, po for 5 days/week after 2 months	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
AID559498	Antibacterial activity against vancomycin- resistant Enterococcus faecium assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID558620	Antimicrobial activity against Streptococcus pneumoniae isolate 3282 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID372978	Antimycobacterial activity against Mycobacterium avium JATA51-01 after 14 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID1476362	Antitubercular activity against bedaquiline resistant Mycobacterium tuberculosis H37Rv after 24 hrs by MABA method	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.
AID406847	Antibacterial activity against Enterobacter cloacae S1 isolate expressing quinolone resistance determinant QnrB4 by E-test	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
AID699000	Half life in human at 400 mg, po	2012	European journal of medicinal chemistry, May, Volume: 51	Tuberculosis: the drug development pipeline at a glance.
AID532966	Antimicrobial activity against quinolone-resistant Mycobacterium tuberculosis isolate 10	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID523313	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC11521 harboring gyrA S84L/S85P, parC E84G mutant gene assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID563037	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID608513	Antibacterial activity against Mycobacterium smegmatis KD1163	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
AID456034	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID159910	In vitro inhibitory activity against hepatic stages of Plasmodium yoelii yoelii 265 BY; No data	2004	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11	Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
AID1318907	Antibacterial activity against Enterococcus faecium ATCC 27270 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID580762	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID540217	Volume of distribution at steady state in dog after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID342073	Effect on growth of nonepidemic Clostridium difficile J29 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID285531	Antibacterial activity against ethidium bromide-resistant Staphylococcus aureus Mu50 in presence of 20 ug/ml reserpine after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID695235	Inhibition of Staphylococcus aureus topoisomerase 4 by decatenation assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID1398604	Antibacterial activity against quinolone-resistant Escherichia coli DNS5101 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID425574	Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 harboring S81Y and S79Y mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively after 42 passages	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID581100	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID406650	Antibacterial activity against Staphylococcus aureus ACH-0216 isolate with grlA Ser80Phe mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID633648	Antibacterial activity against Escherichia coli 09-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID586636	Antibacterial activity against qnrA gene expressing Escherichia coli ATCC 25922 harboring ParC S80R mutant and pBK-QnrA1 by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID530382	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A and I85V mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1877400	Antibacterial activity against Acinetobacter baumannii 140	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID322789	Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID556188	P-glycoprotein-mediated transport in human Calu3 cells assessed as efflux ratio of permeability from apical to basolateral side over basolateral to apical side at 50 uM in presence of 25 uM of p-glycoprotein and MRP transport inducer rifampin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID1585704	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis after 3 to 7 days by rapid direct susceptibility test	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Fluoroquinolone-isatin hybrids and their biological activities.
AID530375	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB R447K mutant gene	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID532973	Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 17	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID559546	Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia assessed as assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID544836	Antibacterial activity against Streptococcus pneumoniae U2A1050 harboring gyrA Ser81Phe mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID285532	Antibacterial activity against ethidium bromide-resistant Staphylococcus aureus BSA643 after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID425804	AUC in human at 400 mg, po	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID574738	Antimicrobial activity against Fusobacterium mortiferum after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID286062	Half life at 200 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID563215	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID586751	Antibacterial activity against Escherichia coli ATCC 25922 harboring GyrA S83L mutant assessed as resistant colonies recovered one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID286060	Half life at 100 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID581306	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID558623	Antimicrobial activity against Streptococcus pneumoniae isolate 3412 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1163995	Antibacterial activity against extended-spectrum beta-lactamase producin Klebsiella pneumoniae 12-3 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID1819730	Antimycobacterial activity against Mycobacterium abscessus subsp. bolletii CCUG 50184T assessed as inhibition of mycobacterial growth incubated for 3 days by broth microdilution method	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Structure-Activity Relationship of Anti-
AID522996	Antibacterial activity against Streptococcus pneumoniae isolate OC6790 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID571869	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID581671	Antibacterial activity against normal phenotype Staphylococcus aureus in cation-adjusted MH 2 broth at pH 5.5 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1602933	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 1 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID570800	Tmax in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID1468622	Antibacterial activity against Staphylococcus aureus ATCC 29213 infected in C57BL6 mouse cornea assessed as decrease in log bacterial load/tissue at 0.3% administered tropically 2 times on day 1, 4 times on day 2 and 2 times on day 3 starting from 6 hrs p	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo.
AID633738	Antibacterial activity against Klebsiella pneumoniae 09-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID530373	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1318928	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86067	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID428791	Antibacterial activity against 200 mg b.i.d. levofloxacin-pretreated Streptococcus pneumoniae isolate SR-26137 after 48 hrs of incubation by population analysis	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID322788	Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID422644	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 44 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1398591	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae J24 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID530377	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA A83S mutant/GyrB R447K mutant gene	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID275462	Inhibition of Staphylococcus aureus topoisomerase 4 by decatenation assay	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
AID562652	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH38004	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID644238	Antitubercular activity against Mycobacterium tuberculosis H37Rv after 16 to 24 hrs by microplate alamar blue assay	2012	European journal of medicinal chemistry, Mar, Volume: 49	Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2.
AID540220	Clearance in human after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID562930	Antimicrobial activity against Clostridium difficile CD07-259 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID523158	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC11696 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID595862	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 after 24 hrs by microdilution method	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
AID533376	Antimicrobial activity against Bacteroides eggerthii assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID424879	Antimicrobial activity against multidrug-resistant Enterobacter cloacae E705 bearing qnrB10 gene with aac(6)-IId-aadA1a integron in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID279275	Antimicrobial activity against Streptococcus pneumoniae R6	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID244935	Minimum inhibitory concentration against Klebsiella pneumoniae ATCC 10031	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID278594	Inhibitory activity against azide-resistant Escherichia coli J53	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID580863	Tmax in patients with pulmonary tuberculosis at 400 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID1297332	Antibacterial activity against Pseudomonas aeruginosa 14-15 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1237428	Bactericidal activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID563023	Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene and deletion of codons 678 and 679 in gyrB mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID533364	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID496641	Antibacterial activity against Streptococcus pneumoniae 1149 by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID521147	Antibacterial activity against extracellular Listeria monocytogenes EGDe assessed as reduction in bacterial count at eight times of MIC after 6 hrs by time-kill study	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID1877403	Antibacterial activity against Escherichia coli 203	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID528835	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID556765	fAUC/MIC in osteomyelitis patient cancellous bone at 400 mg, po administered for every 24 hrs at PKPD breakpoint at 1 mg/liter	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID559538	Antibacterial activity against Neisseria meningitidis assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID522984	Antibacterial activity against Streptococcus pneumoniae isolate OC6608 assessed as log reduction in bacterial growth at 2 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID425073	Antimicrobial activity against Escherichia coli DH10B expressing pCR2.1 in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID533404	Antimicrobial activity against Clostridium subterminale assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID559148	Antimicrobial activity against Clostridium difficile 630c selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID633737	Antibacterial activity against Escherichia coli 10-3 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID733005	Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB A91V mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID559190	Antimicrobial activity against Clostridium difficile CD5C harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1604891	Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in C57BL/6 mouse model of acute infection assessed as reduction in mycobacterial burden in lung at 100 mg/kg, po treated for 8 consecutive days starting from day 1 post-infection an	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID279820	Antimicrobial activity against Mycobacterium tuberculosis H3Rv on day 7	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID571357	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID574528	Antimicrobial activity against Prevotella intermedia assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID498786	Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID562936	Upregulation of cwp84 gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID390114	Protective effect against Staphylococcus aureus ATCC 13709-induced bone infection in CD rat at 10 mg/kg, iv administered as single dose 1 hr after bacterial challenge	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.
AID563332	Upregulation of fbp68 gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1740325	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID391987	Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23 promoter by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID581080	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID508387	Antibacterial activity against macrolide-resistant Streptococcus pyogenes harboring mef(A) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID563039	Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID558628	Antimicrobial activity against Streptococcus pneumoniae isolate 3681 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID572513	Antimicrobial activity against Salmonella enterica serovar Mbandaka isolate s2159 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID562638	Antimicrobial activity against Streptococcus mitis by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID528844	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID286044	Susceptibility of Streptococcus pneumoniae BSP-2443 by microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID428769	Bactericidal activity against Streptococcus pneumoniae isolate SR-23958 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID562441	Antibacterial activity against Staphylococcus aureus SMH37312 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID1164014	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 12-6 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID580893	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID570796	Apparent oral clearance in healthy human at 400 mg, po qd measured on day 4 by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID574027	Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID531851	Clearance in tuberculosis patient at 400 mg/day, po administered for 7 days measured after 24 hrs by HPLC	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
AID1181167	Antimicrobial activity against first mutant generation Mycobacterium tuberculosis 1024_1 assessed as fold shift in MIC relative to parent strain	2014	Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID570923	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559491	Antibacterial activity against Bacteroides fragilis assessed as percent susceptible isolates by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573564	Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID581107	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID283393	Antimicrobial activity against Nocardia abscessus after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID544850	Antibacterial activity against Streptococcus pneumoniae CIP104485 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID559196	Antimicrobial activity against Clostridium difficile CD5F harboring GyrB Ser416Ala mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID227416	Fold reduction in minimum inhibitory concentration of antibiotic in presence of Reserpine	2004	Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4	Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID559240	Antibacterial activity against Streptococcus pneumoniae S001 harboring parC Asp83Asn mutant and wild-type gyrA genes assessed as mutation prevention concentration after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID563335	Upregulation of fbp68 gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1256568	Antibacterial activity against Enterococcus faecium 14-6 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID523298	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in B6 mouse assessed as 2 log reduction in bacterial burden in per lung at 30mg/kg, po	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
AID279835	Drug level in Mycobacterium tuberculosis infected BALB/c mouse model at 38 to 19000 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID523308	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC4222 harboring gyrA S84L and parC S80F mutant gene assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID523141	Antibacterial activity against Streptococcus pneumoniae isolate OC7348 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1297321	Antibacterial activity against Escherichia coli 14-2 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID425349	Antibacterial activity against Streptococcus pneumoniae HMC 1076 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1126758	Antibacterial activity against drug-sensitive 1 ug/ml Mycobacterium tuberculosis clinical isolate 760 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID496639	Ratio of 90% mutant prevention concentration to MIC90 in Streptococcus pneumoniae ATCC 49619	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID499671	Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID532979	Inhibition of DNA supercoiling activity of Mycobacterium tuberculosis DNA gyrase subunit A D94G mutant	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID373008	Antimycobacterial activity against Mycobacterium avium complex N084 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID544301	Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS1 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID528836	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID521326	AUC (0 to 24 hrs) in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1297342	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 14-4 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID571879	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID572272	Antimicrobial activity against Streptococcus pneumoniae ATCC 6301 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID244934	Minimum inhibitory concentration against Enterococcus faecalis ATCC 29212	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID425801	AUC (0 to 24 hrs) in CD-1 mouse at 0.41 to 2.2 ug/kg administered through gavage	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID570891	Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID581089	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID559529	Antibacterial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID528841	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID580861	AUC in healthy human at 400 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID1297350	Antibacterial activity against Enterococcus faecalis 14-1 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1877416	Antibacterial activity against Neisseria gonorrhoeae WHO M	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID561314	Antimicrobial activity against Enterobacter cloacae isolate 37 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID586730	Ratio of mutant prevention concentration to MIC for Escherichia coli ATCC 25922	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID278602	Inhibitory activity against Klebsiella pneumoniae 03-222	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID1318926	Antibacterial activity against Pseudomonas aeruginosa PAO1	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID425968	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 14 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1398593	Antibacterial activity against Streptococcus pyogenes ATCC 12344 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID1635217	Antibacterial activity against Staphylococcus aureus ATCC 700699 by broth microdilution method	2016	Journal of natural products, Apr-22, Volume: 79, Issue:4	Metabolites from the Fungal Endophyte Aspergillus austroafricanus in Axenic Culture and in Fungal-Bacterial Mixed Cultures.
AID733006	Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose gel electro	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
AID286156	Bactericidal activity against Staphylococcus aureus BSP-2443 at fAUC/MIC of 31 after 24 to 96 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID581302	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID518627	Ratio of AUC (0 to 24 hrs) in Mycobacterium avium infected human THP1 cell-based pharmacokinetic-pharmacodynamic model to MIC for Mycobacterium avium at 50% maximal effective concentration	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID1468620	Antibacterial activity against Staphylococcus aureus ATCC 29213 infected in C57BL6 mouse cornea assessed as mean corneal thickness at 0.3% administered tropically 2 times on day 1, 4 times on day 2 and 2 times on day 3 starting from 6 hrs post infection m	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo.
AID586745	Antibacterial activity against qnrS gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrS1 assessed as earliest time required to resistant colonies visible one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID523138	Antibacterial activity against Streptococcus pneumoniae isolate OC7368 assessed as log reduction in bacterial growth at 4 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID581293	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1564358	Antimycobacterial activity against Mycobacterium marinum NCTC 2275 by resazurin dye based fluorimetric assay	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	The synthesis and in vitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis.
AID571344	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID279270	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 24 with GyrA S81Y, GyrB P413S and ParC S79F mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID286080	fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 200 mg	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID559244	Antibacterial activity against Streptococcus pneumoniae D001 harboring parC Ser79Phe and gyrA Gly85Lys mutant genes assessed as mutation prevention concentration after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID279209	Antibacterial activity against Streptococcus pneumoniae 24 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID341080	Plasma concentration in human with MDR1 3435 CC or CT genotype at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID559380	Antimicrobial activity against Clostridium difficile A422E harboring GyrB Leu451Phe mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID562442	Antibacterial activity against Staphylococcus aureus SMH37390 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID580757	Growth rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID425809	Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in CD-1 mouse lung measured after 56 days after aerosol infection	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID562942	Upregulation of cwp84 gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID521340	Tmax in CSF of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID558917	Antimicrobial activity against Clostridium difficile CD5h harboring GyrA Ala118Ser, Thr82Ala and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID572520	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Virginia isolate s2219 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID1067079	Antimicrobial activity against Escherichia coli KCTC 1924 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID1551295	Antibacterial activity against Pseudomonas aeruginosa 2742 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID562654	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH36742	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID570809	Ratio of Volume of distribution in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose to Volume of distribution in healthy human at 400 mg, po qd mea	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID765273	fCmax/MIC in Mycobacterium tuberculosis infected mouse	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID1278839	Antimycobacterial activity against Mycobacterium marinum ATCC BAA-535 infected in Zebra fish model assessed as reduction in bacterial load at 5 mg/kg, po administered for 7 days measured after 14 days by MPN assay	2016	Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6	Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
AID559170	Antimicrobial activity against Clostridium difficile BI2d harboring GyrB Arg447Lys and Asp426Asn mutant gene selected after 32 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1242346	Antimycobacterial activity against moxifloxacin resistant Mycobacterium tuberculosis H37Rv harboring DNA gyraseA G88N mutant incubated for 7 days by microdilution method	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.
AID580880	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1266236	Inhibition of Mycobacterium tuberculosis DNA gyrase assessed as inhibition of supercoiling activity using relaxed pBR322 plasmid as substrate after 30 mins	2016	Bioorganic & medicinal chemistry, Jan-01, Volume: 24, Issue:1	Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
AID1524622	Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID532679	Antimicrobial activity against ciprofloxacin-nonsusceptible, AD PFGE pattern, emm6 type Streptococcus pyogenes with ST382 sequence type, ParC S79A mutant isolated from oropharyngeal colonization, tonsillitis/pharyngitis and skin/soft tissue infection	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID428782	AUC (0 to 24 hrs) in human at 80 mg, po administered once a day	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID577499	Bactericidal activity against Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in planktonic cell count at 400 mg every 24 hrs measured after 72 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID1819099	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv clinical isolates 2 assessed as reduction in bacterial growth incubated for 7 days by resazurin dye based assay	2022	ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1	Structural Rigidification of
AID244953	Minimum inhibitory concentration against Staphylococcus aureus ATCC 25923	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1067080	Antimicrobial activity against Streptococcus mutans 3065 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID586737	Ratio of mutant prevention concentration to MIC for qnrS gene expressing Escherichia coli ATCC 25922 harboring GyrA S83L mutant and pBK-QnrS1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1237423	Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID595856	Inhibition of wild-type Staphylococcus aureus DNA gyrase assessed as inhibition of supercoiling of pBR322 DNA after 60 min by gel electrophoresis assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
AID1067074	Antimicrobial activity against Salmonella typhimurium 1926 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID283169	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5258 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID1868122	Anti-tubercular activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth at 0.07 ug/ml incubated for 12 days by time-kill kinetics analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID522981	Antibacterial activity against Streptococcus pneumoniae isolate OC7189 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID559160	Antimicrobial activity against Clostridium difficile 630i harboring GyrB Asp26Val mutant gene selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID496650	Antibacterial activity against Streptococcus pneumoniae 3321 assessed as mutant prevention concentration by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID279838	Fraction unbound ligand in mouse plasma at 0.01 to 10 mg/litre	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID279285	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79F and gyrA S81F mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID580752	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID521333	fAUC (0 to 24 hrs) in CSF of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1264561	Antibacterial activity against Streptococcus pneumoniae 402 infected in sc dosed mouse assessed as reduction in 3 log CFU in lung compound administered as BID for 1 day measured 24 hrs after last dose	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1868117	Anti-tubercular activity against Mycobacterium tuberculosis CF76 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1909947	Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth measured after 8 days by Alamar blue reagent based broth microdilution method	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID728917	Antibacterial activity against Escherichia coli NIHJ after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID322775	Antimicrobial activity against Bacteroides ovatus isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID456050	Inhibition of Staphylococcus aureus wild type DNA gyrase	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID580903	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID572274	Antimicrobial activity against multiple drug-resistant Streptococcus pneumoniae ATCC 700677 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID528845	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID285961	Antimicrobial susceptibility against Haemophilus influenzae A4 isolate with GyrA Glu83Cys, ParC Ser84Arg and AcrR 97stop codon mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID428294	Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID1067077	Antimicrobial activity against Pseudomonas aeruginosa 2742 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID1297336	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-2 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID575009	Antimicrobial activity against Eubacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1398601	Antibacterial activity against levofloxacin and methicillin-resistant Staphylococcus aureus 870307 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID575078	Antimicrobial activity against Streptococcus pneumoniae serotype 35B assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID562463	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH37503	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID433582	Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1430295	Antibacterial activity against Enterococcus faecalis ATCC 29212 incubated after 24 hrs by resazurin dye based broth microdilution assay	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID278860	Antiproliferative effect against HeLa cells after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID508371	Antibacterial activity against Streptococcus pneumoniae harboring erm(A) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID1181168	Antimicrobial activity against first mutant generation Mycobacterium tuberculosis 1024_18 assessed as fold shift in MIC relative to parent strain	2014	Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID341065	Plasma concentration in human at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID580873	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID556193	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from apical to basolateral side by measuring compound level at 50 uM after 180 mins	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID532959	Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 3	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID433583	Selectivity index, ratio of CC25 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to CC25 for Mycobacterium leprae wild type DNA gyrase A2B2 by DNA cleavage assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID532021	Antimicrobial activity against Mycobacterium ulcerans ATCC 19423 harboring pTY60H containing pCK0601 carrying the luxAB gene under the hsp60 promoter after 14 days determined according to CFU counts by bioluminescence method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
AID428815	Ratio of AUC (0 to 24 hrs) in human at 400 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-23958	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID532967	Antimicrobial activity against quinolone-resistant Mycobacterium tuberculosis isolate 11	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID543399	Cmax in plasma in Listeria monocytogenes EGD-e infected BALB/c mouse central nervous system listeriosis model at 50 mg/kg, ip administered 36 hrs postinfection as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID521101	Antimicrobial activity against Streptococcus sp. 'group B' isolate 16 harboring gyrA Ser81Leu mutant, parC Ser79Tyr mutant and parE Ileu495Leu mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
AID581066	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID428292	Antimicrobial activity against Acinetobacter baumannii BM4579 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID1557279	Antibacterial activity against Escherichia coli by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID518624	Clearance in Mycobacterium avium infected human THP1 cell-based pharmacokinetic-pharmacodynamic modell by LC analysis	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID528970	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID544828	Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID1437922	Antibacterial activity against Enterococcus faecium ATCC 700221 by broth microdilution method	2017	Journal of natural products, 01-27, Volume: 80, Issue:1	Antibacterial and Cytotoxic Phenolic Metabolites from the Fruits of Amorpha fruticosa.
AID237458	Partition coefficient (logD7.4)	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID425342	Antibacterial activity against Streptococcus pneumoniae HMC 1149 harboring S81F and S79Y mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively showing efflux to ciprofloxacin, gemifloxacin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID425569	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA after 50 passages by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID395717	Antibacterial activity against Escherichia coli DH10B containing ORI23 promoter by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1380659	Terminal half life in CD1 mouse plasma at 10 mg/kg, iv by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
AID544302	Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS2 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544851	Antibacterial activity against Streptococcus pneumoniae R6 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1447481	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P259-96918 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1570249	Tmax in SPF ICR mouse at 100 mg/kg, sc	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID1297343	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 14-6 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID523176	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC11696 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1163998	Antibacterial activity against extended-spectrum beta-lactamase producin Klebsiella pneumoniae 12-14 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID581479	Total resistant organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID603879	Antitubercular activity against replicating Mycobacterium tuberculosis H37Rv ATCC 27294 after 1 week by microplate alamar blue assay	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.
AID1237402	Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID570705	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID581311	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1207500	Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) cells stable expressing hERG measured using IonWorks Barracuda automated patch clamp platform
AID508383	Antibacterial activity against Streptococcus pyogenes harboring mef(A) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID520373	Cardiotoxicity in patient with intracerebral and leptomeningeal tuberculosis assessed as QT prolongation at 400 mg/kg, po QID	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID372998	Antimycobacterial activity against Mycobacterium avium complex N016 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID556764	fAUC/MIC in osteomyelitis patient cortical bone at 400 mg, po administered for every 24 hrs at PKPD breakpoint at 1 mg/liter	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID558602	Antimicrobial activity against Streptococcus pneumoniae isolate 33 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID781329	pKa (acid-base dissociation constant) as determined by other workers	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1188156	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID428795	Ratio of AUC (0 to 24 hrs) in human at 400 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-23958	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID522998	Antibacterial activity against Streptococcus pneumoniae isolate OC6790 assessed as log reduction in bacterial growth at 4 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID279290	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC D83Y and gyrA E85K mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID341384	Concentration in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit serum at 20 mg/kg, iv administered every 12 hrs measured 12 hrs after third dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID580867	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID372980	Antimycobacterial activity against Mycobacterium avium complex N016 after 14 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID580879	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1380683	Antibacterial activity against Escherichia coli infected in cyclophosphamide treated neutropenic CD1 mouse septicemia model assessed as mouse survival at 3 mg/kg, iv dosed at 1 hr post infection followed by redosing at 5 hrs post infection measured at 96	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID544842	Antibacterial activity against Streptococcus pneumoniae U2A1413 harboring parC Ser79Tyr mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID553811	Induction of cytotoxin production in Clostridium difficile PCR ribotype 027 in three-stage chemostat gut model at 32 mg/liter	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID496648	Antibacterial activity against Streptococcus pneumoniae 1149 assessed as mutant prevention concentration by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID580749	Antimicrobial activity against toxin and capsule gene-deficient Bacillus anthracis Sterne after 24 hrs by macrobroth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID570807	Ratio of Half life in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose to Half life in healthy human at 400 mg, po qd measured on day 7	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID521102	Antimicrobial activity against Streptococcus sp. 'group B' isolate 9 harboring gyrA Ser81Leu mutant, parC Ser79Tyr mutant and parE Ileu495Leu mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
AID570900	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID245007	Antibacterial activity against Staphylococcus epidermidis 56500 was determined	2004	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
AID521339	Tmax in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID580886	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1237410	Antibacterial activity against Salmonella typhimurium 2421 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID1207406	Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells transfected with KCNQ1 / Kv1.7 / KvLQT1 and KCNE1/minK measured using IonWorks automated patch clamp platform
AID571380	Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID372983	Antimycobacterial activity against Mycobacterium avium complex after 14 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID558624	Antimicrobial activity against Streptococcus pneumoniae isolate 3455 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID580899	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID573573	Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID571113	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID558928	Antimicrobial activity against Clostridium difficile A422d selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1435842	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin reduction microplate assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.
AID559542	Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID570805	Ratio of Cmax in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose to Cmax in healthy human at 400 mg, po qd measured on day 5 post compound dose	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID584564	Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1348981	AUC (0 to infinity) in ICR mouse at 50 mg/kg, po by HPLC analysis
AID1676591	Binding affinity to Nickel cation assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1318936	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 84745	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID530346	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID728915	Antibacterial activity against Moraxella catarrhalis ATCC 25238 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID580751	Antimicrobial activity against toxin and capsule gene-deficient Bacillus anthracis Sterne after 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1067083	Antimicrobial activity against Staphylococcus aureus RN4220 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID1819093	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv clinical isolates 1 assessed as reduction in bacterial growth incubated for 7 days by resazurin dye based assay	2022	ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1	Structural Rigidification of
AID581064	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID523155	Antibacterial activity against Streptococcus pneumoniae isolate OC6610 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1243288	Antimicrobial activity against Streptococcus pyogenes ATCC 19615 by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID1256538	Antibacterial activity against ESBL-positive Klebsiella pneumoniae 14-18 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID1163986	Antibacterial activity against Escherichia coli ATCC 25922 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID558599	Antimicrobial activity against Streptococcus pneumoniae 11 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID580889	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1676593	Binding affinity to Gallium ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID571369	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID558600	Antimicrobial activity against Streptococcus pneumoniae 12 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID372996	Antimycobacterial activity against Mycobacterium avium complex N016 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1154546	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 Y314H mutant assessed as growth inhibition after 5 days by microdilution method	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID563214	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID608511	Antibacterial activity against Escherichia coli KD65	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
AID532962	Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 6	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID540216	Clearance in dog after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1570242	Selectivity index, ratio of CC50 for African green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID341062	AUC (0 to 24 hrs) in human at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID522938	Antibacterial activity against Streptococcus pneumoniae isolate OC6608 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID563059	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID562644	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH36742	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID323889	Antimicrobial activity against qnrA1 expressing Escherichia coli J53/pN5 GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID530386	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA S69V, A71G, E72D, T73V, M74I, N76K, A83S, S84A, I85V, F96W and P101M mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID556784	Ratio of drug level in cancellous bone to serum in osteomyelitis patient at 400 mg, po administered for every 24 hrs by by three stage hierarchical Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID571354	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1185146	Antimicrobial activity against moxicillin resistant Mycobacterium tuberculosis H37Rv ATCC 27294 containing DNA gyrase G88N mutant	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID559201	Antibacterial activity against Streptococcus pneumoniae S002 harboring parC Ser79Phe mutant and wild-type gyrA genes	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID1704241	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).
AID522990	Antibacterial activity against Streptococcus pneumoniae isolate OC5462 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID553688	Antimicrobial activity against Lactobacillus in three-stage chemostat gut model assessed as log reduction in bacterial count at 43 mg/liter administered daily for 7 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID1610997	Bactericidal activity against methicillin-resistant Staphylococcus aureus ATCC 700699 assessed as reduction in bacterial CFU at 4 times MIC measured for 30 mins	2019	Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23	The plant-derived chalcone Xanthoangelol targets the membrane of Gram-positive bacteria.
AID558699	Antimicrobial activity against Clostridium difficile A422 expressing tcdA and tcdB gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1294803	Antibacterial activity against quinolone-resistant Streptococcus pneumoniae TPS3 in rat respiratory tract infection model assessed as decrease in bacterial burden in lung at 100 mg/kg, po bid administered through gavage at 1, 7, 24,31 hrs post infection m	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.
AID575103	Antimicrobial activity against Streptococcus pneumoniae serotype 23A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID523307	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC4222 harboring gyrA S84L and parC S80F mutant gene assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1740326	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 9253 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID494413	Antimycobacterial activity against Mycobacterium phlei CMCC 93201 after 72 hrs by serial double dilution method	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives.
AID1447478	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1888650	Antibacterial activity against ciprofloxacin resistant Staphylococcus aureus harboring ParCS80F and GyrAS84L double mutant assessed as inhibition of bacterial growth	2022	Bioorganic & medicinal chemistry letters, 02-01, Volume: 57	Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
AID534771	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
AID556028	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from basolateral to apical side at 50 uM in presence of 3 uM P-gp inhibitor PSC-833	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID1398599	Antibacterial activity against Moraxella catarrhalis ATCC 25238 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID342063	Antimicrobial activity against nonepidemic Clostridium difficile J29 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID1297324	Antibacterial activity against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae 14-19 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID425559	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID695445	Antibacterial activity against fluoroquinolone resistant Staphylococcus aureus 4-FQR3M BSA643 expressing GyrA Ser84Leu mutant and GrlA Ser80Tyr and Glu84Gly mutant	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID572511	Antimicrobial activity against Salmonella enterica serovar Typhimurium isolate s2878 harboring wild type ParC gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID601789	Antibacterial activity against 10'4 CFU Klebsiella pneumoniae 09-22 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID1676596	Binding affinity to Ferric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID559398	Antimicrobial activity against Clostridium difficile 630E harboring GyrA Ala118Val mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID285964	Antimicrobial susceptibility against Haemophilus influenzae B2 isolate with GyrA Asp88Tyr and AcrR Leu31His mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID563046	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1398609	Apparent partition coefficient, log P of the compound in CHCL3/03.1 M phosphate buffer at pH 7.4	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID422661	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 15 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID529900	Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 9 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID1318963	Antibacterial activity against extremely drug-resistant Pseudomonas aeruginosa isolate 104354 infected in Galleria mellonella assessed as larvae survival at 50 mg/kg administered as single dose measured after 24 hrs (Rvb = 27 %)	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID523310	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC2838 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1430296	Antibacterial activity against Enterococcus faecalis ATCC 51299 incubated after 24 hrs by resazurin dye based broth microdilution assay	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID558604	Antimicrobial activity against Streptococcus pneumoniae isolate 1055 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID565327	Antibacterial activity against Mycoplasma genitalium M6151 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID521336	Cmax in CSF of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID559184	Antimicrobial activity against Clostridium difficile C253F selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID559527	Antibacterial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID520364	Half-life in CSF of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID425985	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 20 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID575946	Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae assessed as susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
AID528842	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID530598	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr10 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID633639	Antibacterial activity against Enterococcus faecium 09-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID580888	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID580878	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID544845	Antibacterial activity against Streptococcus pneumoniae U2A1681 harboring parC Ser79Tyr Asp83Ala mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1318935	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 83182	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID559243	Antibacterial activity against Streptococcus pneumoniae S004 harboring wild-type parC and gyrA Gly85Asn mutant genes assessed as mutation prevention concentration after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID574807	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 horboring rpoB S531L/Q510P, katG S315T/R463L, gyrA D94N/S95T, rrs G1484T by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID261741	Antibacterial activity against Salmonella Typhimurium ATCC 14028	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID556775	Volume of distribution in central compartment in osteomyelitis patient at 400 mg, po administered for every 24 hrs by MAP-Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID581081	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1494127	Antibacterial activity against tetracycline/methicillin-resistant Staphylococcus aureus XU212 after 16 hrs by microdilution method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID759327	Antibacterial activity against Staphylococcus aureus KCTC 209 after 24 hrs by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents.
AID581274	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID563219	Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID572514	Antimicrobial activity against Salmonella enterica serovar Corvallis isolate s2064 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID511402	Antibacterial activity against moxifloxacin resistant Neisseria gonorrhoeae isolates by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID523177	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC11696 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID581301	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1524624	Antibacterial activity against Escherichia coli KCTC 1924 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID1551293	Antibacterial activity against Streptococcus mutans KCTC3289 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID1601843	Antibacterial activity against Streptococcus pyogenes CMCC 32067 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID575081	Antimicrobial activity against Streptococcus pneumoniae serotype 6C assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID581294	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID261734	Antibacterial activity against Enterococcus faecium ATCC 49032	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID601792	Antibacterial activity against 10'4 CFU Pseudomonas aeruginosa 09-32 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID520369	Ratio of fAUC (0 to 24 hrs) in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg to MIC for Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID571836	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID425550	Antibacterial activity against penicillin-susceptible, quinolone-resistant Streptococcus pneumoniae 1072 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460V muta	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID262138	Inhibitory activity against wild type Staphylococcus aureus topoisomerase 4	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
AID593801	Antimicrobial activity against Bacillus thuringiensis var.kurstaki BGSC 4D1 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID581486	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID586651	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrA gene and pBK-QnrA1 assessed as mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1909946	Inhibition of Mycobacterium tuberculosis H37Rv DNA gyrase	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID372986	Antimycobacterial activity against Mycobacterium avium JATA51-01 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID1256551	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-1 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID563042	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID533638	Antimicrobial activity against Propionibacterium sp. assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID285958	Antimicrobial susceptibility against Haemophilus influenzae A1 isolate with GyrA Glu83Cys, ParC Ser84Arg and AcrR 97stop codon mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID425987	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 33 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID572516	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Montevideo isolate s2944 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID570699	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559519	Antibacterial activity against Streptococcus intermedius assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID285310	Susceptibility of drug-selected vancomycin-resistant Enterococcus species mutant by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID422688	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID601785	Antibacterial activity against 10'4 CFU Enterococcus faecium 08-2 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID279282	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with gyrA S81F mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID425979	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 49 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID341380	Antibacterial activity against Staphylococcus aureus infection-induced aortic valve endocarditis in rabbit assessed as reduction in bacterial burdens in blood culture at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 days after last dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID533134	Antimicrobial activity against Bacteroides fragilis assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID562935	Upregulation of slpA gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID698999	Tmax in human at 400 mg, po	2012	European journal of medicinal chemistry, May, Volume: 51	Tuberculosis: the drug development pipeline at a glance.
AID544835	Antibacterial activity against Streptococcus pneumoniae U2A1686 harboring gyrA Glu85Lys mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID520372	Ratio of fAUC (0 to 24 hrs) in CSF of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg to MIC for Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID531727	Antibacterial activity against Bacteroides vulgatus assessed as percent resistant isolates	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID562657	Ratio of AUC (0 to 24 hrs) to MIC required for 3-log drop in bacterial count in Staphylococcus aureus SMH37099	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID1330193	Antifungal activity against Candida albicans 7535 measured after 24 hrs by two-fold serial dilution method	2016	Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24	Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
AID558610	Antimicrobial activity against Streptococcus pneumoniae isolate 1424 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID496643	Antibacterial activity against Streptococcus pneumoniae 3321 by standard agar dilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
AID574973	Antimicrobial activity against Actinomyces israelii assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1330185	Antibacterial activity against Staphylococcus aureus 503 measured after 24 hrs by two-fold serial dilution method	2016	Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24	Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
AID425974	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1600114	Bactericidal activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID530391	Inhibition of Escherichia coli DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID581666	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID528968	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID206629	Antibacterial activity was determined against clinically isolated Levofloxacin-methicillin resistant Staphylococcus aureus (LVFX-r MRSA) strains (74 strains)	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1330189	Antibacterial activity against Escherichia coli 1924 measured after 24 hrs by two-fold serial dilution method	2016	Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24	Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
AID581292	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID422648	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID1297326	Antibacterial activity against Klebsiella pneumoniae 14-2 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID559496	Antibacterial activity against Propionibacterium acnes assessed as percent susceptible isolates by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1348985	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 3 days by rapid direct susceptibility test
AID529901	Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 10 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID633649	Antibacterial activity against Escherichia coli 09-3 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID425812	Half life in mouse	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID574983	Antimicrobial activity against Actinomyces naeslundii assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID530381	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1152758	Antimycobacterial activity against wild-type Mycobacterium tuberculosis H37Rv ATCC 27294 after 16 to 18 days by BACTEC 7H12B microdilution method	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID1743459	Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Ser-91-Pro mutant measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID430967	Antibacterial activity against Escherichia coli SKM18 containing gyrA L83, Y87 and parC L80, G84 mutants assessed as increase in MIC by Etest relative to MIC for Escherichia coli SKM9 containing gyrA L83, Y87 and parC L80 mutants	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
AID508381	Antibacterial activity against macrolide-susceptible Streptococcus pyogenes after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID1430291	Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated after 24 hrs by resazurin dye based broth microdilution assay	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID428797	Ratio of AUC (0 to 24 hrs) in human at 400 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-26137	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID508377	Antibacterial activity against macrolide-resistant Streptococcus pneumoniae harboring erm(B) gene after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID341395	Toxicity in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit assessed as calcification median score at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 days after last dose by histopathology	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID1888651	Antibacterial activity against Staphylococcus aureus harboring RpoBH481Y/ParCS80F/GyrAS84L triple mutant assessed as inhibition of bacterial growth	2022	Bioorganic & medicinal chemistry letters, 02-01, Volume: 57	Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
AID1319009	Selectivity ratio of MIC for Pseudomonas aeruginosa PAO1 to MIC for Pseudomonas aeruginosa PAO200	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID369970	Half life in Staphylococcus aureus infected rabbit arthritis model at 45 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID522992	Antibacterial activity against Streptococcus pneumoniae isolate OC7376 assessed as log reduction in bacterial growth at 2 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1256556	Antibacterial activity against methicillin-resistant Staphylococcus aureus 14-5 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID520376	Ratio of AUC (0 to 24 hrs) in plasma to CSF in patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QID	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID279258	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID586749	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrB gene and pBK-QnrB1 assessed as resistant colonies recovered one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID562658	Ratio of AUC (0 to 24 hrs) to MIC required for 3-log drop in bacterial count in Staphylococcus aureus SMH37312	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID261743	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID341389	AUC (0 to 12 hrs) in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit at 20 mg/kg, iv administered every 12 hrs measured after seventh dose in presence of Dexamethasone	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID1605834	In vivo antibacterial activity against Staphylococcus aureus ATCC 29213 infected in C57BL/6 mouse assessed as reduction in bacterial burden by measuring log10 CFU/cornea at 0.3% administered topically as two times on day 1, four times on day 2 and two tim	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin.
AID572269	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 49951 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID286096	fAUC/MIC ratio of Staphylococcus aureus BSP-2443 at 100 mg	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID562445	Antibacterial activity against Staphylococcus aureus SMH38004 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1676601	Binding affinity to Zinc ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID563012	Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID556025	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from apical to basolateral side at 50 uM in presence of in presence of 10 uM of p-glycoprotein and MRP transport inducer rifampin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID528840	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID572492	Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 infected in po dosed BALB/c mouse pneumonia model assessed as complete eradication of bacteria administered twice daily 3 days starting 16 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID406808	Antibacterial activity against Staphylococcus aureus ATCC 33591 isolate after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID544832	Antibacterial activity against Streptococcus pneumoniae R6 by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID565322	Antibacterial activity against Mycoplasma genitalium M6280 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID563342	Induction of Cwp84 protease expression in Clostridium difficile CD07-259 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID428768	Bactericidal activity against Streptococcus pneumoniae ATCC 49619 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID670862	Antitubercular activity against non-replicating Mycobacterium tuberculosis assessed as minimum concentration required to inhibit 90% growth after 10 days under anaerobic condition by luciferase-based low-oxygen recovery assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents.
AID633643	Antibacterial activity against Enterococcus faecium 09-6 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID559517	Antibacterial activity against Streptococcus bovis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID323885	Antimicrobial activity against Escherichia coli J53 GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID1297317	Antibacterial activity against Escherichia coli ATCC 25922 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID285534	Antibacterial activity against Staphylococcus aureus Mu50 at pH 5	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID529899	Antimicrobial activity against Leptospira weilii isolate 8 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID1570240	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv incubated for 7 days by rapid direct susceptibility test	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID570704	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID532978	Inhibition of DNA supercoiling activitysof Mycobacterium tuberculosis DNA gyrase subunit A A90V mutant	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID1524625	Antifungal activity against Candida albicans 7535 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID369230	Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae assessed as percent sensitive isolates by CLSI breakpoint method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
AID672349	Antibacterial activity against Staphylococcus aureus ATCC 29213	2012	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15	Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives.
AID1557312	AUC in human at 0.4 g, po by HPLC analysis	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID574043	Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID528967	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID544299	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu3 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID765270	AUC/MIC in Mycobacterium tuberculosis infected mouse	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID765268	T>MIC in Mycobacterium tuberculosis infected mouse	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID1723734	Oral bioavailability in human at 400 mg measured every 12 hrs	2020	Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20	Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
AID520370	Ratio of fAUC (0 to 24 hrs) in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg to MIC for Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID593802	Antimicrobial activity against Staphylococcus aureus ATCC 6538 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID428858	Bactericidal activity against Streptococcus pneumoniae isolate SR-23958 assessed as prevention of bacterial regrowth under condition simulating oral administration of 400 mg once daily after 72 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID563010	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID559393	Antimicrobial activity against Clostridium difficile 630C selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID558892	Antimicrobial activity against Clostridium difficile C253g harboring GyrA Ala118Ser mutant gene selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID581279	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID372992	Antimycobacterial activity against Mycobacterium intracellular JATA52-01 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last do	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID1297322	Antibacterial activity against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae 14-17 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID428295	Antimicrobial activity against Acinetobacter baumannii BM4579 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID283161	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2588 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID1877406	Antibacterial activity against Pseudomonas aeruginosa 142	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID342076	Effect on growth of nonepidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID283168	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5256 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID586725	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrS gene and pBK-QnrS1 assessed as mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID323896	Antimicrobial activity against Klebsiella pneumoniae C2/pMG252 GyrA Ser83Phe mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID1179480	Antimycobacterial activity against Mycobacterium marinum ATCC 927 in 7H9 medium after 5 days and 6 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.
AID528837	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID425581	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring I460V mutation in QRDR of ParE gene after 41 passages with gemifloxacin measured after 10 daily antibiotic-free s	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID261729	Antibacterial activity against Escherichia coli ATCC 25922	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID556187	P-glycoprotein-mediated transport in human Calu3 cells assessed as efflux ratio of permeability from apical to basolateral side over basolateral to apical side at 50 uM in presence of 10 uM of p-glycoprotein and MRP transport inducer rifampin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID575101	Antimicrobial activity against Streptococcus pneumoniae serotype 23B assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID425980	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID633647	Antibacterial activity against Escherichia coli 09-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID559379	Antimicrobial activity against Clostridium difficile A422D harboring GyrB Leu451Phe mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID571855	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559188	Antimicrobial activity against Clostridium difficile CD5A harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID425777	Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 after 22 passages by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1524628	Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID1524629	Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by microtiter ELISA	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
AID1664939	Antimalarial activity against CQ-resistant Plasmodium falciparum NF54-R assessed as inhibition of parasite growth	2020	ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7	Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity.
AID580877	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1256554	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-4 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID529894	Antimicrobial activity against Leptospira interrogans serovar Grippotyphosa isolate 2 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID428856	Bactericidal activity against Streptococcus pneumoniae isolate SR-26137 assessed as reduction in number of viable cells under condition simulating oral administration of 400 mg once daily	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID405457	Antibacterial activity against Escherichia coli C600Rif in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID1256540	Antibacterial activity against Klebsiella pneumoniae 14-1 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID498787	Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene at 10 ug by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID1256558	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-21 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID286158	Bactericidal activity against Staphylococcus aureus BSP-2443 with parC S52G, N91D mutation and gyrA S81Y mutation at fAUC/MIC of 16 after 96 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID561328	Antimicrobial activity against Klebsiella pneumoniae isolate 202 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID533408	Antimicrobial activity against Clostridium tertium assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID531860	Ratio of fAUC in patient with tuberculosis at 400 mg/day, po administered for 7 days to MIC for Mycobacterium tuberculosis	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
AID322774	Antimicrobial activity against Bacteroides distasonis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID456032	Antibacterial activity against Escherichia coli NIHJ after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID559189	Antimicrobial activity against Clostridium difficile CD5B harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID425579	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I46	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID544862	Antibacterial activity against Streptococcus pneumoniae U2A1693 harboring parC Asp83Asn mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID581304	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1152778	Antimycobacterial activity against moxifloxacin-resistant Mycobacterium tuberculosis harboring DNA gyraseA G88N mutant	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID1909945	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID1740321	Antimicrobial activity against Escherichia coli O157:H7 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID559515	Antibacterial activity against Streptococcus pyogenes assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1437921	Antibacterial activity against Enterococcus faecium ATCC 35667 by broth microdilution method	2017	Journal of natural products, 01-27, Volume: 80, Issue:1	Antibacterial and Cytotoxic Phenolic Metabolites from the Fruits of Amorpha fruticosa.
AID285299	Effect on 0.5 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID581313	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID285969	Antimicrobial susceptibility against Haemophilus influenzae D isolate with AcrR Leu31His, Ile121Val and Gln134Lys mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID728924	Antibacterial activity against Staphylococcus epidermidis 56500 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID581658	Cmax in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID573565	Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1318920	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 259-96918	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1194333	Inhibition of Mycobacterium tuberculosis GyrA/GyrB using relaxed pBR322 substrate incubated for 30 mins by ethidium bromide staining and electrophoresis based DNA supercoiling assay	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID1053500	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as parasite growth inhibition after 7 days by Alamar Blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
AID369981	Cmax in human serum at 400 mg, po administered as single dose	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID563007	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1330191	Antibacterial activity against Salmonella typhimurium 1926 measured after 24 hrs by two-fold serial dilution method	2016	Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24	Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties.
AID405463	Antibacterial activity against Escherichia coli TOP10 in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID1557314	Protein binding in human at 0.4 g, po by HPLC analysis	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID523135	Antibacterial activity against Streptococcus pneumoniae isolate OC6790 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1067081	Antimicrobial activity against Staphylococcus aureus 503 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID571125	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1676597	Binding affinity to cupric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID571383	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID405114	Antimicrobial activity against Vibrio splendidus 12B01 expressing plasmid-mediated QnrS-like quinolone resistance determinants	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID562621	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1750813	Antibacterial activity against Fluoroquinolone-sensitive Staphylococcus aureus ATCC 49951 assessed as reduction in bacterial growth by CLSI based broth microdilution method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID1877404	Antibacterial activity against Neisseria gonorrhoeae ATCC 19424	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID523157	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC8525 harboring wild type quinolone resistance-determining region by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID562625	Antimicrobial activity against Group A Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID285529	Antibacterial activity against ethidium bromide-resistant Staphylococcus aureus ATCC 29213 in presence of 20 ug/ml reserpine after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID279287	Antimicrobial activity agaisnt Streptococcus pneumoniae R6 transformants with parC S79F and gyrA E85K mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID322783	Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID66576	Antibacterial activity was determined against clinically isolated vancomycin-A resistant enterococci (VRE) strains (33 strains)	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1909952	Selectivity ratio of MIC50 for wild type Mycobacterium tuberculosis H37Rv to MIC50 for Mycobacterium tuberculosis H37Rv gyrA -FDASTetON-1 hypomorph	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID275451	Cytotoxicity against human Hep2 cell line after 72 hrs	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
AID581087	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID428786	Fraction unbound in human serum at 400 mg, po	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1242344	Antimycobacterial activity against 6-((1-(2-(7-chloro-2-oxo-1,8-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one resistant Mycobacterium tuberculosis H37Rv harboring DNA gyraseA A74V mutant incubated for 7 days	2015	ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7	Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.
AID574508	Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID529902	Antimicrobial activity against Leptospira interrogans serovar Pomona isolate 12 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID1877398	Antibacterial activity against Acinetobacter baumannii ATCC 19606	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID563338	Induction of Cwp84 protease expression in Clostridium difficile CD196 M1 at 0.5 times MIC by immunoblot analysis	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID425966	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID523144	Antibacterial activity against Streptococcus pneumoniae isolate OC7348 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1224811	CL/F in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID574806	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 horboring rpoB S531L/G566R/I569L, katG S315T/R463L, gyrA A90V/S95T, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID562828	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID522986	Antibacterial activity against Streptococcus pneumoniae isolate OC5462 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID565310	Antibacterial activity against Mycoplasma genitalium G37 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID528969	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID544838	Antibacterial activity against Streptococcus pneumoniae U2A1266 harboring gyrA Ser81Cys mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID420668	Inhibition of human ERG in MCF7 cells	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID565321	Antibacterial activity against Mycoplasma genitalium M6257 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID581078	Total sensitive organism counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID544840	Antibacterial activity against Streptococcus pneumoniae R6 Tr1 harboring parC Ser79Tyr mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID580869	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID369228	Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae assessed as percent resistant isolates by microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
AID559506	Antibacterial activity against Staphylococcus lugdunensis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1194334	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days by microplate alamar blue assay method	2015	Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9	Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
AID1611012	Induction of membrane integrity impairment in methicillin-resistant Staphylococcus aureus ATCC 700699 at 10 uM measured for 3 hrs by PI staining based fluorescence assay	2019	Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23	The plant-derived chalcone Xanthoangelol targets the membrane of Gram-positive bacteria.
AID577486	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 assessed as inhibition of bacterial biofilm formation by CLSI broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID556774	Apparent total clearance in osteomyelitis patient at 400 mg, po administered for every 24 hrs by three stage hierarchical Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID574754	Antimicrobial activity against Anaerococcus prevotii assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID565316	Antibacterial activity against Mycoplasma genitalium UTMB-10G by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID279278	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC D83Y mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID562825	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID285962	Antimicrobial susceptibility against Haemophilus influenzae B isolate with AcrR Leu31His mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID530350	Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID570987	Tmax in healthy human assessed as 25-desacetyl-rifapentine level at 900 mg, po administered as a single dose measured on day 5 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID1318905	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis isolate CAN-ICU 61589 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID581484	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID559409	Antimicrobial activity against Clostridium difficile BI2D harboring GyrB Glu466Lys mutant gene selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID563052	Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID570797	Volume of distribution in healthy human at 400 mg, po qd measured on day 4 by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID430968	Antibacterial activity against Escherichia coli 1608 containing gyrA L83 mutant assessed as increase in MIC by Etest relative to MIC for wild type Escherichia coli 1609	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
AID428794	Ratio of AUC (0 to 24 hrs) in human at 400 mg, po administered once daily to MIC for Streptococcus pneumoniae ATCC 49619	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID595857	Antibacterial activity against methicillin- and quinolone-resistant Staphylococcus aureus ATCC700699 after 24 hrs by microdilution method	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
AID283167	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5254 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID599556	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Facile transformation of Biginelli pyrimidin-2(1H)-ones to pyrimidines. In vitro evaluation as inhibitors of Mycobacterium tuberculosis and modulators of cytostatic activity.
AID1163990	Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli 12-14 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID1164016	Antibacterial activity against Streptococcus pneumoniae 12-18 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID1740330	Antifungal activity against Fusarium solani ATCC 36031 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID571107	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1152776	Antimycobacterial activity against 2-oxo-1-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)piperidin-1-yl)ethyl)-1,2-dihydroquinoline-7-carbonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA A74V mutant	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID1743439	Antitubercular activity against Mycobacterium tuberculosis H37Rv measured after 7 days by resazurin microtiter assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID279260	Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 1077 with 23S rRNA A2058G mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1188155	Antibacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID1237426	Bactericidal activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID581290	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID520377	Hepatotoxicity in patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID436986	Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
AID341386	AUC (0 to 12 hrs) in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit at 20 mg/kg, iv administered every 12 hrs measured after seventh dose	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID341073	AUC (0 to 24 hrs) in human with MDR1 3435 CC genotype at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg/kg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID1688199	Antimycobacterial activity against dormant form of Mycobacterium tuberculosis H37Rv assessed as log fold reduction in bacterial count at 10 ug/ml under nutrient starvation condition after 7 days by MPN assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity.
AID342067	Antimicrobial activity against fluoroquinolone-susceptible nonepidemic Clostridium difficile strain6 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID530378	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA M74I and A83S mutant/GyrB R447K mutant gene	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID570801	Half life in healthy human at 400 mg, po qd coadministered with 900 mg, po thrice weekly of rifapentine on day 5 post compound dose measured on day 19 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID1877401	Antibacterial activity against Escherichia coli ATCC 35218	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID1256553	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-3 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID1551296	Antifungal activity against Candida albicans 7535 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID425807	Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in CD-1 mouse lung	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID580898	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1399839	Antibacterial activity against Mycobacterium smegmatis ATCC 19420	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID571877	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1254072	Antibacterial activity against Escherichia coli CCARM 1356 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID558911	Antimicrobial activity against Clostridium difficile CD5h harboring GyrA Ala92Glu and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID388879	Protective effect against Staphylococcus aureus ATCC 13709-induced bone infection in CD rat at 10 mg/kg, iv administered as single dose 24 hrs after bacterial challenge	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
AID1750816	Lipophilicity, logD of compound in octanol and water at pH 7.4 incubated overnight by LC/UV/qTOF method	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID530369	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID532680	Antimicrobial activity against ciprofloxacin-nonsusceptible, AD PFGE pattern, emm1 type Streptococcus pyogenes with ST382 sequence type, ParC S79A mutant isolated from oropharyngeal colonization and onsillitis/pharyngitis	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID560260	Antimicrobial activity against Salmonella enterica serovar Typhimurium transconjugant p61/9T expressing qnrB19 gene variant carried by IncL/M-like plasmid by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium.
AID571839	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID424330	Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID558603	Antimicrobial activity against Streptococcus pneumoniae isolate 37 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1602935	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 3 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID208626	Antibacterial activity was determined against clinically isolated penicillin resistant Streptococcus pneumoniae (PRSP) strains (50 strains)	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID521151	Antibacterial activity against intracellular Listeria monocytogenes EGDe infected in bone marrow-derived BALB/c mouse macrophage assessed as reduction in bacterial count at four-eitght times of MIC after 3 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID425765	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID499680	Antimicrobial activity against Haemophilus influenzae ATCC 19418 after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID1551298	Antibacterial activity against Methicillin-resistant Staphylococcus aureus CCARM 3506 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-15, Volume: 172	Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents.
AID206650	Antibacterial activity was determined against clinically isolated Levofloxacin-methicillin resistant Staphylococcus aureus (LVFX-r MRSA) strains (74 strains)	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID581271	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID580860	Oral bioavailability in healthy human at 400 mg/kg, po	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID1514454	Antitubercular activity against d-cycloserine-resistant Mycobacterium tuberculosis after 7 days by resazurin dye based colorimetric assay	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID405118	Antimicrobial activity against Escherichia coli TOP10 harbouring pS1 plasmid expressing quinolone resistant QnrS1 gene	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID1224809	CL/F in CSF of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID529904	Antimicrobial activity against Leptospira interrogans serovar Canicola isolate 11 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID1430293	Antibacterial activity against Escherichia coli ATCC 25922 incubated after 24 hrs by resazurin dye based broth microdilution assay	2017	Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5	New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
AID1256548	Antibacterial activity against Pseudomonas aeruginosa 14-16 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID1740324	Antimicrobial activity against Pseudomonas aeruginosa ATCC 9627 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID425556	Antibacterial activity against quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 441 expressing ermB by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID573595	Antibacterial activity against Fusobacterium nucleatum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID558923	Antimicrobial activity against Clostridium difficile A422b selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID244721	Frequency of resistance emergence for methicillin resistant Staphylococcus aureus-33	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID522982	Antibacterial activity against Streptococcus pneumoniae isolate OC7189 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID563054	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID261731	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID323893	Antimicrobial activity against Escherichia coli J53/p1132 negative GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID633635	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 10-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID424328	Antimicrobial activity against Dialister invisus by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID1868116	Anti-tubercular activity against Mycobacterium tuberculosis CF61 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID530345	Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID428779	Ratio of mutant prevention concentration for Streptococcus pneumoniae isolate SR-26137 to MIC for Streptococcus pneumoniae isolate SR-26137	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1871982	Antimycobacterial activity against Mycobacterium tuberculosis	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
AID1652707	Induction of Escherichia coli K12 MG1655 lexA promotor measured at 30 mins interval for 20 hrs by fluorescence assay relative to control
AID405458	Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID601703	Antibacterial activity against 10'4 CFU Staphylococcus aureus ATCC 25923 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID285957	Antimicrobial susceptibility against Haemophilus influenzae A isolate with GyrA Glu83Cys and AcrR 97stop codon mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID275465	Antibacterial activity against methicillin-sensitive Staphylococcus aureus	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
AID575083	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID279289	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC D83Y and gyrA S81Y mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID570674	Antibacterial activity against Pseudomonas aeruginosa by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID523181	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC8530 harboring gyrA S84L and parC I143V mutant gene assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID494415	Antimycobacterial activity against Mycobacterium tuberculosis 09710 after 72 hrs by serial double dilution method	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives.
AID428855	Bactericidal activity against Streptococcus pneumoniae isolate SR-26134 assessed as reduction in number of viable cells under condition simulating oral administration of 400 mg once daily	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID563022	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID529895	Antimicrobial activity against Leptospira interrogans serovar Icterohaemorrhagiae isolate 3 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID581276	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID635056	Antibacterial activity against methicillin-resistant Staphylococcus aureus 10-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID286063	Half life at 400 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID1318937	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 85322	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID584566	Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID558916	Antimicrobial activity against Clostridium difficile CD5 2-g harboring GyrA Ala118Ser, Thr82Ala and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID580892	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID422645	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID558874	Antimicrobial activity against Clostridium difficile BI2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID571927	Ratio of MIC for Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene to MIC for Escherichia coli K-12 3-AG300	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID1075036	Bactericidal activity against Mycobacterium tuberculosis H37Rv assessed as log reduction of bacterial CFU at 1.2 ug/mL after 1 week	2014	Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4	Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.
AID523163	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC17042 harboring gyrA S84L/G106D, parC S80F and parE D732N mutant gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1297344	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-22 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID533400	Antimicrobial activity against Clostridium paraputrificum assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574496	Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID341388	Concentration in Staphylococcus aureus infection-induced aortic valve endocarditis rabbit serum at 20 mg/kg, iv administered every 12 hrs measured 12hrs after seventh dose in presence of Dexamethasone	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID1437917	Antibacterial activity against Staphylococcus aureus ATCC 25923 by broth microdilution method	2017	Journal of natural products, 01-27, Volume: 80, Issue:1	Antibacterial and Cytotoxic Phenolic Metabolites from the Fruits of Amorpha fruticosa.
AID1557282	Antibacterial activity against Bacteroides fragilis by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID279208	Antibacterial activity against Streptococcus pneumoniae 19 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID593799	Antimicrobial activity against Bacillus megaterium ATCC 19213 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID561320	Antimicrobial activity against Escherichia coli isolate 17 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID728910	Antibacterial activity against Chlamydophila pneumoniae CM-1 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID563031	Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID573574	Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID521831	Antimicrobial activity against Streptococcus pneumoniae isolated from meningitis patient assessed as percent resistant isolates by CLSI method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
AID528971	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1398614	Inhibition of CYP3A4 in human liver microsomes at 10 uM assessed as remaining activity by measuring 1'-hydroxylation of midazolam after 30 mins	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID261733	Cytotoxicity against Hep2 cell line	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID533396	Antimicrobial activity against Clostridium innocuum assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID558631	Antimicrobial activity against Streptococcus pneumoniae isolate 4755 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID559242	Antibacterial activity against Streptococcus pneumoniae S003 harboring wild-type parC and gyrA Ser81Phe mutant genes assessed as mutation prevention concentration after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID341078	Plasma concentration in human with MDR1 3435 CC or CT genotype at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg/kg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID581655	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID561329	Antimicrobial activity against azide-resistant Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID586738	Antibacterial activity against Escherichia coli ATCC 25922 assessed as earliest time required to resistant colonies visible one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID1318933	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 79199	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1691028	Antitubercular activity against 6-weeks nutrient starved phase cultures of Mycobacterium tuberculosis H37Rv assessed as log reduction in bacterial growth at 10 uM treated for 7 days measured after 4 weeks relative to control	2020	European journal of medicinal chemistry, May-01, Volume: 193	Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors.
AID695233	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID425762	Antibacterial activity against penicillin-, macrolide-susceptible and quinolone-resistant Streptococcus pneumoniae HMC 1074 harboring S81F, E85K mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID285963	Antimicrobial susceptibility against Haemophilus influenzae B1 isolate with GyrA Asp88Tyr and AcrR Leu31His mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID532958	Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 2	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID528978	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID584558	Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID279205	Antibacterial activity against Streptococcus pneumoniae 3665 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558625	Antimicrobial activity against Streptococcus pneumoniae isolate 3458 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID759324	Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by broth microdilution method	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents.
AID1179478	Antimycobacterial activity against Mycobacterium abscessus ATCC 19977 in 7H9 medium after 3 days and 4 hrs after adding resazurin dye/Tween 80 by Microplate Alamar Blue assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.
AID574756	Antimicrobial activity against Anaerococcus prevotii assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1685387	Potentiation of conjugate 12-induced antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as conjugate 12 MIC measured after 18 hrs by CLSI protocol based microbroth dilution method (Rvb = 64 to 128 ug/ml)	2019	MedChemComm, Apr-01, Volume: 10, Issue:4	Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria.
AID586750	Antibacterial activity against Escherichia coli ATCC 25922 expressing qnrS gene and pBK-QnrS1 assessed as resistant colonies recovered one step below mutant prevention concentration	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID207483	Antibacterial activity was determined against Staphylococcus aureus FDA 209-P strain after incubation at 37 degrees C for 18 h	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1819727	Antimycobacterial activity against Mycobacterium abscessus subsp. abscessus bamboo strain assessed as inhibition of mycobacterial growth incubated for 3 days by broth microdilution method	2022	ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3	Structure-Activity Relationship of Anti-
AID425346	Antibacterial activity against Streptococcus pneumoniae HMC 1066 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID558888	Antimicrobial activity against Clostridium difficile C253f selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID559504	Antibacterial activity against Staphylococcus haemolyticus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID562461	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH37312	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID574796	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID244891	Minimum inhibitory concentration against Escherichia coli ATCC 25922	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1163992	Antibacterial activity against Klebsiella pneumoniae 12-1 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID1067075	Antimicrobial activity against Salmonella typhimurium 2421 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID559513	Antibacterial activity against levofloxacin susceptible Streptococcus pneumoniae assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID581284	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1067072	Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolate 3167 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID279266	Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 3243 with L22 insertion 93SFRPRA94 mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID570928	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID499673	Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID518621	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 2% FBS	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID1254069	Antibacterial activity against Staphylococcus aureus 503 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID573600	Antibacterial activity against Fusobacterium mortiferum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID556349	Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae ATCC 15531 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
AID428807	Ratio of Cmax in human at 400 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-26137	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID286073	Half life at 800 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID563014	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID422659	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 29 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID428784	AUC (0 to 24 hrs) in human at 200 mg, po administered twice a day	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID573799	Antibacterial activity against Prevotella buccae assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID532682	Antimicrobial activity against ciprofloxacin-nonsusceptible, DX PFGE pattern, emm6 type Streptococcus pyogenes with ST382 sequence type, ParC S79A mutant isolated from oropharyngeal colonization	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID521338	Tmax in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID562447	Antibacterial activity against Staphylococcus aureus SMH36742 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID391986	Antibacterial activity against Staphylococcus aureus RN4220 by twofold dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
AID1909943	Kinetic solubility of compound at 200 uM incubated for 20 hrs by shake flask method based HPLC-DAD analysis	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID244924	Antibacterial activity against Streptococcus mitis IID685 was determined	2004	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
AID573797	Antibacterial activity against Prevotella intermedia assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID499672	Antimicrobial activity against Staphylococcus aureus ATCC 6538 after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID559521	Antibacterial activity against Streptococcus oralis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID532972	Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 16	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID428809	Ratio of Cmax in human at 80 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-26137	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID571342	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID593901	Inhibition of Escherichia coli DNA gyrase assessed as reduction of DNA supercoiling activity using pBR322 DNA substrate after 30 mins by electrophoresis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID285970	Antimicrobial susceptibility against Haemophilus influenzae D1 isolate with GyrA Ser84Tyr, ParC Glu88Lys and AcrR Leu31His, Ile121Val and Gln134Lys mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID559535	Antibacterial activity against Legionella pneumophila assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID390106	Binding affinity to bone assessed as drug level bound to cattle bone meal powder by fluorescence assay	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.
AID498192	Antibacterial activity against Stenotrophomonas maltophilia MBS100 deficient in Smqnr gene by epsilon test	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
AID562460	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH37099	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID1494126	Antibacterial activity against Staphylococcus aureus EMRSA-15 after 16 hrs by microdilution method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID279825	Cmax in BALB/c mouse at 6 to 400 mg/kg, po	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID261732	Inhibitory activity against Staphylococcus aureus ATCC 29213 wild type Topo 4	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID1254067	Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID368419	Antimicrobial activity against Escherichia coli KAM32 expressing deltaacrB ydhE hsd gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID425070	Antimicrobial activity against multidrug-resistant Escherichia coli M7943-TC2 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID558900	Antimicrobial activity against Clostridium difficile CD5c harboring GyrB Ser416Ala mutant gene selected after 2 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID428838	TMSW in Streptococcus pneumoniae isolate SR-26134 infected human at 80 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1877409	Antibacterial activity against Staphylococcus aureus ATCC 29213	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID523159	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC12501 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID529897	Antimicrobial activity against Leptospira interrogans serovar Pyrogenes isolate 5 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID558626	Antimicrobial activity against Streptococcus pneumoniae isolate 3481 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID571768	Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-I626M mutant gene	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID571867	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID558619	Antimicrobial activity against Streptococcus pneumoniae isolate 3275 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID571854	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID244877	Antibacterial activity against Escherichia coli NIHJ was determined	2004	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
AID278863	Increase in lactate production in primary human osteoblasts at 25 to 50 ug/ml by ELISA	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID670861	Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as minimum concentration required to inhibit 90% growth after 1 week by fluorescence-based microplate Alamar Blue assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents.
AID558598	Antimicrobial activity against Streptococcus pneumoniae 10 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1557285	Antibacterial activity against Streptococcus pneumoniae by agar diffusion method	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID558886	Antimicrobial activity against Clostridium difficile C253d selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID533384	Antimicrobial activity against Bacteroides nordii assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID571866	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID261740	Antibacterial activity against Stenotrophomonas maltophilia ATCC 13637	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID425766	Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I46	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID286150	Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 63 after 24 to 96 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1297333	Antibacterial activity against Pseudomonas aeruginosa 14-16 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID559502	Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID563027	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID575100	Antimicrobial activity against Streptococcus pneumoniae serotype 22F assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID571868	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559543	Antibacterial activity against levofloxacin susceptible Serratia marcescens assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1196884	Antimycobacterial activity against dormant Mycobacterium tuberculosis H37Rv model assessed as log reduction at 10 ug/ml incubated for 7 days measured after 28 days in presence of nutrient deprived condition	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors.
AID565330	Antibacterial activity against Mycoplasma genitalium M6284 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID559525	Antibacterial activity against Acinetobacter calcoaceticus assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID601788	Antibacterial activity against 10'4 CFU Escherichia coli 08-21 after 18 hrs by CLSI agar dilution method	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
AID1181170	Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_8.12 assessed as fold shift in MIC relative to parent strain	2014	Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID1398612	Metabolic stability in human microsomes at 1 uM assessed as compound remaining after 30 mins	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID574967	Antimicrobial activity against Actinomyces odontolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID428817	Ratio of AUC (0 to 24 hrs) in human at 400 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-26137	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID422687	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID530588	Antimicrobial activity against Escherichia coli TOP10 by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID558595	Antimicrobial activity against Streptococcus pneumoniae 7 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1655162	Bacteriostatic activity against Mycobacterium tuberculosis H37Rv assessed as reduction in bacterial growth at 0.07 ug/ml incubated for 3 to 4 weeks by time kill assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Improving the Potency of
AID237037	Dissociation constant (pKa) was determined	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID521332	fAUC (0 to 24 hrs) in CSF of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1437919	Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method	2017	Journal of natural products, 01-27, Volume: 80, Issue:1	Antibacterial and Cytotoxic Phenolic Metabolites from the Fruits of Amorpha fruticosa.
AID283160	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2554 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID1585701	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 09710 by rapid direct susceptibility test	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Fluoroquinolone-isatin hybrids and their biological activities.
AID428843	Time above the mutant prevention concentration in Streptococcus pneumoniae ATCC 49619 infected human at 400 mg, po administered once daily after 24 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID574744	Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID278596	Inhibitory activity against Klebsiella pneumoniae 12-1183	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID499675	Antimicrobial activity against quinolone and penicillin-resistant Staphylococcus epidermidis SER after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID520378	Hepatotoxicity in patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID559404	Antimicrobial activity against Clostridium difficile BI2B selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID586732	Ratio of mutant prevention concentration to MIC for Escherichia coli ATCC 25922 expressing qnrB gene and pBK-QnrB1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
AID425551	Antibacterial activity against penicillin-, macrolide- and quinolone-susceptible Streptococcus pneumoniae HMC 63 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1602936	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 4 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID515918	Antibacterial activity against isoniazid-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay	2010	Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20	Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID581065	Hill constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID508385	Antibacterial activity against Streptococcus pyogenes harboring mutation in L4 ribosomal protein after overnight incubation by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
AID581092	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1297329	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1318904	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis isolate CANWARD-2008 81388 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1297346	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-39 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID581275	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID695444	Antibacterial activity against fluoroquinolone resistant Staphylococcus aureus 3-FQR3M ATCC 700699 expressing GyrA Ser84Leu mutant and Glu409Lys mutant and GrlA Ser80Phe mutant	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID69933	Antibacterial activity was determined against Escherichia coli NIHJ strain after incubation at 37 degrees C for 18 h	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID1607522	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in C57BL/6J mouse assessed as reduction in bacterial burden in lung at 100 mg/kg, po administered once daily for 4 consecutive days starting from 5 days post infection and measur	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
AID633641	Antibacterial activity against Enterococcus faecium 09-4 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID341378	Antibacterial activity against Staphylococcus aureus infection-induced aortic valve endocarditis in rabbit assessed as reduction in bacterial burdens in blood culture at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 hrs after end of trea	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID515919	Antibacterial activity against streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay	2010	Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20	Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID580908	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1877399	Antibacterial activity against Acinetobacter baumannii 139	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID563053	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID574780	Antimicrobial activity against Clostridium difficile assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID570921	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1676590	Binding affinity to Nickel cation assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1877411	Antibacterial activity against Neisseria gonorrhoeae WHO K	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID574808	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 horboring rpoB S531L, katG R463L/E217G, gyrA D94N/S95T, rrs A1401G by CLSI method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID1676598	Binding affinity to cupric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID574971	Antimicrobial activity against Actinomyces israelii assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID698998	AUC in human at 400 mg, po	2012	European journal of medicinal chemistry, May, Volume: 51	Tuberculosis: the drug development pipeline at a glance.
AID1380668	Oral bioavailability in CD1 mouse plasma by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID570685	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID577482	fCmax in Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model at 400 mg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID530388	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB N464S mutant gene assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1740331	Antifungal activity against Stachybotrys chartarum IBT 7711 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID428777	Ratio of mutant prevention concentration for Streptococcus pneumoniae isolate SR-23958 to MIC for Streptococcus pneumoniae isolate SR-23958	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID428770	Bactericidal activity against Streptococcus pneumoniae isolate SR-26134 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID571142	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID368423	Antimicrobial activity against Escherichia coli KAM32 pSTVdeltaqepA containing disrupted qepA gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
AID1126763	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 1259 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID523140	Antibacterial activity against Streptococcus pneumoniae isolate OC7368 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID372981	Antimycobacterial activity against Mycobacterium avium complex N018 after 14 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID633636	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 10-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID285297	Effect on 0.03 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID580901	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID262133	Antimicrobial activity against Escherichia coli ATCC 25922	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
AID405469	Antibacterial activity against Escherichia coli TOP10 containing pAT851 in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID1318938	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID341086	Half life in human with MDR1 3435 CC or CT genotype at 400 mg, po once daily after 14 days coadministered with rifampin at 600 mg/kg, po once daily	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID66893	Antibacterial activity was evaluated against Enterococcus faecalis	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID530349	Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID1348980	Tmax in ICR mouse at 50 mg/kg, po by HPLC analysis
AID324745	Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID1237417	Fungicidal activity against Candida albicans 7535 after 24 hrs by agar plate method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID1380666	Volume of distribution at steady state in CD1 mouse plasma at 10 mg/kg, iv by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
AID558905	Antimicrobial activity against Clostridium difficile CD5e harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID563330	Upregulation of cwp84 gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID728912	Antibacterial activity against Mycoplasma pneumoniae ATCC 29085 after 18 hrs by microbroth dilution method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID285292	Effect on 0.5 ug/ml sitafloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID572521	Antimicrobial activity against qnrS-positive Salmonella enterica serovar Montevideo isolate s2209 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID593800	Antimicrobial activity against Bacillus subtilis ATCC 6633 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID571141	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID425802	Drug level in CD-1 mouse serum at 75 ug/ml administered through gavage after 24 hrs	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID1868114	Selectivity index, ratio of IC50 for cytotoxicity against human MRC5 cells to MIC90 for anti-tubercular activity against Mycobacterium tuberculosis H37Rv	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID279288	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC D83Y and gyrA S81F mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID573597	Antibacterial activity against Fusobacterium necrophorum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID556767	fAUC/MIC in osteomyelitis patient serum at 400 mg, po administered for every 24 hrs at PKPD breakpoint at 0.375 mg/liter	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID1391317	Antibacterial activity against Pseudomonas aeruginosa 2742 after 24 hrs by two-fold serial dilution method	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives.
AID1163987	Antibacterial activity against Escherichia coli 12-1 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID577481	Half life in Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model at 400 mg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID563009	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1181172	Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_16.6 assessed as fold shift in MIC relative to parent strain	2014	Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID562453	Ratio of AUC (0 to 24 hrs) to MIC required for 24 hrs bacteriostatic effect in Staphylococcus aureus SMH37503	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID581299	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1316919	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell proliferation at 50 ug/ml after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues endowed with high activity toward non-replicative Mycobacterium tuberculosis.
AID562631	Antimicrobial activity against Group G Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID633633	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 10-6 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID1494121	Antibacterial activity against Bacillus subtilis NCTC 10400 after 16 hrs by microdilution method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID341382	Antibacterial activity against Staphylococcus aureus infection-induced aortic valve endocarditis in rabbit assessed as reduction in bacterial burdens in heart valve tissue culture at 20 mg/kg, iv administered every 12 hrs for 5 days sacrificed 12 days aft	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
AID544864	Antibacterial activity against Streptococcus pneumoniae U2A1681 harboring parC Ser79Tyr Asp83Ala mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID523309	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate OC2838 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID425071	Antimicrobial activity against Escherichia coli J53-AzR in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID565311	Antibacterial activity against Mycoplasma genitalium M30 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID563034	Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID498780	Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID571338	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID286095	fAUC/MIC ratio of Staphylococcus aureus BSP-2443 at 75 mg	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID373003	Antimycobacterial activity against Mycobacterium avium complex N018 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID1185138	Inhibition of Mycobacterium tuberculosis H37Rv DNA gyrase A2B2 holoenzyme supercoiling activity using relaxed pBR322 substrate incubated for 90 mins by ethidium bromide staining based gel electrophoresis method	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.
AID405465	Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID1256542	Antibacterial activity against Klebsiella pneumoniae 14-3 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID532971	Antimicrobial activity against isoniazid-resistant Mycobacterium tuberculosis isolate 15	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID570703	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID574506	Antimicrobial activity against Bacteroides distasonis assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID543392	Antibacterial activity against Listeria monocytogenes EGD-e in BALB/c mouse central nervous system listeriosis model assessed as increase in mouse survival at 50 mg/kg, ip administered 36 hrs postinfection every 12 hrs for 5 days	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID1237406	Antibacterial activity against Escherichia coli KCTC 1924 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID285305	Effect on 2 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID1196886	Cytotoxicity against mouse RAW264.7 cells at 50 uM after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors.
AID570901	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559511	Antibacterial activity against Lancefield Streptococcus sp. group F assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID245029	Minimum inhibitory concentration against Staphylococcus haemolyticus ATCC 29970	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID595934	Inhibition of Staphylococcus aureus DNA gyrase Ser84Leu mutant assessed as inhibition of supercoiling of pBR322 DNA after 60 min by gel electrophoresis assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
AID322792	Antimicrobial activity against Bacteroides stercoris assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID559373	Antimicrobial activity against Clostridium difficile A422A selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID559544	Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498785	Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID285282	Effect on 16 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID521331	fAUC (0 to 24 hrs) in plasma of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1318929	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86079	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID543400	Ratio of AUC (24 hrs) in plasma in Listeria monocytogenes EGD-e infected BALB/c mouse to MIC for Listeria monocytogenes EGD-e	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID633741	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID372991	Antimycobacterial activity against Mycobacterium intracellular JATA52-01 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dos	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
AID570932	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID521142	Antibacterial activity against extracellular Listeria monocytogenes EGDe at MIC by time-kill study	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID633645	Antibacterial activity against Enterococcus faecalis 09-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID279251	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 24 with GyrA S81Y, GyrB P413S and ParC S79F mutation after 50 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID571857	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID244972	Minimum inhibitory concentration against Streptococcus pyogenes ATCC 19615	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID532970	Antimicrobial activity against pansusceptible Mycobacterium tuberculosis isolate 14	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID543395	Antibacterial activity against Listeria monocytogenes EGD-e in BALB/c mouse central nervous system listeriosis model assessed as reduction in bacterial count in spleen at 50 mg/kg, ip administered 36 hrs postinfection as single dose measured within 1 hr	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
AID562826	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID529898	Antimicrobial activity against Leptospira weilii isolate 6 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
AID580910	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID279257	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID563017	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1514450	Antitubercular activity against streptomycin-resistant Mycobacterium tuberculosis after 7 days by resazurin dye based colorimetric assay	2019	Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1	Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID533634	Antimicrobial activity against Propionibacterium acnes assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID633634	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 10-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID531859	Antimicrobial activity against Mycobacterium tuberculosis infected in patient at 400 mg/day, po administered for 7 days by HPLC	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
AID428829	Ratio of Cmax in human at 80 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-26137	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID581091	Resistant spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID563218	Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID577480	AUC (0 to 24 hrs) in Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model at 400 mg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID559522	Antibacterial activity against Streptococcus salivarius assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID633646	Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID1188153	Inhibition of 6-His-tagged Mycobacterium smegmatis GyrB expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 100 mins in presence of ATP by malachite green dye based ATP assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
AID556024	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from apical to basolateral side at 50 uM in presence of 100 uM of MRP inhibitor Probenecid	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID499773	Inhibition of Escherichia coli DNA topoisomerase-4-mediated decatenation of pBR322 by electrophoresis	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID209591	Antibacterial activity was determined against Streptococcus mitis IID685 strain after incubation at 37 degrees C for 18 h	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID369971	Ratio of AUC (0 to 24 hrs) in Staphylococcus aureus infected rabbit arthritis model at 45 mg/kg, po to MIC for methicillin-sensitive Staphylococcus aureus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID1126760	Antibacterial activity against multidrug-resistant 1 ug/ml Mycobacterium tuberculosis clinical isolate 930 assessed as growth inhibition after 7 days by microtiter plate assay	2014	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8	Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
AID533126	Antimicrobial activity against Bacteroides caccae assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID544852	Antibacterial activity against Streptococcus pneumoniae CP1000 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID521337	Cmax in CSF of patient with intracerebral and leptomeningeal tuberculosis at 800 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID1877412	Antibacterial activity against Neisseria gonorrhoeae WHO G	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID1601846	Antibacterial activity against Bacillus subtilis CMCC 63501 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID1297334	Antibacterial activity against Pseudomonas aeruginosa 14-19 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1237425	Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety.
AID1600098	Bactericidal activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID580755	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1877419	Antibacterial activity against Neisseria gonorrhoeae WHO B	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
AID279283	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79Y and gyrA S81F mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID237034	Dissociation constant (pKa) was determined	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID562615	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID695451	Inhibition of human ERG expressed in mammalian cells by patch clamp method	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
AID520103	Antimicrobial activity against Mycobacterium tuberculosis Erdman injected into gamma interferon gene knockout C57BL/6 mouse assessed as bacterial load in spleen of mouse at 300 mg/kg measured 9 days post drug treatment	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
AID279262	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3665 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID553810	Induction of cytotoxin production in Clostridium difficile PCR ribotype 027 in three-stage chemostat gut model at 43 mg/liter administered daily for 7 days measured after 2 days	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
AID593803	Antimicrobial activity against quinilone-pencillin-resistant Staphylococcus aureus isolate SAR 72 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID262137	Inhibitory activity against wild type Escherichia coli gyrase	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
AID285287	Effect on 1 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID261736	Antibacterial activity against Streptococcus pyogenes ATCC 19615	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID575003	Antimicrobial activity against Eubacterium lentum assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID286064	Half life at 50 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID573795	Antibacterial activity against Prevotella buccae assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1600096	Bactericidal activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID342065	Antimicrobial activity against epidemic Clostridium difficile BI6-8-17 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID522991	Antibacterial activity against Streptococcus pneumoniae isolate OC7376 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1297349	Antibacterial activity against Enterococcus faecium 14-2 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID522988	Antibacterial activity against Streptococcus pneumoniae isolate OC5462 assessed as log reduction in bacterial growth at 4 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID1740322	Antimicrobial activity against fluoroquinolone-resistant Escherichia coli assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID342072	Effect on growth of nonepidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID580884	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID405120	Antimicrobial activity against Escherichia coli TOP10 harbouring p0 plasmid expressing pCR-BluntII-TOPO	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
AID563228	Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID559495	Antibacterial activity against Prevotella sp. assessed as percent susceptible isolates by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID562933	Upregulation of slpA gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID580885	Clearance in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID279823	Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 14	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
AID523145	Antibacterial activity against Streptococcus pneumoniae isolate OC7348 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID531514	Antibacterial activity against Bacteroides ovatus assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID532683	Antimicrobial activity against ciprofloxacin-nonsusceptible, DY PFGE pattern, emm6 type Streptococcus pyogenes with ST382 sequence type, ParC S79A mutant isolated from oropharyngeal colonization	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
AID1152759	Inhibition of Mycobacterium tuberculosis H37Rv DNA gyrase holoenzyme-mediated supercoiling of pBR322 DNA after 90 mins by agarose gel electrophoresis	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
AID283164	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2640 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID580912	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID574498	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID286151	Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 114 after 24 to 96 hrs in pharmacodynamic model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID1398594	Antibacterial activity against Enterococcus faecalis ATCC 19433 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID1557311	Cmax in human at 0.4 g, po by HPLC analysis	2019	MedChemComm, Oct-01, Volume: 10, Issue:10	Quinolone antibiotics.
AID565313	Antibacterial activity against Mycoplasma genitalium TW10-5G by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID573835	Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID523149	Antibacterial activity against Streptococcus pneumoniae isolate OC6585 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID369229	Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae assessed as percent resistant isolates by CLSI breakpoint method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
AID559493	Antibacterial activity against Fusobacterium sp. assessed as percent susceptible isolates by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559494	Antibacterial activity against Peptostreptococcus sp. assessed as percent susceptible isolates by CLSI M11-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID285536	Effect on cellular viability of methicillin-resistant Staphylococcus aureus Mu50 at 10 times MIC by measuring the time required for recovery at 10 times MIC after 1 hr	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID1256561	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-39 after 18 to 24 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
AID1348988	Selectivity index, ratio of CC50 against African green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv
AID425343	Antibacterial activity against Streptococcus pneumoniae HMC 1151 harboring D83N, K137N mutation in quinolone-resistant determining regions of ParC gene and I460V mutation in QRDR of ParE gene showing efflux to ciprofloxacin, gemifloxacin by agar dilution	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID573596	Antibacterial activity against Fusobacterium mortiferum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1676594	Binding affinity to gallium ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID523137	Antibacterial activity against Streptococcus pneumoniae isolate OC7368 assessed as log reduction in bacterial growth at 2 times MIC measured at 6 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID570890	Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID562827	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID562943	Upregulation of slpA gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
AID558616	Antimicrobial activity against Streptococcus pneumoniae isolate 2880 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID581280	Concentrations at which the kill rate is half-maximal for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID593807	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID532974	Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 18	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID572273	Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID558608	Antimicrobial activity against Streptococcus pneumoniae isolate 1394 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID593810	Antimicrobial activity against quinilone-pencillin-resistant Escherichia coli clinical isolate by broth dilution method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
AID1207666	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	2012	Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1570243	Inhibition of Mycobacterium tuberculosis DNA gyrase	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID559239	Antibacterial activity against Streptococcus pneumoniae W002 harboring wild-type parC and gyrA genes assessed as mutation prevention concentration after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID728904	Chloroform-phosphate buffer apparent partition coefficient of the compound, log P at pH 7.4	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
AID1468617	Antibacterial activity against Staphylococcus aureus ATCC 29213 infected in C57BL6 mouse cornea assessed as decrease in conjunctival chemosis at 0.3% administered tropically 2 times on day 1, 4 times on day 2 and 2 times on day 3 starting from 6 hrs post	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo.
AID278862	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA at 10 ug/ml after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID245205	Minimum inhibitory concentration against vancomycin intermediate Staphylococcus aureus MU 3	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID261735	Antibacterial activity against Enterococcus faecalis ATCC 29212	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
AID428798	Ratio of AUC (0 to 24 hrs) in human at 80 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-26134	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID559503	Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID342081	Effect on growth of nonepidemic Clostridium difficile J29 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.4 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID562459	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH36633	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID577498	Bactericidal activity against Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in biofilm bacterial count at 400 mg every 24 hrs measured after 72 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID425814	AUC (0 to 24 hrs)/MIC in Mycobacterium tuberculosis H37Rv infected in CD-1 mouse	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID556032	P-glycoprotein-mediated transport in human Calu3 cells assessed as efflux ratio of permeability from apical to basolateral side over basolateral to apical side at 50 uM in presence of 100 uM of p-glycoprotein and MRP inhibitor verapamil	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID531518	Antibacterial activity against Bacteroides uniformis assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID285159	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID544831	Antibacterial activity against Streptococcus pneumoniae CIP104485 by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID633740	Antibacterial activity against Klebsiella pneumoniae 10-3 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID285278	Susceptibility of penicillin-resistant Streptococcus pneumoniae 335 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID425983	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID342075	Effect on growth of epidemic Clostridium difficile BI6-8-17 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID581096	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 150 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1318921	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 260-97103	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1602934	Antibacterial activity against drug-resistant Mycobacterium tuberculosis isolate 2 after 7 days by resazurin microtiter assay	2019	Bioorganic & medicinal chemistry letters, 04-15, Volume: 29, Issue:8	Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
AID521149	Antibacterial activity against intracellular Listeria monocytogenes EGDe infected in bone marrow-derived BALB/c mouse macrophage assessed as reduction in the formation of filopodium-like projections at >= MIC after 48 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID670863	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents.
AID285960	Antimicrobial susceptibility against Haemophilus influenzae A3 isolate with GyrA Glu83Cys, ParC Ser84Arg and AcrR 97stop codon mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID521146	Antibacterial activity against extracellular Listeria monocytogenes EGDe assessed as reduction in bacterial count at four times of MIC after 24 hrs by time-kill study	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID580871	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID633735	Antibacterial activity against Escherichia coli 10-1 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID1652709	Induction of Escherichia coli K12 MG1655 sulA promotor measured at 30 mins interval for 20 hrs by fluorescence assay relative to control
AID574583	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID422651	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 26 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID533416	Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID563019	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID563211	Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene assessed as microbial susceptibility and deletion of codons 678 and 679 in gyrB mutant gene assessed as microbial susceptibility by agar proportion m	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1398615	Cmax in Crj:CD rat at 5 mg/kg, po	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID571842	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID278598	Inhibitory activity against Klebsiella pneumoniae 35	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID425989	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 20 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID559142	Antimicrobial activity against Clostridium difficile A422i harboring GyrA Asp81Asn mutant gene selected after 8 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1593371	Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in Mycobacterium tuberculosis H37Rv assessed as reduction in bacterial growth by microplate alamar blue assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
AID425570	Antibacterial activity against penicillin-susceptible, quinolone-resistant Streptococcus pneumoniae HMC 1072 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460V	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID456047	Inhibition of Staphylococcus aureus wild type DNA topoisomerase 4	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID581286	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 100 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID244722	Frequency of resistance emergence for methicillin resistant Staphylococcus aureus-5023	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1154542	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 5 days by microdilution method	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID425356	Antibacterial activity against Streptococcus pneumoniae HMC 1059 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460N mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID275467	Cytotoxicity against human HepG2 cells after 72 hrs	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
AID571852	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1252463	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition incubated for 7 days by microplate alamar blue assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
AID521143	Antibacterial activity against extracellular Listeria monocytogenes EGDe at four times of MIC by time-kill study	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID530384	Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I mutant assessed as concentration required for inducing cleavage	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID558593	Antimicrobial activity against Streptococcus pneumoniae 5 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID608512	Antibacterial activity against tolC knockout Escherichia coli KD1397	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
AID279255	Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID430966	Antibacterial activity against Escherichia coli SKM9 containing gyrA L83, Y87 and parC L80 mutants assessed as increase in MIC by Etest relative to MIC for Escherichia coli 1596 containing gyrA L83 and parC I80 mutants	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
AID571875	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID556194	P-glycoprotein-mediated transport in human Calu3 cells expressing P-glycoprotein assessed as maximum apparent permeability from basolateral to apical side by measuring compound level at 50 uM after 180 mins	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.
AID521148	Antibacterial activity against extracellular Listeria monocytogenes EGDe assessed as reduction in bacterial count at eight times of MIC after 24 hrs by time-kill study	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
AID575948	Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
AID544298	Antibacterial activity against vancomycin-susceptible methicillin-resistant Staphylococcus aureus 34 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID531515	Antibacterial activity against Bacteroides distasonis assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1743454	Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in human macrophages assessed as intracellular bacterial load at 2 times MIC measured after 6 days (Rvb = 5.57 to 6.43 logCFU/ml)	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID285309	Susceptibility of vancomycin-resistant Enterococcus species single-step mutant by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID428293	Antimicrobial activity against Acinetobacter baumannii BM4651 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID522989	Antibacterial activity against Streptococcus pneumoniae isolate OC5462 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID279203	Antibacterial activity against Streptococcus pneumoniae 1076 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID562655	Ratio of AUC (0 to 24 hrs) to MIC required for 2-log drop in bacterial count in Staphylococcus aureus SMH36945	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID369976	Antibacterial activity against methicillin-resistant Staphylococcus aureus infected rabbit arthritis model assessed as change in bacterial load per gram of synovial fluid at 45 mg/kg, po after 7 days by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.
AID416844	Antimycobacterial activity against Mycobacterium ulcerans isolate CU001 infected in BALB/c mouse left hind foot-pad assessed as bacterial load at 100 mg/kg, po administered for 5 days per week measured after 4 weeks	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
AID1435843	Antimycobacterial activity against Mycobacterium tuberculosis PE-003 clinical isolate after 7 days by resazurin reduction microplate assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.
AID570916	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID562629	Antimicrobial activity against Group C Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID523297	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in B6 mouse assessed as assessed as lowest concentration to reduce bacterial burden in lungs to level of reduction achieved with higher doses orally treated in water-20% captisol	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
AID406656	Antibacterial activity against Staphylococcus aureus ACH-0203 isolate with gyrA Ser84Leu and grlA Ser80Phe, Ala116Val mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID1207530	Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay
AID563030	Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID515917	Antibacterial activity against rifampicin-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay	2010	Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20	Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID580891	Growth rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1600112	Bactericidal activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
AID425806	Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in CD-1 mouse lung after 1 day after 2nd successive aerosol infection run	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID563049	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID581094	Virtual volume of the central compartment in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID523139	Antibacterial activity against Streptococcus pneumoniae isolate OC7368 assessed as log reduction in bacterial growth at 2 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID425576	Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 harboring S79Y mutation in quinolone-resistant determining regions of ParC gene after 34 passages with gemifloxacin measured afte	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID580765	Concentrations at which the kill rate is half-maximal for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered for every 24 hrs	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID595853	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 after 24 hrs by microdilution method	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
AID406809	Antibacterial activity against Staphylococcus aureus NY2746 isolate with gyrA Ser84Leu and grlA Ser80Phe mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID1243293	Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID1264562	Dose-normalized AUC in mouse at 2 mg/kg, iv by LC-MS/MS analysis	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID285161	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID518632	Volume of distribution in human by LC analysis	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID563056	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID1297338	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-4 after 18 to 24 hrs by CLSI M100-S11 method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
AID1319005	Induction of cytoplasmic membrane depolarization in Pseudomonas aeruginosa PAO1 at 1 ug/ml by DiSC3(5) dye based fluorescence assay	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID574790	Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
AID765271	fAUC/MIC in Mycobacterium tuberculosis infected mouse	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID425546	Antibacterial activity against Streptococcus pneumoniae HMC 2536 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1888652	Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth	2022	Bioorganic & medicinal chemistry letters, 02-01, Volume: 57	Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
AID1890602	Antibacterial activity against beta-lactams, macrolide and fluoroquinolone resistant Streptococcus pneumoniae 718 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method	2022	Bioorganic & medicinal chemistry letters, 05-01, Volume: 63	WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID561319	Antimicrobial activity against Escherichia coli isolate 17 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID324747	Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID565319	Antibacterial activity against Mycoplasma genitalium M2321 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID581482	Total spore counts of toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 50 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1743455	Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in human macrophages assessed as intracellular bacterial load at 4 times MIC measured after 6 days (Rvb = 5.57 to 6.43 logCFU/ml)	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
AID456031	Antibacterial activity against Enterococcus faecalis ATCC 19433 after 18 hrs by twofold microbroth dilution method	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
AID544839	Antibacterial activity against Streptococcus pneumoniae H548 clinical isolate harboring gyrA Ser81Phe mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1652706	Induction of Escherichia coli K12 MG1655 recA promotor measured at 30 mins interval for 20 hrs by fluorescence assay relative to control
AID428796	Ratio of AUC (0 to 24 hrs) in human at 400 mg, po administered once daily to MIC for Streptococcus pneumoniae isolate SR-26134	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID531510	Antibacterial activity against Bacteroides stercoris assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID520361	Half-life in plasma of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID518056	Toxicity in healthy human assessed as nausea at 400 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
AID699001	Bioavailability in human	2012	European journal of medicinal chemistry, May, Volume: 51	Tuberculosis: the drug development pipeline at a glance.
AID574979	Antimicrobial activity against Actinomyces meyeri assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID633736	Antibacterial activity against Escherichia coli 10-2 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID571143	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID523315	Antibacterial activity against Streptococcus pneumoniae R6 by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID581069	Hill constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID283246	Reduction of lung lesions in Mycobacterium tuberculosis H37Rv infected Swiss mouse at 100 mg/kg, po for 5 days/week after 2 months	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
AID1819096	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774.A1 cells assessed as log reduction of bacterial growth at 1X MIC measured after 3 days by visual colony counting analysis	2022	ACS medicinal chemistry letters, Jan-13, Volume: 13, Issue:1	Structural Rigidification of
AID405467	Antibacterial activity against Escherichia coli TOP10 containing pAT851 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID428825	Ratio of Cmax in human at 400 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-23958	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID1187834	Inhibition of Mycobacterium tuberculosis GyrA/GyrB using relaxed pBR322 as substrate after 30 mins by DNA supercoiling assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
AID571121	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID533420	Antimicrobial activity against Micromonas micros assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1398602	Antibacterial activity against levofloxacin and methicillin-resistant Staphylococcus aureus 890325-1 after 18 hrs by two-fold microbroth dilution method	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID565323	Antibacterial activity against Mycoplasma genitalium M6285 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
AID558612	Antimicrobial activity against Streptococcus pneumoniae isolate 2617 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1243285	Antimicrobial activity against levofloxacin-resistant Staphylococcus aureus clinical isolates by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID573558	Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID580872	Growth rate constant of spore-phase cells going to vegetative phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model administered as continuous infusion	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID285288	Effect on 4 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID580866	Drug excretion in urine of healthy human at 800 mg/kg	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
AID428790	Antibacterial activity against 80 mg q.d. moxifloxacin-pretreated Streptococcus pneumoniae isolate SR-26137 after 48 hrs of incubation by population analysis	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID544855	Antibacterial activity against Streptococcus pneumoniae U2A1050 harboring gyrA Ser81Phe mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID544300	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID530597	Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr9 carrying Smqnr gene by Etest	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
AID544305	Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS6 harboring GyrA S84L and GrlA S80F, E84G mutant after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID1164008	Antibacterial activity against methicillin-resistant Staphylococcus aureus 12-5 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID563209	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID245172	Minimum inhibitory concentration against methicillin-resistant Staphylococcus aureus-5023	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1399857	Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv harboring katG Y155 mutant	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
AID518631	Clearance in human by LC analysis	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
AID428860	Bactericidal activity against Streptococcus pneumoniae isolate SR-26137 assessed as prevention of bacterial regrowth under condition simulating oral administration of 400 mg once daily after 72 hrs	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID499674	Antimicrobial activity against quinolone and penicillin-resistant Staphylococcus aureus SAR4790 after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID1318919	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 101885	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID532968	Antimicrobial activity against quinolone-resistant Mycobacterium tuberculosis isolate 12	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
AID323891	Antimicrobial activity against qnrA1 expressing Escherichia coli J53/p1960 GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID528850	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1067069	Antimicrobial activity against quinolone-resistant Staphylococcus aureus clinical isolate 3519 after 20 hrs by two-fold serial dilution technique	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives.
AID1447479	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 100036 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID285303	Effect on 0.06 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID633640	Antibacterial activity against Enterococcus faecium 09-3 after 18 hrs by two fold serial dilution method	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
AID425811	Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in CD-1 mouse lung at 75 mg/kg administered through gavage	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
AID559540	Antibacterial activity against Proteus vulgaris assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1750828	Plasma protein binding in human at 10 uM after 4 hrs by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
AID285967	Antimicrobial susceptibility against Haemophilus influenzae C2 isolate with GyrA Asp88Asn, AcrR Leu31His and Arg34Glu mutation	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
AID428828	Ratio of Cmax in human at 80 mg, po administered once daily to mutant prevention concentration for Streptococcus pneumoniae isolate SR-26134	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
AID562642	Ratio of AUC (0 to 24 hrs) to MIC required for 1-log drop in bacterial count in Staphylococcus aureus SMH38004	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.
AID227415	Fold reduction in minimum inhibitory concentration of antibiotic in presence of GG918	2004	Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4	Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID561317	Antimicrobial activity against Enterobacter cloacae isolate 153 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID544834	Antibacterial activity against Streptococcus pneumoniae R6 Tr6 harboring gyrA Ser81Phe mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID1570250	AUC (0 to infinity) in SPF ICR mouse at 100 mg/kg, sc	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
AID572509	Antimicrobial activity against Salmonella enterica serovar Typhimurium isolate SL1344 harboring wild type ParC gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID278599	Inhibitory activity against azide-resistant Escherichia coli J53 T35	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID571864	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559386	Antimicrobial activity against Clostridium difficile A422H harboring GyrA Thr82Ile and GyrB Leu451Phe mutant genes selected after 8 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1254077	Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by two-fold serial dilution method	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
AID1494122	Antibacterial activity against methicillin-sensitive Staphylococcus aureus NCTC 12981 after 16 hrs by microdilution method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1154545	Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring DprE1 C387G mutant assessed as growth inhibition after 5 days by microdilution method	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Lead optimization of 1,4-azaindoles as antimycobacterial agents.
AID1164002	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 12-1 after 18 to 24 hrs by standard twofold serial dilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
AID523150	Antibacterial activity against Streptococcus pneumoniae isolate OC6585 assessed as log reduction in bacterial growth at 4 times MIC measured at 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
AID561321	Antimicrobial activity against Escherichia coli isolate 48 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID533424	Antimicrobial activity against Anaerococcus prevotii assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID556778	Volume of distribution in peripheral compartment in osteomyelitis patient at 400 mg, po administered for every 24 hrs by three stage hierarchical Bayesian method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID1601842	Antibacterial activity against Staphylococcus aureus CMCC 25923 measured after 24 hrs by ELISA	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety.
AID279267	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3243 with 23S rRNA A2059T mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID581073	Growth rate constant of vegetative-phase cells going to spore phase in toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 250 mg administered as continuous infusion by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID1476350	Antitubercular activity against isoniazid resistant Mycobacterium tuberculosis H37Rv ATCC 35822 after 24 hrs by MABA method	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.
AID1504966	Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 10 days under low oxygen condition followed by second incubation under aerobic condition for 28 hrs by LORA	2017	ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12	Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.
AID559516	Antibacterial activity against Streptococcus anginosus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID244929	Antibacterial activity against Streptococcus pyogenes G-36 was determined	2004	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
AID544841	Antibacterial activity against Streptococcus pneumoniae U2A1053 harboring parC Ser79Phe mutant gene by agar disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID581278	Kill rate constant for compound-resistant toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID388877	Protective effect against Staphylococcus aureus ATCC 13709-induced bone infection in CD rat at 10 mg/kg, iv administered as single dose 2 days before bacterial challenge	2008	Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20	Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
AID425357	Antibacterial activity against Streptococcus pneumoniae HMC 1071 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene and S79F, K137N mutation in QRDR of ParC gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
AID1676588	Binding affinity to Zinc ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID499676	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 after 24 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID1264563	Volume of distribution at steady state in mouse at 2 mg/kg, iv by LC-MS/MS analysis	2015	ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10	Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
AID1868115	Anti-tubercular activity against Mycobacterium tuberculosis CF16 assessed as inhibition of mycobacterial growth incubated for 7 days by resazurin-dye based analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
AID573836	Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID571853	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID323881	Antimicrobial activity against Escherichia coli DH10B/pACYC184 GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID573598	Antibacterial activity against Fusobacterium varium assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID581670	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth at pH 5.5 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID544856	Antibacterial activity against Streptococcus pneumoniae U2A1051 harboring gyrA Ser81Tyr mutant gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
AID206728	Antibacterial activity was evaluated against Staphylococcus aureus	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
AID563051	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID556763	fAUC/MIC in osteomyelitis patient serum at 400 mg, po administered for every 24 hrs at PKPD breakpoint at 1 mg/liter	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
AID563025	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene by resazurin microtiter assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID570911	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID559203	Antibacterial activity against Streptococcus pneumoniae S004 harboring wild-type parC and gyrA Gly85Asn mutant genes	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
AID1364753	Antibiofilm activity against Mycobacterium tuberculosis assessed as log reduction in bacterial count at 10 ug/ml measured after 7 days by MPN assay	2017	Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10	Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors.
AID1655163	Bactericidal activity against Mycobacterium tuberculosis H37Rv assessed as reduction in bacterial growth at 0.35 ug/ml incubated for 3 to 4 weeks by time kill assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Improving the Potency of
AID499772	Inhibition of Escherichia coli DNA gyrase-mediated supercoiling of pBR322 using bromothymol blue by electrophoresis	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
AID561325	Antimicrobial activity against Klebsiella pneumoniae isolate 135 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID323883	Antimicrobial activity against qnrA1 expressing Escherichia coli DH10B GyrA/ParC mutant expressing porins by microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
AID422673	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 18 passages with levofloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID563043	Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID283395	Antimicrobial activity against Nocardia nova after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID406811	Antibacterial activity against Staphylococcus aureus BSA643 isolate with gyrA Ser84Leu and grlA Ser80Tyr, Glu84Gly mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID574772	Antimicrobial activity against Clostridium perfringens assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID570912	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID1207316	Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID570828	AUC (0 to 48 hrs) in healthy human assessed as 25-desacetyl-rifapentine level at 900 mg, po administered as a single dose measured on day 5 post compound dose by HPLC	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
AID406655	Antibacterial activity against Staphylococcus aureus ACH-0192 isolate with gyrA Ser84Leu and grlA Ser80Phe, Ala116Val mutant after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
AID540231	Dose normalised AUC in dog after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1476360	Antitubercular activity against rifampicin resistant Mycobacterium tuberculosis H37Rv ATCC 35838 after 24 hrs by MABA method	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.
AID521328	AUC (0 to 24 hrs) in CSF of patient with intracerebral and leptomeningeal tuberculosis at 400 mg/kg, po QD measured on day 3	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
AID237457	Partition coefficient (logD2.0)	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID244968	Minimum inhibitory concentration against Pseudomonas aeruginosa ATCC 27853	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID559374	Antimicrobial activity against Clostridium difficile A422B selected after 4 ug/ml of levofloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID278604	Inhibitory activity against azide-resistant Escherichia coli J53 T12-1502	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
AID530379	Inhibition of Escherichia coli DNA gyrase GyrA/GyrB	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
AID1243286	Antimicrobial activity against Streptococcus pneumoniae ATCC 49619 by standard broth microdilution method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
AID572510	Antimicrobial activity against Salmonella enterica serovar Braenderup isolate s2906 harboring ParC QRDR mutant gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
AID286045	Peak free concentration at 100 mg/24 hrs regimen in vitro PK model	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
AID563222	Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 assessed as microbial susceptibility by agar proportion method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
AID279281	Antimicrobial activity against Streptococcus pneumoniae R6 transformants with gyrA E85K mutation	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
AID1909944	n-Octanol/phosphate buffer partition coefficient, logD of the compound at pH 7.4 incubated for 3 hrs by shake flask method based HPLC-DAD analysis	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
AID558906	Antimicrobial activity against Clostridium difficile CD5f harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of moxifloxacin by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
AID283397	Antimicrobial activity against Nocardia transvalensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID559531	Antibacterial activity against ciprofloxacin-susceptible Haemophilus influenzae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID540214	Clearance in rat after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID342079	Effect on growth of epidemic Clostridium difficile BI6-8-17 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 4 days assessed after 2 days of last treatment	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
AID581273	Kill rate constant for compound-sensitive toxin and capsule gene-deficient Bacillus anthracis Sterne in hollow-fiber pharmacodynamic infection model at 200 mg, qd by Bayesian method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
AID244720	Frequency of resistance emergence for methicillin resistant Staphylococcus aureus-32	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID341063	AUC (0 to 24 hrs) in human at 400 mg, po once daily after 4 days	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
AID1398616	AUC (0 to 8 hrs) in Crj:CD rat at 5 mg/kg, po	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
AID1801385	GyraseB Assay from Article 10.1111/cbdd.12529: \\Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors of Staphylococcus aureus.\\	2015	Chemical biology & drug design, Oct, Volume: 86, Issue:4	Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors of Staphylococcus aureus.
AID1805801	Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	68 (2.25)	18.2507
2000's	1085 (35.97)	29.6817
2010's	1401 (46.45)	24.3611
2020's	462 (15.32)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	552 (17.48%)	5.53%
Reviews	200 (6.34%)	6.00%
Case Studies	349 (11.05%)	4.05%
Observational	22 (0.70%)	0.25%
Other	2,034 (64.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (533)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Four Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of Therapeutic and Supratherapeutic Doses of Cytisinicline in Healthy Smokers [NCT05566288]	Phase 1	27 participants (Actual)	Interventional	2022-10-17	Completed
Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells [NCT00398411]	Phase 3	66 participants (Actual)	Interventional	2006-10-31	Completed
A Randomised, Placebo-controlled, Four-way Crossover Repeat Dose Study to Evaluate the Effect of the Inhaled Fluticasone Furoate (FF)/GW642444M Combination on Electrocardiographic Parameters, With Moxifloxacin as a Positive Control, in Healthy Subjects [NCT01209026]	Phase 1	85 participants (Actual)	Interventional	2010-06-23	Completed
A Single-centre, Randomised, Double-blind, Double-dummy, Placebo Controlled, 4-way Crossover Phase I Study to Investigate the Effect of 2 Single Doses (400 μg and 1200 µg) of Inhaled AZD3199 on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Ave [NCT01222442]	Phase 1	40 participants (Actual)	Interventional	2010-11-30	Completed
A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Parallel-Group Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects [NCT01173536]	Phase 1	61 participants (Actual)	Interventional	2010-08-25	Completed
Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi [NCT01298336]	Phase 3	92 participants (Actual)	Interventional	2011-03-02	Completed
A Prospective, Randomized, Double-blinded, Multi-center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidazole 500mg Every 12h for [NCT00769171]	Phase 3	364 participants (Actual)	Interventional	2005-10-31	Completed
Investigation of the Effect on the QT/QTc Interval After Multiple Dose Oral Administration (100 and 200 mg Bid) of CG5503 PR in a Randomised, Double-blind, Double-dummy Placebo- and Moxifloxacin-controlled 4- Way Cross-over Phase I Study in 48 Healthy Mal [NCT03951402]	Phase 1	48 participants (Actual)	Interventional	2003-03-31	Completed
A Study to Evaluate the Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin in Healthy Adult Participants [NCT04563845]	Phase 1	50 participants (Actual)	Interventional	2020-11-09	Completed
A Double Blind, Randomized, Multiple Dose, Placebo And Active Controlled 4-Way Crossover Study To Investigate The Effects Of Inhaled PF-00610355 On QT/QTC Interval In Healthy Subjects [NCT01107054]	Phase 1	48 participants (Actual)	Interventional	2010-06-30	Completed
Genetics of QT Response to Moxifloxacin [NCT01936480]	Phase 4	51 participants (Actual)	Interventional	2013-10-31	Terminated(stopped due to Recruitment difficulties)
Prospective, Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, 4-way Crossover Phase 1 Study to Assess the Effect of Multiple Therapeutic and Supratherapeutic Doses of Aprocitentan on the QT Interval Duration in Healthy Subjec [NCT04281342]	Phase 1	48 participants (Actual)	Interventional	2020-01-14	Completed
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial [NCT03942354]	Phase 2/Phase 3	54 participants (Anticipated)	Interventional	2019-09-01	Recruiting
Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass. [NCT01130922]	Phase 4	12 participants (Anticipated)	Interventional	2010-03-31	Completed
Double-Blind Randomized Placebo-Control Trial to Evaluate Electrocardiogram Effects of HPN-100 as Defined by Clinical and Supratherapeutic Dose in Healthy Men and Women [NCT01135680]	Phase 1	98 participants (Actual)	Interventional	2010-05-31	Completed
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial [NCT04722978]	Phase 3	228 participants (Anticipated)	Interventional	2021-04-20	Recruiting
The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial [NCT02800785]		1,552 participants (Actual)	Interventional	2016-05-31	Completed
A Randomized, Double-Blind, 3-arm, Parallel Group, Placebo- and Positive-controlled Study to Investigate the Effects of Setmelanotide on QTc Interval in Healthy Subjects [NCT05046132]	Phase 4	77 participants (Actual)	Interventional	2021-08-05	Completed
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia [NCT01606436]	Phase 1	86 participants (Actual)	Interventional	2012-06-30	Completed
Single-dose, Open-label, Randomized, Non-blinded, Three-fold Crossover Study in Healthy Subjects to Compare the Bioavailability of Moxifloxacin (BAY12-8039) 400 mg Tablet and 400 mg Oral Suspension Under Fasting Conditions, and to Investigate the Effect o [NCT01073891]	Phase 1	24 participants (Actual)	Interventional	2010-05-31	Completed
A Double-blind, Double-dummy, Randomized, 4-period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of TMC435 on the QTc Interval in Healthy Subjects [NCT01269294]	Phase 1	60 participants (Actual)	Interventional	2011-01-31	Completed
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Co [NCT01290900]	Phase 1	54 participants (Actual)	Interventional	2011-02-28	Completed
Randomized, Single-blind, Double-dummy, 4-fold Cross-over, Placebo- and Active-controlled Study to Investigate the Influence of BAY 1817080 on the QTc Interval in Healthy Male and Female Participants (TQT Study) [NCT04423744]	Phase 1	42 participants (Actual)	Interventional	2020-06-18	Completed
Single-dose and Randomized, Single-center, Placebo- and Active-controlled, Crossover Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Subjects [NCT04175808]	Phase 1	70 participants (Actual)	Interventional	2019-11-14	Completed
Utility of Antibiotic Treatment in Acute Non-purulent Exacerbations of COPD: a Double Blinded, Randomized, Placebo-controlled Trial of Security and Efficacy [NCT01091493]	Phase 4	73 participants (Actual)	Interventional	2010-07-31	Completed
Evaluation of Topical Vigamox in the Initial Management of Ocular Graft-Versus-Host Disease [NCT04204122]	Phase 2	0 participants (Actual)	Interventional	2020-06-15	Withdrawn(stopped due to Investigator decided to close study)
A Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, Oral) Moxifloxacin Versus Comparator in Pediatric Subjects With Complicated Intra-abdominal Infection [NCT01069900]	Phase 3	458 participants (Actual)	Interventional	2010-07-21	Completed
Thorough QT Study to Evaluate the Effects of BI 409306 as Single Dose on Cardiac Safety Parameters in Healthy Male and Female Subjects. A Randomized, Placebo Controlled, Double-blind, Five-period Crossover Study With (Open-label) Moxifloxacin as Positive [NCT03934203]	Phase 1	47 participants (Actual)	Interventional	2019-05-09	Completed
Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial [NCT02754765]	Phase 3	754 participants (Actual)	Interventional	2016-12-31	Completed
A Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group Trial to Evaluate the Effect of Single-dose TMC207 on the QT/QTc Interval in Healthy Subjects [NCT01291563]	Phase 1	88 participants (Actual)	Interventional	2011-02-28	Completed
A Phase 1, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Crossover Study to Evaluate the Effect of Repeat Oral Doses of Mirabegron on Cardiac Repolarization in Healthy Male and Female Adult Subjects [NCT01199523]	Phase 1	352 participants (Actual)	Interventional	2010-05-31	Completed
Microbiome Effect of Omadacycline on Healthy Volunteers [NCT06030219]	Phase 1	32 participants (Actual)	Interventional	2020-10-12	Completed
A Single-centre, Randomised, Double-blind, Placebo Controlled Phase I Study in Two Parts: Part A to Assess a Safe and Tolerable Supratherapeutic Dose of TC-5214 After Single Ascending Oral Doses in Healthy Male Subjects, Followed by Part B: A Four-period [NCT01359618]	Phase 1	16 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Sponsor decision to terminate)
A Phase I, Randomized, Placebo-Controlled, Four-Way Crossover Study to Evaluate the Effect of Intravenous (IV) Zanamivir on Cardiac Conduction as Assessed by 12-lead Electrocardiogram (ECG) With Moxifloxacin as a Positive Control in Healthy Volunteers [NCT01353729]	Phase 1	40 participants (Actual)	Interventional	2011-05-19	Completed
A Single-Center, Randomized, Placebo-Controlled, 3 Treatment Period Crossover Study to Assess the Effect of Padsevonil on Cardiac Repolarization (QTc Interval) (Using Moxifloxacin as a Positive Control) in Healthy Study Participants [NCT04126343]	Phase 1	54 participants (Actual)	Interventional	2019-10-23	Terminated(stopped due to Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures)
Evaluation of the Effects of Sequential Multiple-Dose Regimens of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia [NCT01376076]	Phase 1	129 participants (Actual)	Interventional	2011-06-30	Completed
A Randomized, Double-Blind, Placebo/Positive Controlled, Evaluation of the Effects of MNTX on ECG Parameters and Cardiac Repolarization in Normal Volunteers [NCT01363323]	Phase 1	546 participants (Actual)	Interventional	2004-11-30	Completed
A Phase 1, Randomized, Double-blinded, Four-period Crossover, Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects [NCT03613649]	Phase 1	72 participants (Actual)	Interventional	2018-09-25	Completed
A Phase 1, Randomized, Blinded, Placebo and Moxifloxacin Controlled, 4-Period Crossover, Study Evaluating the Effect of ZTI-01 on 12-Lead Electrocardiogram Parameters in Healthy Adult Subject [NCT03709927]	Phase 1	41 participants (Actual)	Interventional	2018-01-11	Completed
Randomized, Double-blind (for Clazosentan), Placebo- and Moxifloxacincontrolled, 3-way Cross-over Phase 1 Study to Assess the Effect of Two Intravenous Doses of Clazosentan on the QTc Interval Duration in Healthy Subjects [NCT03657446]	Phase 1	36 participants (Actual)	Interventional	2018-09-18	Completed
A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori [NCT02373280]		600 participants (Anticipated)	Interventional	2014-08-31	Recruiting
Thorough QT/QTc Study to Assess the Electrocardiographic Safety of a New Gadolinium-based Contrast Agent P03277 in Healthy Volunteers [NCT03657264]	Phase 1	48 participants (Actual)	Interventional	2017-08-21	Completed
A Phase 1 Active- and Placebo-Controlled Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women [NCT00360425]	Phase 1	174 participants	Interventional	2006-05-31	Completed
A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of LC350189 on the QTc (Corrected QT) Interval in Healthy Adult Subjects [NCT04966325]	Early Phase 1	37 participants (Actual)	Interventional	2021-09-23	Completed
A PHASE 1, RANDOMIZED, PLACEBO-AND POSITIVE-CONTROLLED CROSSOVER STUDY TO DETERMINE THE EFFECT OF SINGLE-DOSE PF-06700841 ON QTC INTERVAL IN HEALTHY VOLUNTEERS [NCT03656952]	Phase 1	33 participants (Actual)	Interventional	2018-09-05	Completed
"A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)" [NCT03187301]	Phase 2	48 participants (Actual)	Interventional	2017-08-03	Completed
Study on Pharmacokinetics of Moxifloxacin in Serum and Liver Tissue of Patients Undergoing Liver Resection Due to Primary or Secondary Tumor of the Liver [NCT01302951]	Phase 4	34 participants (Actual)	Interventional	2008-07-31	Completed
A Phase 1, Randomized, Placebo-And Positive-Controlled Crossover Study To Determine The Effect Of A Single-Dose Of PH-797804 On QTc Interval In Healthy Volunteers [NCT01862887]	Phase 1	48 participants (Actual)	Interventional	2013-04-30	Completed
A Two-part Phase I Study Composed of a Randomized, Double-blind, 4-parallel Group Study to Evaluate the Effect of Multiple Oral Doses of GFT505 on the QT/QTc Interval Compared to Placebo With Moxifloxacin (400 mg in Single Oral Dose) as a Positive Control [NCT02091310]	Phase 1	200 participants (Actual)	Interventional	2014-02-28	Completed
Antibiotic Prophylaxis for ERCP: a Comparison of Intravenous Ceftriaxone With Intravenous Moxifloxacin in the Prophylaxis of Cholangitis [NCT02098486]	Phase 2	86 participants (Actual)	Interventional	2014-03-31	Completed
A 2 PART STUDY IN HEALTHY SUBJECTS: PART A: A MULTIPLE DOSE, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SUPRA-THERAPEUTIC DOSES OF RO4602522; PART B: A MULTIPLE-DOSE, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CON [NCT02104648]	Phase 1	203 participants (Actual)	Interventional	2014-04-30	Completed
A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects [NCT02117830]	Phase 1	54 participants (Anticipated)	Interventional	2014-04-30	Completed
A Randomized, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of Meropenem-Vaborbactam on the QT/QTc Interval in Healthy Volunteers [NCT03564158]	Phase 1	53 participants (Actual)	Interventional	2018-05-01	Completed
A Double-blind, Randomized, Placebo-controlled, Four-way Crossover Phase 1 Study Including an Open-label Positive Control (Moxifloxacin) to Assess the Effect of Repeated Daily Doses of 10 mg and 30 mg Macitentan on the QT/QTc Interval of the ECG in Health [NCT02050802]	Phase 1	64 participants (Actual)	Interventional	2011-08-31	Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
A Prospective, Single-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare the 14-day Bismuth Quadruple Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter as a Rescue 2nd Therapy. [NCT02359331]		370 participants (Actual)	Interventional	2014-08-31	Terminated
Contraceptive Hormones and Women With Cystic Fibrosis: Satisfaction and Effects on Disease [NCT02144246]	Phase 1	5 participants (Actual)	Interventional	2014-05-31	Terminated
A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia [NCT02813694]	Phase 3	738 participants (Actual)	Interventional	2016-08-31	Completed
STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB [NCT02409290]	Phase 3	588 participants (Actual)	Interventional	2016-03-31	Completed
Efficacy of the Application of Moxifloxacin and Cefixime in Reduction of Inflammatory Sequelae and Complications After Mandibular Third Molar Surgery [NCT05027893]		157 participants (Actual)	Interventional	2019-06-07	Active, not recruiting
A Double-blind, Randomized, Placebo-controlled, 4-Period Cross-over Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Subjects [NCT03696459]	Phase 1	52 participants (Actual)	Interventional	2018-10-02	Completed
Assessment of the Effect of 480 mg and 1200 mg of BI 201335 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Phase-I-study With Moxifloxacin as Positive Control [NCT02182310]	Phase 1	56 participants (Actual)	Interventional	2008-06-30	Completed
A Randomized, Multiple-dose, Placebo- and Positive-controlled Parallel Group Study to Evaluate the Effects of Indacaterol on Cardiac Safety in Healthy Subjects [NCT01263808]	Phase 1	404 participants (Actual)	Interventional	2008-04-30	Completed
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Ortho Tri-Cyclen Lo on Hormone Withdrawal-associated Symptoms After 6 Cycles of Treatment. [NCT00754065]	Phase 3	409 participants (Actual)	Interventional	2008-09-30	Completed
Phase 2 Randomized Trial of a Moxifloxacin-Containing Regimen For Treatment of Smear-Positive Pulmonary Tuberculosis in Adults With and Without HIV Infection [NCT00082173]	Phase 2	170 participants (Actual)	Interventional	2004-10-31	Completed
A Single-Center, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects [NCT03808298]	Phase 1	57 participants (Actual)	Interventional	2019-02-07	Completed
A Randomized, Double-Blind and Nested Crossover (For Placebo and Moxifloxacin) Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat, and Its Major Metabolites on Cardiac Repolarization in Healthy Volunteers [NCT05933447]	Phase 1	27 participants (Actual)	Interventional	2023-05-12	Completed
A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Repolarization Duration as Well as Other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) With Those of Moxifl [NCT03465436]	Phase 1	56 participants (Actual)	Interventional	2011-09-16	Completed
An Open-Label Phase 2 Trial to Evaluate the Male Reproductive Safety of a 6-Month Combination Treatment for Pulmonary Tuberculosis (TB) of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) in Adult Male Participants With Drug Resista [NCT04179500]	Phase 2	26 participants (Actual)	Interventional	2021-09-16	Active, not recruiting
A Double-blinded, Randomised, Placebo Controlled, Five-way Crossover Study With One Positive Control (Open-label) (Moxifloxacin) to Assess the Influence of Oral Single Dose KUC 7483 BS (40 mg, 80 mg, 160 mg, 320 mg) on the QT/QTc Interval of the ECG in He [NCT02256735]	Phase 1	39 participants (Actual)	Interventional	2005-08-31	Completed
[NCT00750633]	Phase 3	990 participants (Actual)	Interventional	2008-06-30	Completed
A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia [NCT02559310]	Phase 3	551 participants (Actual)	Interventional	2015-09-30	Completed
Reason Evaluation of Initial Treatment Failure in Patients With Community Acquired Pneumonia [NCT03280004]		314 participants (Anticipated)	Observational [Patient Registry]	2017-11-20	Recruiting
A Randomized, Placebo-Controlled, Four-Period Crossover, Study to Evaluate the Effect of Volanesorsen on the QTc Interval Using a Therapeutic and Supra-Therapeutic Dose Compared With Placebo in Healthy Volunteers: a Thorough QT Study [NCT02910635]	Phase 1	52 participants (Actual)	Interventional	2016-09-19	Completed
Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT) [NCT00579189]	Phase 3	776 participants (Actual)	Interventional	2006-01-31	Completed
A Phase 1, Randomized, Double-Blind, Cross-Over, Placebo- and Active-Controlled Cardiac Safety Study of Therapeutic and Supratherapeutic Doses of Fumaryl Diketopiperazine Administered as Technosphere® Inhalation Powder in Healthy Subjects [NCT00721344]	Phase 1	48 participants (Actual)	Interventional	2008-04-30	Completed
Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis [NCT03625739]		800 participants (Anticipated)	Observational [Patient Registry]	2018-07-01	Recruiting
A Randomized, Double-blind, Placebo- and Positive-controlled, Single-dose, 4-way Crossover Study to Evaluate the Effects of Seltorexant (JNJ-42847922) on Electrocardiogram Intervals in Healthy Adult Subjects [NCT03494907]	Phase 1	52 participants (Actual)	Interventional	2018-04-09	Completed
Clinical Trials to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease. [NCT01658020]	Phase 3	345 participants (Actual)	Interventional	2012-08-31	Completed
A Phase IIb, Open Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of Delpazolid in Combination With Bedaquiline Delamanid Moxifloxaci [NCT04550832]	Phase 2	76 participants (Actual)	Interventional	2021-10-22	Active, not recruiting
Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial [NCT05162625]	Phase 2	100 participants (Anticipated)	Interventional	2021-12-10	Recruiting
A Randomized, Double Blind, Phase II Multicenter Trial to Evaluate the Safety and Efficacy of PRO-157 Ophthalmic Solution in Three Different Dosing Regimen Versus Moxifloxacin Versus Gatifloxacin in Patients With Bacterial Conjunctivitis. [NCT02980523]	Phase 2	150 participants (Actual)	Interventional	2015-03-31	Completed
A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP) [NCT04779242]	Phase 3	670 participants (Anticipated)	Interventional	2021-02-25	Recruiting
A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects: A Randomised, Double-Blind,Placebo-Controlled, Three-Arm Parallel Trial With a Nested Cross-Over Design for Positive Control With Moxifloxacin Administra [NCT02064348]	Phase 1	168 participants (Actual)	Interventional	2014-02-26	Completed
Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital [NCT02068170]		178 participants (Actual)	Observational	2014-02-28	Completed
[NCT02073084]	Phase 1	56 participants (Actual)	Interventional	2014-01-31	Completed
A Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, 4-Treatment Crossover Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects [NCT02222324]	Phase 1	60 participants (Actual)	Interventional	2014-08-31	Completed
A Phase 1, Randomized, Double-blind, Sponsor-Open, Placebo- and Positive-Controlled Crossover Study to Investigate the Effect of Multiple Doses of Sisunatovir on QTc Interval in Healthy Adult Participants [NCT05878522]	Phase 1	43 participants (Actual)	Interventional	2023-05-15	Active, not recruiting
Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media With Otorrhea in Tympanostomy Tubes [NCT01071902]	Phase 3	400 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Management decision)
An Evaluation of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates [NCT00579020]	Phase 2	144 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Management decision)
A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers [NCT03554304]	Phase 1	60 participants (Actual)	Interventional	2017-02-09	Completed
Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis: Double-blind Controlled Clinical Trial [NCT02125812]	Phase 4	40 participants (Actual)	Interventional	2011-08-31	Completed
A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers [NCT02128308]	Phase 1	16 participants (Actual)	Interventional	2013-11-30	Completed
A Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group, Multiple-dose, Up-titration Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects [NCT02136888]	Phase 1	116 participants (Actual)	Interventional	2011-08-31	Completed
A Phase 1, Single-dose, Randomized, 4-treatment, 4-period Crossover, Placebo- And Positive-controlled, Double-blind (Open-label For Positive Control), Sponsor-open Study To Determine The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects [NCT02785770]	Phase 1	44 participants (Actual)	Interventional	2016-06-29	Completed
A Two-part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a High, Single Oral Dose of GSK1278863 (Part A), and a Randomized, Single-blind, Placebo- and Positive-controlled, Four-way Crossover Study to Assess the Effect of Single, Oral [NCT02293148]	Phase 1	61 participants (Actual)	Interventional	2014-11-17	Completed
A Randomized, Double-blind, Placebo- and Positive-controlled, Multiple-dose, Four-way, Cross-over Study to Evaluate the Effects of Repeated Oral Doses of JNJ-54861911 on Electrocardiogram Intervals in Healthy Subjects [NCT02152332]	Phase 1	64 participants (Actual)	Interventional	2014-07-31	Completed
Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response [NCT03609099]	Phase 4	424 participants (Anticipated)	Interventional	2019-02-15	Recruiting
A Randomized, Double-Blind, Parallel, Nested Crossover Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a P [NCT03606057]	Phase 1	188 participants (Actual)	Interventional	2018-07-13	Completed
A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects [NCT06161220]	Phase 1	36 participants (Anticipated)	Interventional	2023-10-30	Recruiting
A Study to Determine the Concentration-Electrocardiographic Effects of Efavirenz in Healthy Subjects Enriched for CYP2B6 Polymorphisms [NCT02164812]	Phase 1	58 participants (Actual)	Interventional	2014-07-31	Completed
A Double-blind, Randomised, Placebo Controlled, Six-way Crossover Study Including an Open-label Positive Control (Moxifloxacin) to Assess the Influence of Via Respimat® Inhaled BI 1744 CL (Single Doses of 10 μg, 20 μg, 30 μg and 50 μg) on the QT/QTc Inter [NCT02172144]	Phase 1	24 participants (Actual)	Interventional	2007-06-30	Completed
A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers [NCT02257398]	Phase 1	55 participants (Actual)	Interventional	2014-10-06	Completed
Is Combination Antibiotic Therapy Superior to Monotherapy in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [NCT04879030]	Phase 2/Phase 3	170 participants (Actual)	Interventional	2020-01-01	Completed
A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers [NCT02062203]	Phase 1	50 participants (Actual)	Interventional	2014-01-31	Completed
Evaluation of the Efficacy and Safety of a Short-course, Daily, 4-month Regimen Including Isoniazid, Pyrazinamide, Rifapentine and Moxifloxacin (2HZPM/2HPM) for the Treatment of Drug-susceptible Pulmonary Tuberculosis in Taiwan (ESCAPE-TB) [NCT04856644]	Phase 3	366 participants (Anticipated)	Interventional	2021-05-01	Not yet recruiting
A Double-blind, Randomised, Placebo Controlled Study With Two Sequential Two-way Cross-over Parts to Demonstrate That the Influence of Pramipexole up to 4.5 mg Daily on the QT Interval of the ECG in Healthy Male and Female Volunteers is Comparable With Pl [NCT02262546]	Phase 1	60 participants (Actual)	Interventional	2007-05-31	Completed
A Seamless Phase 2B/C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary Tuberculosis [NCT06114628]	Phase 2	2,500 participants (Anticipated)	Interventional	2023-12-08	Not yet recruiting
A Double-Blind, Placebo-Controlled, Randomized, Crossover Design Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers: A Thorough QT/QTc Study [NCT02236026]	Phase 1	44 participants (Actual)	Interventional	2014-09-30	Completed
A Randomized, Controlled, Double Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia (CABP) [NCT01198626]	Phase 2	32 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Enrollment would not have been met prior to the end of the pneumonia season. Termination is based on slow enrollment and not related to safety or efficacy.)
A Two-Part Study Consisting of a Randomized, Placebo-Controlled, Single Dose Safety and Tolerability Study (Part A) Evaluating a Supratherapeutic Dose of Zanubrutinib Followed by a Randomized, Placebo- and Positive-Controlled, Crossover Study (Part B) to [NCT03432884]	Phase 1	40 participants (Actual)	Interventional	2018-01-25	Completed
A Randomized, Placebo- and Positive Controlled, Three-Way, Crossover Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization in Healthy Male and Female Subjects: A Thorough QT/QTc Study [NCT01941446]	Phase 1	54 participants (Actual)	Interventional	2013-03-31	Completed
A Phase 1, Double-blind, Four Period Crossover Study to Investigate the Effects of Pomalidomide (CC 4047) on the QT Interval in Healthy Male Subjects [NCT01986894]	Phase 1	72 participants (Actual)	Interventional	2013-10-18	Completed
Single Centre, Single Dose, Randomised, Negative and Positive-controlled, Double-blind Trazodone vs. Negative Control (Placebo), Open-label vs. Positive Control (Moxifloxacin), 5-way Cross-over QT/QTc Study [NCT03516630]	Phase 1	20 participants (Actual)	Interventional	2017-03-20	Completed
A Randomized, Double-Blind, Placebo- and Positive-Controlled, Multiple Dose, Four Way Crossover Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Subjects at Therapeutic and Supratherapeutic Dose Levels [NCT02307864]	Phase 1	68 participants (Actual)	Interventional	2014-12-04	Completed
Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers [NCT01103830]	Phase 1	287 participants (Actual)	Interventional	2010-02-28	Completed
Pharmacokinetics and Safety of Moxifloxacin; a Dose Escalation in Patients With Tuberculosis [NCT01329250]	Phase 4	9 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to slow enrolment of patients and new insights)
[NCT00414011]		40 participants (Actual)	Interventional		Completed
Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group With Nested Cross-over, Multiple-dose, Up-titration Study of the Effects of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Fem [NCT02206204]	Phase 1	159 participants (Actual)	Interventional	2012-06-30	Completed
A Randomized Double-Blinded Crossover Trial to Define the ECG Effects of Mipomersen (ISIS 301012) Using a Therapeutic and Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial [NCT01090661]	Phase 1	60 participants (Actual)	Interventional	2010-03-31	Completed
Clinical Effectiveness and Safety Study of Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI) [NCT01096511]		1,001 participants (Actual)	Observational	2009-12-31	Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]		1,578 participants (Actual)	Observational	2003-06-09	Completed
A Randomized, Positive and Placebo-Controlled Trial to Evaluate the Effects of Milademetan Administration on Cardiac Repolarization in Healthy Subjects [NCT05758818]	Phase 1	6 participants (Actual)	Interventional	2023-04-17	Terminated(stopped due to sponsor decision)
A Thorough QTc Study Evaluating the Effect of Cagrilintide on Cardiac Repolarisation in Healthy Participants [NCT05804162]	Phase 1	107 participants (Actual)	Interventional	2023-04-12	Completed
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) [NCT04310930]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2020-03-02	Recruiting
Study to Clinically Evaluate the QT/QTc Interval Prolongation Potential of Vericiguat in Patients With Stable Coronary Artery Disease in a 2-arm, Placebo-controlled, Randomized, Double-blind, Double-dummy Design Including a Vericiguat Multiple-dose Part W [NCT03504982]	Phase 1	74 participants (Actual)	Interventional	2018-05-17	Completed
A Phase 1, Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Repeat Oral Doses of ASP1941 on Cardiac Repolarization in Healthy Male and Female Adult Subjects [NCT01232413]	Phase 1	88 participants (Actual)	Interventional	2010-09-30	Completed
Characterization of Immune Responses in Treatment-induced Latency in Pulmonary Tuberculosis [NCT01154959]	Phase 3	120 participants (Actual)	Interventional	2010-02-28	Completed
A Single-centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four-period Crossover Study in Healthy Male Volunteers, to Assess the Effect on QT/QTc Interval of Single Oral Doses of AZD1981 (200 mg and 2000 mg) Using Moxifloxacin (Avelox®) [NCT01265641]	Phase 1	44 participants (Anticipated)	Interventional	2011-01-31	Completed
A Single-center, Randomized, Double-blind (for OPC-61815 and Placebo), Placebo- and Moxifloxacin Positive-controlled, 4-Period Crossover Trial to Evaluate the Effect of Single Intravenous Administration of OPC-61815 at 16 and 32 mg on QT/QTc Interval in H [NCT03510663]	Phase 1	48 participants (Actual)	Interventional	2018-05-08	Completed
Randomized, 4-Way, Crossover Single Dose, Placebo And Active Controlled Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects [NCT01287793]	Phase 1	48 participants (Anticipated)	Interventional	2011-01-31	Completed
A Phase 1, Randomized, Multiple Dose, Placebo And Active Controlled, 4-Way Crossover Study To Evaluate The Effect Of A Multiple Oral Dose of PF-00232798 On Qt Intervals In Healthy Subjects [NCT01140425]	Phase 1	44 participants (Actual)	Interventional	2010-07-31	Completed
A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Positive-Controlled, Four-Way Crossover Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects [NCT05293171]	Phase 1	38 participants (Actual)	Interventional	2021-06-11	Completed
The Optimization of Mycoplasm Pneumonia Antibiotic Therapy: Multi-centre, Prospective, Randomized Controlled Study [NCT01259141]		208 participants (Actual)	Interventional	2010-10-31	Completed
Comparison of Intensive Treatment Regimens and Standard Treatment Regimen for Tuberculous Meningitis: Pharmacokinetics, Pharmacodynamics and Tolerability Study [NCT01158755]	Phase 2	60 participants (Actual)	Interventional	2010-10-31	Completed
A Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Volunteers in Order to Define Lanifibranor (IVA337) Supra-therapeutic Dose in a Multiple Dosing Regimen [NCT03866369]	Phase 1	36 participants (Actual)	Interventional	2019-01-17	Completed
A Crossover Study to Assess the Effects of FYU-981 on the QT/QTc Interval in Healthy Male and Female Volunteers [NCT02515864]	Phase 2	48 participants (Actual)	Interventional	2015-08-31	Completed
High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials [NCT05863858]	Phase 3	162 participants (Actual)	Interventional	2020-06-01	Completed
A Phase 1, Randomized, Partially Double-Blind, Placebo- and Positive-controlled Study to Evaluate the Effect of Tucatinib on Cardiac Repolarization in Healthy Subjects [NCT03777761]	Phase 1	55 participants (Actual)	Interventional	2018-12-06	Completed
A Randomized, Phase 1, Three-Period, Placebo- and Positive-Controlled, Double-Blind, Crossover Study to Assess the Electrophysiological Effects of Exenatide at Therapeutic and Supratherapeutic Concentrations on the 12-Lead Electrocardiogram QT Interval in [NCT01297062]	Phase 1	94 participants (Actual)	Interventional	2011-02-28	Completed
A Randomized, Double-Blind, Double-Dummy, Positive-Controlled, Crossover Study to Determine Electrocardiographic Effects of BMS-955176 in Healthy Subjects [NCT02576119]	Phase 1	315 participants (Actual)	Interventional	2015-10-19	Terminated(stopped due to This study was terminated early due to neuropsychiatric serious adverse events reported by 2 participants.)
A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer [NCT01017731]	Phase 2	68 participants (Actual)	Interventional	2009-11-30	Completed
[NCT00759148]	Phase 3	1,179 participants (Actual)	Interventional	2008-10-31	Completed
TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling [NCT02563327]	Phase 3	60 participants (Anticipated)	Interventional	2016-05-30	Recruiting
Comparison of Efficacy and Safety of Tricilest (Norgestimate-ethinyl Estradiol) and Diane-35 (Cyproterone Acetate-ethinyl Estradiol) in the Treatment of Acne Vulgaris [NCT00752635]	Phase 4	48 participants (Actual)	Interventional	2004-09-30	Completed
Multi-Centre, Prospective, Open Label, Randomized Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Levofloxacin Plus Metronidazole in the Treatment of Community-Acquired Pneumonia With Aspiration Factors [NCT00752947]	Phase 4	186 participants (Anticipated)	Interventional	2008-09-30	Recruiting
A Randomized, Double Blind, Single Dose, Positive and Placebo Controlled, Crossover Study of the Effects of Inhaled Carmoterol, at the Proposed Therapeutic and Supratherapeutic Doses, on the QTc Intervals in Healthy Subjects [NCT00777595]	Phase 1	47 participants (Actual)	Interventional	2008-10-31	Completed
A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effe [NCT01039610]	Phase 1	0 participants (Actual)	Interventional	2009-11-30	Withdrawn(stopped due to Internal decision to progress alternate molecule with more preferable profile)
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects [NCT00672399]	Phase 1	70 participants (Actual)	Interventional	2008-04-30	Completed
Single Centre, Prospective, Comparative, Open-label, Randomised Study to Evaluate the Efficacy and Tolerability of the Combination of Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscess [NCT00629135]	Phase 3	180 participants (Actual)	Interventional	2005-11-15	Completed
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
VICTOR - Avelox® i.v. in Acute Exacerbations of Chronic Bronchitis [NCT00876577]		1,206 participants (Actual)	Observational	2009-05-31	Completed
Thorough QT Study to Evaluate the Effects of BI 1015550 as Single Doses Following Oral Administration on Cardiac Safety Parameters (Double-blind, Randomized, Placebo-controlled, Five-period Crossover, With Open-label Moxifloxacin as Positive Control) in H [NCT06107036]	Phase 1	45 participants (Anticipated)	Interventional	2024-02-26	Not yet recruiting
Effects of Iclepertin on the QT Interval Following Oral Administration in Healthy Male and Female Subjects (a Double-blind, Randomised, Placebo-controlled, Multiple-dose, Parallel Group With Nested Crossover Design Trial, With Moxifloxacin as Positive Con [NCT06070597]	Phase 1	56 participants (Anticipated)	Interventional	2024-01-25	Not yet recruiting
A Randomized Clinical Trial of Oral Clarithromycin in Community-acquired Pneumonia to Attenuate Inflammatory Responses and Improve Outcomes: the ACCESS Clinical Trial [NCT04724044]	Phase 3	278 participants (Actual)	Interventional	2021-01-25	Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia [NCT02679573]	Phase 3	860 participants (Actual)	Interventional	2016-12-14	Completed
A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers [NCT03164109]	Phase 1	28 participants (Actual)	Interventional	2017-08-18	Completed
The Effect of Coadministration of BMS-955176 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Female Subjects [NCT02157467]	Phase 1	46 participants (Actual)	Interventional	2014-06-02	Completed
A Single Dose, Crossover, Placebo- and Moxifloxacin- Controlled Study of the Effects of Bosutinib on Cardiac Repolarization in Healthy Adult Subjects [NCT00914121]	Phase 1	60 participants (Anticipated)	Interventional	2009-06-30	Completed
Effect of LY2216684 on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects [NCT01373931]	Phase 1	20 participants (Actual)	Interventional	2011-06-30	Completed
Randomized, Double-blind, Placebo-controlled, Positive Controlled, 3-period, 6-sequence, Crossover Study to Define the Electrocardiogram Effects of a Single Dose of Telotristat Etiprate (LX1606) 1500 mg Compared With Placebo and Open Label Moxifloxacin in [NCT02155205]	Phase 1	48 participants (Actual)	Interventional	2014-05-31	Completed
A Phase 1, Randomized, Single Dose, Placebo And Active Controlled, 3-Way Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects [NCT00936871]	Phase 1	66 participants (Anticipated)	Interventional	2010-01-31	Completed
Safety and Efficacy of a Topical Otic Formulation in the Treatment of Peri-Operative Tube Otorrhea [NCT00578773]	Phase 2	303 participants (Actual)	Interventional	2007-11-30	Completed
A Study to Evaluate the Effect of Extended Release Rosiglitazone (RSG XR) on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin [NCT00884533]	Phase 1	0 participants (Actual)	Interventional	2009-06-30	Withdrawn(stopped due to The whole project was terminated)
A Randomized, Double-blind, Placebo- and Moxifloxacin-controlled Study to Investigate the Safety and Pharmacokinetics of Single Ascending Supratherapeutic Doses of Elinzanetant in Healthy Participants [NCT05481528]	Phase 1	51 participants (Actual)	Interventional	2022-08-19	Completed
A Randomized, Single-center, Placebo and Positive Control, 4-period and 4-crossover Clinical Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Malate Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects as Well as t [NCT03362853]	Phase 1	48 participants (Actual)	Interventional	2012-06-25	Completed
A PHASE 1, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY ON THE EFFECTS OF CC-99677 ON THE PHARMACOKINETICS OF AN ORAL CONTRACEPTIVE IN HEALTHY FEMALE SUBJECTS [NCT04718636]	Phase 1	28 participants (Actual)	Interventional	2020-09-30	Completed
A Double-Blind, Double-Dummy, Randomized, Moxifloxacin and Placebo Controlled, Four-Way Crossover Study of the Effects of a Single Intravenous Supra-Therapeutic Dose and Single Intravenous Therapeutic Dose of CXA-101/Tazobactam on the QT/QTC Intervals in [NCT02508753]	Phase 1	52 participants (Actual)	Interventional	2010-06-30	Completed
Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis [NCT05079854]	Phase 4	100 participants (Anticipated)	Interventional	2021-10-01	Recruiting
A Multicenter, Placebo-Controlled, Phase III Trial of Standard Adjuvant Chemotherapy Plus Moxifloxacin in Operable Breast Cancer [NCT05114720]	Phase 3	520 participants (Anticipated)	Interventional	2021-11-11	Recruiting
A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease [NCT05400369]	Phase 4	268 participants (Anticipated)	Interventional	2022-08-10	Recruiting
A Randomized, Double-Blinded, Positive-Controlled, Placebo-Controlled, 3-Way Crossover Study to Determine the Electrocardiographic Effects of BMS-791325 in Healthy Subjects [NCT02084953]	Phase 1	59 participants (Actual)	Interventional	2014-04-30	Completed
A Single Ascending Dose, Randomized, Double-Blind, Double-Dummy, Placebo- and Positive Controlled Study to Evaluate the Effect of ACH-0144471 on the QT Interval in Healthy Adult Subjects [NCT05016206]	Phase 1	33 participants (Actual)	Interventional	2018-07-26	Completed
Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis: a Prospective Randomised Multicenter Study (The APPAC II Study) [NCT03236961]		552 participants (Anticipated)	Interventional	2017-04-03	Active, not recruiting
A Double-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study: Comparison of Single Oral Dose 400mg Moxifloxacin-induced QT Prolongation Between Healthy Chinese Volunteers and Caucasian Volunteers [NCT02119091]	Phase 1	80 participants (Anticipated)	Interventional	2014-04-30	Recruiting
Steroids and Cross-linking for Ulcer Treatment [NCT04097730]	Phase 3	279 participants (Actual)	Interventional	2020-09-24	Active, not recruiting
A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of NGM/EE Tablets Manufactured at 2 Different Facilities [NCT02127593]	Phase 1	101 participants (Actual)	Interventional	2013-06-30	Completed
Assessment of Electrophysiological Effects of 150 mg and 600 mg of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind Three-way Crossover Study With an Open Label Posi [NCT02170987]	Phase 1	40 participants (Actual)	Interventional	2006-03-31	Completed
A Randomized, Double-blind, Positive and Placebo-controlled, Single-dose, Crossover Study of the Effects of CHF5993 pMDI (BDP/FF/GB) at the Proposed Therapeutic and Supratherapeutic Doses, on the Cardiovascular Safety in Healthy Subjects [NCT05830071]	Phase 1	95 participants (Actual)	Interventional	2023-03-29	Completed
A Non-randomized, Non-Interventional, Prospective, Multicenter, Post Marketing Surveillance Study to Assess the Antibacterial Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative (Preoperative and Postoperative) [NCT05413980]		102 participants (Anticipated)	Observational	2023-11-15	Not yet recruiting
Assessment of the Effect of 5 mg and 100 mg of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Study With Moxifloxacin as Positive Control [NCT02183467]	Phase 1	44 participants (Actual)	Interventional	2008-01-31	Completed
A Single-Center, Randomized, Masked Study Comparing the Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After a Single Topical Instillation [NCT00905762]	Phase 1	119 participants (Actual)	Interventional	2009-03-31	Completed
A Phase IIb, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of BTZ-043 in Combination With Bedaquiline and Delamanid in Adult S [NCT05926466]	Phase 2	90 participants (Anticipated)	Interventional	2023-09-21	Recruiting
Treatment of Patients With Acute Sinusitis in Daily Practice [NCT00930488]		6,777 participants (Actual)	Observational	2007-03-31	Completed
A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections [NCT00952796]	Phase 4	100 participants (Anticipated)	Interventional	2009-01-31	Completed
A Phase I, Double-blind, Double-dummy, Randomized, Placebo Controlled and Active Controlled Trial to Evaluate the Effect of TMC278 25 mg Daily at Steady-state and the Effect of Efavirenz (EFV) 600 mg Daily at Steady-state on the QT/QTc Interval, in 2 Rand [NCT00744809]	Phase 1	120 participants (Actual)	Interventional	2008-08-31	Completed
CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients [NCT00987792]		2,595 participants (Actual)	Observational	2009-09-30	Completed
A Phase I, Single-Center, Double-Blind, Randomized, Placebo- and Positive- Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Talampanel on Cardiac Repolarization in Healthy Male and Female Volunteers [NCT00964730]	Phase 1	135 participants (Anticipated)	Interventional	2009-10-31	Completed
A Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled, Four-period Crossover Trial to Evaluate the Effect of Telaprevir (TVR) on the QT/QTc Interval in Healthy Subjects [NCT00973388]	Phase 1	44 participants (Actual)	Interventional	2009-10-31	Completed
Randomized, Double-Blinded, Placebo-Controlled, Open Label Positive- Controlled, Four-Way Crossover Study of the Electrocardiographic Effects of BMS-708163 in Healthy Subjects [NCT00979316]	Phase 1	62 participants (Actual)	Interventional	2009-09-30	Completed
Thorough QT/QTc Study of Staccato® Prochlorperazine for Inhalation in Healthy Volunteers [NCT00543062]	Phase 1	48 participants (Actual)	Interventional	2007-10-31	Completed
A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers [NCT04045769]	Phase 1	52 participants (Actual)	Interventional	2019-08-19	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single- and Multiple-Dose, 4-Way Crossover Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Subjects [NCT01643889]	Phase 1	44 participants (Actual)	Interventional	2012-07-31	Completed
Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers [NCT02207699]	Phase 1	68 participants (Actual)	Interventional	2014-05-31	Completed
A Randomized, Blinded, Placebo- and Positive-Controlled, Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects [NCT05660720]	Phase 1	48 participants (Anticipated)	Interventional	2022-11-19	Active, not recruiting
A Phase 1, Double-blind, Single-dose, Randomized, Placebo and Active-Controlled, Four-Way Crossover Study Evaluating the Effects of Bemnifosbuvir on Cardiac Repolarization in Healthy Adult Subjects [NCT05905484]	Phase 1	35 participants (Actual)	Interventional	2023-04-25	Completed
A Double-Blind, Cross-Over Placebo-Controlled and Active-Controlled Trial To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia [NCT05893862]	Phase 1	84 participants (Anticipated)	Interventional	2023-06-26	Recruiting
Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery [NCT05741632]	Phase 1	68 participants (Actual)	Interventional	2023-02-01	Completed
A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Subjects [NCT02658825]	Phase 1	66 participants (Actual)	Interventional	2016-01-31	Completed
Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers [NCT02650479]	Phase 1	82 participants (Actual)	Interventional	2016-01-31	Completed
The Effect of Pink Grapefruit Juice on the QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome [NCT02680080]		25 participants (Actual)	Interventional	2016-12-01	Completed
Efficacy of Moxifloxacin, Amoxicillin+Metronidazole for Aggressive Periodontitis Treatment [NCT02839421]	Phase 4	36 participants (Actual)	Interventional	2015-12-31	Active, not recruiting
A Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Way Crossover Study in Healthy Subjects to Determine the Effect of Omaveloxolone on QTc Interval [NCT05927649]	Phase 1	30 participants (Actual)	Interventional	2023-07-11	Completed
A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects [NCT04238195]	Phase 1	24 participants (Actual)	Interventional	2020-01-19	Completed
Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic [NCT00683865]	Phase 3	749 participants (Actual)	Interventional	2003-04-30	Completed
A Phase I Single Centre, Randomized, Double Blind (Except For Moxifloxacin), Placebo And Active Controlled, Four Way Cross Over Study Investigating The Effect Of Single Therapeutic And Supra Therapeutic Doses Of Fedovapagon On The QT/QTC Interval In Healt [NCT02537288]	Phase 1	43 participants (Actual)	Interventional	2015-10-31	Completed
Laboratory-masked, Randomized Parallel, Comparative, Pilot Study on the Bioavailability of Vigamox in the Aqueous Humor When Administered Either as Commercially Available Eye Drops or in a Spray Form [NCT00666042]		16 participants (Anticipated)	Interventional	2009-02-28	Completed
Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial Eradication and Key Symptom Relief in the Treatment of Acute Bacterial Maxillary Sinusitis With Moxifloxacin 400 mg QD [NCT00668304]	Phase 4	192 participants (Actual)	Interventional	2004-06-30	Completed
A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis. [NCT00581542]	Phase 4	124 participants (Actual)	Interventional	2007-03-31	Completed
A Randomized, Double-Blind, Placebo- and Moxifloxacin Positive-Controlled (Open-Label), Cross-Over Study to Evaluate the Potential Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Subjects [NCT02735603]	Phase 1	84 participants (Actual)	Interventional	2016-04-30	Completed
A Prospective, Randomized, Open Label, Active Comparator, Multicenter, National Trial to Compare the Efficacy and Safety of Sequential IV/PO Moxifloxacin 400 mg Once Daily Versus IV Amoxicillin/Clavulanate 2,0/0,2 g Every 8 Hours Followed by Oral Amoxicil [NCT00828971]	Phase 3	16 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors [NCT00861029]	Phase 1	2 participants (Actual)	Interventional	2009-03-19	Completed
COVID-19: A MULTIPART, PHASE 1 STUDY WITH RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-DOSE ESCALATION TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07817883 AND OPTIONAL OPEN-LABEL, RANDOMIZED STUDY T [NCT05580003]	Phase 1	94 participants (Actual)	Interventional	2022-10-17	Completed
A Prospective, Randomized, Double-dummy, Double-blind, Multicenter Trial Comparing the Safety and Efficacy of Intravenous Moxifloxacin 400 mg IV QD 24 Hours to That of Ertapenem 1.0 g IV QD 24 Hours for 5 to 14 Days for the Treatment of Subjects With Comp [NCT00492726]	Phase 3	804 participants (Actual)	Interventional	2006-07-31	Completed
Prospective, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg QD for 5 Days Versus Placebo in the Treatment of Acute Bacterial Sinusitis [NCT00492024]	Phase 3	374 participants (Actual)	Interventional	2005-01-31	Completed
A Phase 1, Randomized, Double Blind, Placebo and Active Controlled, Parallel Study to Evaluate the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization in Healthy Adult Subjects [NCT01565720]	Phase 1	161 participants (Actual)	Interventional	2012-03-31	Completed
Prospective, Multicenter, Randomized, Double Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg OD for 7 Days Versus a Standard Antibiotic Therapy for 10 Days in the Treatment of Acute Bacterial Rhino Sinusitis [NCT00493038]	Phase 4	293 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to The study was prematurely terminated due to slow enrollment beyond the planned study timelines.)
A Randomized, Double-Blind, Positive-Controlled, Placebo-Controlled, 4-Period Crossover Study to Investigate the Electrocardiographic Effects of BMS-986165 in Healthy Subjects [NCT03541564]	Phase 1	84 participants (Actual)	Interventional	2018-05-30	Completed
A Two-part, Single-center, Single-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Four-way Crossover Study to Investigate the Effect of RO7033877 on the QT/QTc Interval in Healthy Subjects [NCT02165332]	Phase 1	64 participants (Actual)	Interventional	2014-07-31	Completed
A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study of the Effects of HKI-272 on Cardiac Repolarization in Healthy Adult Subjects [NCT00708903]	Phase 1	60 participants (Actual)	Interventional	2008-05-31	Completed
Prospective, Randomized Study Comparing Effect on Wound Healing of Vigamox (Moxifloxacin 0.5% Ophthalmic Solution) and Cravit (Levofloxacin 0.5% Ophthalmic Solution) Administered Post-Surgically in Patients Undergoing Cataract Extraction [NCT00840580]	Phase 4	79 participants (Actual)	Interventional	2009-01-31	Completed
[NCT00703313]	Phase 4	72 participants (Anticipated)	Interventional	2008-05-31	Completed
A Prospective, Randomized, Double Dummy, Double Blind, Multi-center Multinational Trial Comparing the Efficacy and Safety of Moxifloxacin 400 mg PO QD 24 Hours for 14 Days to That of Levofloxacin 500 mg PO QD 24 Hours Plus Metronidazole 500 mg BID for 14 [NCT00453349]	Phase 3	460 participants (Actual)	Interventional	2007-01-31	Completed
A Double-blind, Randomized, Placebo-controlled Study to Investigate Chronic Intermittent-pulse-therapy of Moxifloxacin as a Prevention of Acute in Exacerbation Out-patients With Chronic Bronchitis. [NCT00473460]	Phase 3	1,404 participants (Actual)	Interventional	2004-10-31	Completed
Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients [NCT00458900]	Phase 2	4 participants (Actual)	Interventional	2007-07-31	Completed
MAESTRAL - A Prospective, Multinational, Multicenter, Randomized, Double Blind, Double Dummy, Controlled Study Comparing the Efficacy and Safety of Moxifloxacin to That of Amoxicillin Clavulanic Acid for the Treatment of Subjects With Acute Exacerbations [NCT00656747]	Phase 4	1,372 participants (Actual)	Interventional	2008-03-31	Completed
A Double Blind, Randomized, Repeat-Dose, Parallel Group Study to Define the ECG Effects of Lixivaptan Using a Clinical and a Supratherapeutic Dose, Compared to Placebo and Moxifloxacin (a Positive Control), in Healthy Adult Men and Women: A Thorough ECG S [NCT00675701]	Phase 1	298 participants (Actual)	Interventional	2008-05-31	Completed
A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoi [NCT00575380]	Phase 4	116 participants (Actual)	Interventional	2007-12-31	Completed
A Double-blind, Randomized, Four-period Crossover Study to Assess the Effects of Single Oral Dose Dapagliflozin Administration on QTc Interval Compared to Placebo, Using AVELOX™ (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Age 18 to 45 [NCT00688493]	Phase 1	36 participants (Actual)	Interventional	2007-07-31	Completed
A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection [NCT00865280]	Phase 3	143 participants (Actual)	Interventional	2009-04-04	Terminated(stopped due to Terminated)
Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives [NCT00775190]		12 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to unale to recruit , progress report not filed by PI)
Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) [NCT04081077]	Phase 2/Phase 3	240 participants (Anticipated)	Interventional	2019-08-06	Active, not recruiting
A Randomized, Double-Blind, Placebo- and Positive-Controlled, Four-way Crossover Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects [NCT04019574]	Phase 1	57 participants (Actual)	Interventional	2019-06-20	Completed
A Phase 1, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Effects of Sapropterin Dihydrochloride Oral Administration on QTc Intervals in Healthy Adult Subjects [NCT00789568]	Phase 1	56 participants (Actual)	Interventional	2008-10-31	Completed
A National, Prospective, Randomized, Open Label Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin vs IV Ceftriaxone + IV Azithromycin Followed by PO Amoxicilline/Clavulanate and PO Clarithromycin in Subjects With Community-acquired Pneumonia [NCT00717561]	Phase 3	60 participants (Actual)	Interventional	2008-02-29	Completed
A Randomized, Double-Blind, Single-Dose, Placebo- and Positive-Controlled Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Exposure to CS-3150 on QTc Interval Duration in Healthy Male and Female Subjects [NCT04019652]	Phase 1	55 participants (Actual)	Interventional	2015-11-19	Completed
Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole as Adjunctive Therapy to Mechanical Treatment of Patients With Chronic Periodontitis [NCT00805558]	Phase 4	76 participants (Actual)	Interventional	2009-02-28	Completed
A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis [NCT02589782]	Phase 2/Phase 3	552 participants (Actual)	Interventional	2017-01-31	Active, not recruiting
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery [NCT00758199]	Phase 4	49 participants (Actual)	Interventional	2008-07-31	Completed
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% [NCT04214821]	Phase 1/Phase 2	128 participants (Anticipated)	Interventional	2019-09-23	Recruiting
A Blinded, Randomized Crossover Trial to Define the ECG Effects of TA-1790 (Avanafil) Using a Single Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin in Healthy Men: A Thorough ECG Trial [NCT00769041]	Phase 1	57 participants (Actual)	Interventional	2008-10-31	Completed
A Prospective Trial Evaluating a Intracanalicular Insert Delivery System Compared to Traditional Topical Drops in Controlling Post-operative Pain and inFlammation in Subjects Undergoing Sequential Bilateral Cataract Surgery [NCT04205916]	Phase 4	50 participants (Anticipated)	Interventional	2019-11-04	Recruiting
A Phase I, Double-blind, Double-dummy, Placebo-controlled, Randomised, Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Posi [NCT00713336]	Phase 1	40 participants (Anticipated)	Interventional	2008-06-30	Completed
A Phase 1, Single-Center, Double-Blind, Randomized, Placebo- and Positive Controlled, Double-Dummy, Parallel-Group, Repeated Dose Study With a Nested Cross-Over Comparison Between Moxifloxacin and Placebo to Evaluate the Effect of MD1003 on Cardiac Repola [NCT04168723]	Phase 1	64 participants (Anticipated)	Interventional	2019-11-11	Recruiting
EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE LEVEL OF EUGLYCEMICS:A PRE-CLINICAL AND CLINICAL STUDY [NCT04692623]	Phase 1	25 participants (Actual)	Interventional	2021-03-01	Completed
Efficacy of Antibiotic Steroid Combination Compared With Individual Administration in Prevention of Post Operative Inflammation in Patients Having LASIK Surgery [NCT00330824]		64 participants (Actual)	Interventional	2006-04-30	Completed
An Evaluation of the Safety and Efficacy of the Administration of a Fixed Combination of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops Compared With the Individual Administration of Moxifloxacin 0.5% and Dexamethasone 0.1% in the Treatment of Bacteri [NCT00732446]	Phase 3	100 participants (Anticipated)	Interventional	2008-08-31	Completed
A Randomized, Multiple Dose, Placebo and Active Controlled 3-way Crossover Study to Investigate the Effects of Esreboxetine on QTc Interval in Healthy Volunteers [NCT00809289]	Phase 1	40 participants (Anticipated)	Interventional	2008-12-31	Completed
A Single Center, Three Period, Randomized, Three-way Crossover, Double-blind Placebo And Moxifloxacincontrolled Study To Assess The Effects Of Effexor Xr On Cardiac Repolarization In Healthy Adult Subjects [NCT02637193]	Phase 1	54 participants (Actual)	Interventional	2015-12-31	Completed
A Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, Phase 1 Study to Assess the Effect of Single Therapeutic and Supratherapeutic Doses of Daridorexant on the QT Interval Duration in Healthy Subjects [NCT04250506]	Phase 1	36 participants (Actual)	Interventional	2020-02-28	Completed
A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Or [NCT00402727]	Phase 3	813 participants (Actual)	Interventional	2006-09-30	Completed
A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Po [NCT00887770]	Phase 1	64 participants (Anticipated)	Interventional	2009-04-30	Completed
A Randomized Clinical Trial Comparing the Effect of Moxifloxacin Versus Gatifloxacin Following Pterygium Excision on Corneal Epithelial Healing and Epithelial Toxicity. [NCT00892918]		40 participants (Anticipated)	Interventional	2009-06-30	Not yet recruiting
Interventional, Randomised, Partially Double-blind, Crossover, Positive-controlled, Single-dose Trial Investigating the Effect of LEO 152020 on Cardiac Repolarisation in Healthy Men and Women [NCT05508776]	Phase 1	28 participants (Actual)	Interventional	2022-09-16	Completed
A Double-Blind, Randomised, Multicentre, Placebo-Controlled, 4-Ways Crossover Study to Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days, Using Moxifloxacin as a Positive Control, in Healthy Male Volun [NCT00686179]	Phase 1	75 participants (Actual)	Interventional	2008-01-31	Completed
To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection [NCT00690313]	Phase 4	22 participants (Actual)	Interventional	2008-08-31	Completed
Thorough QT/QTc Study of Staccato® Loxapine for Inhalation in Healthy Volunteers [NCT00874237]	Phase 1	48 participants (Actual)	Interventional	2009-04-30	Completed
A Randomized, Double-blind, Placebo- & Positive-Controlled, Parallel Group, Dose Escalating Study to Evaluate the Effect of Buprenorphine Delivered by Buprenorphine Transdermal System at 10- and 40-mg Dose Levels on QT Intervals in Healthy Adult Volunteer [NCT01148537]	Phase 1	132 participants (Actual)	Interventional	2004-07-31	Completed
A Single Dose, Double Blind, Randomized, Crossover Placebo- and Moxifloxacin (Open Label)-Controlled Study to Evaluate the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects [NCT02616913]		48 participants (Actual)	Interventional	2013-03-31	Completed
A Randomized, Double-blind, Placebo- and Positive-Controlled, Parallel Group, Dose Escalating Study of the Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets at Doses up to 160 mg on QT/QTc in Healthy Adult Subjects [NCT02243241]	Phase 1	208 participants (Actual)	Interventional	2012-11-30	Completed
Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery [NCT00924729]	Phase 4	50 participants (Actual)	Interventional	2009-09-30	Completed
A Phase I, Randomized, Gender Stratified, Double-Blind, Placebo- and Positive-Controlled, Three Period Crossover Trial to Assess the Effect of Guanfacine Hydrochloride on QT/QTc Interval in Healthy Men and Women [NCT00672984]	Phase 1	83 participants (Actual)	Interventional	2008-04-18	Completed
A Blinded Randomized Parallel Trial to Define the ECG Effects of Bardoxolone Methyl Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial. [NCT01689116]	Phase 1	179 participants (Actual)	Interventional	2012-08-31	Completed
A Single-center, Single-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Four-way Crossover Study to Investigate the Effect of Danoprevir With Low Dose Ritonavir (DNV/r) on the QT/QTc Interval in Healthy Subjects [NCT01398293]	Phase 1	52 participants (Actual)	Interventional	2011-08-31	Completed
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB [NCT00879008]		345 participants (Actual)	Observational	2009-12-31	Completed
A Study to Evaluate the Effect of a Single 250 mg Oral Dose of GSK1349572 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin (ING111856). [NCT00996021]	Phase 1	42 participants (Actual)	Interventional	2009-09-30	Completed
Prospective, Randomized, Open-Labeled, Active-Controlled Comparison of Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess: A Pilot Study [NCT00895089]	Phase 4	24 participants (Actual)	Interventional	2009-05-31	Completed
A Phase I Thorough QT/QTc Study To Evaluate The Effect of Therapeutic and Supratherapeutic Multiple Doses of Prucalopride on Cardiac Repolarisation in Healthy Male and Female Volunteers [NCT00903747]	Phase 1	120 participants (Actual)	Interventional	2009-01-31	Completed
An Open-Label Study to Evaluate Pharmacokinetic Profile of Agile TCDS AG200-15 and to Compare Exposure to Ethinyl Estradiol to Oral Contraceptive (Orthocyclen®) in Healthy Female Volunteers [NCT01243580]	Phase 1	36 participants (Actual)	Interventional	2009-08-31	Completed
A Randomized, Placebo- and Positive-Controlled, Multiple-Dose, 4-Way Crossover Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Subjects [NCT02816853]	Phase 1	44 participants (Actual)	Interventional	2016-05-31	Completed
A Randomized, Double-blind, Placebo and Positive Controlled, Parallel Group Trial to Investigate the Effect of Multiple Doses of NOMAC-E2 on QT/QTc Interval in Healthy Women [NCT00779532]	Phase 1	189 participants (Actual)	Interventional	2008-05-31	Completed
A Phase 1, Single-Dose, Randomized, Placebo- and Positive-Control, Four-Way, Crossover Study for the Evaluation of the Effect of Epetraborole on QT Intervals in Healthy Adult Subjects [NCT05995444]	Phase 1	24 participants (Actual)	Interventional	2023-06-05	Completed
Comparative Evaluation of Intensified Short Course Regimen and Standard Regimen for Adults TB Meningitis : an Open-label Randomized Controlled Trial [NCT05917340]	Phase 3	372 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
A Randomized, Observer-masked, Parallel-group, Multicenter Trial Evaluating the Ocular Penetration of 1.5% Levofloxacin Ophthalmic Solution and 0.5% Moxifloxacin Ophthalmic Solution in Subjects Undergoing Corneal Transplant Surgery [NCT00764582]	Phase 4	60 participants (Anticipated)	Interventional	2008-09-30	Terminated(stopped due to Study terminated due to lack of enrollment.)
A Randomized, Double-Blind (Periods 1 to 3), Placebo- and Positive-Controlled, Single Dose, 4-Period, Crossover Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Subjects [NCT02737605]	Phase 1	62 participants (Actual)	Interventional	2016-07-01	Completed
Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery [NCT00816426]	Phase 1	19 participants (Actual)	Interventional	2008-12-29	Completed
A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, [NCT02040987]	Phase 1	52 participants (Actual)	Interventional	2014-01-31	Completed
A Phase 1, Randomized, Double-Blind, Placebo- and Active- Controlled, Crossover Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Male and Female Adult Subjects [NCT00850746]	Phase 1	80 participants (Actual)	Interventional	2009-02-28	Completed
Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis [NCT02595359]	Phase 2	1,000 participants (Actual)	Interventional	2013-01-31	Completed
Evaluation of the Effects of Multiple Therapeutic and Supratherapeutic Doses of Cebranopadol on Cardiac Repolarization in Healthy Subjects [NCT03958123]	Phase 1	171 participants (Actual)	Interventional	2013-07-10	Completed
A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled, Thorough QT Study to Evaluate the Effect of Ampreloxetine on Cardiac Repolarization in Healthy Subjects [NCT04688632]	Phase 1	72 participants (Actual)	Interventional	2021-01-18	Completed
A Two-part, Phase I, Double-blind, Placebo- and Positive-controlled Crossover Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Subjects [NCT05355935]	Phase 1	48 participants (Actual)	Interventional	2022-04-27	Completed
A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects [NCT02911870]	Phase 1	84 participants (Actual)	Interventional	2016-09-23	Completed
Acceptability of the NuvaRing Among College and Graduate Students [NCT00635570]	Phase 4	273 participants (Actual)	Interventional	2008-07-31	Completed
A Randomized, Parallel Group Safety Evaluation of Electrocardiographic Intervals and Blood Pressure in Normal Healthy Volunteers After Nebivolol, Atenolol, Moxifloxacin, or Placebo Administration After Single and Repeated Doses [NCT00158093]	Phase 1	260 participants	Interventional	2003-06-30	Completed
GIANT - Greatest International Antiinfective Trial With Avelox® [NCT00932802]		50,000 participants (Actual)	Observational	2004-02-29	Completed
Comparison of the Effect Between Levofloxacin and Moxifloxacin on the Culture Conversion After 3 Months Treatment Among MDR-TB Patients; Prospective Multicenter Randomized Open Label Phase III Trial [NCT01055145]	Phase 3	182 participants (Actual)	Interventional	2010-03-31	Terminated
ARTOS - Avelox® in Routine Treatment of Complicated Skin and Skin Structure Infections [NCT00997997]		6,127 participants (Actual)	Observational	2005-10-31	Completed
A Single Center, Randomized, Double-blinded, Placebo-controlled, Open-label, Positive-controlled, Four-way Crossover Study to Assess the Effect of a Single Oral Dose NKTR-118 Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) [NCT01325415]	Phase 1	45 participants (Actual)	Interventional	2011-04-30	Completed
A Phase 1, Single Center Randomized, Three-way Crossover, Double-blinded, Placebo- And Moxifloxacin-controlled Thorough Qt (Tqt) Study To Determine The Effects Of Sertraline (Zoloft (Registered)) On The Cardiac Repolarization In Healthy Subjects [NCT02651623]	Phase 1	54 participants (Actual)	Interventional	2016-01-31	Completed
Effect of BMS-650032 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri- Cyclen (R)) in Healthy Female Subjects [NCT01063023]	Phase 1	20 participants (Actual)	Interventional	2010-01-31	Completed
Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia [NCT01045902]	Phase 3	139 participants (Actual)	Interventional	2001-02-28	Completed
Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease [NCT00292227]	Phase 1	130 participants (Actual)	Interventional	2006-01-31	Completed
Randomized, Open Label, Multiple Dose Phase I Study of the Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, and Moxifloxacin in HIV-non-infected Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis [NCT00396084]	Phase 1/Phase 2	70 participants (Actual)	Interventional	2004-02-10	Completed
A Phase 3B Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial To Evaluate The Efficacy and Safety Of Azithromycin SR (Microspheres Formulation) Versus Moxifloxacin For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB). [NCT00254566]	Phase 3	398 participants (Actual)	Interventional	2006-02-28	Completed
Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients [NCT01049022]	Phase 1	31 participants (Actual)	Interventional	2010-05-31	Completed
A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis [NCT00348348]	Phase 3	1,161 participants (Actual)	Interventional	2006-06-30	Completed
A Randomized, Three Period Crossover Thorough QT (TQT) Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers [NCT03985410]	Phase 1	32 participants (Actual)	Interventional	2019-05-23	Completed
A Double Blind, Placebo Controlled, Positive Controlled, Randomized, Crossover Study to Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers [NCT00699504]	Phase 1	67 participants (Actual)	Interventional	2008-06-30	Completed
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora [NCT00312338]	Phase 4	137 participants (Actual)	Interventional	2006-06-30	Completed
A Double-Blind Randomized Crossover Trial to Define the Ecg Effects of Droxidopa Using a Clinical and a Supratherapeutic Dose Compared With Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: a Thorough ECG Trial [NCT01327066]	Phase 1	52 participants (Actual)	Interventional	2011-03-31	Completed
Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects [NCT01874314]	Phase 1	0 participants (Actual)	Interventional		Withdrawn
A Single-Center, Double-Blind, Randomized, Placebo- and Positive-Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Custirsen (640 mg) on Cardiac Repolarization in Healthy Men [NCT01874561]	Phase 1	155 participants (Actual)	Interventional	2013-05-31	Completed
A Randomized, Double-blind, Placebo-controlled, Two-way Crossover Trial to Compare Moxifloxacin Induced QT Interval Prolongation in Japanese and Korean Healthy Subjects [NCT01876316]		40 participants (Actual)	Interventional	2011-11-30	Completed
A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects [NCT01910415]	Phase 1	200 participants (Actual)	Interventional	2013-06-30	Completed
Randomized, Double-blind, Placebo-controlled, Positive-controlled, 4-period, 4-way Crossover Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 800 mg and 2000 mg Compared With Placebo and Open-label Moxifloxacin in Healthy Subjects: [NCT01913002]	Phase 1	63 participants (Actual)	Interventional	2013-07-31	Completed
A Single Centre, Placebo Controlled, Phase I Study to Evaluate the Effect of Glucose and Moxifloxacin on Cardiac Repolarisation in Male and Female Patients With Type I Diabetes. [NCT01984827]	Phase 1	24 participants (Actual)	Interventional	2019-02-10	Completed
A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification [NCT01296542]	Phase 4	60 participants (Actual)	Interventional	2011-05-31	Completed
Effect of Gatifloxacin 0.3% and Moxifloxacin 0.5% on Epithelial Wound Healing After Photorefractive Keratectomy [NCT00569881]		22 participants (Actual)	Observational	2007-01-31	Completed
[NCT00630019]	Phase 4	96 participants (Anticipated)	Interventional	2008-02-29	Completed
Moxifloxacin In Situ Gel as an Adjunct in the Treatment of Periodontal Pocket: A Randomized Clinical Trial. [NCT02016157]	Phase 4	5 participants (Actual)	Interventional	2011-09-30	Completed
A Study to Evaluate the Effect of GSK1265744 150mg Administered Orally Every 12h x 3 Doses on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin [NCT02027454]	Phase 1	42 participants (Actual)	Interventional	2014-01-31	Completed
A Randomized, Double-blind, 2-way Crossover, Placebo-controlled Study to Investigate the Influence of a Single-dose of Moxifloxacin on the QTc Interval in Healthy Male and Female Subjects for Positive Control Validation in Selected Centers of the PATENT-1 [NCT01014247]	Phase 1	56 participants (Actual)	Interventional	2009-11-30	Completed
A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive- Controlled, Crossover Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers [NCT02217930]	Phase 1	80 participants (Actual)	Interventional	2014-08-31	Completed
Assessment of the Effect of 25 mg and 200 mg of BI 10773 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Five-period Crossover Phase-I-study With Moxifloxacin as Positive Control [NCT01195675]	Phase 1	30 participants (Actual)	Interventional	2010-08-31	Completed
A Study of Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia [NCT00665327]	Phase 4	401 participants (Actual)	Interventional	2002-11-30	Completed
A Randomized, Double-blind, Placebo- and Positive-controlled, Single-dose, 4-way Crossover Study to Evaluate the Effects of Aticaprant (JNJ-67953964) on Electrocardiogram Intervals in Healthy Adult Participants [NCT05387759]	Phase 1	60 participants (Actual)	Interventional	2022-05-30	Completed
TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment [NCT00144417]	Phase 2	433 participants (Actual)	Interventional	2006-02-28	Completed
A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single-Dose, Four-Way Crossover Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Subjects [NCT02271438]	Phase 1	28 participants (Actual)	Interventional	2014-10-31	Completed
Reduction of Premature Discontinuation of Contraceptive Implants by Advance Provision of an OCP-based Participant Intervention: Randomized Clinical Trial [NCT04828824]	Phase 4	600 participants (Anticipated)	Interventional	2021-06-18	Recruiting
Use of Intracameral Moxifloxacin for the Prevention of Acute Endophthalmitis Following Cataract Surgery: a Controlled and Randomized Clinical Trial [NCT02770729]	Phase 3	3,640 participants (Actual)	Interventional	2017-01-31	Terminated
A Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Alone, TMC207 Plus Pyrazinamide,TMC207 Plus PA-824,PA-824 Plus Pyrazinamide and PA-824 Plus Pyrazinamide and Moxifloxacin, in Adult Patients Wit [NCT01215851]	Phase 2	85 participants (Actual)	Interventional	2010-10-31	Completed
Economic Evaluation of New MDR TB Regimens (PRACTECAL EE) [NCT04207112]	Phase 2/Phase 3	200 participants (Anticipated)	Interventional	2020-10-20	Recruiting
An Evaluation of the Prophylactic Efficacy and Safety of the Administration of the Combination Formulation of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops in Inflammation and Infection Post-cataract Surgery [NCT00870103]	Phase 4	64 participants (Actual)	Interventional	2008-09-30	Completed
A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis [NCT04187469]		286 participants (Anticipated)	Interventional	2020-03-01	Not yet recruiting
A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive Controlled Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Subjects [NCT02833831]	Phase 1	103 participants (Actual)	Interventional	2016-06-02	Completed
Prospective, Randomized, Open, Multicentre Study About the Effect of an Empirical Antibiotic Monotherapy With Meropenem (Meronem®) Versus a Combination Therapy With Moxifloxacin (Avalox®) on Organ Dysfunction in Patients With Severe Sepsis and Septic Shoc [NCT00534287]	Phase 3	600 participants (Actual)	Interventional	2007-10-31	Completed
A Phase I, Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Positive-Controlled Study to Investigate the Effects of CBP-307 on the QTc Interval in Healthy Subjects [NCT04818229]	Phase 1	112 participants (Actual)	Interventional	2021-06-01	Completed
A Phase III Single-blind, Randomised Placebo Controlled Trial of Long Term Therapy in Patients With Stable COPD Using Moxifloxacin, Azithromycin and Doxycycline: a Bayesian Decision Analysis, Including Other Criteria, Will be Used to Distinguish the Optim [NCT01398072]	Phase 3	200 participants (Anticipated)	Interventional	2011-12-31	Recruiting
A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albi [NCT01406262]	Phase 1	94 participants (Actual)	Interventional	2011-07-06	Completed
A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia [NCT01968733]	Phase 3	863 participants (Actual)	Interventional	2013-11-30	Completed
A Methodological Open-Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarisation and QT Interval At Fixed Heart Rate Under Autonomic Blockade [NCT00174512]	Phase 1	36 participants	Interventional	2005-03-31	Completed
Prospective, Doubleblind, Randomized Multicenter Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia [NCT00887276]	Phase 4	290 participants (Actual)	Interventional	2008-11-30	Terminated
Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis [NCT02717871]	Phase 3	35 participants (Actual)	Interventional	2016-03-31	Completed
The Clinical Safety of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% [NCT04212429]	Phase 1/Phase 2	128 participants (Anticipated)	Interventional	2019-09-23	Recruiting
Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers: A Randomised, Parallel, Placebo and Positive Controlled Study [NCT00199225]	Phase 1	160 participants	Interventional	2005-02-28	Completed
Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs in Healthy Korean Adults After a Single Oral Administration of Escitalopram, Quetiapine, and Moxifloxacin [NCT01871701]	Phase 1	40 participants (Actual)	Interventional	2012-11-30	Completed
A Randomised, Double-blind, Placebo and Active Controlled Crossover Study to Assess the Effect of Single Dose Administration of 2 Doses of Imeglimin on QT/QTc Intervals in Healthy Subjects [NCT02924337]	Phase 1	55 participants (Actual)	Interventional	2016-09-30	Completed
Impact of Different DAV132 Dose Regimens (From 2 to 22.5 g/Day During 7 Days, Bid and Tid) on the Fecal Moxifloxacin Concentrations and the Intestinal Microbiota of Healthy Volunteers Treated With Moxifloxacin 400 mg/Day During 5 Days [NCT02917200]	Phase 1	150 participants (Actual)	Interventional	2016-05-11	Completed
A Randomized, 2-Part, Crossover Trial to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects [NCT05924321]	Phase 1	40 participants (Actual)	Interventional	2023-05-25	Completed
A Phase 1 Blinded, Placebo-controlled Crossover Study to Evaluate the Effects of Oral TR 701 Free Acid on the Electrocardiogram [NCT01461460]	Phase 1	48 participants (Actual)	Interventional	2011-11-28	Completed
Influence of the Administration of DAV132 7.5g Tid for 7 Days on the Fecal Levels of Moxifloxacin During and After a 5-day Oral Treatment With Moxifloxacin 400mg Oad in Healthy Volunteers [NCT02176005]	Phase 1	44 participants (Actual)	Interventional	2014-03-31	Completed
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer [NCT03405168]	Phase 2	35 participants (Actual)	Interventional	2018-01-01	Completed
A Randomized, Single-dose, Crossover Study of the Effects of SEP-363856 on Electrocardiogram (ECG) Intervals in Subjects With Schizophrenia [NCT04369391]	Phase 1	150 participants (Actual)	Interventional	2020-06-18	Completed
Prospective Study Comparing the Effectiveness of Zymar and Vigamox for Preoperative Antibiotic Sterilization of the Ocular Surface After Loading Dose [NCT00347828]	Phase 4	40 participants	Interventional	2006-06-30	Active, not recruiting
A Multinational, Prospective, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Tr [NCT00431678]	Phase 3	738 participants (Actual)	Interventional	2004-01-31	Completed
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery [NCT03244072]	Phase 2/Phase 3	60,000 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects [NCT00549666]	Phase 1	23 participants (Actual)	Interventional	2007-08-31	Completed
[NCT00874887]	Phase 4	66 participants (Actual)	Interventional	2009-03-31	Completed
A Phase 1, Randomized, Partial Double-Blind, Placebo- and Positive-Controlled, Three-way Crossover Study to Evaluate the Effect of MT-7117 on the QT/QTc Interval in Healthy Subjects [NCT05241535]	Phase 1	29 participants (Actual)	Interventional	2022-01-12	Completed
A Phase I, Single-Centre, Randomised, Placebo and Positive- Controlled, Parallel-Group Study of the Electrocardiographic Effects of TA-8995 in Healthy Male and Female Subjects [NCT02241759]	Phase 1	136 participants (Actual)	Interventional	2014-08-31	Completed
A Four-Arm, Randomized, Crossover, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Doses of CTP-543 on the QT/QTc Intervals in Healthy Volunteers [NCT05192369]	Phase 1	48 participants (Actual)	Interventional	2022-01-04	Completed
A Randomized, Double-blind, Placebo- and Active-controlled, 3-way Crossover, Phase 1 Study to Evaluate the Effect of EVP-6124 at Therapeutic and Supratherapeutic Concentrations Following a 2-dose EVP-6124 Regimen on the QT Interval in Healthy Male and Fem [NCT01487135]	Phase 1	60 participants (Actual)	Interventional	2011-12-31	Completed
A Double-blind, Randomised, Placebo Controlled, Three-way Cross-over Study With an Open Label Positive Control (Moxifloxacin) to Assess the Influence of Inhaled Tiotropium Once Daily Over Twelve Days on the QTC Interval of the ECG in Healthy Male and Fema [NCT00257452]	Phase 1	56 participants	Interventional	2004-10-31	Completed
Pharmacokinetic Interaction Study of Rifampicin, Isoniazid and Moxifloxacin in Tuberculosis Patients in Bandung, Indonesia [NCT00306319]	Phase 2	23 participants	Interventional	2006-01-31	Completed
Dropless Pars Plana Vitrectomy Study [NCT05331664]	Phase 4	168 participants (Anticipated)	Interventional	2022-07-25	Recruiting
An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India [NCT00332293]	Phase 3	695 participants (Actual)	Interventional	2006-05-31	Completed
Efficacy of Antibiotic Steroid Combination Compared With Individual Administration in Prevention of Postoperative Inflammation in Patients Having Cataract Surgery [NCT00331084]		132 participants (Actual)	Interventional	2006-04-30	Completed
A Randomized, Placebo-Controlled, Double-Blind, Four-way Crossover Study to Assess the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers [NCT01702376]	Phase 1	52 participants (Actual)	Interventional	2012-10-03	Completed
Comparison of Oral and Patch Forms of Hormonal Contraception on Plasma Lipoproteins, Glycemia, Clotting Factors, Indices of Inflammation and Vascular Reactivity [NCT00439972]	Phase 2	36 participants (Anticipated)	Interventional	2007-02-28	Active, not recruiting
Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection [NCT00455806]	Phase 3	132 participants	Interventional	2007-01-31	Recruiting
Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy = ACDC-study [NCT00447304]	Phase 3	644 participants (Anticipated)	Interventional	2006-10-31	Completed
Pharmacokinetic Issues in the Use of Moxifloxacin Plus Rifapentine [NCT00460759]	Phase 1	15 participants (Actual)	Interventional	2007-06-30	Terminated
A Single-Dose, Double-Blind, Crossover, Placebo- and Moxifloxacin (Open-Label)-Controlled Study of the Effects of Lecozotan SR on Cardiac Repolarization in Healthy Adult Subjects [NCT00499642]	Phase 1	0 participants	Interventional	2007-06-30	Completed
TBTC Study 27: An Evaluation of the Activity and Tolerability of Moxifloxacin During the First Two Months of Treatment for Pulmonary Tuberculosis--A Double-Blind, Randomized, Multicenter Study by the Tuberculosis Trials Consortium [NCT00140309]	Phase 2	350 participants	Interventional	2003-07-31	Completed
Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour [NCT00466570]		0 participants (Actual)	Interventional	2007-04-30	Withdrawn
Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment) [NCT05766267]	Phase 2/Phase 3	288 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
An Open-Label, Randomized Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects After a Single Topical Dose [NCT00824070]	Phase 1	105 participants (Actual)	Interventional	2009-02-28	Completed
A Randomized, Partially Double-Blind, Four-Period, Four-Treatment, Crossover Study Investigating the Placebo-Corrected Effects of a Therapeutic Dose (100 mg) and a Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval [NCT04821063]	Phase 1	31 participants (Actual)	Interventional	2021-04-13	Completed
TBTC Study 27/28 PK: Pharmacokinetic Issues in the Use of Moxifloxacin for Treatment of Tuberculosis [NCT00164463]	Phase 2	72 participants (Actual)	Interventional	2004-07-31	Completed
A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia [NCT01756339]	Phase 3	860 participants (Actual)	Interventional	2012-12-31	Completed
A Phase II Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 8 Weeks of Treatment in Adult Patients With Newly Diagnosed Drug-Sensitive or Multi D [NCT01498419]	Phase 2	207 participants (Actual)	Interventional	2012-03-31	Completed
Pilot Study on Bioavailability of Vigamox Administered as Drops vs. as Spray [NCT00565630]		16 participants (Anticipated)	Interventional	2008-01-31	Withdrawn(stopped due to Replaced with ongoing study)
Evaluation of the Effects of Therapeutic and Supra-therapeutic Single Doses of SKY0402 Given as Subcutaneous Injection on the QT/QTc Interval in Young Healthy Volunteers. A Prospective, Randomized, Placebo- and Positive-controlled, Double Blind, Single-ce [NCT00485667]	Phase 1	48 participants (Actual)	Interventional	2007-06-30	Completed
Evaluation of the Safety and Efficacy of VIGADEXA Ophthalmic Gel Compared to VIGADEXA Ophthalmic Solution in Preventing Inflammation and Infection Following Cataract Surgery [NCT01515826]	Phase 3	0 participants (Actual)	Interventional	2014-03-31	Withdrawn(stopped due to Management decision)
A Thorough QTc Evaluation of the Effect of Liraglutide on Cardiac Repolarization in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled, Two Period Crossover Study Followed by Open-label Moxifloxacin (Positive Control) Administration [NCT01516255]	Phase 1	64 participants (Actual)	Interventional	2006-07-31	Completed
A Randomized, Double-blind, Single Dose Crossover Study to Assess the Effect of Gabapentin Enacarbil on Cardiac Conduction as Compared With Placebo and Moxifloxacin in Healthy Volunteers [NCT01516372]	Phase 1	52 participants (Actual)	Interventional	2012-01-31	Completed
A Randomised, Placebo-controlled, Incomplete Block, Four Period Crossover , Repeat Dose Study to Evaluate the Effect of the Inhaled GSK573719/Vilanterol Combination and GSK573719 Monotherapy on Electrocardiographic Parameters, With Moxifloxacin as a Posit [NCT01521377]	Phase 1	100 participants (Actual)	Interventional	2011-12-19	Completed
A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women [NCT01532115]	Phase 1	64 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Double-Blind, Double-Dummy Pharmacokinetic and Exploratory Electrocardiogram (ECG) Safety Study of a Standard Acute Gout Regimen [NCT01018420]	Phase 1	18 participants (Actual)	Interventional	2007-11-30	Completed
A Phase I, Double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled, Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc [NCT02056392]	Phase 1	54 participants (Actual)	Interventional	2014-03-31	Completed
A Randomized, Double-Blind, Placebo and Positive-Controlled, Crossover Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers [NCT01514929]	Phase 1	64 participants (Actual)	Interventional	2011-10-31	Completed
Study to Evaluate the Effect of Efavirenz Coadministration on the Pharmacokinetics of the Active Moieties of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects [NCT00399685]	Phase 1	28 participants (Actual)	Interventional	2006-12-31	Completed
AVANTI - Avelox® in Acute Exacerbations of Chronic Bronchitis [NCT00846911]		2,672 participants (Actual)	Observational	2008-04-30	Completed
Assistant Professor, Ophthalmology Department, Al Azhar University [NCT05428683]		84 participants (Actual)	Interventional	2020-12-03	Completed
A Single Part, Four-Way Crossover, Randomized, Partially-Blinded Study to Evaluate the Effect of Intravenous ANG-3777 on Baseline-Adjusted QT/QTc Interval in the Fasted State in Healthy Male and Female Subjects [NCT04898907]	Phase 1	48 participants (Anticipated)	Interventional	2021-06-30	Not yet recruiting
[NCT00407017]	Phase 4	0 participants	Interventional		Completed
A Phase IIB, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of Sutezolid in Combination With Bedaquiline, Delamanid and Moxiflo [NCT03959566]	Phase 2	75 participants (Actual)	Interventional	2021-05-06	Completed
Oral Empirical Therapy of Fever in Low-Risk Neutropenic Cancer Patients: A Prospective, Double-Blind, Randomized, Multicenter Trial Comparing Monotherapy (Single Daily Dose Moxifloxacin) With Combination Therapy (Ciprofloxacin Plus Amoxicillin/Clavulanic [NCT00062231]		351 participants (Actual)	Interventional	2002-04-30	Terminated(stopped due to low accrual)
A Four Period, Four-Arm, Crossover Design, Randomized, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Single-Dose ANX-188 on the QT/QTc Intervals in Healthy Volunteers [NCT01790087]	Phase 1	72 participants (Actual)	Interventional	2013-02-28	Completed
The Effect of ALKS 5461 on QT Intervals in Healthy Volunteers [NCT02479308]	Phase 1	129 participants (Actual)	Interventional	2015-06-30	Completed
A Parallel-arm, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder [NCT01423916]	Phase 1	218 participants (Actual)	Interventional	2011-07-31	Completed
A Single-center, Double-blind for Cenerimod, Open-label for Moxifloxacin, Placebo-controlled, Parallel-group, Randomized Study in Healthy Male and Female Subjects to Investigate I: the Effect of Cenerimod on the QTc Interval II: the Effect of Cenerimod on [NCT04255277]	Phase 1	97 participants (Actual)	Interventional	2020-01-31	Completed
Phase I, Double-Blind, Randomized, Single-Center, Five-Period Crossover Study to Assess the Effects of Single Oral Doses of 400 mg and 1000 mg of PA-824 and 400 mg of PA-824 Plus 400 mg of Moxifloxacin on QTc Interval Compared to Placebo, Using AVELOX™ (M [NCT01674218]	Phase 1	74 participants (Actual)	Interventional	2012-09-30	Completed
New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis [NCT02331823]	Phase 4	864 participants (Anticipated)	Interventional	2013-06-30	Recruiting
A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis [NCT00728507]	Phase 2	121 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to Funding withdrawn)
Evaluation of Energy Drink Consumption on Electrocardiographic, Vascular and Hematologic Parameters in Young Healthy Volunteers: A Randomized, Double Blind, Active-Controlled, Crossover Study [NCT03021616]		2 participants (Actual)	Interventional	2017-06-26	Terminated(stopped due to Results from sister study at University of the Pacific were conclusive.)
[NCT01792700]	Phase 4	648 participants (Actual)	Interventional	2003-01-31	Completed
A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening [NCT00864383]	Phase 3	1,931 participants (Actual)	Interventional	2008-01-31	Completed
A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis [NCT01785186]	Phase 2	365 participants (Actual)	Interventional	2013-04-30	Completed
Clinical Evaluation of Systemic Moxifloxacin Compared to Amoxicillin Plus Metronidazole Adjunct to Non-surgical Treatment in Generalized Aggressive Periodontitis: A Randomized Clinical Trial [NCT02223702]	Phase 4	39 participants (Actual)	Interventional	2011-05-31	Completed
[NCT00464438]	Phase 4	171 participants (Actual)	Interventional	2007-06-30	Completed
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification [NCT01296191]	Phase 4	120 participants (Actual)	Interventional	2011-05-31	Completed
A Randomized, Double-Blind, Placebo- and Positive Controlled, Crossover, Thorough QT/QTc Study to Evaluate the Effects of a Therapeutic and Supratherapeutic Dose of Ecopipam (EBS-101) on Cardiac Repolarization in Healthy Subjects [NCT05841160]	Phase 1	29 participants (Actual)	Interventional	2023-03-15	Completed
Efficacy of Moxifloxacin 0.5%/Prednisolone 1% Fixed Combination Compared With Individual Administration of Moxifloxacin 0.5% and Prednisolone 1% in the Prevention of Post Operative Inflammation in Patients Having Lasik Surgery [NCT01603030]	Phase 3	66 participants (Anticipated)	Interventional	2012-06-30	Not yet recruiting
A Randomized, Double-Blind, Two-Part, Parallel-Group, Comparative Study to Evaluate Blood Folate Levels in Women Taking an Oral Contraceptive With and Without Folic Acid [NCT00301587]	Phase 3	0 participants (Actual)	Interventional		Withdrawn(stopped due to Company decision to not fund further development of women's health new drug development programs.)
Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration [NCT00280514]	Phase 4	20 participants (Anticipated)	Interventional	2006-01-31	Completed
Cardiovascular Safety Study of 0.1 and 0.3 mmol/kg Magnevist® Injection at Two Injection Rates (Bolus and 10 mL/15 Sec.) in Normal Subjects Following a Randomized, Cross-over Design Using Placebo and a Concurrent Positive Control [NCT00310596]	Phase 1	71 participants (Actual)	Interventional	2004-01-31	Completed
Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation [NCT00324324]	Phase 3	240 participants (Anticipated)	Interventional	2006-05-31	Terminated
[NCT00335088]	Phase 3	500 participants (Anticipated)	Interventional	2006-06-30	Recruiting
A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol When Co-administered With Dolutegravir in Healthy Adult Female Subjects [NCT01498861]	Phase 1	16 participants (Actual)	Interventional	2011-12-31	Completed
Single Dose Safety, Tolerability And Pharmacokinetics Of Escalating Intravenous Doses Of Linezolid Followed By Evaluation Of The Effect Of Single Intravenous Doses Of Linezolid On QTc Interval In Healthy Subjects [NCT00795145]	Phase 1	49 participants (Actual)	Interventional	2008-12-31	Completed
A Single-Center, Randomized, Blinded, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Dexpramipexole (BIIB050) on the QTc Interval in Healthy Volunteers [NCT01511029]	Phase 1	68 participants (Actual)	Interventional	2012-01-31	Completed
A Thorough QTc Evaluation of the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel Study With a Nested Crossover Design for Positive Control With Moxifloxacin Administrat [NCT05668936]	Phase 1	31 participants (Actual)	Interventional	2023-01-03	Terminated(stopped due to Discontinuing the development of cotadutide, a daily injectable GLP-1/glucagon co-agonist, is based on strategic pipeline considerations. The premature closure is not due to any newly observed safety signals or a change in the risk/benefit profile.)
A Single-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study to Assess the QT/QTc Interval After Administration of Single Oral Dose of 400mg Moxifloxacin in Healthy Chinese Subjects [NCT01653990]		36 participants (Anticipated)	Interventional	2012-07-31	Recruiting
Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease [NCT01690533]		497 participants (Actual)	Observational	2008-05-13	Completed
A Placebo-Controlled, Single Dose, Dose Escalation (Part A) and a Placebo- and Positive-Controlled Study of the Effect on the Electrocardiographic QT Interval of a Single Dose (Part B) of LY3009104 in Healthy Subjects [NCT01536951]	Phase 1	62 participants (Actual)	Interventional	2012-02-29	Completed
A Four-Arm, Parallel Design, Randomized, Double-Blinded, Placebo and Active Controlled Study for the Evaluation of the Effect of Maximum Therapeutic and Supratherapeutic Single-Dose ATX-101 on the QT/QTc Intervals in Healthy Volunteers [NCT01706679]	Phase 1	218 participants (Actual)	Interventional	2012-10-31	Completed
A Randomized, 2-Part, Single-Dose, Crossover Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval in Healthy Participants [NCT05924815]	Phase 1	44 participants (Actual)	Interventional	2023-05-15	Completed
A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects [NCT01756495]	Phase 1	56 participants (Actual)	Interventional	2013-01-10	Completed
A Multi-center, Randomized, Open-label, Placebo-controlled, 3-way Crossover Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects [NCT01756521]	Phase 1	39 participants (Actual)	Interventional	2013-01-31	Completed
Bacteriology and Sputum and Systemic Inflammation in Steady-state, Acute Exacerbation and Recovery of Bronchiectasis [NCT01761214]		80 participants (Anticipated)	Interventional	2012-09-30	Recruiting
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers [NCT01762839]	Phase 1	150 participants (Actual)	Interventional	2013-01-31	Completed
A Randomized, Placebo- And Positive-Controlled Cross-Over Study To Evaluate The Effect Of Tafamidis On The QTC Interval In Healthy Volunteers [NCT01775761]	Phase 1	42 participants (Actual)	Interventional	2013-01-31	Completed
A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Four-Way Crossover Study Evaluating ECG Intervals in Healthy Adults Receiving a Single, Oral Dose of JNJ-28431754 at Therapeutic and Supra-Therapeutic Doses [NCT01787357]	Phase 1	60 participants (Actual)	Interventional	2008-06-30	Completed
A Phase I, Randomized, Partially Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers (PDF112166) [NCT01803399]	Phase 1	0 participants (Actual)	Interventional	2014-08-31	Withdrawn(stopped due to Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not seen that changed the risk: benefit profile and led to a termination)
A Single Center, Open Label, Randomized, Single-dose, 2 Way Cross-over Study to Explore the Relative Bioavailability of Moksi 400mg (Moxifloxacin) Tablet and Avelox 400mg (Moxifloxacin) Tablet Under Fasting Conditions in Healthy Male Pakistani Subjects [NCT05307614]	Phase 1	38 participants (Actual)	Interventional	2019-03-27	Completed
Essentiality of Isoniazid in Tuberculosis Therapy [NCT01589497]	Phase 2	69 participants (Actual)	Interventional	2015-06-30	Completed
A PHASE 1, RANDOMIZED, PLACEBO- AND POSITIVE-CONTROLLED CROSS-OVER STUDY TO DETERMINE THE EFFECT OF SINGLE-DOSE CP-690,550 ON QTC INTERVAL IN HEALTHY VOLUNTEERS [NCT01743677]	Phase 1	60 participants (Actual)	Interventional	2007-10-26	Completed
A Randomized Controlled Non-Inferiority Study for Shortening Tuberculosis Treatment With Sitafloxacin-Containing Regimens [NCT05454345]	Phase 3	620 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
Intraperitoneal (IP) Vancomycin Plus Oral Moxifloxacin Versus IP Vancomycin Plus IP Ceftazidime for the Treatment of Peritoneal Dialysis-related Peritonitis: a Pilot Randomized Controlled Study [NCT02787057]		80 participants (Actual)	Interventional	2012-11-30	Completed
A Single-site, Single Masked, Prospective Comparison of Three Fluoroquinolone Topical Therapies (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%) in the Treatment of Infectious Corneal Ulcers. [NCT01928693]	Phase 2	2 participants (Actual)	Interventional	2013-07-31	Terminated(stopped due to study terminated due to slow accrual)
A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmo [NCT02342886]	Phase 3	284 participants (Actual)	Interventional	2015-02-28	Completed
A Randomised, Partially Double Blind, Placebo and Positive Controlled, 4 Way Crossover Study to Evaluate the Effect of Icosabutate (NST 4016) on the QT/QTc Interval in Healthy Subjects [NCT03577275]	Phase 1	32 participants (Actual)	Interventional	2018-06-15	Completed
Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects [NCT01746732]	Phase 1	23 participants (Actual)	Interventional	2012-12-31	Completed
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction [NCT05110001]	Phase 3	330 participants (Anticipated)	Interventional	2022-08-03	Recruiting
A Multiple-Dose, Randomized, Double-Blind, Placebo- and Active-Controlled, Four-Arm, Parallel Group Thorough QT/QTc Study to Evaluate the Electrophysiologic Effects of Sativex. [NCT01322139]	Phase 1	258 participants (Actual)	Interventional	2007-12-31	Completed
A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of LOXO-292 on the QTc Interval in Healthy Adult Subjects [NCT05630274]	Phase 1	32 participants (Actual)	Interventional	2019-04-16	Completed
Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population [NCT01434173]		1,299,056 participants (Actual)	Observational	2001-07-31	Completed
A Randomized, Double-blind, Four-period Crossover Study to Investigate the Effect of Intravenous Ondansetron, a 5-HT3 Antagonist, on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects [NCT01449188]	Phase 1	60 participants (Actual)	Interventional	2011-08-16	Completed
A Phase 1, Randomized, Double-blind, Placebo- and Active-controlled, Thorough QT/QTc Study of VX-548 in Healthy Subjects [NCT05818852]	Phase 1	72 participants (Actual)	Interventional	2023-04-12	Completed
A Randomized, Placebo- and Active-controlled 4-way Crossover Study in Healthy Subjects to Evaluate the Effect of E4 on the QTc Interval [NCT04819906]	Phase 1	32 participants (Actual)	Interventional	2021-03-09	Completed
A Phase 1, Single-Center, Pacritinib- Versus Placebo-Blinded, Active- and Placebo-Controlled, Randomized, 3-Way Crossover Study to Evaluate the Cardiac Safety and Pharmacokinetics Following a Single Oral Dose Administration of Pacritinib in Healthy Subjec [NCT02807207]	Phase 1	42 participants (Actual)	Interventional	2014-10-31	Completed
Pharmacodynamic Effects, Safety and Tolerability of 2 mg and 5 mg Cilobradine, Administered p.o. Once Daily Over 14 Days to Healthy Male and Female Volunteers in a Randomised, Placebo-controlled, Double Blind Study, With an Open-label Uncontrolled Intra-i [NCT02264015]	Phase 1	125 participants (Actual)	Interventional	2004-01-31	Completed
Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349 [NCT02410772]	Phase 3	2,516 participants (Actual)	Interventional	2016-01-25	Completed
A Randomized, Double Blind, Placebo Controlled, Three- Period Crossover Study Comparing the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo on QT Intervals in Healthy Adults [NCT01191723]	Phase 1	54 participants (Actual)	Interventional	2010-08-31	Completed
The Effect of the Co-administration of BMS-790052 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri-Cyclen®) in Healthy Female Subjects [NCT00983957]	Phase 1	47 participants (Actual)	Interventional	2009-10-31	Completed
Randomized, Double-Blind, Double-Dummy, Placebo- and Positive Controlled, 4-Way Crossover Study to Assess the Effect of Single-Dose ACP-196 on the QTc Interval in Healthy Adult Subjects [NCT04867980]	Phase 1	48 participants (Actual)	Interventional	2016-04-01	Completed
Phase IV Study: A Prospective Two-Site Study to Evaluate the Safety and Tolerance of Besivance Versus Vigamox Prophylactically Pre and Post Operatively in Subjects Undergoing Routine Cataract Surgery [NCT01455233]	Phase 4	60 participants (Actual)	Interventional	2010-09-30	Completed
Evaluation of the Effect of Different Foods, Carbohydrate Meal, and a Euglycaemic Insulin Clamp on the QT/QTc Interval Using a Single Dose of Moxifloxacin as a Positive Control in Healthy Male and Female, Caucasian and Japanese Volunteers [NCT01642485]	Phase 1	32 participants (Actual)	Interventional	2011-07-31	Completed
Postoperative Safety Outcomes in Patients Undergoing Routine Phacoemulsification Cataract Surgery With Intraoperative Intracameral Injection of Preservative-Free Moxifloxacin Versus Levofloxacin [NCT04403334]	Phase 4	114 participants (Actual)	Interventional	2018-01-02	Completed
A Randomized, Double-blind, Placebo- and Positive-controlled, Single-dose, 4 Way Crossover Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Subjects [NCT04225078]	Phase 1	66 participants (Actual)	Interventional	2020-01-17	Completed
A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in A [NCT02903836]	Phase 2	231 participants (Actual)	Interventional	2016-11-18	Completed
A Phase 1, Open Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, And Effect On QT/QTc Interval For CP-751,871 Following Single Intravenous Administration To Healthy Adult Subjects [NCT00926263]	Phase 1	28 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to See termination reason in detailed description.)
A Randomised, Placebo Controlled, Four-way Cross-over Study to Assess Cardiac Re-polarisation Following Repeat Dosing With GSK2190915 and Placebo for Five Days, With Moxifloxacin as a Positive Control, in Healthy Male and Female Subjects. [NCT01721135]	Phase 1	0 participants (Actual)	Interventional	2010-09-30	Withdrawn(stopped due to Study was terminated due to toxicology findings after screening started but before first subject first dose.)
A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, Thorough QT/QTc Study of Vanzacaftor Monotherapy in Healthy Subjects [NCT05867147]	Phase 1	56 participants (Actual)	Interventional	2023-04-26	Completed
A Two Different Chemoprophylaxis Approaches After Phacoemulsification Surgery in One Thousand Patients in Iraq :a Clinical Trial [NCT03634852]	Phase 4	1,000 participants (Actual)	Interventional	2016-10-01	Completed
A Study to Evaluate the Effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects [NCT04873323]	Phase 1	59 participants (Actual)	Interventional	2021-06-07	Completed
Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora [NCT01577342]		56 participants (Actual)	Interventional	2010-11-30	Completed
A Randomized, Partially Blinded, 4-period, Crossover Study to Assess the Effects of Single-dose AEB071 Administration (300 and 900 mg) on Electrocardiographic QT Intervals Compared to Placebo in Healthy Volunteers [NCT01594255]	Phase 1	100 participants (Actual)	Interventional	2009-07-31	Completed
A Multiple-center, Multiple-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Parallel Group Study to Investigate the Effect of RO4917838 on the QTc Interval in Healthy Subjects. [NCT01613040]	Phase 1	169 participants (Actual)	Interventional	2009-01-31	Completed
Prospective, Single-center, Randomized, Double-blind, Placebo-controlled, Two-part Phase 1 Study to Assess the Effect of Single Therapeutic and Supra-therapeutic Doses of Lucerastat on the QT/QTc Interval Duration in Healthy Subjects [NCT03832452]	Phase 1	44 participants (Actual)	Interventional	2019-02-14	Completed
Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department [NCT00323219]	Phase 3	390 participants (Anticipated)	Interventional	2004-01-31	Recruiting
A Phase 1, Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic Effects of Bilastine in Healthy Adult Subjects [NCT00419783]	Phase 1	30 participants (Actual)	Interventional	2006-08-31	Completed
Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen [NCT02515045]	Phase 4	59 participants (Actual)	Interventional	2015-01-31	Completed
A Phase 2 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide During 8 Weeks of Treatment in Adult Subjects With Newly Diagnosed Drug-Sensitive or Mu [NCT02193776]	Phase 2	240 participants (Actual)	Interventional	2014-10-23	Completed
A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia (CAP) [NCT01944774]	Phase 2	207 participants (Actual)	Interventional	2013-03-31	Completed
A Randomized, Double-blinded, Double-dummy, Placebo-controlled Thorough QTC Study With Single Oral Doses of Cedazuridine in Healthy Subjects [NCT04953923]	Phase 1	36 participants (Actual)	Interventional	2021-07-01	Completed
A Multiple Arm, Multiple Stage (MAMS), Phase 2B/C, Open Label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including an Increased Dose of Rifampicin, an Optimized Dose of Pyrazinamide, Moxifloxacin and Sutezolid, in Adult Subjects [NCT05807399]	Phase 2	360 participants (Anticipated)	Interventional	2023-04-14	Recruiting
The Physiological Effects of hERG Blockade on Metabolism [NCT03868657]		44 participants (Actual)	Interventional	2019-01-28	Completed
Intracameral Antibiotic Safety Study [NCT02590523]	Phase 3	500 participants (Anticipated)	Interventional	2023-01-31	Suspended(stopped due to Lack of antibiotic availability)
A Multiple-dose, Randomized, Double-blind, Placebo-controlled, Active-Comparator, Parallel Study to Investigate the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Subjects [NCT05988034]	Phase 1	58 participants (Actual)	Interventional	2019-11-08	Completed
A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics [NCT05478278]	Phase 1	60 participants (Actual)	Interventional	2022-06-22	Completed
A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults [NCT04342273]	Phase 1	128 participants (Actual)	Interventional	2020-03-31	Completed
A Randomised, Double-blind, Four-period Crossover Study to Investigate the Effect of Intravenous APD421 on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects [NCT02661594]	Phase 1	40 participants (Actual)	Interventional	2013-11-30	Completed
Evaluation of Antibiogram Results and Clinical Response to Prescribed Antimicrobials in Microbial Keratitis Patients [NCT05655689]		123 participants (Actual)	Observational	2021-12-31	Completed
A Single-center, Randomized, Double-blind, Placebo-controlled, Three-way Crossover Phase I Study to Investigate the Effect on the QTc Interval of a Single Dose of AZD6094 (600 mg) Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positiv [NCT03258515]	Phase 1	45 participants (Actual)	Interventional	2017-09-06	Completed
Acute Appendicitis and Microbiota - Ethology of Appendicitis and Effects of the Antimicrobial Treatment - The MAPPAC (Microbiology Appendicitis Acuta) Trial [NCT03257423]		200 participants (Anticipated)	Interventional	2017-04-04	Enrolling by invitation
A Randomized, Partial Double-Blind, Placebo- and Positive- Controlled, Multiple-Dose, 4-Way Crossover, Thorough QT/QTc (TQT) Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers [NCT04795479]	Phase 1	36 participants (Actual)	Interventional	2021-01-22	Completed
A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Thorough QT Study to Evaluate the Effect of a Single Dose of TD-4208 on Cardiac Repolarization in Healthy Subjects [NCT02820311]	Phase 1	48 participants (Actual)	Interventional	2016-05-31	Completed
A Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of A Contezolid, Delamanid and Bedaquiline-Containing Short Regimen For The Treatment Of Rifampicin-Resistant Pulmonary Tuberculosis [NCT06081361]	Phase 3	186 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects [NCT01999114]	Phase 1	328 participants (Actual)	Interventional	2012-03-31	Completed
Multi-centric Prospective Cohort Study of TB Recurrence Free Cure Among Microbiologically Confirmed New Pulmonary Tuberculosis Patients Treated Under NTEP With the 4-month Moxifloxacin Containing Daily Regimen [NCT05047055]		550 participants (Anticipated)	Observational	2021-10-01	Not yet recruiting
A Double-blind, Single-center, Randomized, Placebo- and Positive-controlled, Parallel-group Trial With a Nested Crossover Part on the Electrocardiographic Effects 100 and 400 mg Pritelivir Per Day in Healthy Subjects: a Thorough QT/QTc Trial [NCT05671029]	Phase 1	64 participants (Actual)	Interventional	2022-12-04	Completed
A Randomized, 3-Treatment, 3-Period, 6-Sequence, Crossover, Placebo- and Active-Controlled, Double-Blind for ALXN1840 (Open-Label for Moxifloxacin) Thorough QT/QTc Study to Evaluate ALXN1840 on Cardiac Repolarization in Healthy Adults [NCT04560816]	Phase 1	57 participants (Actual)	Interventional	2020-07-24	Completed
Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis [NCT05716854]	Phase 1	44 participants (Actual)	Interventional	2023-03-21	Completed
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval [NCT01525394]	Phase 1	52 participants (Actual)	Interventional	2010-12-31	Completed
A Single-dose, Open-label, Fixed Sequence, Two Period Cross Over Study to Assess the Tolerability of a Supra Therapeutic Dose of TRV130 Followed by A Single Dose, Randomized, Double Blind, Comparative, Positive and Placebo Controlled, Four Period Cross-ov [NCT02344303]	Phase 1	63 participants (Actual)	Interventional	2014-12-31	Completed
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients [NCT01573910]	Phase 3	985 participants (Actual)	Interventional	2012-05-31	Completed
A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, 4-Period Crossover Trial to Assess the Effect of Anagrelide Hydrochloride on QT/QTc Interval in Healthy Men and Women. [NCT01552928]	Phase 1	60 participants (Actual)	Interventional	2012-03-29	Completed
A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration [NCT00564447]	Phase 4	48 participants (Actual)	Interventional	2007-12-31	Completed
A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Tears of Healthy Volunteers Following a Single Ocular Administration [NCT00575367]	Phase 4	37 participants (Actual)	Interventional	2008-03-31	Completed
Assessment of Electrophysiological Effects of Tipranavir Co-administered With Ritonavir Given b.i.d. for 2.5 Days on the QT Interval in Healthy Female and Male Subjects. A Double-blind, Randomised, Placebo Controlled, Two-way Crossover Study With a Positi [NCT02248883]	Phase 1	81 participants (Actual)	Interventional	2005-12-31	Completed
Thorough QT/QTc Study of 2 Doses of ADASUVE® in Healthy Volunteers [NCT01854710]	Phase 4	60 participants (Actual)	Interventional	2013-05-31	Completed
The D3 Study: Drug Delivery vs Drops - A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% in Controlling Post-operative Pain and Inflammation in Patients Undergoing Sequential Cataract Surgery [NCT04273282]	Phase 4	31 participants (Actual)	Interventional	2019-12-16	Completed
A Randomized, Open-label, Negative and Positive Control, Crossover Clinical Study to Evaluate Effect on QT/QTc Interval After Multiple Dose of Celecoxib in Healthy Adult Volunteers [NCT03822520]	Phase 1	28 participants (Actual)	Interventional	2017-06-30	Completed
A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects [NCT01537887]	Phase 1	72 participants (Actual)	Interventional	2012-02-29	Completed
A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tafenoquine (SB252263) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Healthy Subjects [NCT01928914]	Phase 1	260 participants (Actual)	Interventional	2011-07-26	Completed
Oral Contraceptives in the Metabolic Syndrome [NCT00205504]	Phase 4	46 participants (Actual)	Interventional	2005-06-30	Completed
Comparative Study of the Effect on Acne With Norgestimate Containing Triphasic Oral Contraceptive and Biphasic Preparation Containing Desogestrel [NCT01466673]	Phase 4	201 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Effect of Ha44 Gel on the ECG in Healthy Adult Subjects [NCT01518699]	Phase 1	57 participants (Actual)	Interventional	2012-01-31	Completed
A Double-Blind, Randomized, Crossover, Thorough QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects [NCT01860703]	Phase 4	50 participants (Actual)	Interventional	2012-11-30	Completed
[NCT01799356]	Phase 4	1,303 participants (Actual)	Interventional	2010-06-30	Completed
Phase II, National, Multicenter, Randomized, Double Blind Clinical Trial, to Evaluate the Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification [NCT03580473]	Phase 2	118 participants (Actual)	Interventional	2020-02-27	Completed
Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Female and Male Subjects. Randomised, Placebo Controlled, Single-blind, Three-period Crossover Phase-I-study With Moxiflo [NCT01965431]	Phase 1	48 participants (Actual)	Interventional	2013-10-31	Completed
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) [NCT06162286]	Phase 3	100 participants (Anticipated)	Interventional	2023-11-17	Recruiting
Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections [NCT05902221]	Phase 3	235 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women [NCT01475513]	Phase 4	47 participants (Actual)	Interventional	2011-11-30	Completed
Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients [NCT01859702]	Phase 4	36 participants (Actual)	Interventional	2012-04-30	Completed
A Multiple-Ascending-Dose, Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled Study to Evaluate the Effect of ALXN2050 on the QT Interval in Healthy Adult Participants [NCT04660890]	Phase 1	39 participants (Actual)	Interventional	2020-12-12	Completed
A Randomized, Double-blind, Placebo-controlled and Open-label, Active Controlled, 4 Period Crossover Trial to Evaluate the Effect of BIA 5 1058 on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions [NCT03489005]	Phase 1	49 participants (Actual)	Interventional	2018-04-09	Completed
Effect of Dulaglutide (LY2189265) on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects [NCT01458210]	Phase 1	22 participants (Actual)	Interventional	2011-10-31	Completed
A Randomized, Double-blind, Double-dummy, Placebo- and Positive-controlled Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in He [NCT03155893]	Phase 1	59 participants (Actual)	Interventional	2017-05-12	Completed
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia [NCT02531438]	Phase 3	774 participants (Actual)	Interventional	2015-11-30	Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Moxifloxacin Tablets, 400 mg of Dr. Reddy's Laboratories Limited, Comparing With Avelox® Tablets 400 mg of Bayer Healthcare [NCT02322619]	Phase 1	26 participants (Actual)	Interventional	2012-11-30	Completed
A Single Center, Open Label, Randomized, Single-dose, Two-period, Two-way Cross-over Study to Compare the Rate and Extent of Absorption of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects. [NCT04873570]	Phase 1	38 participants (Actual)	Interventional	2021-05-28	Completed
A Phase 1, Double-Blinded, Placebo- and Active-Controlled, Randomized Study to Investigate the Potential of Soticlestat to Prolong the QTc Interval in Healthy Adult Participants [NCT05309902]	Phase 1	0 participants (Actual)	Interventional	2022-10-11	Withdrawn(stopped due to Study not needed)
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis [NCT05398679]	Phase 4	360 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
A PHASE 1, RANDOMIZED, PLACEBO-AND POSITIVE-CONTROLLED CROSSOVER STUDY TO DETERMINE THE EFFECT OF SINGLE-DOSE PF-04965842 ON QTC INTERVAL IN HEALTHY VOLUNTEERS [NCT03386279]	Phase 1	36 participants (Actual)	Interventional	2018-07-02	Completed
Evaluation and Comparison of Macular and Choroidal Thickness After Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis [NCT03363295]	Phase 4	120 participants (Actual)	Interventional	2017-07-01	Completed
An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Par [NCT03338621]	Phase 2/Phase 3	455 participants (Actual)	Interventional	2018-07-30	Completed
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Supratherapeutic Dose of LY2409021 in Healthy Subjects [NCT01460368]	Phase 1	67 participants (Actual)	Interventional	2011-10-31	Completed
Antibiotic Resistance In Eye Surgeries (ARIES) [NCT04750655]	Phase 4	108 participants (Anticipated)	Interventional	2021-03-01	Recruiting
An Open Label Randomized Controlled Clinical Trial Comparing a 24Week Oral Regimen Containing Moxifloxacin With a 24 Week Standard Drug Regimen for the Treatment of Smear-positive Pulmonary Tuberculosis in Patients Previously Treated for TB [NCT02114684]	Phase 1/Phase 2	197 participants (Actual)	Interventional	2013-11-30	Completed
A Partial-Blind, Randomized, Parallel Design Study With a Nested Crossover Comparison to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough EC [NCT01839279]	Phase 2	136 participants (Actual)	Interventional	2013-04-30	Completed
Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial [NCT02454205]	Phase 2/Phase 3	154 participants (Actual)	Interventional	2015-11-12	Completed
The Effect of the Co-administration of Atazanavir (ATV) and Ritonavir (RTV) on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects [NCT00357604]	Phase 1	22 participants	Interventional	2006-07-31	Completed
Interventional, Randomised, Double-blind, Placebo- and Positive Controlled, Single-dose, Cross-over Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men [NCT02436486]	Phase 1	76 participants (Actual)	Interventional	2015-05-31	Completed
A PHASE 1, SINGLE CENTER, RANDOMIZED, 4-WAY CROSSOVER, DOUBLE BLINDED, PLACEBO AND MOXIFLOXACIN CONTROLLED STUDY TO EVALUATE THE EFFECT OF GLASDEGIB ON THE CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS [NCT03162900]	Phase 1	36 participants (Actual)	Interventional	2017-06-09	Completed
Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin) [NCT02308748]	Phase 1	22 participants (Actual)	Interventional	2014-05-31	Completed
A Randomized, Double-blind, Placebo-controlled and Open Label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization in Healthy Adult Men and Women [NCT02283788]	Phase 1	67 participants (Actual)	Interventional	2007-03-31	Completed
Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS) [NCT02168816]	Phase 2	30 participants (Actual)	Interventional	2014-03-19	Terminated(stopped due to The study was stopped for feasibility (i.e., low recruitment))
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00082173 (2) [back to overview]	Proportion of Patients With Sterile Sputum Cultures
NCT00082173 (2) [back to overview]	Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications
NCT00205504 (10) [back to overview]	Changes in Waist-to-Hip Ratio Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women
NCT00205504 (10) [back to overview]	Inflammatory Marker Changes, High Sensitive C-reactive Protein (Hs-CRP) and Adiponectin, Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women
NCT00205504 (10) [back to overview]	Inflammatory Marker Changes (MCP-1) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women
NCT00205504 (10) [back to overview]	Changes in Waist Circumference Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women
NCT00205504 (10) [back to overview]	Changes in Lipid Profile Compared Associated With OC Use Among (1) Obese Women and (2) Lean Women
NCT00205504 (10) [back to overview]	Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women
NCT00205504 (10) [back to overview]	Changes in Estrogen Metabolites (Plasma) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women
NCT00205504 (10) [back to overview]	Changes in Blood Pressure Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women
NCT00205504 (10) [back to overview]	Changes in Body Mass Index (BMI) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women
NCT00205504 (10) [back to overview]	Inflammatory Marker Changes, Soluble Vascular Cell Adhesion Molecule (sVCAM) and Soluble Intercellular Adhesion Molecule (sICAM), Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women
NCT00254566 (9) [back to overview]	Percentage of Bacteriologic Response at Test of Cure Visit
NCT00254566 (9) [back to overview]	Percentage of Clinical Cure (Success) at Test of Cure Visit (Full Analysis Set)
NCT00254566 (9) [back to overview]	Percentage of Clinical Cure (Success) at Test of Cure Visit(Clinical Per Protocol Population)
NCT00254566 (9) [back to overview]	Percentage of Clinical Cure (Success)at Test of Cure Visit(Clinically Eligible Set)
NCT00254566 (9) [back to overview]	Change From Baseline in Clinical COPD Questionnaire(CCQ)Functional State Score
NCT00254566 (9) [back to overview]	Change From Baseline in Clinical COPD Questionnaire(CCQ)Symptoms Score
NCT00254566 (9) [back to overview]	Change From Baseline in Clinical COPD Questionnaire(CCQ)Total Score
NCT00254566 (9) [back to overview]	Time Taken for First Quartile (25%) of Subjects to Have AECB Recurrence
NCT00254566 (9) [back to overview]	Change From Baseline in Clinical COPD Questionnaire(CCQ)Mental State Score
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 17 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 16 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 15 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 14 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 13 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 11 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 10 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 1 Hour After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 18 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 7 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 6 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 5 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 4 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 3 Hours After Patch Application on Day 42(Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 12 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 24 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 23 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 22 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 21 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 20 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 2 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI at Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 9 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 8 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 7 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 6 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 5 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 4 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 3 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 2 Hours Before Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 2 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 10 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 19 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 1 Hour Before Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 1 Hour After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI at Time of Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 9 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00292227 (38) [back to overview]	Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 8 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
NCT00312338 (3) [back to overview]	Susceptability Changes in Haemophilus Influenzae Distal to the Site of Instillation
NCT00312338 (3) [back to overview]	Susceptability Changes in Staphylococcus Aureus Distal to the Site of Instillation
NCT00312338 (3) [back to overview]	Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation
NCT00348348 (4) [back to overview]	Clinical Resolution
NCT00348348 (4) [back to overview]	Clinical Resolution
NCT00348348 (4) [back to overview]	Microbial Eradication
NCT00348348 (4) [back to overview]	Microbial Eradication
NCT00396084 (19) [back to overview]	Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC) Adjusted for Free Drug Concentrations
NCT00396084 (19) [back to overview]	Maximum Plasma Drug Concentration/Minimum Inhibitory Concentration (Cmax/MIC)
NCT00396084 (19) [back to overview]	Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)
NCT00396084 (19) [back to overview]	Time to Maximum Plasma Drug Concentration (Tmax) and Half-life
NCT00396084 (19) [back to overview]	Time to Maximum Plasma Drug Concentration (Tmax) and Half-life
NCT00396084 (19) [back to overview]	Pharmacokinetic Parameters: Area Under the Curve (AUC) During First 12 and 24 Hours
NCT00396084 (19) [back to overview]	Maximum Plasma Drug Concentration (Cmax)
NCT00396084 (19) [back to overview]	Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Fluoroquinolones/Isoniazid (INH) Comparison
NCT00396084 (19) [back to overview]	Maximum Plasma Drug Concentration (Cmax)
NCT00396084 (19) [back to overview]	Difference in Sputum Bacillary Loads: Extended Early Bactericidal Activity (EBA) From Days 2 to 7; Linezolid Once Daily/Linezolid Twice Daily/INH Comparison
NCT00396084 (19) [back to overview]	Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Linezolid Once Daily/Linezolid Twice Daily/Isoniazid (INH) Comparison
NCT00396084 (19) [back to overview]	Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2; Fluoroquinolones/Isoniazid (INH) Comparison
NCT00396084 (19) [back to overview]	Area Under the Curve During First 12 or 24 Hours / Minimum Inhibitory Concentration (AUC/MIC)
NCT00396084 (19) [back to overview]	Area Under the Curve (AUC) Adjusted for Free Drug Concentrations/Minimum Inhibitory Concentration (MIC)
NCT00396084 (19) [back to overview]	Area Under the Curve (AUC) During First 12 and 24 Hours Adjusted for Free Drug Concentrations
NCT00396084 (19) [back to overview]	Pharmacokinetic Parameters: Area Under the Curve During First 12 and 24 Hours
NCT00396084 (19) [back to overview]	Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)
NCT00396084 (19) [back to overview]	Percent Dosing Interval Above Minimum Inhibitory Concentration (MIC)
NCT00396084 (19) [back to overview]	Maximum Plasma Drug Concentrations (Cmax), Adjusted for Free Drug Concentration
NCT00398411 (6) [back to overview]	Incidence of Clinically Significant Bacteremia
NCT00398411 (6) [back to overview]	Overall Survival
NCT00398411 (6) [back to overview]	Time to Occurrence of Fever >= 38°C
NCT00398411 (6) [back to overview]	Reason for Discontinuation of Treatment
NCT00398411 (6) [back to overview]	Type of Infection
NCT00398411 (6) [back to overview]	Type of Isolates and Infections
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the Microbiological Valid (MBV) Population
NCT00402727 (12) [back to overview]	Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Intent to Treat (ITT) Population
NCT00402727 (12) [back to overview]	Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Per Protocol (PP) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Intent to Treat (ITT) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Per Protocol (PP) Population
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the ITT Population With Causative Organisms
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the ITT Population With Causative Organisms
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the ITT Population With Causative Organisms
NCT00402727 (12) [back to overview]	Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the Microbiological Valid (MBV) Population
NCT00402727 (12) [back to overview]	Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Intent to Treat (ITT) Population
NCT00414011 (1) [back to overview]	Corneal Epithelial Healing Time
NCT00453349 (11) [back to overview]	Number of Subjects Who Received Alternative Medicine
NCT00453349 (11) [back to overview]	Bacteriological Response at Test Of Cure (TOC) Visit in Intent To Treat Population With Causative Organism
NCT00453349 (11) [back to overview]	Bacteriological Response at Test Of Cure (TOC) Visit Microbiologically Valid
NCT00453349 (11) [back to overview]	Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population
NCT00453349 (11) [back to overview]	Clinical Response 7 to 14 Days After Completion of Study Drug Therapy on Intent To Treat (ITT) Population
NCT00453349 (11) [back to overview]	Clinical Response at Follow-up Visit on Per Protocol Population
NCT00453349 (11) [back to overview]	Clinical Response on Treatment for Intent To Treat Population
NCT00453349 (11) [back to overview]	Clinical Response at Follow-up Visit on Intent To Treat Population
NCT00453349 (11) [back to overview]	Clinical Response on Treatment for Per Protocol Population
NCT00453349 (11) [back to overview]	Bacteriological Response at Follow-up Visit in Intent To Treat Population With Causative Organism
NCT00453349 (11) [back to overview]	Bacteriological Response at Follow-up Visit Microbiologically Valid
NCT00464438 (4) [back to overview]	Percentage of Patients With Microbiological Improvement
NCT00464438 (4) [back to overview]	Percentage of Patients With Clearing (Clinical Success) of Conjunctival Erythema and Conjunctival Discharge at Day 7
NCT00464438 (4) [back to overview]	Percentage of Patients With Improvement in Ocular Signs for Conjunctival Discharge at Day 7
NCT00464438 (4) [back to overview]	Percentage of Patients With Improvement in Ocular Signs for Lid Erythema
NCT00492024 (6) [back to overview]	Treatment Day When Patients Returned to Normal Activities as Measured by Patient Reported Data, Using LOCF Approach
NCT00492024 (6) [back to overview]	Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT))
NCT00492024 (6) [back to overview]	Percentage of Subjects With Clinical Cure (Per Protocol Population (PP))
NCT00492024 (6) [back to overview]	Percentage of Subjects With Clinical Improvement During Therapy
NCT00492024 (6) [back to overview]	Percentage of Subjects With Continued Clinical Cure During Long-Term Follow-Up
NCT00492024 (6) [back to overview]	Treatment Day When Patients Reached Symptom Improvement as Measured by Patient Reported Data, Using Last Observation Carried Forward (LOCF) Approach
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population
NCT00492726 (10) [back to overview]	Duration of Hospitalization
NCT00492726 (10) [back to overview]	Duration of Hospitalization Postoperatively
NCT00492726 (10) [back to overview]	Number of Subjects Who Died Due to Intra-abdominal Infections
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population
NCT00492726 (10) [back to overview]	Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)
NCT00493038 (5) [back to overview]	Number of Participants With Response (Intent-to-treat Population)
NCT00493038 (5) [back to overview]	Number of Participants With Response (Per-protocol Population)
NCT00493038 (5) [back to overview]	Number of Participants With Response (Per-protocol Population)
NCT00493038 (5) [back to overview]	Number of Participants With Response (Microbiologically Valid Patients)
NCT00493038 (5) [back to overview]	Number of Participants With Response (Microbiologically Valid Patients)
NCT00543062 (7) [back to overview]	Numbers and % of Subjects With QTcI Change > 30 ms
NCT00543062 (7) [back to overview]	Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo
NCT00543062 (7) [back to overview]	QTcI Versus Prochlorperazine Concentration
NCT00543062 (7) [back to overview]	Numbers and % of Subjects With QTcI Change > 60 ms
NCT00543062 (7) [back to overview]	Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)
NCT00543062 (7) [back to overview]	Numbers and % of Subjects With QTcI > 450 ms
NCT00543062 (7) [back to overview]	Numbers and % of Subjects With QTcI > 480 ms
NCT00564447 (1) [back to overview]	Assessment of Pharmacokinetic Parameters
NCT00575367 (1) [back to overview]	Concentration of AzaSite and Vigamox in the Tear Fluid Across Six Time Points Ranging From 15 Minutes to 24 Hours Following Administration.
NCT00575380 (2) [back to overview]	Conjunctiva Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)
NCT00575380 (2) [back to overview]	Aqueous Humor Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)
NCT00581542 (2) [back to overview]	Number of Participants With a Negative Bacterial Culture
NCT00581542 (2) [back to overview]	Number of Participants With Normal Physical Examination of the Eye
NCT00635570 (4) [back to overview]	Satisfaction Rate
NCT00635570 (4) [back to overview]	Continuation Rate
NCT00635570 (4) [back to overview]	Adherence Rate (Rate of Perfect Method Use)
NCT00635570 (4) [back to overview]	Continuation Rate
NCT00672984 (14) [back to overview]	Change From Baseline in Electrocardiogram Results (QTcF) at Tmax on Day 6
NCT00672984 (14) [back to overview]	Change From Baseline in Electrocardiogram Results (QTcNi) at Time of Maximum Plasma Concentration (Tmax) on Day 1
NCT00672984 (14) [back to overview]	Change From Baseline in Electrocardiogram Results (QTcNi) at Tmax on Day 6
NCT00672984 (14) [back to overview]	Change From Baseline in Heart Rate (HR) at Tmax on Day 1
NCT00672984 (14) [back to overview]	Change From Baseline in Heart Rate (HR) at Tmax on Day 6
NCT00672984 (14) [back to overview]	Area Under the Steady-state Plasma Concentration-time Curve (AUC) for Guanfacine and Moxifloxacin on Day 1
NCT00672984 (14) [back to overview]	Time of Maximum Plasma Concentration (Tmax) of Guanfacine and Moxifloxacin on Day 6
NCT00672984 (14) [back to overview]	Time of Maximum Plasma Concentration (Tmax) of Guanfacine and Moxifloxacin on Day 1
NCT00672984 (14) [back to overview]	Maximum Plasma Concentration (Cmax) of Guanfacine and Moxifloxacin on Day 6
NCT00672984 (14) [back to overview]	Change From Baseline in Electrocardiogram Results (QT) Interval at Tmax on Day 6
NCT00672984 (14) [back to overview]	Maximum Plasma Concentration (Cmax) of Guanfacine and Moxifloxacin on Day 1
NCT00672984 (14) [back to overview]	Area Under the Steady-state Plasma Concentration-time Curve (AUC) for Guanfacine and Moxifloxacin on Day 6
NCT00672984 (14) [back to overview]	Change From Baseline in Electrocardiogram Results (QT) Interval at Tmax on Day 1
NCT00672984 (14) [back to overview]	Change From Baseline in Electrocardiogram Results (QTcF) at Tmax on Day 1
NCT00728507 (1) [back to overview]	To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - General Activities
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Household Duties
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Item Satisfaction
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Leisure Time Activities
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Overall Life Satisfaction and Contentment
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Participant Feeling
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Physical Health
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - School/Course Work
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Social Relationship
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Work
NCT00754065 (117) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Number of Days With Bleeding or Spotting in Reference Period 1
NCT00754065 (117) [back to overview]	Number of Days With Bleeding or Spotting in Reference Period 2
NCT00754065 (117) [back to overview]	Number of Days With Bleeding or Spotting in Reference Period 3
NCT00754065 (117) [back to overview]	Number of Days With Bleeding or Spotting in Reference Period 4
NCT00754065 (117) [back to overview]	Number of Days With Spotting-only in Reference Period 1
NCT00754065 (117) [back to overview]	Number of Days With Spotting-only in Reference Period 2
NCT00754065 (117) [back to overview]	Number of Days With Spotting-only in Reference Period 3
NCT00754065 (117) [back to overview]	Number of Days With Spotting-only in Reference Period 4
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 1
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 13
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 3
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 6
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Number of Spotting-only Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Number of Spotting-only Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Number of Spotting-only Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Number of Spotting-only Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	The Change in Average of the 3 Highest Visual Analog Scale (VAS) Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28 From Baseline to Cycle 6
NCT00754065 (117) [back to overview]	The Change of Pelvic Pain or Headache as Determined by the Highest Visual Analog Scale (VAS) Values During Cycle Days 22 to 28 From Baseline to Cycle 6
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 13 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During Cycle Days 1-21
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 13 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During the Hormone-free Interval Cycle Days 27 to 28 for EV/DNG and Cycle Days 22 to 28 for EE/NGM
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 13 in the Number of Days With at Least Moderate Pain/Intensity of Other Hormone-related Symptoms During Cycle Days 22-28
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 6 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During Cycle Days 1-21
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 6 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During the Hormone-free Interval Cycle Days 27 to 28 for EV/DNG and Cycle Days 22 to 28 for EE/NGM
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 6 in the Number of Days With at Least Moderate Pain/Intensity of Other Hormone-related Symptoms During Cycle Days 22-28
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Psychological General Well-Being Index (PGWBI)
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI)
NCT00754065 (117) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1
NCT00754065 (117) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3
NCT00754065 (117) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With at Least 1 Intracyclic Bleeding Episode at Cycles 2 to 13
NCT00754065 (117) [back to overview]	Percentage of Participants With at Least 1 Intracyclic Bleeding Episode at Cycles 2 to 6
NCT00754065 (117) [back to overview]	Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With Improvement in the Participant's Assessment in Clinical Global Impression (CGI) at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants With Improvement in the Participant's Assessment in Clinical Global Impression (CGI) at Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With no Increase in Rescue Medication and VAS Decrease During Cycle Days 22 to 28 From Baseline to Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1
NCT00754065 (117) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3
NCT00754065 (117) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6
NCT00754065 (117) [back to overview]	The Change From Baseline to Cycle 13 in the Number of Ibuprofen Tablets Used as Rescue Medication
NCT00754065 (117) [back to overview]	The Change From Baseline to Cycle 6 in the Number of Ibuprofen Tablets Used as Rescue Medication
NCT00754065 (117) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 13 in the Average of the Three Highest VAS Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 3 in the Average of the Three Highest VAS Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - General Activities
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Household Duties
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Item Satisfaction
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Leisure Time Activities
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Overall Life Satisfaction and Contentment
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Participant Feeling
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Physical Health
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - School/Course Work
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Social Relationship
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Work
NCT00759148 (2) [back to overview]	Microbiological Success at the Day 4 (EOT)/Exit Visit
NCT00759148 (2) [back to overview]	Clinical Cure at the Day 4 (EOT)/Exit Visit
NCT00795145 (15) [back to overview]	Cohort 2: Tmax and t1/2
NCT00795145 (15) [back to overview]	Cohort 1: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00795145 (15) [back to overview]	Cohort 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) and Plasma Decay Half-Life (t1/2)
NCT00795145 (15) [back to overview]	Cohort 2: AUC Inf and AUC Last
NCT00795145 (15) [back to overview]	Cohort 2: Mean Time-Matched Difference in Time Corresponding to Beginning of Depolarization to Repolarization of the Ventricles, Corrected for Heart Rate Using Fridericia's Formula (QTcF Interval) Between Linezolid 600 mg and 1200 mg Compared to Placebo
NCT00795145 (15) [back to overview]	Cohort 2: Mean Time-Matched Difference in Uncorrected QT Intervals Between Linezolid 600 mg and 1200 mg Compared to Placebo
NCT00795145 (15) [back to overview]	Cohort 2: Number of Subjects With AEs and SAEs
NCT00795145 (15) [back to overview]	Cohort 2: Cmax
NCT00795145 (15) [back to overview]	Cohort 2: CL
NCT00795145 (15) [back to overview]	Cohort 1: Steady-State Volume of Distribution (Vss)
NCT00795145 (15) [back to overview]	Cohort 1: Maximum Observed Plasma Concentration (Cmax)
NCT00795145 (15) [back to overview]	Cohort 1: Clearance of Linezolid (CL)
NCT00795145 (15) [back to overview]	Cohort 2: Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin and Placebo
NCT00795145 (15) [back to overview]	Cohort 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Inf) and Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC Last)
NCT00795145 (15) [back to overview]	Cohort 2: Vss
NCT00824070 (1) [back to overview]	The Aqueous Humor Drug Concentration.
NCT00864383 (9) [back to overview]	Number of Patients Who Are Culture Negative (Liquid MGIT Culture)
NCT00864383 (9) [back to overview]	Time to First Culture Negative Sputum Sample (MGIT Liquid Media)
NCT00864383 (9) [back to overview]	Combined Failure of Bacteriological Cure and Relapse as Defined by Culture Using Liquid Media (Mycobacteria Growth Indicator Tube-MGIT).
NCT00864383 (9) [back to overview]	Time to First Culture Negative Sputum Sample (LJ Solid Media)
NCT00864383 (9) [back to overview]	Sensitivity Analysis Assuming All Losses to Follow-up and Non-tuberculous Deaths Have an Unfavorable Outcome Using Solid (L-J) Media.
NCT00864383 (9) [back to overview]	Sensitivity Analyses Assuming All Losses to Follow-up and Non-tuberculous Deaths Have a Favourable Outcome Using Solid (L-J) Media.
NCT00864383 (9) [back to overview]	Number of Patients With Grade 3 or 4 Adverse Events (Using a Modified Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases [DAIDS] Scale of Adverse Event Reporting)
NCT00864383 (9) [back to overview]	Number of Patients Who Are Culture Negative (Solid LJ Culture)
NCT00864383 (9) [back to overview]	Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).
NCT00865280 (7) [back to overview]	Number of Participants Classified as a Sponsor-defined Clinical Success in the ITT Population at Test of Cure
NCT00865280 (7) [back to overview]	Number of Participants With Cellulitis Classified as a Sponsor-defined Clinical Success in the CE Population at Test of Cure
NCT00865280 (7) [back to overview]	Number of Participants With Wound Infections Classified as a Sponsor-defined Clinical Success in the CE Population at Test of Cure
NCT00865280 (7) [back to overview]	Number of Participants With Cellulitis Classified as a Sponsor-defined Clinical Success in the CE Population at End of Treatment
NCT00865280 (7) [back to overview]	Number of Participants Classified as a Sponsor-defined Clinical Success in the Intent-to-Treat (ITT) Population at End of Treatment
NCT00865280 (7) [back to overview]	Number of Participants With the Indicated Type of Adverse Event (AE)
NCT00865280 (7) [back to overview]	Number of Participants With Wound Infections Classified as a Sponsor-defined Clinical Success in the Clinically Evaluable (CE) Population at End of Treatment
NCT00870103 (2) [back to overview]	The Percentage of Patients With no Ocular Pain
NCT00870103 (2) [back to overview]	The Percentage of Patients With a Score of Zero for Anterior Chamber Cells.
NCT00874237 (7) [back to overview]	Numbers and % of Subjects With QTcI Change > 30 ms
NCT00874237 (7) [back to overview]	Numbers and % of Subjects With QTcI Change > 60 ms
NCT00874237 (7) [back to overview]	Numbers and % of Subjects With QTcI > 480 ms
NCT00874237 (7) [back to overview]	Numbers and % of Subjects With QTcI > 450 ms
NCT00874237 (7) [back to overview]	Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)
NCT00874237 (7) [back to overview]	Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo
NCT00874237 (7) [back to overview]	Cardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers.
NCT00874887 (1) [back to overview]	Percentage of Subjects With Strain Resistance of the Conjunctiva as Determined by Minimum Inhibitory Concentration (MIC) at Day 14
NCT00924729 (1) [back to overview]	Aqueous Humor Concentration of Study Drug
NCT00926263 (12) [back to overview]	Serum Concentration of Fasting Glucose
NCT00926263 (12) [back to overview]	Anti-drug Antibodies (ADA) Against CP-751,871 in Serum Samples
NCT00926263 (12) [back to overview]	Serum Concentration of Insulin-like Growth Factor Binding Protein 3 (IGFBP-3)
NCT00926263 (12) [back to overview]	Serum Concentration of Free Insulin-like Growth Factor 1 (IGF-1)
NCT00926263 (12) [back to overview]	Serum Concentration of Insulin
NCT00926263 (12) [back to overview]	Plasma Decay Half-Life (t1/2)
NCT00926263 (12) [back to overview]	Plasma Clearance (CL)
NCT00926263 (12) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT00926263 (12) [back to overview]	Area Under the Curve From Time Zero to the Last Time Point With Quantifiable Concentration (AUClast)
NCT00926263 (12) [back to overview]	Apparent Volume of Distribution (Vz)
NCT00926263 (12) [back to overview]	Serum Concentration of Insulin-like Growth Factor 1 (IGF-1)
NCT00926263 (12) [back to overview]	Serum Concentration of Insulin-like Growth Factor 2 (IGF-2)
NCT00983957 (13) [back to overview]	Area Under the Concentration-Time Curve in 1 Dosing Interval of Norgestrel
NCT00983957 (13) [back to overview]	Area Under the Concentration-Time Curve in 1 Dosing Interval of Norelgestromin
NCT00983957 (13) [back to overview]	Maximum Observed Plasma Concentration of Norelgestromin
NCT00983957 (13) [back to overview]	Number of Participants Demonstrating a Clinically Meaningful Effect in Vital Signs
NCT00983957 (13) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol
NCT00983957 (13) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Who Died
NCT00983957 (13) [back to overview]	Number of Participants With Laboratory Test Abnormalities
NCT00983957 (13) [back to overview]	Area Under the Concentration-Time Curve (AUC) in 1 Dosing Interval of Ethinyl Estradiol
NCT00983957 (13) [back to overview]	Time of Maximum Observed Plasma Concentration of Norgestrel
NCT00983957 (13) [back to overview]	Time of Maximum Observed Plasma Concentration of Norelgestromin
NCT00983957 (13) [back to overview]	Time of Maximum Observed Plasma Concentration of Ethinyl Estradiol
NCT00983957 (13) [back to overview]	Number of Participants Demonstrating a Clinically Meaningful Effect in ECG Parameters
NCT00983957 (13) [back to overview]	Maximum Observed Plasma Concentration of Norgestrel
NCT01017731 (6) [back to overview]	Area Under Concentration (AUC) During Cycle 1
NCT01017731 (6) [back to overview]	Number of Participants With Drug-Related Adverse Events (AEs)
NCT01017731 (6) [back to overview]	Maximum Concentration (Cmax) During Cycle 3
NCT01017731 (6) [back to overview]	Maximum Concentration (Cmax) During Cycle 1
NCT01017731 (6) [back to overview]	Area Under Concentration (AUC) During Cycle 3
NCT01017731 (6) [back to overview]	Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants
NCT01018420 (5) [back to overview]	Maximum Plasma Concentration (Cmax)
NCT01018420 (5) [back to overview]	Electrocardiogram (ECG) Evaluation of the QTcF Interval (Moxifloxacin)
NCT01018420 (5) [back to overview]	Electrocardiogram (ECG) Evaluation of the QTcF Interval (Colchicine)
NCT01018420 (5) [back to overview]	Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
NCT01018420 (5) [back to overview]	Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
NCT01069900 (20) [back to overview]	QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3
NCT01069900 (20) [back to overview]	Bacteriological Response at the End of Treatment (EOT) Visit
NCT01069900 (20) [back to overview]	Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3
NCT01069900 (20) [back to overview]	Number of Subjects With Adverse Events
NCT01069900 (20) [back to overview]	Bacteriological Response at Test-of-Cure (TOC) Visit
NCT01069900 (20) [back to overview]	Bacteriological Response at a 'During Therapy' Visit
NCT01069900 (20) [back to overview]	Number of Subjects With Musculoskeletal Adverse Events
NCT01069900 (20) [back to overview]	Number of Subjects With Clinical Cardiac Adverse Events
NCT01069900 (20) [back to overview]	Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term
NCT01069900 (20) [back to overview]	Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01069900 (20) [back to overview]	Clinical Response at the End-of-Treatment (EOT) Visit
NCT01069900 (20) [back to overview]	Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)
NCT01069900 (20) [back to overview]	Clinical Response at Test-of-Cure (TOC) Visit
NCT01069900 (20) [back to overview]	Clinical Response at a 'During Therapy' Visit
NCT01069900 (20) [back to overview]	RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
NCT01148537 (8) [back to overview]	The Average Differences From Baseline Between Moxifloxacin and Placebo by Fridericia's Corrected Interval (QTcF) on Day 6 and Day 13
NCT01148537 (8) [back to overview]	The Average Differences From Baseline Between BTDS and Placebo by Fridericia's Corrected Interval (QTcF) on Day 6 and Day 13
NCT01148537 (8) [back to overview]	The Average Differences From Baseline Between BTDS and Placebo by Bazett Corrected QT Interval (QTcB) on Day 6 and Day 13
NCT01148537 (8) [back to overview]	The Comparison of Moxifloxacin to Placebo Transdermal System (TDS): the Average Difference From Baseline Using QT Interval Corrected From Within-subject Data (QTci) on Day 13
NCT01148537 (8) [back to overview]	The Comparison of BTDS to Placebo Transdermal System (TDS): the Average Difference From Baseline Using QT Corrected From Within-subject Data (QTci) on Day 13
NCT01148537 (8) [back to overview]	The Average Differences Between Moxifloxacin vs Placebo From Baseline by Interval Corrected From Within-subject Data (QTci) on Day 6
NCT01148537 (8) [back to overview]	The Average Differences Between BTDS vs Placebo From Baseline by Interval Corrected From Within-subject Data (QTci) on Day 6
NCT01148537 (8) [back to overview]	The Average Differences From Baseline Between Moxifloxacin and Placebo of Bazett Corrected QT Interval (QTcB) on Day 6 and Day 13
NCT01191723 (5) [back to overview]	Change From Baseline in QTcI for MAP0004 3.0mg and Placebo at 30 Minutes
NCT01191723 (5) [back to overview]	Change From Baseline in QTcF for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours
NCT01191723 (5) [back to overview]	Change From Baseline in QTcF for MAP0004 3.0mg and Placebo at 30 Minutes
NCT01191723 (5) [back to overview]	Change From Baseline in Heart Rate for MAP0004 3.0mg, Placebo, and Moxifloxacin at 30 Minutes and 2 Hours
NCT01191723 (5) [back to overview]	Change From Baseline in QTcI for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours
NCT01195675 (10) [back to overview]	Empa 25 mg: Mean QTcN Change From Baseline Between 30 Minutes and 24 Hours After Dosing
NCT01195675 (10) [back to overview]	Mean QTcN Change From Baseline Between 2 and 4 Hours After Dosing
NCT01195675 (10) [back to overview]	Placebo Corrected Change From Mean Baseline at Any Time Point Between 30 Minutes and 24 Hours After Dosings.
NCT01195675 (10) [back to overview]	Time-matched Change From Placebo in QTcN Between 30 Minutes and 24 Hours After Dosing.
NCT01195675 (10) [back to overview]	Empa 200mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing
NCT01195675 (10) [back to overview]	Empa 200mg: Change From Mean Baseline in QTcN at Each Time Point Between 30 Minutes and 24 Hours After Dosings
NCT01195675 (10) [back to overview]	Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator
NCT01195675 (10) [back to overview]	Empa 200 mg: Mean QTcN Change From Baseline Between 30 Minutes and 24 Hours After Dosing
NCT01195675 (10) [back to overview]	Empa 25mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing
NCT01195675 (10) [back to overview]	Empa 25mg: Change From Mean Baseline in QTcN at Each Time Point Between 30 Minutes and 24 Hours After Dosings
NCT01215851 (5) [back to overview]	Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).
NCT01215851 (5) [back to overview]	Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 7-14).
NCT01215851 (5) [back to overview]	Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14)
NCT01215851 (5) [back to overview]	Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).
NCT01215851 (5) [back to overview]	Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).
NCT01243580 (13) [back to overview]	Evaluation of LNG Css (1) Between AG200-15 in Week 1 and 3
NCT01243580 (13) [back to overview]	Evaluation of LNG Cmax Between AG200-15 in Week 1 and 3
NCT01243580 (13) [back to overview]	Evaluation of LNG AUC (0-168hrs Post-first Dose) Between AG200-15 in Week 1 and 3
NCT01243580 (13) [back to overview]	Comparative Evaluation of Ethinyl Estradiol (EE) Cmax Between AG200-15 and Ortho-Cyclen® in Week 1
NCT01243580 (13) [back to overview]	Comparative Evaluation of EE Css (2) Between AG200-15 and Ortho-Cyclen® in Week 1
NCT01243580 (13) [back to overview]	Comparative Evaluation of EE Css (2) Between AG200-15 and Ortho-Cyclen® in Week 3
NCT01243580 (13) [back to overview]	Comparative Evaluation of EE Css (3) Between AG200-15 and Ortho-Cyclen® in Week 3
NCT01243580 (13) [back to overview]	Comparative Evaluation of EE AUC (0-168hrs Post-first Dose) Between AG200-15 and Ortho-Cyclen® in Week 3
NCT01243580 (13) [back to overview]	Comparative Evaluation of EE AUC(0-168hrs Post-first Dose) Between AG200-15 and Ortho-Cyclen® in Week 1
NCT01243580 (13) [back to overview]	Comparative Evaluation of EE Cmax Between AG200-15 and Ortho-Cyclen® in Week 3
NCT01243580 (13) [back to overview]	Comparative Evaluation of EE Css (1) Between AG200-15 and Ortho-Cyclen® in Week 1
NCT01243580 (13) [back to overview]	Comparative Evaluation of EE Css (1) Between AG200-15 and Ortho-Cyclen® in Week 3
NCT01243580 (13) [back to overview]	Comparative Evaluation of EE Css (3) Between AG200-15 and Ortho-Cyclen® in Week 1
NCT01296191 (1) [back to overview]	Pharmacokinetics in Aqueous Humor Samples.
NCT01296542 (1) [back to overview]	Number of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days
NCT01297062 (9) [back to overview]	Number of Subjects With Increase of QTcP Interval From Baseline >30msec at Any Timepoint on Any Day in Exenatide and Placebo
NCT01297062 (9) [back to overview]	Comparison of LS Mean Changes From Baseline in QTcP Intervals Between Exenatide and Placebo on Day 3 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 500 pg/mL)
NCT01297062 (9) [back to overview]	Comparison of LS Mean Changes From Baseline in QTcP Intervals Between Exenatide and Placebo on Day 2 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 300 pg/mL)
NCT01297062 (9) [back to overview]	Comparison of Least Squares (LS) Mean Changes From Baseline in Population-based Corrected QT Intervals (QTcP) Between Exenatide and Placebo on Day 1 Averaged Over 1300h, 1400h, 1500h (Target Steady State Exenatide Concentration of 200 pg/mL)
NCT01297062 (9) [back to overview]	Assay Sensitivity of Moxifloxacin at 1100h (2 Hour Post-administration of Moxifloxacin) on Day 2
NCT01297062 (9) [back to overview]	Assay Sensitivity of Moxifloxacin at 1000h (1 Hour Post-administration of Moxifloxacin) on Day 2
NCT01297062 (9) [back to overview]	Assay Sensitivity of Moxifloxacin at 1200h (3 Hour Post-administration of Moxifloxacin) on Day 2
NCT01297062 (9) [back to overview]	Plasma Exenatide Concentrations at Steady State on Day 1, 2 and 3
NCT01297062 (9) [back to overview]	Number of Subjects With QTcP Interval >450msec at Any Timepoint on Any Day in Exenatide and Placebo
NCT01373931 (3) [back to overview]	Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax) of Ethinyl Estradiol and Norelgestromin
NCT01373931 (3) [back to overview]	Area Under the Concentration-Time Curve Over a Dosing Interval (AUCτ) of Ethinyl Estradiol and Norelgestromin
NCT01373931 (3) [back to overview]	Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norelgestromin
NCT01423916 (13) [back to overview]	Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Mean QTcI on Day -1 (Baseline).
NCT01423916 (13) [back to overview]	Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Maximum QTcI on Day -1 (Baseline).
NCT01423916 (13) [back to overview]	Area Under the Plasma Concentration-time Curve During Dosing (AUCT).
NCT01423916 (13) [back to overview]	Number Participants Noted With New Incidence of QT Interval of > 500 Msec on Day 11.
NCT01423916 (13) [back to overview]	Number of Participants With QTcI Interval Between 30 and 60 Msec on Day 11.
NCT01423916 (13) [back to overview]	Maximum Peak Plasma Concentration (Cmax) of Brexpiprazole and Moxifloxacin.
NCT01423916 (13) [back to overview]	Time-matched QTcI Change From Baseline (Day -1) Corrected for Placebo on Day 11 Following Brexpiprazole Treatment.
NCT01423916 (13) [back to overview]	Number of Participants With New Incidence of ECG Morphology Abnormalities on Day 11.
NCT01423916 (13) [back to overview]	Number of Participants With Maximum Change From Baseline to the On-treatment ECG Values on Day 11 for Heart Rate (HR), PR Interval, and QRS Interval.
NCT01423916 (13) [back to overview]	Number of Participants With Adverse Events (AE) and Clinically Important Changes in Vital Signs, Physical Examinations, Laboratory Tests, and Standard ECGs (Electrocardiogram).
NCT01423916 (13) [back to overview]	Number of Participants Noted With Time-matched Change in Mean QTcI Change From Baseline for Assay Sensitivity of Moxifloxacin Treatment Corrected for Placebo at Day 11.
NCT01423916 (13) [back to overview]	Number of Participants With QTcI Interval > 60 Msec on Day 11.
NCT01423916 (13) [back to overview]	Time to Maximum (Peak) Plasma Concentration (Tmax) of Brexpiprazole and Moxifloxacin.
NCT01458210 (6) [back to overview]	Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Ortho-Cyclen - Norelgestromin (NGMN)
NCT01458210 (6) [back to overview]	Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Ortho-Cyclen - Ethinyl Estradiol (EE)
NCT01458210 (6) [back to overview]	Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Ortho-Cyclen - Norelgestromin (NGMN)
NCT01458210 (6) [back to overview]	Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Ortho-Cyclen - Ethinyl Estradiol (EE)
NCT01458210 (6) [back to overview]	Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Ortho-Cyclen - Norelgestromin (NGMN)
NCT01458210 (6) [back to overview]	Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Ortho-Cyclen - Ethinyl Estradiol (EE)
NCT01460368 (2) [back to overview]	Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (Moxifloxacin)
NCT01460368 (2) [back to overview]	Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (LY2409021)
NCT01466673 (10) [back to overview]	Change From Baseline in Blood Pressure (BP) at Month 6
NCT01466673 (10) [back to overview]	Change From Baseline in Body Weight at Month 6
NCT01466673 (10) [back to overview]	Change From Baseline in Total and Each Type of Acne Lesions Count at Month 6
NCT01466673 (10) [back to overview]	Number of Participants Non-Compliant With Therapy
NCT01466673 (10) [back to overview]	Number of Participants With Treatment Response at the End-of-Therapy by Participant's Self-Assessment at Month 6
NCT01466673 (10) [back to overview]	Percentage of Participants Showing Treatment Response on the Investigator's Global Assessment at Month 6
NCT01466673 (10) [back to overview]	Number of Participants With Abnormal Vaginal Blood Loss at Month 1, 3 and 6
NCT01466673 (10) [back to overview]	Change From Baseline in Total and Each Type of Acne Lesions Count at Month 3
NCT01466673 (10) [back to overview]	Percentage of Participants With Categorical Score for Sebum Assessment at Month 1, 3 and 6
NCT01466673 (10) [back to overview]	Change From Baseline in Total and Each Type of Acne Lesions Count at Month 1
NCT01475513 (16) [back to overview]	Change From Baseline in Fasting Glucose at 6 Months
NCT01475513 (16) [back to overview]	Change From Baseline in Body Mass Index in 6 Months
NCT01475513 (16) [back to overview]	Change From Baseline in Disposition Index at 6 Months
NCT01475513 (16) [back to overview]	Change From Baseline in Carotid Intima Media Thickness
NCT01475513 (16) [back to overview]	Change From Baseline in Areas-under-the-curve for Insulin at 6 Months
NCT01475513 (16) [back to overview]	Change From Baseline in Areas-under-the-curve for Glucose
NCT01475513 (16) [back to overview]	Change From Baseline in Acute Insulin Response to Glucose
NCT01475513 (16) [back to overview]	Change in Triglycerides From Baseline to 6 Months
NCT01475513 (16) [back to overview]	Change in LDL From Baseline to 6 Months
NCT01475513 (16) [back to overview]	Change in Diastolic Blood Pressure From Baseline to 6 Months
NCT01475513 (16) [back to overview]	Change From Baseline in Systolic Blood Pressure at 6 Months
NCT01475513 (16) [back to overview]	Change From Baseline in Insulin Sensitivity
NCT01475513 (16) [back to overview]	Change From Baseline in HDL at 6 Months
NCT01475513 (16) [back to overview]	Change From Baseline in Glucose Effectiveness
NCT01475513 (16) [back to overview]	Change From Baseline in Flow-mediated Vasodilatation
NCT01475513 (16) [back to overview]	Change From Baseline in Fasting Insulin at 6 Months
NCT01498419 (7) [back to overview]	Percentage of Participants Who Discontinue Due to an Adverse Event in Each Experimental Arm.
NCT01498419 (7) [back to overview]	Percentage of Patients With Sputum Culture Conversion at 8 Weeks on Liquid Media
NCT01498419 (7) [back to overview]	Percentage of Patients With Sputum Culture Conversion at 8 Weeks on Solid Media
NCT01498419 (7) [back to overview]	The Rate of Change in Colony Forming Units (CFUs) Using Non-linear Mixed Effects Modeling of the Serial Sputum Colony Counts (SSCC) Over 8 Weeks of Treatment.
NCT01498419 (7) [back to overview]	The Rate of Change in Time to Sputum Culture Positivity (TTP) Through 8 Weeks in the MGIT System in Sputum Over 8 Weeks in Participants as Derived From a Non-linear Regression Model.
NCT01498419 (7) [back to overview]	Time to Sputum Conversion Using Data From Weekly Cultures Through 8 Weeks on Liquid Media
NCT01498419 (7) [back to overview]	Time to Sputum Conversion Using Data From Weekly Cultures Through 8 Weeks on Solid Media
NCT01518699 (1) [back to overview]	Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF
NCT01536951 (4) [back to overview]	Pharmacokinetics: Area Under the Concentration Curve From Time 0 to Infinity [AUC(0-inf)] of LY3009104
NCT01536951 (4) [back to overview]	Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104
NCT01536951 (4) [back to overview]	Change From Baseline Through 24 Hours Postdose in Population-Corrected QT (QTcP) Interval
NCT01536951 (4) [back to overview]	Number of Participants With 1 or More Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)
NCT01537887 (4) [back to overview]	Change From Baseline to Day 10 in QT Interval Corrected for Heart Rate (QTc) for LY2484595 Versus Placebo
NCT01537887 (4) [back to overview]	Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2484595 During One Dosing Interval at Steady State
NCT01537887 (4) [back to overview]	Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2484595 During One Dosing Interval at Steady State
NCT01537887 (4) [back to overview]	Percentage Change From Baseline to Day 11 in Fasting Lipids and Apolipoproteins
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in Heart Rate From Time-Matched Analysis by Largest Time Point
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in QTcF Intervals at Subject-Specific Tmax
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in QTcF Intervals From Time-Matched Analysis by Largest Time Point
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in QTcNi Intervals at Subject-Specific Time of Maximum Plasma Concentration (Tmax)
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in QTcNi Intervals From Time-Matched Analysis by Largest Time Point
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in Heart Rate at Subject-Specific Tmax
NCT01552928 (14) [back to overview]	Maximum Plasma Concentration (Cmax) of Metabolite of 2.5 mg Anagrelide (BCH24426) in Males and Females
NCT01552928 (14) [back to overview]	Maximum Plasma Concentration (Cmax) of 2.5 mg Anagrelide in Males and Females
NCT01552928 (14) [back to overview]	Maximum Plasma Concentration (Cmax) of 0.5 mg Anagrelide in Males and Females
NCT01552928 (14) [back to overview]	Maximum Plasma Concentration (Cmax) of Metabolite of 0.5 mg Anagrelide (BCH24426) in Males and Females
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in QTcB Intervals From Time-Matched Analysis by Largest Time Point
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in QTcB Intervals at Subject-Specific Tmax
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in QT Intervals From Time-Matched Analysis by Largest Time Point
NCT01552928 (14) [back to overview]	Mean Difference Changes From Baseline Versus Placebo in QT Intervals at Subject-Specific Tmax
NCT01573910 (2) [back to overview]	Clinical Cure Rate
NCT01573910 (2) [back to overview]	Microbiological Success Rate
NCT01589497 (32) [back to overview]	AUC0-24hour for Pyrazinamide (PZA)
NCT01589497 (32) [back to overview]	Isoniazid PK Parameter Cmax at Day 1
NCT01589497 (32) [back to overview]	Isoniazid PK Parameter CLast at Day 14
NCT01589497 (32) [back to overview]	Isoniazid PK Parameter CLast at Day 1
NCT01589497 (32) [back to overview]	Isoniazid PK Parameter CL/F at Day 14
NCT01589497 (32) [back to overview]	Isoniazid PK Parameter CL/F at Day 1
NCT01589497 (32) [back to overview]	Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14
NCT01589497 (32) [back to overview]	Daily Change in Time to Positivity (TTP) From Day 2 to Day 14
NCT01589497 (32) [back to overview]	Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 2
NCT01589497 (32) [back to overview]	Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 14
NCT01589497 (32) [back to overview]	Daily Change in log10 Transformed Colony-forming Unit (CFU) Counts Per mL Sputum From Baseline (Study Treatment Initiation) to Day 2
NCT01589497 (32) [back to overview]	Daily Change in log10 Colony-forming Unit (CFU) Counts Per mL Sputum From Day 2 to Day 14
NCT01589497 (32) [back to overview]	Correlation Between Time to Positivity (TTP) and log10 Transformed Colony-forming Unit (CFU) Counts Per mL
NCT01589497 (32) [back to overview]	AUC0-24hour for Isoniazid at Day 14
NCT01589497 (32) [back to overview]	AUC0-24hour for Isoniazid (INH) at Day 1
NCT01589497 (32) [back to overview]	Rifampicin PK Parameter Maximum Plasma Concentration (Cmax)
NCT01589497 (32) [back to overview]	Rifampicin PK Parameter Last Concentration (CLast)
NCT01589497 (32) [back to overview]	Rifampicin PK Parameter Clearance (CL/F)
NCT01589497 (32) [back to overview]	Pyrazinamide PK Parameter Cmax
NCT01589497 (32) [back to overview]	Pyrazinamide PK Parameter CLast
NCT01589497 (32) [back to overview]	Pyrazinamide PK Parameter CL/F
NCT01589497 (32) [back to overview]	Pharmacokinetic Parameter (PK) Area Under the Concentration-time Curve (AUC0-24hour) for Rifampicin (RIF)
NCT01589497 (32) [back to overview]	Log10 Transformed Colony-forming Unit (CFU) Count Per mL From Sputum Samples at Baseline and Day 14
NCT01589497 (32) [back to overview]	Ethambutol PK Parameter Cmax
NCT01589497 (32) [back to overview]	Ethambutol PK Parameter CLast
NCT01589497 (32) [back to overview]	Ethambutol PK Parameter CL/F
NCT01589497 (32) [back to overview]	AUC0-24hour for Ethambutol (EMB)
NCT01589497 (32) [back to overview]	Moxifloxacin PK Parameter Cmax at Day 14
NCT01589497 (32) [back to overview]	Moxifloxacin PK Parameter CLast at Day 14
NCT01589497 (32) [back to overview]	Moxifloxacin PK Parameter CL/F at Day 14
NCT01589497 (32) [back to overview]	Isoniazid PK Parameter Cmax at Day 14
NCT01589497 (32) [back to overview]	AUC0-24hour for Moxifloxacin (Mox) at Day 14
NCT01606436 (2) [back to overview]	Change From Baseline up to 12 Hours Postdose in QT Interval Corrected for Heart Rate (QTc)
NCT01606436 (2) [back to overview]	Change From Baseline up to 12 Hours Postdose in QT Interval Corrected for Heart Rate (QTc)
NCT01642485 (5) [back to overview]	The QTcF Profile of Oral Moxifloxacin (400 mg) in Healthy Japanese Versus Caucasian Subjects
NCT01642485 (5) [back to overview]	The Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin
NCT01642485 (5) [back to overview]	The Food Effects (Calorie Reduced FDA Breakfast and Carbohydrate Rich Continental Style) on QTcF
NCT01642485 (5) [back to overview]	Moxifloxacin 400 mg (Single Dose) Compared to Placebo on the Mean QT/QTc Interval.
NCT01642485 (5) [back to overview]	Insulin, Glucose and C-Peptide Effects on the QT/QTc Interval
NCT01658020 (6) [back to overview]	Clinical Response in the Clinical Population
NCT01658020 (6) [back to overview]	Clinical Cure Rate in the Microbiological Per Protocol(PP) Population
NCT01658020 (6) [back to overview]	Change in EXACT-PRO Score
NCT01658020 (6) [back to overview]	Change in CAT Scores
NCT01658020 (6) [back to overview]	Microbiological Response Rate
NCT01658020 (6) [back to overview]	Clinical Response in the Clinical Populations
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 12 Hours Post-Dose
NCT01743677 (21) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-690,550
NCT01743677 (21) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of CP-690,550
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.5 Hour Post-Dose
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 1 Hour Post-Dose
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 16 Hours Post-Dose
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 24 Hours Post-Dose
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 4 Hours Post-Dose
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 8 Hours Post-Dose
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin Compared to Placebo
NCT01743677 (21) [back to overview]	Plasma Decay Half-Life (t1/2) of CP-690,550
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcB Intervals Between CP-690,550 Compared to Placebo
NCT01743677 (21) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for CP-690,550
NCT01743677 (21) [back to overview]	Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 2 Hours Post-Dose
NCT01743677 (21) [back to overview]	Plasma Decay Half-Life (t1/2) of CP-690,550 by CYP2C19 Genotype
NCT01743677 (21) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of CP-690,550 by Cytochrome P450 2C19 (CYP2C19) Genotype
NCT01743677 (21) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550
NCT01743677 (21) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of CP-690,550 by CYP2C19 Genotype
NCT01743677 (21) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-690,550 by CYP2C19 Genotype
NCT01743677 (21) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-690,550 by CYP2C19 Genotype
NCT01746732 (8) [back to overview]	PK: Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Ethinyl Estradiol
NCT01746732 (8) [back to overview]	PK: Time of Maximum Observed Drug Concentration (Tmax) of Norelgestromin
NCT01746732 (8) [back to overview]	PK: Time of Maximum Observed Drug Concentration (Tmax) of Ethinyl Estradiol
NCT01746732 (8) [back to overview]	PK: Minimum Observed Drug Concentration (Cmin) of Norelgestromin
NCT01746732 (8) [back to overview]	PK: Minimum Observed Drug Concentration (Cmin) of Ethinyl Estradiol
NCT01746732 (8) [back to overview]	Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol
NCT01746732 (8) [back to overview]	PK: Maximum Concentration (Cmax) of Norelgestromin
NCT01746732 (8) [back to overview]	PK: Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Norelgestromin
NCT01785186 (3) [back to overview]	Frequency of Adverse Events
NCT01785186 (3) [back to overview]	Pharmacokinetics Including AUC, Cl, t1/2, Vd, and Protein Binding
NCT01785186 (3) [back to overview]	Sputum Culture Conversion (2 Negative Cultures) Using Liquid Media
NCT01839279 (6) [back to overview]	Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
NCT01839279 (6) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
NCT01839279 (6) [back to overview]	The Baseline-adjusted, Placebo-corrected (ΔΔQTc) on QTc Method Not Selected as Primary Endpoint.
NCT01839279 (6) [back to overview]	Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling
NCT01839279 (6) [back to overview]	The Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (ΔΔQTc) on Day 14.
NCT01839279 (6) [back to overview]	Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
NCT01854710 (7) [back to overview]	Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo
NCT01854710 (7) [back to overview]	QTc Versus Loxapine Concentration
NCT01854710 (7) [back to overview]	Subjects With QTcI > 450 ms
NCT01854710 (7) [back to overview]	Subjects With QTcI > 480 ms
NCT01854710 (7) [back to overview]	Subjects With QTcI Increase > 30 ms From Baseline
NCT01854710 (7) [back to overview]	Subjects With QTcI Increase > 60 ms From Baseline
NCT01854710 (7) [back to overview]	Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)
NCT01859702 (1) [back to overview]	Mean Aqueous Humor Concentration of Moxifloxacin
NCT01860703 (10) [back to overview]	Tmax of Deferiprone and Deferiprone 3-O-glucuronide
NCT01860703 (10) [back to overview]	T1/2 for Serum Deferiprone and Deferiprone 3-O-glucuronide
NCT01860703 (10) [back to overview]	Maximum Postdose QT/QTc Interval
NCT01860703 (10) [back to overview]	Maximum Change From Baseline (dQT/dQTc)
NCT01860703 (10) [back to overview]	Cmax of Deferiprone and Deferiprone 3-O Glucuronide
NCT01860703 (10) [back to overview]	AUC0-infinity for Serum Deferiprone and Deferiprone 3-O-glucuronide
NCT01860703 (10) [back to overview]	Number of Participants With Adverse Events
NCT01860703 (10) [back to overview]	Maximum Difference in Change From Baseline in ddQTcF Following a Single Dose of Moxifloxacin
NCT01860703 (10) [back to overview]	Maximum Difference in Change From Baseline in ddQTcF Following a Single Dose of 50 mg/kg Deferiprone
NCT01860703 (10) [back to overview]	Maximum Difference in Change From Baseline in ddQTcF Following a Single Dose of 33 mg/kg Deferiprone
NCT01928693 (6) [back to overview]	Scarring
NCT01928693 (6) [back to overview]	Complete Healing
NCT01928693 (6) [back to overview]	Healing Rate
NCT01928693 (6) [back to overview]	Number of Participants With Treatment Failure
NCT01928693 (6) [back to overview]	Patient Pain Scores
NCT01928693 (6) [back to overview]	Patient Satisfaction Scores
NCT01944774 (12) [back to overview]	Subject Number for Microbiologically Cured and Failure at Visit 3 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]	Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the mITT Population
NCT01944774 (12) [back to overview]	Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the Clinically Evaluable (CE) Population
NCT01944774 (12) [back to overview]	Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the mITT Population
NCT01944774 (12) [back to overview]	Subject Number for Microbiologically Cured and Failure at Visit 3 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]	Subject Number for Microbiologically Cured and Failure at Visit 4 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]	Subject Number of Success and Failure in Overall Efficacy at Visit 3 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]	Subject Number for Microbiologically Cured and Failure at Visit 4 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]	Subject Number of Success and Failure in Overall Efficacy at Visit 3 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]	Subject Number of Success and Failure in Overall Efficacy at Visit 4 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]	Subject Number of Success and Failure in Overall Efficacy at Visit 4 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]	Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the CE Population
NCT01965431 (4) [back to overview]	Maximum Mean Placebo-corrected QTcN Change From Baseline Between 1 to 24 Hours on Day 1 for the Combination Therapy
NCT01965431 (4) [back to overview]	Maximum Mean Placebo-corrected HR Change From Baseline Between 1 to 24 Hours on Day 1 for the Combination Therapy
NCT01965431 (4) [back to overview]	Minimum Mean Placebo-corrected HR (Heart Rate) Change From Baseline Between 1 to 24 Hours on Day 1 for the Combination Therapy
NCT01965431 (4) [back to overview]	Maximum Mean Placebo-corrected QTcN Change From Baseline Between 1 to 6 Hours on Day 1 for the Moxifloxacin Treatment
NCT01999114 (12) [back to overview]	ECG Morphology
NCT01999114 (12) [back to overview]	ECG Morphology
NCT01999114 (12) [back to overview]	The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)
NCT01999114 (12) [back to overview]	The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)
NCT01999114 (12) [back to overview]	The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)
NCT01999114 (12) [back to overview]	Heart Rate (HR)
NCT01999114 (12) [back to overview]	Heart Rate (HR)
NCT01999114 (12) [back to overview]	Heart Rate (HR)
NCT01999114 (12) [back to overview]	QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval
NCT01999114 (12) [back to overview]	QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval
NCT01999114 (12) [back to overview]	QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval
NCT01999114 (12) [back to overview]	ECG Morphology
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02056392 (10) [back to overview]	Change From Baseline in QTcF
NCT02114684 (5) [back to overview]	Sputum Culture Conversion Rates at Week 8 and Month 6 Post Tuberculosis Treatment Initiation
NCT02114684 (5) [back to overview]	Number of Participants With Adverse Events and 8-week Culture Conversion Rates Among HIV-infected Patients vs. HIV-uninfected Patients
NCT02114684 (5) [back to overview]	Time to Culture-conversion of the Moxifloxacin Regimen and the Ethambutol Regimen
NCT02114684 (5) [back to overview]	Proportion of Patients With Unfavourable Outcomes or Tuberculosis Recurrence in the Moxifloxacin and Control Arm.
NCT02114684 (5) [back to overview]	Proportion of Patients With Any Grade 3 or 4 Adverse Reactions in the Two Study Arms
NCT02176005 (8) [back to overview]	Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37)
NCT02176005 (8) [back to overview]	Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D1
NCT02176005 (8) [back to overview]	Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D5
NCT02176005 (8) [back to overview]	Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D1
NCT02176005 (8) [back to overview]	Percentage of Subjects With Adverse Events Related to Study Product
NCT02176005 (8) [back to overview]	Number of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product
NCT02176005 (8) [back to overview]	Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D5
NCT02176005 (8) [back to overview]	Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16)
NCT02193776 (2) [back to overview]	Rate of Change in Time to Sputum Culture Positivity (TTP) Over 8 Weeks in the Mycobacterial Growth Indicator Tube (MGIT) System
NCT02193776 (2) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT02223702 (2) [back to overview]	The Primary Outcome Variable Was Probing Depth.
NCT02223702 (2) [back to overview]	The Attachment Loss Were Considered as a Secondary Measure.
NCT02283788 (1) [back to overview]	QTcI - QT Interval Individually Corrected for Heart Rate - Day 5
NCT02308748 (2) [back to overview]	Change in Placebo Corrected Change From Baseline QTc Interval on the ECG Measured in Milliseconds When Moxifloxacin is Administered With Diltiazem at the Evening Dose Compared to When Moxifloxacin is Administered Alone at Afternoon Dose on Treatment Day.
NCT02308748 (2) [back to overview]	Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or Lidocaine Compared to When Dofetilide is Administered Alone at Evening Dose on Treatment Day
NCT02409290 (5) [back to overview]	Failure or Recurrence (FoR)
NCT02409290 (5) [back to overview]	Favourable Outcome After Long-term Follow-up (132 Weeks)
NCT02409290 (5) [back to overview]	Proportion of Patients With Acquired Drug Resistance
NCT02409290 (5) [back to overview]	STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76)
NCT02409290 (5) [back to overview]	Failure or Recurrence (FoR)
NCT02410772 (1) [back to overview]	TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Assessable Population)
NCT02515045 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Pachymetry (Corneal Thickness)
NCT02515045 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Macular Thickness
NCT02515045 (3) [back to overview]	Change From Baseline (Preoperative Exam) in Intraocular Pressure (IOP)
NCT02531438 (3) [back to overview]	Number of Participants With Early Clinical Response
NCT02531438 (3) [back to overview]	Number of Participants With the Indicated Investigator Assessment of Clinical Response in the ITT Population at the Post Therapy Evaluation (PTE) Visit
NCT02531438 (3) [back to overview]	Number of Participants With the Indicated Investigator Assessment of Clinical Response in the Clinically Evaluable-Post Therapy Evaluation (CT-PTE) Population
NCT02559310 (1) [back to overview]	Early Clinical Response (ECR)
NCT02661594 (1) [back to overview]	Maximal Mean ΔΔQTcF
NCT02679573 (4) [back to overview]	Microbiologic Response
NCT02679573 (4) [back to overview]	Early Clinical Response Plus Improvement in Vital Signs and no Worsening of the 4 Symptoms
NCT02679573 (4) [back to overview]	All-cause Mortality
NCT02679573 (4) [back to overview]	Early Clinical Response
NCT02785770 (20) [back to overview]	Number of Participants With Laboratory Test Abnormalities
NCT02785770 (20) [back to overview]	Maximum Plasma Concentration (Cmax) of PF-04447943
NCT02785770 (20) [back to overview]	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of PF-04447943
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in QRS Interval for PF-04447943 and Placebo
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Heart Rate for PF-04447943 and Placebo
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in PR Interval for PF-04447943 and Placebo
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for Moxifloxacin and Placebo
NCT02785770 (20) [back to overview]	Number of Participants With Vital Sign Abnormalities
NCT02785770 (20) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02785770 (20) [back to overview]	Number of Participants With Electrocardiogram (ECG) Abnormalities
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 8 Hours Post-Dose
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 3 Hours Post-Dose
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 24 Hours Post-Dose
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 2 Hours Post-Dose
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 4 Hours Post-Dose
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 1 Hour Post-Dose
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 0.5 Hour Post-Dose
NCT02785770 (20) [back to overview]	Time of Observed Maximum Plasma Concentration (Tmax) of PF-04447943
NCT02785770 (20) [back to overview]	Number of Participants With Physical Examination Abnormalities
NCT02785770 (20) [back to overview]	Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 12 Hours Post-Dose
NCT02787057 (4) [back to overview]	Secondary Treatment Failure Rate
NCT02787057 (4) [back to overview]	Primary Treatment Failure Rate
NCT02787057 (4) [back to overview]	Primary Response Rate
NCT02787057 (4) [back to overview]	Complete Cure Rate
NCT02800785 (8) [back to overview]	Number of Participants With at Least One Complications From Treatment
NCT02800785 (8) [back to overview]	Number of Clinic Visits or Emergency Room Visits
NCT02800785 (8) [back to overview]	Total Number of Patients Who Had Resolution of Appendicitis Symptoms at 30 Days
NCT02800785 (8) [back to overview]	Eventual Appendectomy Incidence Proportion
NCT02800785 (8) [back to overview]	Rates of Participants With Appendiceal Cancer
NCT02800785 (8) [back to overview]	Rate of Participants With Perforated Appendicitis
NCT02800785 (8) [back to overview]	Patient-reported Quality of Life as Measured by EuroQol (EQ-5D)
NCT02800785 (8) [back to overview]	Days in Hospital After Index Treatment Within 90 Days
NCT02903836 (2) [back to overview]	Clinical Response in the Micro-ITT Population
NCT02903836 (2) [back to overview]	Clinical Response in the ITT Population
NCT02980523 (7) [back to overview]	Change From Baseline Bacterial Culture
NCT02980523 (7) [back to overview]	Number of Cases of Conjunctival Hyperemia
NCT02980523 (7) [back to overview]	Frequency of Corneal Epithelial Defects
NCT02980523 (7) [back to overview]	Eyelid Edema Frequency
NCT02980523 (7) [back to overview]	Chemosis Frequency
NCT02980523 (7) [back to overview]	Cases Frequency of Ocular Secretion
NCT02980523 (7) [back to overview]	Adverse Events
NCT03187301 (14) [back to overview]	Number of Patients With Treatment-Emergent Adverse Events (TEAEs)
NCT03187301 (14) [back to overview]	ECG Assessments: Mean Change From Baseline to Post-Baseline Value for Uncorrected QT Interval During Randomized Crossover Assessment Phase
NCT03187301 (14) [back to overview]	ECG Assessments: Mean Change From Baseline to Post-Baseline Value for QRS Interval During Randomized Crossover Assessment Phase
NCT03187301 (14) [back to overview]	Tmax of Apomorphine and Apomorphine Sulfate (Metabolite) Following the Administration of APL-130277
NCT03187301 (14) [back to overview]	ECG Assessments: Mean Change From Baseline to Post-Baseline Value for QTcB Interval During Randomized Crossover Assessment Phase
NCT03187301 (14) [back to overview]	Median Duration of 'ON' During the Dose Titration Phase
NCT03187301 (14) [back to overview]	Mean Change From Pre-Dose to Post-Baseline Value in the Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Motor Examination (MDS-UPDRS Part III) Score During the Dose Titration Phase
NCT03187301 (14) [back to overview]	AUClast of Apomorphine and Apomorphine Sulfate (Metabolite) Following the Administration of APL-130277
NCT03187301 (14) [back to overview]	Cmax of Apomorphine and Apomorphine Sulfate (Metabolite) Following the Administration of APL-130277
NCT03187301 (14) [back to overview]	ECG Assessments: Mean Change From Baseline to Post-Baseline Value for Heart Rate During Randomized Crossover Assessment Phase
NCT03187301 (14) [back to overview]	ECG Assessments: Mean Change From Baseline to Post-Baseline Value for PR Interval During Randomized Crossover Assessment Phase
NCT03187301 (14) [back to overview]	Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on QTcF Using ΔΔQTcF: Comparison Between Moxifloxacin and Placebo (Assay Sensitivity Analysis)
NCT03187301 (14) [back to overview]	Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis)
NCT03187301 (14) [back to overview]	Median Time to 'ON' During the Dose Titration Phase
NCT03338621 (2) [back to overview]	Number of Participants With Culture Negative Status by 8 Weeks
NCT03338621 (2) [back to overview]	Time to Culture Negative Status
NCT03465436 (8) [back to overview]	Change From Time Matched Baseline in Mean Individually-Corrected QT (QTcI) Values of Lasmiditan and Moxifloxacin
NCT03465436 (8) [back to overview]	Change From Baseline in Mean Heart Rate (HR) of Lasmiditan and Moxifloxacin
NCT03465436 (8) [back to overview]	Change From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin
NCT03465436 (8) [back to overview]	Number of Incidents in Electrocardiogram (ECG) Abnormalities in QTcF Interval Greater Than 450 Milliseconds
NCT03465436 (8) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan
NCT03465436 (8) [back to overview]	Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan
NCT03465436 (8) [back to overview]	Change From Baseline in Mean Cardiac Intervals: RR Interval of Lasmiditan and Moxifloxacin
NCT03465436 (8) [back to overview]	Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin
NCT03510663 (1) [back to overview]	Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram (ECG)
NCT03577275 (5) [back to overview]	Change From Baseline in PR Interval (PR)
NCT03577275 (5) [back to overview]	Change From Baseline in QRS Interval (QRS)
NCT03577275 (5) [back to overview]	Change From Baseline in Fridericia's Correction for QT Interval (QTcF)
NCT03577275 (5) [back to overview]	Change From Baseline in Fridericia's Correction for QT Interval (QTcF)
NCT03577275 (5) [back to overview]	Change From Baseline in Heart Rate (HR)
NCT03613649 (36) [back to overview]	Changes From Baseline in ECG Measures: Ventricular Rate
NCT03613649 (36) [back to overview]	Changes From Baseline in ECG Measures: PR Interval, QRS Duration, QT Interval, QTcF Interval and RR Interval
NCT03613649 (36) [back to overview]	Changes From Baseline for Blood Pressure - Diastolic
NCT03613649 (36) [back to overview]	Time-matched, Placebo-corrected, Baseline-adjusted, the Time From the Onset of the P Wave to the Start of the QRS Complex (PR Interval) Following Administration of Zoliflodacin
NCT03613649 (36) [back to overview]	Time-matched, Placebo-corrected, Baseline-adjusted QRS Duration Following Administration of Zoliflodacin
NCT03613649 (36) [back to overview]	Number of Participants With Treatment-emergent Adverse Events Following Administration of Study Product
NCT03613649 (36) [back to overview]	Maximum Observed Concentration (Cmax) of Zoliflodacin
NCT03613649 (36) [back to overview]	Elimination Rate Constant (Ke) of Zoliflodacin
NCT03613649 (36) [back to overview]	Area Under the Concentration Time-curve From Time Zero to the Last Concentration Above the Lower Limit of Quantitation (AUC(0-last)) for Zoliflodacin
NCT03613649 (36) [back to overview]	Time-matched, Placebo-corrected, Baseline-adjusted the Time Elapsed Between Two Successive R Waves of the QRS (RR Interval) Following Administration of Zoliflodacin
NCT03613649 (36) [back to overview]	Area Under the Concentration Time-curve From Time Zero to Infinity (AUC(0 - Infinity)) for Zoliflodacin
NCT03613649 (36) [back to overview]	Apparent Volume of Distribution (Vz/F) of Zoliflodacin
NCT03613649 (36) [back to overview]	Apparent Oral Clearance (CL/F) of Zoliflodacin
NCT03613649 (36) [back to overview]	Changes From Baseline for Temperature
NCT03613649 (36) [back to overview]	Changes From Baseline for Blood Pressure - Systolic
NCT03613649 (36) [back to overview]	Changes From Baseline for Glomerular Filtration Rate (GFR) - Estimated
NCT03613649 (36) [back to overview]	Changes From Baseline for Hematocrit
NCT03613649 (36) [back to overview]	Changes From Baseline for Hemoglobin
NCT03613649 (36) [back to overview]	Changes From Baseline for Magnesium, Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Total Bilirubin, Direct Bilirubin
NCT03613649 (36) [back to overview]	Changes From Baseline for Platelets
NCT03613649 (36) [back to overview]	Changes From Baseline for Pulse Rate
NCT03613649 (36) [back to overview]	Changes From Baseline for Respiratory Rate
NCT03613649 (36) [back to overview]	Changes From Baseline for Erythrocytes
NCT03613649 (36) [back to overview]	Changes From Baseline for Total Protein and Albumin
NCT03613649 (36) [back to overview]	Incidence of Abnormal T-wave Morphology Following Administration of Zoliflodacin
NCT03613649 (36) [back to overview]	Occurrence of Urinalysis Adverse Events Following Administration of Study Product
NCT03613649 (36) [back to overview]	The One-sided 95% Confidence Interval (CI) for the Largest Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following Administration of Zoliflodacin
NCT03613649 (36) [back to overview]	The One-sided 95% Confidence Interval (CI) of the Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) After a Single Dose of Moxifloxacin
NCT03613649 (36) [back to overview]	Number of Participants With Treatment-emergent Serious Adverse Events Following Administration of Zoliflodacin and Moxifloxacin
NCT03613649 (36) [back to overview]	Time-matched, Placebo-corrected, Baseline-adjusted Heart Rate (HR) Following Administration of Zoliflodacin
NCT03613649 (36) [back to overview]	Changes From Baseline for White Blood Cells With Differentials
NCT03613649 (36) [back to overview]	Changes From Baseline for Sodium, Potassium, Chloride and Bicarbonate
NCT03613649 (36) [back to overview]	Relationship Between Plasma Concentrations of Zoliflodacin and Time-matched, Placebo-corrected, Baseline-adjusted Mean QTcF Interval (Delta Delta QTcF) Following Administration of Zoliflodacin
NCT03613649 (36) [back to overview]	Terminal Elimination Half-life (t1/2) of Zoliflodacin
NCT03613649 (36) [back to overview]	Time of Maximum Observed Concentration (Tmax) of Zoliflodacin
NCT03613649 (36) [back to overview]	Changes From Baseline for Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (AP)
NCT03657264 (3) [back to overview]	Predicted Value of ∆∆QTc at Cmax
NCT03657264 (3) [back to overview]	Change-from-baseline Mean Effect of Moxifloxacin on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF)
NCT03657264 (3) [back to overview]	Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF)
NCT03808298 (29) [back to overview]	Number of Categorical Outliers for PR
NCT03808298 (29) [back to overview]	Tmax of M2 Metabolite
NCT03808298 (29) [back to overview]	Tmax of Balovaptan
NCT03808298 (29) [back to overview]	Tmax M3 Metabolite
NCT03808298 (29) [back to overview]	Number of Treatment Emergent Changes of T-Wave Morphology
NCT03808298 (29) [back to overview]	Number of Categorical Outliers for QTcF
NCT03808298 (29) [back to overview]	Number of Categorical Outliers for HR
NCT03808298 (29) [back to overview]	Cmax of M2 Metabolite
NCT03808298 (29) [back to overview]	Cmax of Balovaptan
NCT03808298 (29) [back to overview]	Change-From-Baseline QTcF Measured on 12 Lead ECGs Extracted From Continuous Records
NCT03808298 (29) [back to overview]	Change-From-Baseline QTcF at Dose Level B Measured on 12-Lead ECGs Extracted From Continuous Recordings
NCT03808298 (29) [back to overview]	Change-From-Baseline QTcF at Dose Level B Measured on 12-Lead ECGs Extracted From Continuous Recordings
NCT03808298 (29) [back to overview]	Change-From-Baseline QRS Interval Measured on 12-Lead ECGs Extracted From Continuous Recordings
NCT03808298 (29) [back to overview]	Change-From-Baseline QTcF of Balovaptan at Dose Level A Measurred on 12-Lead ECGs Extracted From Continuous Recordings
NCT03808298 (29) [back to overview]	Change-From-Baseline PR Interval Measured on 12-Lead ECGs Extracted From Continuous Recordings
NCT03808298 (29) [back to overview]	Change-From-Baseline Heart Rate Measured on 12-Lead ECGs Extracted From Continuous Recordings
NCT03808298 (29) [back to overview]	AUC0-24 of M3 Metabolite
NCT03808298 (29) [back to overview]	AUC0-24 of M2 Metabolite
NCT03808298 (29) [back to overview]	AUC0-24 of Balovaptan
NCT03808298 (29) [back to overview]	Tmax of Moxifloxacin
NCT03808298 (29) [back to overview]	Predicted ΔΔQTcF Interval at Geometric Mean Peak Concentrations at Tmax of M2 From Concentration-QTc Analysis
NCT03808298 (29) [back to overview]	Predicted ΔΔQTcF Interval at Geometric Mean Peak Concentrations at Tmax of Balovaptan From Concentration-QTc Analysis
NCT03808298 (29) [back to overview]	Predicted ΔΔQTcF Interval at Geometric Mean Peak Concentration for M3 From Concentration-QTc Analysis
NCT03808298 (29) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events
NCT03808298 (29) [back to overview]	Number of Treatment Emergent Changes of U-Wave Presence
NCT03808298 (29) [back to overview]	Cmax of Moxifloxacin
NCT03808298 (29) [back to overview]	Number of Categorical Outliers for QRS
NCT03808298 (29) [back to overview]	Cmax of M3 Metabolite
NCT03808298 (29) [back to overview]	AUC0-24 of Moxifloxacin
NCT04126343 (19) [back to overview]	Placebo-corrected Change From Baseline for PR Interval on Day 8
NCT04126343 (19) [back to overview]	Placebo-corrected Change From Baseline for QRS Interval on Day 1
NCT04126343 (19) [back to overview]	Placebo-corrected Change From Baseline for QRS Interval on Day 8
NCT04126343 (19) [back to overview]	Placebo-corrected Change From Baseline in Heart Rate (HR) Interval on Day 1
NCT04126343 (19) [back to overview]	Placebo-corrected Change From Baseline in Heart Rate (HR) Interval on Day 8
NCT04126343 (19) [back to overview]	Placebo-corrected Change From Baseline in QTcF After a Single Dose of Moxifloxacin on Day 8
NCT04126343 (19) [back to overview]	Placebo-corrected Change From Baseline in QTcF on Day 8 for Padsevonil
NCT04126343 (19) [back to overview]	Time of Observed Maximum Concentration (Tmax) at Steady State for Padsevonil
NCT04126343 (19) [back to overview]	Percentage of Participants With Treatment Related Adverse Events From Baseline to Safety Follow-up (up to Day 67)
NCT04126343 (19) [back to overview]	Percentage of Participants With Serious Adverse Events From Baseline to Safety Follow-up (up to Day 67)
NCT04126343 (19) [back to overview]	Percentage of Participants With Adverse Events Leading to Discontinuation of the Study From Baseline to Safety Follow-up (up to Day 67)
NCT04126343 (19) [back to overview]	Percentage of Participants With Adverse Events From Baseline to Safety Follow-up (up to Day 67)
NCT04126343 (19) [back to overview]	Maximum Observed Plasma Concentration at Steady State (Cmax, ss) for Padsevonil
NCT04126343 (19) [back to overview]	Change From Baseline in QTcF Evaluated at Drug-specific Tmax for Padsevonil
NCT04126343 (19) [back to overview]	Change From Baseline in QTcF Evaluated at Drug-Specific Tmax for Metabolite 2
NCT04126343 (19) [back to overview]	Change From Baseline in QTcF Evaluated at Drug-specific Tmax for Metabolite 1
NCT04126343 (19) [back to overview]	Area Under the Plasma Concentration Time Curve (AUCtau) at Steady State for Padsevonil
NCT04126343 (19) [back to overview]	Number of Participants With Treatment-emergent Changes for T-wave Morphology and U-wave Presence
NCT04126343 (19) [back to overview]	Placebo-corrected Change From Baseline for PR Interval on Day 1
NCT04175808 (25) [back to overview]	Change From Baseline in QRS After Each Treatment In Part 2
NCT04175808 (25) [back to overview]	Change From Baseline in QRS After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Change From Baseline in QTcF After Each Treatment In Part 2
NCT04175808 (25) [back to overview]	Change From Baseline in QTcF After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Tests, or Electrocardiogram Findings
NCT04175808 (25) [back to overview]	Number of Participants With Recorded Outlier Values for QTcF, HR, PR, and QRS After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Placebo-corrected Change From Baseline in QRS After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil in Part B
NCT04175808 (25) [back to overview]	Apparent Total Plasma Clearance (CL/F) for Omecamtiv Mecarbil in Part B
NCT04175808 (25) [back to overview]	Apparent Volume of Distribution (VZ/F) for Omecamtiv Mecarbil in Part B
NCT04175808 (25) [back to overview]	Area Under the Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-t) for Omecamtiv Mecarbil in Part B
NCT04175808 (25) [back to overview]	AUC From Time 0 to Infinity (AUCinf) for Omecamtiv Mecarbil in Part B
NCT04175808 (25) [back to overview]	Slope of Omecamtiv Mecarbil Plasma Concentration Estimated From Concentration-QTc Analysis in Part B
NCT04175808 (25) [back to overview]	Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil In Part B
NCT04175808 (25) [back to overview]	Change From Baseline in Heart Rate After Each Treatment In Part 2
NCT04175808 (25) [back to overview]	Change From Baseline in Heart Rate After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Change From Baseline in PR Interval After Each Treatment In Part 2
NCT04175808 (25) [back to overview]	Apparent Terminal Elimination Half-life (T1/2) of Omecamtiv Mecarbil in Part B
NCT04175808 (25) [back to overview]	Change From Baseline in PR Interval After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT04175808 (25) [back to overview]	Number of Participants With Treatment-emergent Changes in T-wave Morphology and U-wave Presence After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Placebo-corrected Change From Baseline in Heart Rate After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Placebo-corrected Change From Baseline in PR Interval After Omecamtiv Mecarbil Dosing in Part B
NCT04175808 (25) [back to overview]	Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Moxifloxacin Dosing in Part B
NCT04560816 (14) [back to overview]	ALXN1840 PK Parameter: Area Under The Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUC0-t) Of Total Molybdenum And Plasma Ultrafiltrate (PUF) Molybdenum Following a Single Oral Dose of ALXN1840
NCT04560816 (14) [back to overview]	ALXN1840 PK Parameter: Maximum Observed Concentration (Cmax) Of Total Molybdenum And PUF Molybdenum Following a Single Oral Dose of ALXN1840
NCT04560816 (14) [back to overview]	ALXN1840 PK Parameter: Time To Maximum Observed Concentration (Tmax) Of Total Molybdenum And PUF Molybdenum Following a Single Oral Dose of ALXN1840
NCT04560816 (14) [back to overview]	Change From Baseline For Heart Rate (ΔHR)
NCT04560816 (14) [back to overview]	Change From Baseline PR Interval (ΔPR)
NCT04560816 (14) [back to overview]	Change From Baseline QRS Interval (ΔQRS)
NCT04560816 (14) [back to overview]	Change From Baseline QT Interval Using Fridericia's Formula (ΔQTcF)
NCT04560816 (14) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT04560816 (14) [back to overview]	Number of Participants With Treatment-emergent T-wave Morphology Abnormalities and U-waves
NCT04560816 (14) [back to overview]	Placebo-corrected Change From Baseline For QTcF (ΔΔQTcF) for ALXN1840 Using The By-time Point Analysis
NCT04560816 (14) [back to overview]	Placebo-corrected Change From Baseline Heart Rate (ΔΔHR)
NCT04560816 (14) [back to overview]	Placebo-corrected Change From Baseline PR Interval (ΔΔPR)
NCT04560816 (14) [back to overview]	Placebo-corrected Change From Baseline QRS Interval (ΔΔQRS)
NCT04560816 (14) [back to overview]	ΔΔQTcF For Moxifloxacin Using The By-time Point Analysis
NCT04563845 (89) [back to overview]	Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) of GSK3640254
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Chemistry Parameters: Albumin, Globulin, and Total Protein
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Vital Parameter: Temperature
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Vital Parameter: Pulse Rate
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Urinalysis Parameter: Specific Gravity
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Urinalysis Parameter: pH
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) - For GSK3640254 100 mg, GSK3640254 500 mg and Placebo Arms
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Urinalysis Parameter: Potential of Hydrogen (pH)
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Hematology Parameter: Hemoglobin
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Hematology Parameter: Hematocrit
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Hematology Parameter: Erythrocytes
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in QRS Interval - For GSK3640254 100 mg, GSK3640254 500 mg and Placebo Arms
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in PR Interval - For GSK3640254 100 mg, GSK3640254 500 mg and Placebo Arms
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Hematology Parameter: Hemoglobin
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Hematology Parameter: Hematocrit
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Hematology Parameter: Erythrocytes
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Heart Rate (HR) - For GSK3640254 100 mg, GSK3640254 500 mg and Placebo Arms
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein
NCT04563845 (89) [back to overview]	Part 2: Plasma Concentration of GSK3640254
NCT04563845 (89) [back to overview]	Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase
NCT04563845 (89) [back to overview]	Part 2: Tmax of Moxifloxacin 400 mg
NCT04563845 (89) [back to overview]	Part 2: Tmax of GSK3640254 100 mg and GSK3640254 500 mg
NCT04563845 (89) [back to overview]	Part 2: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) Following Administration of GSK3640254 100 mg and GSK3640254 500 mg Using Concentration-QTc (C-QTc) Analysis
NCT04563845 (89) [back to overview]	Part 2: Ctau of GSK3640254 100 mg and GSK3640254 500 mg
NCT04563845 (89) [back to overview]	Part 2: Cmax of Moxifloxacin 400 mg
NCT04563845 (89) [back to overview]	Part 2: Cmax of GSK3640254 100 mg and GSK3640254 500 mg
NCT04563845 (89) [back to overview]	Part 2: AUC(0-tau) of GSK3640254 100 mg and GSK3640254 500 mg
NCT04563845 (89) [back to overview]	Part 2: AUC(0-t) of GSK3640254 100 mg and GSK3640254 500 mg
NCT04563845 (89) [back to overview]	Part 1: Time of Maximum Observed Concentration (Tmax) of GSK3640254
NCT04563845 (89) [back to overview]	Part 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of GSK3640254
NCT04563845 (89) [back to overview]	Part 1: Maximum Observed Concentration (Cmax) of GSK3640254
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase
NCT04563845 (89) [back to overview]	Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Vital Parameters: SBP and DBP
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Vital Parameter: Temperature
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Vital Parameter: Pulse Rate
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Urinalysis Parameter: Specific Gravity
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Urinalysis Parameter: pH
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Hematology Parameter: Hemoglobin
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Hematology Parameter: Hematocrit
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume
NCT04563845 (89) [back to overview]	Part 2: Placebo-corrected Change From Baseline in QTcF Following Administration of Moxifloxacin
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Hematology Parameter: Erythrocytes
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin
NCT04563845 (89) [back to overview]	Part 1: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3640254
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein
NCT04563845 (89) [back to overview]	Part 1: Plasma Concentration of GSK3640254
NCT04563845 (89) [back to overview]	Part 1: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs
NCT04563845 (89) [back to overview]	Part 1: Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings
NCT04563845 (89) [back to overview]	Part 2: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) Following Administration of GSK3640254 100 mg and GSK3640254 500 mg By-time Point Analysis
NCT04563845 (89) [back to overview]	Part 2: Placebo-corrected Change From Baseline in QRS Following Administration of GSK3640254 100 mg and GSK3640254 500 mg
NCT04563845 (89) [back to overview]	Part 2: Placebo-corrected Change From Baseline in PR Following Administration of GSK3640254 100 mg and GSK3640254 500 mg
NCT04563845 (89) [back to overview]	Part 2: Placebo-corrected Change From Baseline in HR Following Administration of GSK3640254 100 mg and GSK3640254 500 mg
NCT04563845 (89) [back to overview]	Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Urinalysis Parameter: Specific Gravity
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Urinalysis Parameter: pH
NCT04563845 (89) [back to overview]	Part 2: Number of Participants With Treatment Emergent Changes of T-wave Morphology and Presence of U-wave Following Administration of GSK3640254 100 mg and GSK3640254 500 mg
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen
NCT04563845 (89) [back to overview]	Part 2: Number of Participants With Non-SAEs and SAEs
NCT04563845 (89) [back to overview]	Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Hematology Parameter: Hemoglobin
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Hematology Parameter: Hematocrit
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Hematology Parameter: Erythrocytes
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Chemistry Parameters: Amylase and Lipase
NCT04563845 (89) [back to overview]	Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase
NCT04563845 (89) [back to overview]	Part 2: Number of Participants With Outlier Results for HR, QTcF, ΔQTcF, PR Interval and QRS Interval for GSK3640254 100 mg and GSK3640254 500 mg

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,

Intervention	mg*hour/L (Median)
	2nd Trimester	3rd Trimester	Postpartum
ETR 200mg b.i.d.	4.5	8.3	5.3
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	14.9	16.1	27.1
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	72	96	133
RAL 400mg b.i.d.	6.6	5.4	11.6

Intervention	mcg/mL (Median)
	2-10 hours after birth	18-28 hours after birth	36-72 hours after birth	5-9 days after birth
DRV/COBI 800/150 mg q.d.	0.35	1.43	1.87	1.72
DTG 50mg q.d.	1.73	1.53	1.00	0.06
EFV 600 mg q.d. (Outside THA)	1.1	1.0	0.9	0.4
EVG/COBI 150/150mg q.d.	0.132	0.032	0.005	0.005

Intervention	Participants (Count of Participants)
	3rd Trimester	Postpartum
EFV 600mg q.d.	20	21
MVC 150 or 300mg b.i.d.	8	7

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG	53.96	55.25
EFV 600mg q.d. With ENG	53.64	56.65

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG	115.97	100.20

Intervention	unitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	0.15
DTG 50mg q.d.	1.25
EVG/COBI 150/150mg q.d.	0.91
DRV/COBI 800/150 mg q.d.	0.07
ATV/COBI 300/150 mg q.d.	0.07
TFV 300mg q.d.	0.88

Intervention	hour (Median)
DTG 50mg q.d.	32.8
EVG/COBI 150/150mg q.d.	7.6
DRV/COBI 800/150 mg q.d.	NA
EFV 600 mg q.d. (Outside THA)	65.6

Intervention	unitless (Median)
TAF 10mg q.d. w/COBI	0.97
EFV 600 mg q.d. (Outside THA)	0.67
EFV 600mg q.d.	0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	0.2
RAL 400mg b.i.d.	1.5
ETR 200mg b.i.d.	0.52
MVC 150 or 300mg b.i.d.	0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.	0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	0.12
RPV 25mg q.d.	0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.	0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.	0.18

Intervention	ratio (Mean)
	Baseline Waist-Hip Ratio	6 months Waist-Hip Ratio
Lean Women	0.73	0.73
Obese Women	0.79	0.81

Intervention	ng/mL (Mean)
	Baseline Hs-CRP	6 months Hs-CRP	Baseline Adiponectin	6 months Adiponectin
Lean Women	2050.77	2266.02	21976.53	22221.36
Obese Women	4908.76	6207.76	17568.86	18408.43

Intervention	pg/mL (Mean)
	Baseline MCP-1	6 months MCP-1
Lean Women	156.14	206.66
Obese Women	209.56	219.86

Intervention	cm (Mean)
	Baseline Waist circumference	6 months Waist circumference
Lean Women	70.2	70.9
Obese Women	100.0	101.0

Intervention	mg/dL (Mean)
	Baseline LDL	6 months LDL	Baseline Triglycerides	6 months Triglycerides	Baseline HDL	6 months HDL
Lean Women	84	104	72	106	53	61
Obese Women	95	113	72	83	51	58

Intervention	mIU/L (Mean)
	Baseline Insulin sensitivity	6 months Insulin sensitivity
Lean Women	6.62	8.23
Obese Women	4.36	3.82

Intervention	pg/mL (Mean)
	Baseline 16aE1	6 months 16aE1	Baseline 2ME1	6 months 2ME1	Baseline 4ME1	6 months 4ME1	Baseline 2ME2	6 months 2ME2	Baseline E1	6 months E1	Baseline 4ME2	6 months 4ME2	Baseline E2	6 months E2	Baseline 2OHE1	6 months 2OHE1	Baseline 2OHE2	6 months 2OHE2	Baseline 4OHE1	6 months 4OHE1	Baseline Total plasma	6 months Total plasma
Lean Women	317.47	383.39	32.39	45.58	4.45	7.42	0.91	1.74	245.99	227.4	0.59	1.14	36.796	47.32	85.62	57.96	8.01	6.05	33.98	29.12	1022.16	1007.89
Obese Women	314.76	421.6	25.92	52.84	5.26	6.1	1.48	1.5	217.23	315.03	0.73	0.89	34.11	74.73	101.07	135.95	9.81	11.55	33.78	27.29	1068	1342.21

Intervention	mm Hg (Mean)
	Baseline Systolic Blood Pressure	6 months Systolic Blood Pressure	Baseline Diastolic Blood Pressure	6 months Diastolic Blood Pressure
Lean Women	105.7	106.5	68.0	66.5
Obese Women	121.1	123.5	74.4	73.4

Intervention	kg/m² (Mean)
	Baseline BMI	6 months BMI
Lean Women	21.3	21.4
Obese Women	37.1	37.6

Intervention	ng/mL (Mean)
	Baseline sVCAM	6 months sVCAM	Baseline sICAM	6 months sICAM
Lean Women	1139.6	1003.29	182.11	160.21
Obese Women	905	880.14	163.34	163.2

Intervention	ug/ml (Median)
Isoniazid 300 mg/Day	62.7
Linezolid 600 mg/Once Daily	20.0
Linezolid 600 mg/Twice Daily	16.2

Intervention	ug/ml (Median)
Gatifloxacin 400 mg/Day	9.5
Levofloxacin 1000 mg/Day	15.6
Moxifloxacin 400 mg/Day	12.3
Isoniazid (INH) 300 mg/Day	70.6

Intervention	Percentage (Mean)
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
Gatifloxacin 400 mg/Day	0.98	0.96	0.92	0.89	0.87	0.85	0.82
Isoniazid (INH) 300 mg/Day	0.95	0.90	0.87	0.84	0.81	0.80	0.80
Levofloxacin 1000 mg/Day	0.98	0.95	0.91	0.88	0.85	0.83	0.81
Moxifloxacin 400 mg/Day	0.96	0.94	0.91	0.89	0.87	0.85	0.83

moxifloxacin

Description

Cross-References

Synonyms (80)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (7)

Protein Targets (24)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (190)

Molecular Functions (97)

Ceullar Components (62)

Bioassays (3673)

Research

Studies (3,016)

Market Indicators

Research Demand Index: 111.00

Study Types

Clinical Trials (533)

Trial Overview

Trial Outcomes

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

Plasma Concentration for Contraceptives

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

Proportion of Patients With Sterile Sputum Cultures

Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications

Changes in Waist-to-Hip Ratio Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women

Inflammatory Marker Changes, High Sensitive C-reactive Protein (Hs-CRP) and Adiponectin, Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women

Inflammatory Marker Changes (MCP-1) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women

Changes in Waist Circumference Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women

Changes in Lipid Profile Compared Associated With OC Use Among (1) Obese Women and (2) Lean Women

Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women

Changes in Estrogen Metabolites (Plasma) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women

Changes in Blood Pressure Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women

Changes in Body Mass Index (BMI) Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women

Inflammatory Marker Changes, Soluble Vascular Cell Adhesion Molecule (sVCAM) and Soluble Intercellular Adhesion Molecule (sICAM), Associated With OC Use Compared Among (1) Obese Women and (2) Lean Women

Percentage of Bacteriologic Response at Test of Cure Visit

Percentage of Clinical Cure (Success) at Test of Cure Visit (Full Analysis Set)

Percentage of Clinical Cure (Success) at Test of Cure Visit(Clinical Per Protocol Population)

Percentage of Clinical Cure (Success)at Test of Cure Visit(Clinically Eligible Set)

Change From Baseline in Clinical COPD Questionnaire(CCQ)Functional State Score

Change From Baseline in Clinical COPD Questionnaire(CCQ)Symptoms Score

Change From Baseline in Clinical COPD Questionnaire(CCQ)Total Score

Time Taken for First Quartile (25%) of Subjects to Have AECB Recurrence

Change From Baseline in Clinical COPD Questionnaire(CCQ)Mental State Score

Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 17 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)

Intervention	hours (Median)
	Tmax in h (apparent time of max plasma conc.)	Half-life
Isoniazid 300 mg/Day	1.0	3.6
Linezolid 600 mg/Once Daily	1.5	3.20
Linezolid 600 mg/Twice Daily	1.0	4.56

Intervention	hours (Median)
	Tmax	Half-life
Gatifloxacin 400 mg/Day	1.5	6.0
Isoniazid (INH) 300 mg/Day	1	2.5
Levofloxacin 1000 mg/Day	1.0	7.6
Moxifloxacin 400 mg/Day	1.0	8.1

Intervention	ug/h/ml (Median)
Gatifloxacin 400 mg/Day	42.8
Levofloxacin 1000 mg/Day	129.1
Moxifloxacin 400 mg/Day	55.3
Isoniazid (INH) 300 mg/Day	11.9

Intervention	log10 cfu/ml/day (Mean)
Gatifloxacin 400 mg/Day	0.17
Levofloxacin 1000 mg/Day	0.18
Moxifloxacin 400 mg/Day	0.17
Isoniazid (INH) 300 mg/Day	0.08

Intervention	ug/ml (Median)
Isoniazid 300 mg/Day	3.3
Linezolid 600 mg/Once Daily	15.0
Linezolid 600 mg/Twice Daily	19.4

Intervention	ug/ml (Median)
Gatifloxacin 400 mg/Day	85.6
Levofloxacin 1000 mg/Day	129.1
Moxifloxacin 400 mg/Day	110.5
Isoniazid (INH) 300 mg/Day	215.2

Intervention	ug/h/ml (Median)
	AUC 0-12/MIC	AUC 0-24/MIC
Isoniazid 300 mg/Day	306.7	344.6
Linezolid 600 mg/Once Daily	107.8	116.2
Linezolid 600 mg/Twice Daily	121.6	243.2

Intervention	ug/h/ml (Median)
	AUC 0-12	AUC 0-24
Isoniazid 300 mg/Day	15.3	17.2
Linezolid 600 mg/Once Daily	60.1	66.8
Linezolid 600 mg/Twice Daily	80.3	160.7

Intervention	ug/h/ml (Median)
	AUC 0-12 (ug/h/ml)	AUC 0-24 (ug/h/ml)
Isoniazid 300 mg/Day	17.0	19.2
Linezolid 600 mg/Once Daily	87.0	96.9
Linezolid 600 mg/Twice Daily	116.4	232.9

Intervention	Percentage (Mean)
Isoniazid (INH) 300 mg/Day	95.5
Linezolid 600 mg/Once Daily	62.8
Linezolid 600 mg/Twice Daily	100.0